Rituximab Clinical Trials (2026): 2,053 Studies for Lymphoma & Chronic Lymphocytic Leukemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2,053 Rituximab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 683 indications (including Lymphoma & Chronic Lymphocytic Leukemia) and 253,093 total planned enrollment. 367 Phase 3 Rituximab trials and 950 Phase 2, 77 Phase 4 are listed. 314 Rituximab clinical trials are actively recruiting at 1,419 U.S. sites across 50 states. Most recent activity: NCT04196413 (Jul 2043).
Where to Participate: All Rituximab Trial Sites in the U.S. (1,419 sites across 50 states)
Every actively recruiting Rituximabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT05533775 | Map |
| AL | University Hospital (University Of Alabama Hospital) | Birmingham35233 | NCT04884035 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT06337318 | Map |
| AL | University of Alabama at Birmingham School of Medicine: Division of Nephrology | Birmingham35294 | NCT03949855 | Map |
| AL | Infirmary Cancer Care | Mobile36607 | NCT06911502 | Map |
| AL | Infirmary Cancer Care ( Site 0157) | Mobile36607 | NCT06890884 | Map |
| AK | Alaska Oncology and Hematology | Anchorage99508 | NCT06911502 | Map |
| AZ | Ironwood Cancer & Research Centers ( Site 0204) | Chandler85224 | NCT06890884 | Map |
| AZ | Banner MD Anderson Cancer Center ( Site 0165) | Gilbert85234 | NCT06717347 | Map |
| AZ | Palo Verde Cancer Specialists ( Site 0105) | Glendale85304 | NCT06890884 | Map |
| AZ | Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) | Glendale85304 | NCT05139017 | Map |
| AZ | City of Hope - Phoenix ( Site 0202) | Goodyear85338 | NCT06890884 | Map |
| AZ | Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) | Phoenix85006 | NCT06717347 | Map |
| AZ | City of Hope at Phoenix | Phoenix85338 | NCT06918431 | Map |
| AZ | Mayo Clinic Cancer Center | Phoenix85054 | NCT07104032 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT06337318 | Map |
| AZ | Mayo Clinic in Arizona - Phoenix | Phoenix85054 | NCT06090539 | Map |
| AZ | HonorHealth Cancer Center | Scottsdale85251 | NCT07104032 | Map |
| AZ | Mayo Clinic - Arizona | Scottsdale85259 | NCT04884035 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT06834373 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT04840602 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT06337318 | Map |
| AZ | The University of Arizona Cancer Center - North Campus ( Site 0124) | Tucson85719 | NCT06717347 | Map |
| AZ | University of Arizona Cancer Center | Tucson85724 | NCT06091254 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT04840602 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT06337318 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT06337318 | Map |
| AR | Genesis Cancer and Blood Institute ( Site 0193) | Hot Springs71913 | NCT06890884 | Map |
| AR | St Bernards Medical Center | Jonesboro72401 | NCT06846671 | Map |
| AR | University of Arkansas | Little Rock72205 | NCT03949855 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05976763 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT06337318 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT06337318 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT06337318 | Map |
| AR | Highlands Oncology Group ( Site 5405) | Springdale72762 | NCT05947851 | Map |
| CA | Kaiser Permanente-Deer Valley Medical Center | Antioch94531 | NCT03150693 | Map |
| CA | Beverly Hills Cancer Center ( Site 0184) | Beverly Hills90211 | NCT05139017 | Map |
| CA | Tower Cancer Research Foundation | Beverly Hills90211 | NCT05976763 | Map |
| CA | Tower Cancer Research Foundation | Beverly Hills90211 | NCT06337318 | Map |
| CA | Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) | Burbank91505 | NCT06890884 | Map |
| CA | Community Cancer Institute | Clovis93611 | NCT03150693 | Map |
| CA | UC Irvine Health Cancer Center-Newport | Costa Mesa92627 | NCT03150693 | Map |
| CA | City of Hope | Duarte91010 | NCT07226843 | Map |
| CA | City of Hope Cancer Center | Duarte91010 | NCT06084936 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT05886036 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06090539 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06337318 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06911502 | Map |
| CA | City of Hope Comprehensive Cancer Center ( Site 0191) | Duarte91010 | NCT06890884 | Map |
| CA | City of Hope Medical center | Duarte91010 | NCT03523975 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06572618 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06918431 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT07365306 | Map |
| CA | City Of Hope National Medical Center | Duarte91010 | NCT04884035 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT03150693 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT03150693 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT03150693 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT03150693 | Map |
| CA | UCSF Fresno /ID# 264712 | Fresno93701-2302 | NCT06191744 | Map |
| CA | Providence Medical Foundation | Fullerton92835 | NCT07104032 | Map |
| CA | Providence Medical Foundation-Oncology ( Site 0168) | Fullerton92835 | NCT06717347 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT06337318 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT03150693 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT06337318 | Map |
| CA | University of California, San Diego | La Jolla92093 | NCT07222631 | Map |
| CA | Uci Health Laguna Hills | Laguna Hills92653 | NCT06943872 | Map |
| CA | City of Hope Antelope Valley | Lancaster93534 | NCT06337318 | Map |
| CA | City of Hope at Long Beach Elm | Long Beach90813 | NCT06337318 | Map |
| CA | MemorialCare Health System - Long Beach Medical Center ( Site 5421) | Long Beach90806 | NCT05947851 | Map |
| CA | MemorialCare Health System - Long Beach Medical Center ( Site 9559) | Long Beach90806 | NCT06717347 | Map |
| CA | Tibor Rubin VA Medical Center | Long Beach90822 | NCT06337318 | Map |
| CA | Cancer Blood and Specialty Clinic ( Site 0109) | Los Alamitos90720 | NCT06717347 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT04609046 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05976763 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06337318 | Map |
| CA | Cedars-Sinai Medical Center ( Site 0115) | Los Angeles90048 | NCT06717347 | Map |
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT06091254 | Map |
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT06091865 | Map |
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT06149286 | Map |
| CA | UCLA | Los Angeles90095 | NCT06655896 | Map |
| CA | UCLA Department of Medicine Hematologyoncology | Los Angeles90095-3075 | NCT06846671 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90670 | NCT06119685 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT03150693 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT03150693 | Map |
| CA | Hoag Memorial Hospital | Newport Beach92663 | NCT05618925 | Map |
| CA | Kaiser Permanente Oakland Medical Center | Oakland94611 | NCT05533775 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT03150693 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT05533775 | Map |
| CA | Chao Family Comprehensive Cancer Center | Orange92868-3201 | NCT06943872 | Map |
| CA | Research Site | Orange92868 | NCT05952024 | Map |
| CA | UC Irvine Health | Orange92868 | NCT07104032 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT03150693 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT06337318 | Map |
| CA | University of California Irvine Medical Center | Orange92868 | NCT06091865 | Map |
| CA | Lucile Packard Children's Hospital | Palo Alto94305 | NCT05508009 | Map |
| CA | Stanford Cancer Institute | Palo Alto94304-2205 | NCT06943872 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT03150693 | Map |
| CA | Kaiser Permanente-Richmond | Richmond94801 | NCT03150693 | Map |
| CA | Kaiser Permanente - Roseville | Roseville95661 | NCT05533775 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT03150693 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT03150693 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT03150693 | Map |
| CA | University of California (UC) Davis | Sacramento95817 | NCT06091865 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT03150693 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT05600686 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06905509 | Map |
| CA | Scripps Mercy Hospital /ID# 265393 | San Diego92103 | NCT06191744 | Map |
| CA | Scripps Prebys Cancer Center | San Diego92103-2106 | NCT06943872 | Map |
| CA | UC San Diego Moores Cancer Center | San Diego92037 | NCT05600686 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT03150693 | Map |
| CA | Pacific Hematology Oncology Associates ( Site 0131) | San Francisco94115 | NCT06717347 | Map |
| CA | UCSF | San Francisco94115 | NCT06655896 | Map |
| CA | UCSF | San Francisco94115 | NCT06655896 | Map |
| CA | UCSF Helen Diller Medical Center at Parnassus Heights | San Francisco94143 | NCT06911502 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT04609046 | Map |
| CA | University of California San Francisco | San Francisco94146 | NCT03949855 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT03150693 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT03150693 | Map |
| CA | Sutter Health Network | San Pablo94806 | NCT06655896 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT03150693 | Map |
| CA | Sansum Clinic Research /ID# 261596 | Santa Barbara93105 | NCT06191744 | Map |
| CA | Kaiser Permanente - Santa Clara | Santa Clara95051 | NCT05533775 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT03150693 | Map |
| CA | University of California Los Angeles (UCLA) - Cancer Care - Santa Monica | Santa Monica90404-2023 | NCT06084936 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT03150693 | Map |
| CA | City of Hope South Pasadena | South Pasadena91030 | NCT06337318 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT03150693 | Map |
| CA | Lucile Packard Children's Hospital (LPCH) | Stanford94304 | NCT04196413 | Map |
| CA | Stanford University | Stanford94305 | NCT04784052 | Map |
| CA | Stanford University School of Medicine: Division of Nephrology | Stanford94305 | NCT03949855 | Map |
| CA | Kaiser Permanente-Stockton | Stockton95210 | NCT03150693 | Map |
| CA | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension | Torrance90502 | NCT03949855 | Map |
| CA | Torrance Memorial Physician Network - Cancer Care | Torrance90505 | NCT06337318 | Map |
| CA | City of Hope Upland | Upland91786 | NCT06337318 | Map |
| CA | Kaiser Permanente Medical Center-Vacaville | Vacaville95688 | NCT03150693 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT03150693 | Map |
| CA | Bass Medical Group ( Site 0123) | Walnut Creek94598 | NCT06890884 | Map |
| CA | Bass Medical Group ( Site 0166) | Walnut Creek94598 | NCT05139017 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT03150693 | Map |
| CA | Pih Health Whittier Hospital | Whittier90602 | NCT06846671 | Map |
| CO | Rocky Mountain Cancer Centers (RMCC) ( Site 8001) | Aurora80012 | NCT06890884 | Map |
| CO | Rocky Mountain Cancer Centers (Williams) Usor | Aurora80012-5405 | NCT06846671 | Map |
| CO | Rocky Mountain Cancer Centers (Williams) Usor | Aurora80012-5405 | NCT06943872 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT06337318 | Map |
| CO | University of Colorado | Aurora80045 | NCT03949855 | Map |
| CO | University Of Colorado | Aurora80045 | NCT07015242 | Map |
| CO | University of Colorado Anschutz Medical Campus | Aurora80045 | NCT07335562 | Map |
| CO | Rocky Mountain Cancer Centers - Boulder /ID# 261203 | Boulder80303 | NCT06191744 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT07226843 | Map |
| CO | Colorado Blood Cancer Institute (CBCI) | Denver80218 | NCT06561347 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT06337318 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT06337318 | Map |
| CO | Lutheran Hospital - Cancer Centers of Colorado ( Site 0180) | Golden80401 | NCT06717347 | Map |
| CO | Colorado West Healthcare System-Grand Valley Oncology ( Site 0165) | Grand Junction81505 | NCT06890884 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT06337318 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT06337318 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT05976763 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT06084936 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT07104032 | Map |
| CT | Yale University | New Haven06520 | NCT03150693 | Map |
| CT | Yale University | New Haven06520 | NCT05976763 | Map |
| CT | Yale University School of Medicine /ID# 242089 | New Haven06510 | NCT05283720 | Map |
| CT | Yale University Yale Cancer Center | New Haven06520-8028 | NCT06943872 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT05976763 | Map |
| CT | Eastern Connecticut Hematology and Oncology | Norwich06360-2700 | NCT06943872 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT05976763 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT05976763 | Map |
| DE | Christiana Care Health Service /ID# 242301 | Newark19713 | NCT05283720 | Map |
| DE | Christiana Care Health Service /ID# 261207 | Newark19713 | NCT06191744 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05976763 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06337318 | Map |
| DE | Medical Oncology Hematology Consultants (MOHC) ( Site 8007) | Newark19713 | NCT06890884 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05976763 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06337318 | Map |
| DC | Georgetown University | Washington D.C.20007 | NCT06084936 | Map |
| DC | Georgetown University Medical Center ( Site 0117) | Washington D.C.20007 | NCT06890884 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT06337318 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT06337318 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT06337318 | Map |
| FL | Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163) | Boca Raton33486 | NCT05139017 | Map |
| FL | Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130) | Boca Raton33486 | NCT06890884 | Map |
| FL | Clermont Oncology Center ( Site 0174) | Clermont34711 | NCT05139017 | Map |
| FL | Clermont Oncology Center ( Site 0182) | Clermont34711 | NCT06717347 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT06337318 | Map |
| FL | University of Miami | Coral Gables33146 | NCT06084936 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs33065 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs33065 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs33065 | NCT06337318 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT06337318 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Doral | Doral33166 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Doral | Doral33166 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Doral | Doral33166 | NCT06337318 | Map |
| FL | Florida Oncology and Hematology | Fort Myers33912 | NCT06846671 | Map |
| FL | Bioresearch Partner ( Site 0157) | Hialeah33013 | NCT06717347 | Map |
| FL | BRP-Hialeah Hospital ( Site 0182) | Hialeah33013 | NCT05139017 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT03150693 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT06337318 | Map |
| FL | Baptist Md Anderson Cancer Center | Jacksonville32207-8432 | NCT06846671 | Map |
| FL | Baptist MD Anderson Cancer Center ( Site 0176) | Jacksonville32207 | NCT06890884 | Map |
| FL | Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 | Jacksonville32256 | NCT06191744 | Map |
| FL | Mayo Clinic Cancer Center | Jacksonville32224 | NCT07104032 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT04840602 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT06337318 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT06834373 | Map |
| FL | Mayo Clinic Jacksonville - PPDS | Jacksonville32224 | NCT04884035 | Map |
| FL | Mayo Clinic Jacksonville: Department of Nephrology and Hypertension | Jacksonville32224 | NCT03949855 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT06337318 | Map |
| FL | University of Miami | Miami33136 | NCT04998669 | Map |
| FL | University of Miami | Miami33136 | NCT06730542 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04609046 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04840602 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05886036 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06337318 | Map |
| FL | University of Miami Miller School of Medicine, Div of Nephrology | Miami33136 | NCT03949855 | Map |
| FL | University of Miami Sylvester Cancer Center | Miami33136 | NCT05800366 | Map |
| FL | Mount Sinai Braman Comprehensive Cancer Center ( Site 0140) | Miami Beach33140 | NCT06890884 | Map |
| FL | Mount Sinai Medical Center | Miami Beach33140 | NCT06337318 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT04609046 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT04840602 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT06337318 | Map |
| FL | Orlando Health Cancer Institute ( Site 0169) | Ocoee34761 | NCT06717347 | Map |
| FL | Mid Florida Hematology and Oncology Center ( Site 0152) | Orange City32763 | NCT06890884 | Map |
| FL | Mid Florida Hematology and Oncology Center ( Site 0172) | Orange City32763 | NCT06717347 | Map |
| FL | Advent Health /ID# 261578 | Orlando32803 | NCT06191744 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT03150693 | Map |
| FL | Orlando Health Cancer Institute /ID# 260983 | Orlando32806 | NCT06191744 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT06337318 | Map |
| FL | Memorial Hospital West ( Site 5410) | Pembroke Pines33028 | NCT05947851 | Map |
| FL | Boca Raton Clinical Research (BRCR) Global | Plantation33322 | NCT06149286 | Map |
| FL | BRCR Medical Center | Plantation33322 | NCT06351527 | Map |
| FL | IRIS Research and Development, LLC | Plantation33324 | NCT06581562 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT04609046 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT04840602 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05886036 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT06337318 | Map |
| FL | Florida Cancer Specialists - Sarasota | Sarasota34236 | NCT07226843 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05581030 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06090539 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06350318 | Map |
| FL | Moffitt Cancer Center | Tampa33612-9416 | NCT07015242 | Map |
| FL | Moffitt Cancer Center /ID# 259487 | Tampa33612-9416 | NCT06191744 | Map |
| FL | Tampa General Hospital /ID# 246748 | Tampa33606 | NCT05283720 | Map |
| FL | Cleveland Clinic Florida | Weston33331-3609 | NCT06846671 | Map |
| FL | Cleveland Clinic Florida | Weston33331-3609 | NCT06943872 | Map |
| FL | FL Medical Clinic Orlando Health | Zephyrhills33542 | NCT06655896 | Map |
| GA | Phoebe Putney Memorial Hospital | Albany31701 | NCT05976763 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT05976763 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06337318 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT06119685 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT07226843 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT05976763 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06337318 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT03150693 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05886036 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05976763 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06337318 | Map |
| GA | Emory University School of Medicine | Atlanta30322 | NCT07335562 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322-1013 | NCT06846671 | Map |
| GA | Grady Health System | Atlanta30303 | NCT05976763 | Map |
| GA | Northside Cancer Center | Atlanta30342 | NCT06846671 | Map |
| GA | Northside Hospital | Atlanta30342 | NCT06046248 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT03150693 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT05976763 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT06337318 | Map |
| GA | Emory Johns Creek Hospital | Johns Creek30097 | NCT05976763 | Map |
| GA | Northwest Georgia Oncology Centers PC | Marietta30060 | NCT04884035 | Map |
| GA | Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta30060 | NCT06911502 | Map |
| GA | Southeastern Regional Medical Center | Newnan30265 | NCT06911502 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT03150693 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT03150693 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT03150693 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05976763 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT06337318 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT03150693 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05976763 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT03150693 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05976763 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT06337318 | Map |
| ID | Beacon Cancer Care - Coeur d'Alene /ID# 260670 | Coeur d'Alene83814 | NCT06191744 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT03150693 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05976763 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06337318 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT03150693 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05976763 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT03150693 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05976763 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04840602 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT03150693 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05976763 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT06337318 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT03150693 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05976763 | Map |
| ID | Beacon Cancer Care ( Site 0142) | Post Falls83854 | NCT06890884 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT03150693 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05976763 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06337318 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT03150693 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05976763 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06337318 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT03150693 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05976763 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05976763 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05976763 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04840602 | Map |
| IL | Alliance for Clinical Trials in Oncology | Chicago60606 | NCT05976763 | Map |
| IL | Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814 | Chicago60611 | NCT06191744 | Map |
| IL | Northwestern University | Chicago60611 | NCT03150693 | Map |
| IL | Northwestern University | Chicago60611 | NCT06655896 | Map |
| IL | Northwestern University | Chicago60611 | NCT06943872 | Map |
| IL | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago60611 | NCT07015242 | Map |
| IL | Rush MD Anderson Cancer Center | Chicago60612 | NCT03150693 | Map |
| IL | Swedish Covenant Hospital | Chicago60625 | NCT06337318 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT03150693 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06337318 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT03571321 | Map |
| IL | University of Chicago Medical Center ( Site 0126) | Chicago60637 | NCT06890884 | Map |
| IL | University of Chicago Medicine Comprehensive Cancer Center | Chicago60637 | NCT07294677 | Map |
| IL | University of Illinois | Chicago60612 | NCT03150693 | Map |
| IL | University of Illinois | Chicago60612 | NCT05976763 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04840602 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05976763 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06337318 | Map |
| IL | Cancer Care Specialists Of Central Illinois /ID# 272464 | Decatur62526 | NCT06191744 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04840602 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05976763 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06337318 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05976763 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06337318 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05976763 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04840602 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05976763 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06337318 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04840602 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05976763 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06337318 | Map |
| IL | Elmhurst Memorial Hospital | Elmhurst60126 | NCT06337318 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05976763 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT03150693 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT06337318 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05976763 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT03150693 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT06337318 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT03150693 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT06337318 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05976763 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05976763 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT04840602 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05976763 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06337318 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT03150693 | Map |
| IL | Edward Hospital/Cancer Center | Naperville60540 | NCT06337318 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT03150693 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT06337318 | Map |
| IL | Illinois Cancer Specialists ( Site 8000) | Niles60714 | NCT05139017 | Map |
| IL | Illinois Cancer Specialists (Niles) Usor | Niles60714-5905 | NCT06943872 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04840602 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05976763 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06337318 | Map |
| IL | Cancer Care Specialists of Illinois ( Site 0152) | O'Fallon62269 | NCT06717347 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT03150693 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT06337318 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05976763 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05976763 | Map |
| IL | Illinois Cancer Care ( Site 7005) | Peoria61615 | NCT06890884 | Map |
| IL | Illinois Cancer Care, PC /ID# 261526 | Peoria61615 | NCT06191744 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05976763 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05976763 | Map |
| IL | Edward Hospital/Cancer Center?Plainfield | Plainfield60585 | NCT06337318 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05976763 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05976763 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT06337318 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04840602 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05976763 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06337318 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04840602 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05976763 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06337318 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT04840602 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05976763 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06337318 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04840602 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05976763 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06337318 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05976763 | Map |
| IN | Northwest Cancer Center - Crown Point | Crown Point46307 | NCT06337318 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT06337318 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT06337318 | Map |
| IN | Fort Wayne Medical Oncology and Hematology ( Site 0149) | Fort Wayne46804 | NCT06717347 | Map |
| IN | Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583 | Fort Wayne46804 | NCT06191744 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT05976763 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT06337318 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT06337318 | Map |
| IN | Indiana University and Comprehensive Cancer Center | Indianapolis46202 | NCT06149286 | Map |
| IN | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis46202 | NCT06091865 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT06337318 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT06337318 | Map |
| IN | St Vincent Ascension at Peyton Manning Childrens Hospital | Indianapolis46260 | NCT06091865 | Map |
| IN | The Community Hospital | Munster46321 | NCT06337318 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT06337318 | Map |
| IN | Investigative Clinical Research of Indiana | Noblesville46062 | NCT06091254 | Map |
| IN | Investigative Clinical Research of Indiana | Noblesville46062 | NCT06091865 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT06337318 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04840602 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05976763 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT06337318 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04840602 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05976763 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT06337318 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05976763 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT06337318 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT06337318 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04609046 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT05976763 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06337318 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06337318 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05976763 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT06337318 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04609046 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT05976763 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04609046 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05976763 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT06337318 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04609046 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05976763 | Map |
| IA | Research Site | Des Moines50309 | NCT05952024 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05976763 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT06337318 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05976763 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT06337318 | Map |
| IA | University of Iowa Health Care /ID# 262132 | Des Moines50314-3017 | NCT06191744 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04840602 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT05976763 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT06337318 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge50501 | NCT05976763 | Map |
| IA | University Of Iowa | Iowa City52242 | NCT06655896 | Map |
| IA | University of Iowa-Holden Comprehensive Cancer Center ( Site 0139) | Iowa City52242 | NCT06890884 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT03150693 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05976763 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT06337318 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04840602 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT05976763 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT06337318 | Map |
| IA | Mission Blood & Cancer Care ( Site 0114) | Waukee50263 | NCT06890884 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04609046 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05976763 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT06337318 | Map |
| KS | HaysMed | Hays67601 | NCT05976763 | Map |
| KS | HaysMed | Hays67601 | NCT06337318 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT03150693 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05886036 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05976763 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06337318 | Map |
| KS | University Of Kansas Medical Center | Kansas City66160 | NCT04884035 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT05976763 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT06337318 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT05976763 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT06337318 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT05886036 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT05976763 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT06337318 | Map |
| KS | Freeman Physician Group of Pittsburg | Pittsburg66762 | NCT05976763 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT05976763 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT06337318 | Map |
| KS | Cotton O'Neil Cancer Center ( Site 0108) | Topeka66606 | NCT06717347 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT05976763 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT06337318 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT03150693 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05886036 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05976763 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06337318 | Map |
| KS | Cancer Center of Kansas - Wichita | Wichita67214 | NCT03150693 | Map |
| KS | Cancer Center Of Kansas-Wichita | Wichita67214 | NCT04884035 | Map |
| KY | Saint Elizabeth Medical Center Edgewood ( Site 0141) | Edgewood41017 | NCT06890884 | Map |
| KY | Saint Elizabeth Medical Center Edgewood ( Site 0165) | Edgewood41017 | NCT05139017 | Map |
| KY | Baptist Health Hardin ( Site 0154) | Elizabethtown42701 | NCT06890884 | Map |
| KY | Baptist Health Lexington ( Site 0127) | Lexington40503 | NCT06890884 | Map |
| KY | University of Kentucky | Lexington40536 | NCT06091865 | Map |
| KY | University of Kentucky ( Site 0106) | Lexington40536 | NCT06717347 | Map |
| KY | University of Kentucky Chandler Medical Center ( Site 0158) | Lexington40536 | NCT05139017 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT03150693 | Map |
| KY | Norton Cancer Institute - St. Matthews /ID# 261076 | Louisville40207 | NCT06191744 | Map |
| KY | Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405 | Louisville40207 | NCT03571568 | Map |
| KY | Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133) | Louisville40207 | NCT05139017 | Map |
| KY | Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163) | Louisville40207 | NCT06717347 | Map |
| KY | Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185) | Louisville40207 | NCT06890884 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05976763 | Map |
| KY | University of Louisville Hospital /ID# 260544 | Louisville40202 | NCT06191744 | Map |
| KY | University of Louisville, Brown Cancer Center | Louisville40202 | NCT06943872 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05976763 | Map |
| KY | Owensboro Medical Health System ( Site 0195) | Owensboro42303 | NCT06717347 | Map |
| LA | CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184) | Alexandria71301 | NCT06717347 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT06337318 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809-3738 | NCT06943872 | Map |
| LA | Our Lady of the Lake Hospital | Baton Rouge70808-4365 | NCT06846671 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT06337318 | Map |
| LA | Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180) | Baton Rouge70808 | NCT06890884 | Map |
| LA | Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209) | Monroe71202 | NCT06890884 | Map |
| LA | Ochsner Clinic Foundation ( Site 0189) | New Orleans70121 | NCT06890884 | Map |
| LA | Louisiana State University Health Sciences Shreveport ( Site 0195) | Shreveport71103 | NCT06890884 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT04609046 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT04609046 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT04609046 | Map |
| ME | New England Cancer Specialists - Westbrook /ID# 260672 | Westbrook04092 | NCT06191744 | Map |
| MD | Johns Hopkins | Baltimore21287 | NCT03949855 | Map |
| MD | Johns Hopkins University | Baltimore21231 | NCT05533775 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06337318 | Map |
| MD | University of Maryland ( Site 0123) | Baltimore21201 | NCT05139017 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT06091865 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201-1544 | NCT06943872 | Map |
| MD | University of Maryland, Baltimore /ID# 242218 | Baltimore21201 | NCT05283720 | Map |
| MD | University of Maryland, Baltimore /ID# 259538 | Baltimore21201 | NCT06191744 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT03150693 | Map |
| MD | American Oncology Partners of Maryland Pa | Bethesda20817-7847 | NCT06846671 | Map |
| MD | American Oncology Partners, P.A. ( Site 0185) | Bethesda20817 | NCT06717347 | Map |
| MD | Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476 | Bethesda20817 | NCT06191744 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03949855 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03952637 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT04002947 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT01419561 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT00977977 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05389423 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06364423 | Map |
| MD | National Naval Medical Center | Bethesda20889 | NCT00977977 | Map |
| MD | NCI - Center for Cancer Research | Bethesda20892 | NCT06965114 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT06337318 | Map |
| MD | Greater Baltimore Medical Center | Towson21204 | NCT06911502 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT04421560 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06561347 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05783609 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05800366 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06091254 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06091865 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06510309 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06854003 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02115 | NCT07104032 | Map |
| MA | Beth Israel Deaconess Medical Center (Data Collection Only) | Boston02215 | NCT07231952 | Map |
| MA | Boston Medical Center | Boston02118 | NCT06655896 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT06475235 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT04669171 | Map |
| MA | Dana Farber Cancer Institute | Boston02115 | NCT04421560 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06561347 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05800366 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06475235 | Map |
| MA | Dana Farber Cancer Institute | Boston02215-5418 | NCT06943872 | Map |
| MA | Dana Farber Cancer Institute ( Site 0111) | Boston02215 | NCT06890884 | Map |
| MA | Dana Farber Cancer Institute (Data Collection and Specimen Analysis) | Boston02115 | NCT07231952 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT03150693 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06563596 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05533775 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05783609 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06090539 | Map |
| MA | Dana-Farber Cancer Institute | Boston02115 | NCT06644183 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06854003 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07015242 | Map |
| MA | Dana-Farber Cancer Institute | Boston02115 | NCT07104032 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07226843 | Map |
| MA | Dana-Farber Cancer Institute-Lymphoma ( Site 0111) | Boston02215 | NCT05139017 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06561347 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07104032 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07226843 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT03150693 | Map |
| MA | Research Site | Boston02215 | NCT06564038 | Map |
| MA | University of Massachusetts Medical School ( Site 0119) | Worcester01655 | NCT05139017 | Map |
| MI | Michigan Med University of Michigan | Ann Arbor48109 5271 | NCT06655896 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT04840602 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT03150693 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05976763 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT03523975 | Map |
| MI | University of Michigan | Ann Arbor48104 | NCT03949855 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT04998669 | Map |
| MI | University of Michigan Health System | Ann Arbor48109 | NCT06084936 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT06337318 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT06337318 | Map |
| MI | McLaren Cancer Institute-Bay City | Bay City48706 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT03150693 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06337318 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04840602 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT03150693 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05976763 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT06337318 | — |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT03150693 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06337318 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04840602 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT03150693 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05976763 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04840602 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT03150693 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT03150693 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06337318 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT04840602 | Map |
| MI | McLaren Cancer Institute-Clarkston | Clarkston48346 | NCT05976763 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT04840602 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT06337318 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT06337318 | Map |
| MI | Henry Ford Health System | Detroit48202 | NCT06091865 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT04840602 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06337318 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT06091254 | Map |
| MI | Karmanos Cancer Institute ( Site 0174) | Detroit48201 | NCT06717347 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT03150693 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05976763 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT06337318 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05976763 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT03150693 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05976763 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT06337318 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT04840602 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT03150693 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05976763 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT06337318 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04840602 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT03150693 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05976763 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT06337318 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT04840602 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT03150693 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05976763 | Map |
| MI | McLaren Cancer Institute-Flint | Flint48532 | NCT05976763 | Map |
| MI | Cancer and Hematology Centers of Western Michigan | Grand Rapids49503 | NCT06091865 | Map |
| MI | Corewell Health ( Site 0130) | Grand Rapids49503 | NCT06717347 | Map |
| MI | Corewell Health ( Site 0162) | Grand Rapids49503 | NCT05139017 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT03150693 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT06337318 | Map |
| MI | The Cancer and Hematology Centers | Grand Rapids49503-2563 | NCT06943872 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT03150693 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT06337318 | Map |
| MI | Allegiance Health | Jackson49201 | NCT06337318 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT03150693 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT03150693 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06337318 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT03150693 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT06337318 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT04840602 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05976763 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT06337318 | Map |
| MI | McLaren Cancer Institute-Lapeer Region | Lapeer48446 | NCT05976763 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04840602 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT03150693 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05976763 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06337318 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT03150693 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT05976763 | Map |
| MI | McLaren Cancer Institute-Central Michigan | Mount Pleasant48858 | NCT05976763 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT03150693 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT06337318 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT03150693 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT06337318 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT03150693 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT06337318 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT06337318 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT04840602 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT06337318 | Map |
| MI | McLaren Cancer Institute-Northern Michigan | Petoskey49770 | NCT05976763 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT06337318 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT04840602 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT04840602 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT04840602 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT03150693 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05976763 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06337318 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT03150693 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT06337318 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05976763 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04840602 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT05976763 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT03150693 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT06337318 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT06337318 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT06337318 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04840602 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT05976763 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT03150693 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT06337318 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05976763 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT04840602 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT06337318 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT06337318 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT03150693 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT06337318 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT04840602 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT03150693 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT04840602 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT03150693 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05976763 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06337318 | Map |
| MN | Mayo Clinic Health System in Albert Lea | Albert Lea56007 | NCT06834373 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05976763 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05976763 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT06337318 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT06337318 | Map |
| MN | Minnesota Oncology Hematology (MNO) ( Site 8004) | Burnsville55337 | NCT06890884 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05976763 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06337318 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05976763 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06337318 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT03150693 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05976763 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06337318 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06337318 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05976763 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06337318 | Map |
| MN | Mayo Clinic Health Systems-Mankato | Mankato56001 | NCT06834373 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT05976763 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04840602 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT03150693 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05976763 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06337318 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT04840602 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05976763 | Map |
| MN | Masonic Cancer Center | Minneapolis55455 | NCT06792825 | Map |
| MN | Masonic Cancer Center at University of Minnesota | Minneapolis55455 | NCT03579875 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06119685 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06655896 | Map |
| MN | University of Minnesota Health Clinical Research Unit | Minneapolis55455 | NCT03949855 | Map |
| MN | University of Minnesota Masonic Cancer Center | Minneapolis55455 | NCT05735717 | Map |
| MN | University of Minnesota Masonic Cancer Center | Minneapolis55455 | NCT06412497 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT04669171 | Map |
| MN | Mayo Clinic - Rochester | Rochester55905-0001 | NCT04884035 | Map |
| MN | Mayo Clinic Cancer Center | Rochester55905 | NCT07104032 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03418038 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT04840602 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03150693 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06337318 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06834373 | Map |
| MN | Mayo Clinic in Rochester, Minnesota | Rochester55905 | NCT06090539 | Map |
| MN | Mayo Clinic Rochester | Rochester55905-0001 | NCT06943872 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT05976763 | Map |
| MN | HealthPartners Cancer Research Center | Saint Louis Park55426 | NCT04884035 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04840602 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05976763 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06337318 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04840602 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05976763 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06337318 | Map |
| MN | United Hospital | Saint Paul55102 | NCT04840602 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05976763 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06337318 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05976763 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06337318 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT06337318 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05976763 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06337318 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT05976763 | Map |
| MS | Hattiesburg Clinic | Hattiesburg39401 | NCT06149286 | Map |
| MS | Hattiesburg Clinic Hematology/Oncology | Hattiesburg39401-7233 | NCT06911502 | Map |
| MS | The University of Mississippi Medical Center ( Site 0161) | Jackson39216 | NCT06717347 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06337318 | Map |
| MO | Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166) | Bridgeton63044 | NCT06717347 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04840602 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05976763 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT06337318 | Map |
| MO | Saint Luke's Hospital | Chesterfield63017 | NCT05976763 | Map |
| MO | Saint Luke's Hospital | Chesterfield63017 | NCT06337318 | Map |
| MO | St. Luke's Hospital | Chesterfield63017 | NCT06084936 | Map |
| MO | St. Luke's Hospital - Chesterfield /ID# 260489 | Chesterfield63017 | NCT06191744 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT04609046 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT03150693 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05976763 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06337318 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT04609046 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT03150693 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05976763 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06337318 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT06337318 | Map |
| MO | Childrens Mercy Hosp & Clinics | Kansas City64108 | NCT05533775 | Map |
| MO | Kansas City Veterans Affairs Medical Center | Kansas City64128 | NCT05976763 | Map |
| MO | Kansas City Veterans Affairs Medical Center | Kansas City64128 | NCT06337318 | Map |
| MO | Truman Medical Center ( Site 0122) | Kansas City64108 | NCT06717347 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT05976763 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT06337318 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT05886036 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT05976763 | Map |
| MO | University of Kansas Cancer Center - Briarcliff | Kansas City64116 | NCT06337318 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT05886036 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT05976763 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT06337318 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT05886036 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT05976763 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT06337318 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT04840602 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT06337318 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT05976763 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05976763 | Map |
| MO | Oncology Hematology Associates | Springfield65807-5288 | NCT06846671 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT03150693 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04840602 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT03150693 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05976763 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT06337318 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT04609046 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05976763 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06337318 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT04609046 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT03150693 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05976763 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06337318 | Map |
| MO | Washington University | St Louis63130 | NCT06390956 | Map |
| MO | Washington University | St Louis63110 | NCT06854003 | Map |
| MO | Washington University in St. Louis | St Louis63110 | NCT03949855 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT04609046 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT03150693 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05976763 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06040320 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06337318 | Map |
| MO | Washington University School of Medicine in St. Louis | St Louis63110-1010 | NCT07015242 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT06337318 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT06337318 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT03150693 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05976763 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06337318 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT03150693 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05976763 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06337318 | Map |
| MT | Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178) | Billings59102 | NCT06717347 | Map |
| MT | Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006 | Billings59102 | NCT06191744 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT04840602 | Map |
| MT | St. Vincent Frontier Cancer Center-Research ( Site 0108) | Billings59102 | NCT05139017 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT03150693 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05976763 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06337318 | Map |
| MT | Bozeman Health Deaconess Hospital ( Site 0183) | Bozeman59715 | NCT06890884 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT03150693 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05976763 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06337318 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT03150693 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05976763 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06337318 | Map |
| MT | Community Medical Center | Missoula59804 | NCT03150693 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05976763 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06337318 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT03150693 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05976763 | Map |
| NE | Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506 | Grand Island68803 | NCT06191744 | Map |
| NE | Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188) | Grand Island68803 | NCT05139017 | Map |
| NE | Fred and Pamela Buffett Cancer Center - Kearney | Kearney68845 | NCT05976763 | Map |
| NE | NHO - Nebraska Hematology-Oncology /ID# 269692 | Lincoln68506 | NCT06191744 | Map |
| NE | NHO Revive Research Institute, LLC ( Site 0121) | Lincoln68506 | NCT06890884 | Map |
| NE | Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505 | Omaha68130 | NCT06191744 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT03150693 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05976763 | Map |
| NE | Oncology Hematology West, Pc Dba Nebraska Cancer Specialists | Omaha68130-2042 | NCT06846671 | Map |
| NE | Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177) | Omaha68130 | NCT05139017 | Map |
| NE | University of Nebraska | Omaha68198 | NCT03949855 | Map |
| NE | University of Nebraska - Fred and Pamela Buffet Center | Omaha68198 | NCT04884035 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03414502 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03150693 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05976763 | Map |
| NE | University Of Nebraska Medical Center ( Site 0110) | Omaha68198 | NCT06890884 | Map |
| NE | University of Nebraska Medical Center /ID# 261996 | Omaha68198 | NCT06191744 | Map |
| NV | Comprehensive Cancer Centers of Nevada ( Site 0113) | Las Vegas89169 | NCT06717347 | Map |
| NV | Comprehensive Cancer Centers of Nevada ( Site 0168) | Las Vegas89169 | NCT05139017 | Map |
| NV | OptumCare Cancer Care ( Site 0121) | Las Vegas89102 | NCT06717347 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT03150693 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT06337318 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT03150693 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT06337318 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT06084936 | Map |
| NH | Dartmouth Cancer Center | Lebanon03756 | NCT06149286 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05976763 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06337318 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) | Basking Ridge07920 | NCT06561360 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge (Consent only) | Basking Ridge07920 | NCT05736419 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06756308 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT04840602 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05886036 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT07231952 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06765317 | Map |
| NJ | Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) | Basking Ridge07920 | NCT06756308 | Map |
| NJ | Hackensack Meridian Health (Data collection only) | Hackensack07601 | NCT06765317 | Map |
| NJ | Research Site | Hackensack07601 | NCT06564038 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT06337318 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT06337318 | Map |
| NJ | Memoral Sloan Kettering Monmouth | Middletown07748 | NCT07231952 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT04840602 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05886036 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Consent only) | Middletown07748 | NCT05736419 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown07748 | NCT06756308 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06561360 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06765317 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT04840602 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05886036 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT07231952 | Map |
| NJ | Memorial Sloan Kettering Bergen (Consent only) | Montvale07645 | NCT05736419 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06561360 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06756308 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06765317 | Map |
| NJ | Atlantic Health Morristown Medical Center ( Site 0163) | Morristown07960 | NCT06890884 | Map |
| NJ | Research Site | New Brunswick08901 | NCT06564038 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT04998669 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05786040 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT06084936 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT06091865 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT06337318 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT07015242 | Map |
| NJ | Valley Health Systems - Ridgewood Campus ( Site 0125) | Paramus07652 | NCT06890884 | Map |
| NJ | Sidney Kimmel Comprehensive Cancer Center Washington Twp | Sewell08080 | NCT06943872 | Map |
| NJ | Atlantic Health Overlook Medical Center | Summit07901 | NCT07104032 | Map |
| NM | Presbyterian Kaseman Hospital /ID# 262451 | Albuquerque87110 | NCT06191744 | Map |
| NM | University of New Mexico /ID# 261083 | Albuquerque87102-4517 | NCT06191744 | Map |
| NM | Presbyterian Rust Jorgensen Cancer ( Site 9506) | Rio Rancho87124 | NCT05139017 | Map |
| NM | Presbyterian Rust Medical Center /ID# 262447 | Rio Rancho87124 | NCT06191744 | Map |
| NM | Christus St Vincent Regional Cancer Center | Santa Fe87505 | NCT06943872 | Map |
| NY | New York Oncology Hematology, P.C. ( Site 0129) | Albany12206 | NCT06717347 | Map |
| NY | Erie County Medical Center ( Site 0175) | Buffalo14215 | NCT06890884 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT03150693 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05976763 | Map |
| NY | Roswell Park Cancer Institute ( Site 0192) | Buffalo14263 | NCT06890884 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT07015242 | Map |
| NY | Hematology Oncology Associates of CNY at Camillus | Camillus13031 | NCT05976763 | Map |
| NY | Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06765317 | Map |
| NY | Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) | Commack11725 | NCT06561360 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05886036 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack | Commack11725 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (Consent only) | Commack11725 | NCT05736419 | Map |
| NY | Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) | Commack11725 | NCT06756308 | Map |
| NY | North Shore Hematology Oncology Associates | East Setauket11733 | NCT05279300 | Map |
| NY | Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse13057 | NCT05976763 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05886036 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Westchester (All protocol activities) | Harrison10604 | NCT06756308 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT06561360 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT06765317 | Map |
| NY | Memorial Sloan Kettering Westchester (Consent only) | Harrison10604 | NCT05736419 | Map |
| NY | Northwell Health - Monter Cancer Center /ID# 245435 | Lake Success11042 | NCT05283720 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT04609046 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT03150693 | Map |
| NY | North Shore University Hospital | Manhasset11030 | NCT04609046 | Map |
| NY | North Shore University Hospital | Manhasset11030 | NCT03150693 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05976763 | Map |
| NY | NYU Langone Hospital - Long Island /ID# 265531 | Mineola11501 | NCT06191744 | Map |
| NY | Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208) | Mineola11501 | NCT06890884 | Map |
| NY | Long Island Jewish Medical Center | New Hyde Park11040 | NCT03150693 | Map |
| NY | Columbia U. - Herbert Irving Comprehensive Cancer Center | New York10032 | NCT05279300 | Map |
| NY | Columbia University | New York10032 | NCT07226843 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT06954805 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT07104032 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT04679012 | Map |
| NY | Columbia University Medical Center: Division of Nephrology | New York10032 | NCT03949855 | Map |
| NY | Hospital for Special Surgery | New York10021 | NCT03844061 | Map |
| NY | Icahn School of Medicine at Mount Sinai ( Site 0164) | New York10029 | NCT06717347 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 242123 | New York10029 | NCT05283720 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 259595 | New York10029 | NCT06191744 | Map |
| NY | Icahn School of Medicine at Mount Sinai Hospital | New York10029 | NCT05783609 | Map |
| NY | Icahn School of Medicine at Mt Sinai | New York10029 | NCT06091254 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05976763 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108) | New York10016 | NCT06890884 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04421560 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT06563596 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05886036 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06090539 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06854003 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT07015242 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07104032 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06561360 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06765317 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06846671 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06943872 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT03150693 | Map |
| NY | Mount Sinai- Icahn School of Medicine | New York10029 | NCT04679012 | Map |
| NY | MSKCC | New York10065 | NCT05533775 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT04609046 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT04609046 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT03150693 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT05976763 | Map |
| NY | NYU Langone Health | New York10016 | NCT07104032 | Map |
| NY | NYU Langone Medical Center /ID# 264518 | New York10016-6402 | NCT06191744 | Map |
| NY | Research Site | New York10029 | NCT06564038 | Map |
| NY | Weill Cornell Medicine | New York10065 | NCT04679012 | Map |
| NY | University of Rochester | Rochester14642 | NCT03758989 | Map |
| NY | University of Rochester | Rochester14642 | NCT04840602 | Map |
| NY | University of Rochester | Rochester14642 | NCT03150693 | Map |
| NY | University of Rochester | Rochester14642 | NCT05976763 | Map |
| NY | University of Rochester | Rochester14642 | NCT06084936 | Map |
| NY | University of Rochester | Rochester14642 | NCT06337318 | Map |
| NY | University of Rochester | Rochester14618 | NCT07226843 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT05783609 | Map |
| NY | University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) | Rochester14642 | NCT04669171 | Map |
| NY | Memorial Sloan Kettering Nassau (All protocol activities) | Rockville Centre11553 | NCT05736419 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Rockville Centre11553 | NCT06765317 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06091254 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06091865 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06149286 | Map |
| NY | SUNY Upstate Cancer Center ( Site 0178) | Syracuse13210 | NCT06890884 | Map |
| NY | New York Oncology Hematology /ID# 270208 | Troy12180 | NCT06191744 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT04840602 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05886036 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT07231952 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited protocol activities) | Uniondale11553 | NCT06756308 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06561360 | Map |
| NY | New York Medical College ( Site 0113) | Valhalla10595 | NCT05139017 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05976763 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT06337318 | Map |
| NY | Clinical Research Alliance | Westbury11590 | NCT06351527 | Map |
| NY | Clinical Research Alliance - Westbury /ID# 261078 | Westbury11590 | NCT06191744 | Map |
| NY | Clinical Research Alliance ( Site 0122) | Westbury11590 | NCT06890884 | Map |
| NY | Clinical Research Alliance, Inc | Westbury11590-5119 | NCT06846671 | Map |
| NY | Clinical Research Alliance, Inc | Westbury11590-5119 | NCT06943872 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT04609046 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05976763 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06337318 | Map |
| NC | University of North Carolina | Chapel Hill27514 | NCT06091254 | Map |
| NC | University of North Carolina At Chapel Hill | Chapel Hill27514-4220 | NCT06943872 | Map |
| NC | University of North Carolina Medical Center ( Site 0136) | Chapel Hill27514 | NCT06890884 | Map |
| NC | University of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney Center | Chapel Hill27599- | NCT03949855 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT06337318 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT06337318 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04626791 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04840602 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06337318 | Map |
| NC | Levine Cancer Center | Charlotte28204-2990 | NCT06943872 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT04884035 | Map |
| NC | Levine Cancer Institute | Charlotte28207 | NCT06091254 | Map |
| NC | Levine Cancer Institute-SouthPark | Charlotte28211 | NCT06337318 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT06337318 | Map |
| NC | Novant Health Presbyterian Medical Center ( Site 0177) | Charlotte28204 | NCT06890884 | Map |
| NC | Novant Health Presbyterian Medical Center /ID# 259740 | Charlotte28204 | NCT06191744 | Map |
| NC | Research Site | Charlotte28204 | NCT06564038 | Map |
| NC | Wake Forest University at Clemmons | Clemmons27012 | NCT06337318 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT06337318 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT06337318 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06091865 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06337318 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT07104032 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT06337318 | Map |
| NC | East Carolina University | Greenville27834 | NCT03150693 | Map |
| NC | East Carolina University | Greenville27834 | NCT06091865 | Map |
| NC | East Carolina University - Brody School of Medicine /ID# 242506 | Greenville27834 | NCT05283720 | Map |
| NC | University of North Carolina-Hillsborough Campus | Hillsborough27278 | NCT05786040 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04840602 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT06337318 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT04840602 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT06337318 | Map |
| NC | Novant Health Cancer Institute - Mooresville | Mooresville28117 | NCT06337318 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT04884035 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT06119685 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT06943872 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT06337318 | Map |
| NC | Novant Health Forsyth Medical Center ( Site 0206) | Winston-Salem27103 | NCT06890884 | Map |
| NC | Novant Health Forsyth Medical Center /ID# 259741 | Winston-Salem27103 | NCT06191744 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT03150693 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05886036 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06337318 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05976763 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05976763 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT06337318 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05976763 | Map |
| ND | Sanford Health Roger Maris Cancer Center ( Site 0189) | Fargo58102 | NCT06717347 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05976763 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT05533775 | Map |
| OH | Oncology Hematology Care Clinical Trials, Llc | Cincinnati45245-1995 | NCT06943872 | Map |
| OH | Oncology Hematology Care, Inc - Blue Ash /ID# 261204 | Cincinnati45252 | NCT06191744 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT03150693 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT05886036 | Map |
| OH | University of Cincinnati Medical Center ( Site 0156) | Cincinnati45219 | NCT06890884 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT03150693 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT03949855 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT07015242 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT03150693 | Map |
| OH | Cleveland Clinic Main ( Site 0101) | Cleveland44195 | NCT06890884 | Map |
| OH | Fairview Hospital-Moll Cancer Center ( Site 0198) | Cleveland44111 | NCT06890884 | Map |
| OH | University Hospitals | Cleveland44106-1716 | NCT06846671 | Map |
| OH | University Hospitals Cleveland | Cleveland44106 | NCT06119685 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06091254 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06091865 | Map |
| OH | University Hospitals of Cleveland ( Site 0155) | Cleveland44106 | NCT06890884 | Map |
| OH | James Cancer Hospital | Columbus43210 | NCT06655896 | Map |
| OH | Ohio state University | Columbus43210 | NCT04679012 | Map |
| OH | Ohio State University | Columbus43210 | NCT06561360 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04609046 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03150693 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05786040 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05886036 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05976763 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06209619 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06337318 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06965114 | Map |
| OH | Ohio State University Wexner Medical Center: Division of Nephrology | Columbus43210 | NCT03949855 | Map |
| OH | Research Site | Columbus43210 | NCT06564038 | Map |
| OH | The Ohio State University (OSU) | Columbus43210 | NCT07226843 | Map |
| OH | The Ohio State University Comprehensive Cancer Center | Columbus43202-2224 | NCT07015242 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT06563596 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT05783609 | Map |
| OH | Dayton Physician Network | Dayton45415 | NCT06846671 | Map |
| OH | Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199) | Mayfield Heights44124 | NCT06890884 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT04840602 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT03150693 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT05886036 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT05976763 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04609046 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT03150693 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05886036 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05976763 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06337318 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT05976763 | Map |
| OR | Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene97401 | NCT06846671 | Map |
| OR | Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene97401 | NCT06943872 | Map |
| OR | Oncology Associates of Oregon, P.C. /ID# 261816 | Eugene97401 | NCT06191744 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04840602 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT03150693 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05976763 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06337318 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT03150693 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05976763 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT06337318 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04840602 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05976763 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06337318 | Map |
| OR | Kaiser Permanente Northwest | Portland97227 | NCT06337318 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT03150693 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06337318 | Map |
| OR | Oregon Health and Science University ( Site 5425) | Portland97239-3011 | NCT05947851 | Map |
| OR | Oregon Health Sciences University | Portland97239 | NCT06655896 | Map |
| OR | Providence Neurological Specialties West | Portland97225 | NCT07104032 | Map |
| OR | Providence Oncology and Hematology Clinic Westside ( Site 0179) | Portland97225 | NCT06890884 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04840602 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT03150693 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05976763 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06337318 | Map |
| OR | Providence Portland Medical Center ( Site 0120) | Portland97213 | NCT06890884 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04840602 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT03150693 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05976763 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06337318 | Map |
| OR | Research Site | Portland97239 | NCT06564038 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT03150693 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT03150693 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033 | NCT06943872 | Map |
| PA | Alliance Cancer Specialists (ACS) ( Site 8001) | Horsham19044 | NCT05139017 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06337318 | Map |
| PA | Research Site | Philadelphia19104 | NCT06564038 | Map |
| PA | Temple University Hospital ( Site 0133) | Philadelphia19140 | NCT06890884 | Map |
| PA | Thomas Jefferson University | Philadelphia19107-4216 | NCT06943872 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT03150693 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06337318 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT06973096 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT07015242 | Map |
| PA | University of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension Division | Philadelphia19104 | NCT03949855 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT03150693 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT03500731 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15213 | NCT03630211 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT03653338 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team | Pittsburgh15224 | NCT00692939 | Map |
| PA | Research Site | Pittsburgh15232 | NCT06564038 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT06965114 | Map |
| PA | University of Pittsburgh Medical Center | Pittsburgh15261 | NCT03630211 | Map |
| PA | University of Pittsburgh Medical Center | Pittsburgh15261 | NCT03630211 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT07104032 | Map |
| PA | Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh15232-1309 | NCT06943872 | Map |
| PA | UPMC Prebyterian- Adult Gastroenterology | Pittsburgh15213 | NCT00692939 | Map |
| PA | UPMC Presbyterian | Pittsburgh15214 | NCT03500731 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT06846671 | Map |
| PA | Alliance Cancer Specialists (ACS) ( Site 8010) | Sellersville18960 | NCT06890884 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT06337318 | Map |
| PA | Cancer Care Associates of York | York17403-5049 | NCT06846671 | Map |
| PA | Cancer Care Associates Of York ( Site 0174) | York17403 | NCT06890884 | Map |
| RI | Research Site | Providence02903 | NCT06564038 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT04609046 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT03150693 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05976763 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06119685 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06337318 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT07104032 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT05976763 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05976763 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT04609046 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05976763 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06337318 | Map |
| SC | Medical University of South Carolina ( Site 0153) | Charleston29425 | NCT06890884 | Map |
| SC | MUSC Hollings Cancer Center /ID# 259604 | Charleston29425 | NCT06191744 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05976763 | Map |
| SC | Prisma Health - Upstate ( Site 0158) | Greenville29605 | NCT06717347 | Map |
| SC | Prisma Health /ID# 259602 | Greenville29605 | NCT06191744 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05976763 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05976763 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05976763 | Map |
| SC | Prisma Health Greenville Memorial Hospital | Greenville29605 | NCT03150693 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT03150693 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05976763 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT03150693 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05976763 | Map |
| SD | Avera Cancer | Sioux Falls57105 | NCT06655896 | Map |
| SD | Sanford Cancer Center ( Site 0143) | Sioux Falls57104 | NCT06717347 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05976763 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05976763 | Map |
| TN | Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga | Chattanooga37404 | NCT06943872 | Map |
| TN | Tennessee Cancer Specialists ( Site 7000) | Knoxville37909 | NCT05139017 | Map |
| TN | Tennessee Cancer Specialists ( Site 7004) | Knoxville37909 | NCT06890884 | Map |
| TN | The University of Tennessee Medical Center ( Site 0142) | Knoxville37920 | NCT06717347 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06337318 | Map |
| TN | St Jude Children's Research Hospital | Memphis38105 | NCT04318678 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT04318678 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT07226843 | Map |
| TN | Sarah Cannon Research Institute - Tristar Centennial Medical Center /ID# 274985 | Nashville37203 | NCT06191744 | Map |
| TN | Sarah Cannon Research Institute Oncology Partners | Nashville37203 | NCT07015242 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06119685 | Map |
| TN | SCRI Oncology Partners ( Site 7002) | Nashville37203 | NCT06890884 | Map |
| TN | Tennessee Oncology | Nashville37205 | NCT06943872 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06091254 | Map |
| TN | Vanderbilt University Medical Center | Nashville37212 | NCT07226843 | Map |
| TX | Texas Oncology - West Texas ( Site 8008) | Amarillo79124 | NCT06890884 | Map |
| TX | Texas Oncology - Austin Midtown /ID# 261208 | Austin78705 | NCT06191744 | Map |
| TX | Texas Oncology - Central/South Texas | Austin78705 | NCT06911502 | Map |
| TX | Texas Oncology - Central/South Texas ( Site 8006) | Austin78705 | NCT06890884 | Map |
| TX | BUMC - Mary Crowley Cancer Research Centers (MCCRC) | Dallas75201-7307 | NCT05279300 | Map |
| TX | Texas Oncology Baylorcharles A Sammons Cancer Center | Dallas75246-2003 | NCT06943872 | Map |
| TX | Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206 | Dallas75246-2003 | NCT06191744 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06561347 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT04609046 | Map |
| TX | Renovatio Clinical - El Paso | El Paso79915 | NCT06084936 | Map |
| TX | Center for Oncology and Blood Disorders | Houston77030 | NCT06091254 | Map |
| TX | Center for Oncology and Blood Disorders ( Site 0153) | Houston77030 | NCT06717347 | Map |
| TX | Houston Methodist Cancer Center ( Site 0154) | Houston77030 | NCT06717347 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT03150693 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04745949 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04022239 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT02727803 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT02877303 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT00412594 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03136146 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT01371630 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04216524 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05645718 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05683171 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT06045247 | Map |
| TX | MD Anderson Cancer Center | Houston77003 | NCT04884035 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06263491 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07015242 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07257055 | Map |
| TX | MD Anderson Cancer Center /ID# 260984 | Houston77030-4000 | NCT06191744 | Map |
| TX | Oncology Consultants /ID# 268390 | Houston77030 | NCT06191744 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06119685 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT05886036 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT06337318 | Map |
| TX | Joe Arrington Cancer Research /ID# 260382 | Lubbock79410 | NCT06191744 | Map |
| TX | Texas Oncology - Northeast Texas ( Site 8002) | Palestine75801 | NCT06890884 | Map |
| TX | Texas Oncology - San Antonio ( Site 8009) | San Antonio78240 | NCT06890884 | Map |
| TX | Texas Oncology San Antonio Medical Center Usor | San Antonio78240-5251 | NCT06943872 | Map |
| TX | University Hospital System | San Antonio78228 | NCT06977711 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT06337318 | Map |
| TX | University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center | San Antonio78229 | NCT06977711 | Map |
| TX | Renovatio Clinical | The Woodlands77380 | NCT06084936 | Map |
| TX | Texas Oncology | Tyler75702 | NCT05618925 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT06911502 | Map |
| TX | Texas Oncology Tyler | Tyler75702-7522 | NCT06846671 | Map |
| TX | Texas Oncology Tyler | Tyler75702-7522 | NCT06943872 | Map |
| UT | Intermountain Medical Center ( Site 0182) | Murray84107 | NCT06890884 | Map |
| UT | Intermountain Medical Oncology | Murray84107 | NCT04884035 | Map |
| UT | Community Cancer Trials of Utah | Ogden84405 | NCT06091865 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05786040 | Map |
| UT | Huntsman Cancer Institute - Oncology Division | Salt Lake City84112 | NCT06091254 | Map |
| UT | Huntsman Cancer Institute at University of Utah | Salt Lake City84112 | NCT06390956 | Map |
| UT | Huntsman Cancer Institute at University of Utah | Salt Lake City84112 | NCT06607549 | Map |
| UT | Huntsman Cancer Institute at University of Utah | Salt Lake City84112 | NCT06788964 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT03150693 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05886036 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05976763 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06337318 | Map |
| UT | Intermountain Healthcare LDS Hospital /ID# 259759 | Salt Lake City84143 | NCT06191744 | Map |
| UT | LDS Hospital | Salt Lake City84143 | NCT06655896 | Map |
| UT | Intermountain Cancer Center - St George | St. George84790 | NCT04884035 | Map |
| UT | Intermountain Healthcare - St. George ( Site 0203) | St. George84790 | NCT06890884 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT05976763 | Map |
| VA | University of Virginia | Charlottesville22906 | NCT06084936 | Map |
| VA | University of Virginia | Charlottesville22908 | NCT06091254 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22903 | NCT03523975 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05886036 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06337318 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06965114 | Map |
| VA | University of Virginia Cancer Center ( Site 0138) | Charlottesville22903 | NCT06717347 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT06119685 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 261205 | Fairfax22031 | NCT06191744 | Map |
| VA | Hematology Oncology Associates of Fredericksburg | Fredericksburg22408 | NCT06911502 | Map |
| VA | Virginia Cancer Specialists, PC ( Site 8003) | Manassas20110 | NCT06890884 | Map |
| VA | VCU Health Adult Outpatient Pavillion ( Site 0138) | Richmond23219 | NCT06890884 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05976763 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT06337318 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT04840602 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT03150693 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05886036 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05976763 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06337318 | Map |
| VA | Virginia Cancer Institute ( Site 0148) | Richmond23229 | NCT06717347 | Map |
| VA | Blue Ridge Cancer Care | Roanoke24014 | NCT06911502 | Map |
| VA | Blue Ridge Cancer Care ( Site 0132) | Roanoke24014 | NCT06717347 | Map |
| VA | Blue Ridge Cancer Care ( Site 0169) | Roanoke24014 | NCT05139017 | Map |
| VA | Oncology and Hematology Associates of Southwest Virginia /ID# 261592 | Roanoke98684 | NCT06191744 | Map |
| WA | Swedish Cancer Institute - Edmonds /ID# 266356 | Edmonds98026 | NCT06191744 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04840602 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05976763 | Map |
| WA | Swedish Cancer Institute - Issaquah /ID# 266358 | Issaquah98029 | NCT06191744 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04840602 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05976763 | Map |
| WA | Vista Oncology - East Olympia /ID# 261360 | Olympia98506-5028 | NCT06191744 | Map |
| WA | Vista Oncology ( Site 4201) | Olympia98506 | NCT06717347 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT04231877 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT05455697 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT06738368 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT06839053 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT07097363 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT07224100 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT07015242 | Map |
| WA | Swedish Medical Center - Seattle /ID# 242269 | Seattle98104 | NCT05283720 | Map |
| WA | Swedish Medical Center - Seattle /ID# 260370 | Seattle98104 | NCT06191744 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04840602 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05976763 | Map |
| WA | University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance) | Seattle98195 | NCT07226843 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT04626791 | Map |
| WA | University of Washington-Seattle Cancer Care Alliance | Seattle98109 | NCT04669171 | Map |
| WA | Virginia Mason Hospital & Medical Center /ID# 260549 | Seattle98101 | NCT06191744 | Map |
| WA | Medical Oncology Associates, PS ( Site 5406) | Spokane99208 | NCT05947851 | Map |
| WA | Providence Medical Research Center, Providence Health Care: Nephrology | Spokane99204 | NCT03949855 | Map |
| WA | Northwest Medical Specialties - Tacoma /ID# 262133 | Tacoma98405 | NCT06191744 | Map |
| WA | Research Site | Tacoma98405 | NCT05952024 | Map |
| WA | Northwest Cancer Specialist, Pc(Us Oncology Research) | Vancouver98684-6930 | NCT06943872 | Map |
| WA | Northwest Cancer Specialists (Compass Oncology) ( Site 8000) | Vancouver98684 | NCT06890884 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT06337318 | Map |
| WV | West Virginia University | Morgantown26506 | NCT06084936 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT04609046 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT04840602 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05976763 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT06337318 | Map |
| WI | ThedaCare Regional Medical Center - Appleton | Appleton54911 | NCT05976763 | Map |
| WI | ThedaCare Regional Medical Center - Appleton | Appleton54911 | NCT06337318 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05976763 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06337318 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04609046 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05976763 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT06337318 | Map |
| WI | Mayo Clinic Health System-Eau Claire Clinic | Eau Claire54701 | NCT06834373 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Johnson Creek | Johnson Creek53038 | NCT05976763 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04609046 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04840602 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05976763 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06337318 | Map |
| WI | Mayo Clinic Health System-Franciscan Healthcare | La Crosse54601 | NCT06834373 | Map |
| WI | SSM Health Dean Medical Group ( Site 0106) | Madison53715 | NCT06890884 | Map |
| WI | SSM Health Dean Medical Group ( Site 0140) | Madison53715 | NCT06717347 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT03150693 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05976763 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT03150693 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05976763 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04609046 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT03150693 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05976763 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT06337318 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT06337318 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT03150693 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05783609 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05976763 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06337318 | Map |
| WI | Medical College of Wisconsin ( Site 0103) | Milwaukee53226 | NCT06890884 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT04609046 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05976763 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05976763 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06337318 | Map |
| WI | Froedtert and MCW Moorland Reserve Health Center | New Berlin53151 | NCT05976763 | Map |
| WI | Froedtert and MCW Moorland Reserve Health Center | New Berlin53151 | NCT06337318 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT06337318 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05976763 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06337318 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05976763 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04609046 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05976763 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06337318 | Map |
| WI | Prohealth Care Inc | Waukesha53188 | NCT06149286 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06337318 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05976763 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06337318 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT06337318 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04609046 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05976763 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06337318 | Map |
Rituximab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 3 | 9 | 3 | 2 | 1 | 18 | |||||
| P1 | 23 | 26 | 123 | 45 | 11 | 2 | 5 | 11 | 246 | ||
| P1/P2 | 32 | 20 | 102 | 38 | 12 | 1 | 10 | 16 | 231 | ||
| P2 | 126 | 69 | 2 | 451 | 134 | 42 | 2 | 20 | 104 | 950 | |
| P2/P3 | 4 | 4 | 28 | 2 | 2 | 1 | 5 | 46 | |||
| P3 | 52 | 43 | 170 | 42 | 15 | 1 | 8 | 36 | 367 | ||
| P4 | 12 | 40 | 6 | 2 | 2 | 15 | 77 | ||||
| N/A | 10 | 2 | 1 | 64 | 6 | 6 | 6 | 22 | 1 | 118 |
Recruiting Rituximab clinical trials (314)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04196413 | DIPGGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) | P1 | Glioma of Spinal Cord | 97 | Jun 2020 |
| NCT06973096 | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | P1 | Glioblastoma | 9 | Jul 2025 |
| NCT06986382 | Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease | P1/P2 | Crohn Disease | 14 | Jul 2025 |
| NCT06854003 | BRAZANBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 60 | Apr 2025 |
| NCT05976763 | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | P3 | Mantle Cell Lymphoma | 421 | Oct 2023 |
| NCT06191744 | EPCORE™FL-2Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | P3 | Follicular Lymphoma (FL) | 1,095 | Feb 2024 |
| NCT07220187 | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial | P3 | Richter Syndrome | 102 | Aug 2026 |
| NCT06412497 | MT2023-20MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. | P2 | Severe Aplastic Anemia | 60 | Jun 2024 |
| NCT05947851 | VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | P3 | Leukemia, Lymphocytic, Chronic, B-Cell | 735 | Aug 2023 |
| NCT05508009 | Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor | P1/P2 | SIOD | 12 | Jan 2023 |
| NCT04669171 | SIDNEYA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma | P1/P2 | Follicular Lymphoma | 80 | Jul 2021 |
| NCT06284122 | MorningLyteStudy of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | P3 | Follicular Lymphoma | 790 | Jun 2024 |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | P2 | Clonal Cytopenia of Undetermined Significance | 80 | Mar 2018 |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | P1/P2 | B-cell Lymphoma | 150 | May 2026 |
| NCT05991388 | Glo-BNHLA Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | P2/P3 | B-cell Non Hodgkin Lymphoma | 210 | May 2024 |
| NCT05099471 | VIWA-1Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | P2 | Waldenstrom Macroglobulinemia | 80 | Mar 2025 |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | P1/P2 | Non Hodgkin Lymphoma | 48 | Feb 2026 |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma (MCL) | 50 | Apr 2025 |
| NCT07285590 | IMCL-2023Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma (MCL) | 50 | Sep 2025 |
| NCT06688331 | PreTregTreatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody | P2 | Presymptomatic Diabetes Type 1 (Stage 1) | 150 | Mar 2025 |
| NCT06390956 | PIONEER-MZLPirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | P2 | Marginal Zone Lymphoma | 23 | Feb 2025 |
| NCT06890884 | MK-2140A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | P2 | Lymphoma, Large B-Cell, Diffuse | 594 | Apr 2025 |
| NCT05533775 | iMATRIX GLOA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | P1/P2 | Mature B-Cell Non-Hodgkin Lymphoma | 65 | Nov 2022 |
| NCT05283720 | SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | P2 | Non-Hodgkin Lymphoma | 496 | Jun 2022 |
| NCT06644183 | IOA-244Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | P1/P2 | Leukemia | 64 | Mar 2025 |
| NCT06006117 | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | P3 | Marginal Zone Lymphoma | 260 | Sep 2023 |
| NCT06655896 | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | P2 | Scleroderma, Diffuse | 96 | Oct 2024 |
| NCT07137481 | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies | P2 | Hematological Malignancies | 70 | Feb 2027 |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | P2 | Chronic Lymphocytic Leukemia | 30 | Jun 2025 |
| NCT07259122 | ZBR in WMA Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia | P2 | Waldenström Macroglobulinemia (WM) | 43 | Dec 2025 |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | P3 | Mantle Cell Lymphoma | 476 | May 2024 |
| NCT05389423 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | P1 | Diffuse Large Cell Lymphoma | 25 | Jun 2023 |
| NCT06040320 | RPolatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) | P1/P2 | Post-transplant Lymphoproliferative Disorder | 12 | Oct 2023 |
| NCT05898308 | RITUX4Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus | P4 | Pemphigus | 133 | Dec 2024 |
| NCT07294677 | CAVALRYCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | P1/P2 | Leukemia | 104 | Mar 2026 |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | P3 | Classic Follicular Lymphoma | 600 | Oct 2024 |
| NCT06717347 | MK-2140A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | P3 | Diffuse Large B-Cell Lymphoma | 1,046 | Jan 2025 |
| NCT07509840 | REFINEImmunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency | P3 | Autoimmune Prematur Ovarian Insuffience | 40 | Feb 2026 |
| NCT06943872 | CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | P3 | Chronic Lymphocytic Leukemia | 630 | Jun 2025 |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | P1 | Aggressive Non-Hodgkin Lymphoma | 56 | Oct 2020 |
| NCT05848765 | REFRACTRelapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | P2 | Relapsed Follicular Lymphoma | 284 | Sep 2023 |
| NCT06510309 | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma | P2 | Lymphoma | 33 | Feb 2026 |
| NCT06341205 | iRITUXPersonalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) | P3 | Membranous Nephropathy | 120 | Feb 2025 |
| NCT06792825 | HM2023-43HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | P2 | Follicular Lymphoma | 65 | Aug 2025 |
| NCT07573436 | PLUTOLoncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) | P1/P2 | Post-transplant Lymphoproliferative Disorder | 23 | Jun 2026 |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | P2 | Marginal Zone Lymphoma(MZL) | 169 | Aug 2025 |
| NCT07299331 | Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma | N/A | Marginal Zone Lymphoma(MZL) | 50 | Jan 2026 |
| NCT07415980 | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL | P1/P2 | Double Expressor DLBCL | 68 | Apr 2026 |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | P2 | Non-Hodgkin's Lymphoma | 132 | Aug 2019 |
| NCT07517185 | HiHatThe HIt HArd and hiT Early in Multiple Sclerosis Trial | P2 | Relapsing-remitting Multiple Sclerosis | 60 | Apr 2026 |
| NCT06682169 | Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease | P3 | Graft-versus-host Disease | 182 | Nov 2024 |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | P2 | Diffuse Large B-cell Lymphoma | 80 | Sep 2024 |
| NCT06607549 | SOLARLoncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) | P1 | Central Nervous System Lymphoma | 12 | Mar 2025 |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | P2 | Hematologic Malignancy | 70 | May 2023 |
| NCT07257055 | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study | P2 | Phase 2 Study | 30 | Apr 2026 |
| NCT07335562 | Breakfree-SScA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis | P3 | Systemic Sclerosis | 92 | Aug 2026 |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 29 | Nov 2025 |
| NCT07189325 | DESIRE MSA Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis | P3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | 250 | Sep 2025 |
| NCT04518475 | ITPEltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults | P4 | Primary Immune Thrombocytopenia (ITP) | 224 | Aug 2020 |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | P2 | Recurrent Diffuse Large B-Cell Lymphoma | 25 | Jul 2025 |
| NCT04998669 | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | P2 | Follicular Lymphoma | 100 | Feb 2022 |
| NCT06911502 | GOLSEEK-4A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | P3 | Follicular Lymphoma | 400 | Jul 2025 |
| NCT06045247 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | Large B-cell Lymphoma | 40 | Jan 2024 |
| NCT04318678 | CATCHAMLCD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | P1 | AML/MDS | 108 | Jul 2020 |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | P1/P2 | Leukemia, Lymphocytic, Chronic, B-Cell | 132 | Sep 2024 |
| NCT07233720 | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma | — | Marginal Zone Lymphoma | 30 | Nov 2025 |
| NCT05100862 | MAHOGANYA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | P3 | Relapsed/Refractory Follicular Lymphoma | 780 | Mar 2022 |
| NCT07010302 | BEST-NMOSDRituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | P4 | NMOSD | 540 | May 2026 |
| NCT07097363 | EPOCH-REpcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | P2 | B-Cell Non-Hodgkin Lymphoma | 18 | Dec 2025 |
| NCT05758831 | TRIORItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. | P3 | Multiple Sclerosis | 386 | Jun 2023 |
| NCT05545384 | IDARImmediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial | P3 | Acute Demyelinating Syndrome | 86 | Apr 2025 |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | P1 | CNS Lymphoma | 20 | Apr 2025 |
| NCT06835530 | FIL_RICCOA Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) | P2 | Diffuse Large B Cell Non-Hodgkin Lymphoma | 47 | Apr 2025 |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | P1/P2 | Recurrent Mantle Cell Lymphoma | 58 | Dec 2026 |
| NCT06788964 | CORALLoncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) | P2 | Relapsed or Refractory Large B-cell Lymphoma | 29 | Aug 2025 |
| NCT06336395 | Ma-Spore ALL 2020 Study | P2 | B Lymphoblastic Leukemia | 500 | Mar 2020 |
| NCT04061512 | RAINBOWRituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia | P2/P3 | Waldenstrom Macroglobulinemia | 148 | Feb 2020 |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | P1/P2 | Hairy Cell Leukemia | 84 | May 2026 |
| NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | P2 | Follicular Lymphoma | 45 | Jan 2025 |
| NCT03949855 | REBOOTBelimumab With Rituximab for Primary Membranous Nephropathy | P2 | Membranous Nephropathy | 58 | Mar 2020 |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | P1 | Lymphoma, Non-Hodgkin's | 460 | Apr 2026 |
| NCT07451847 | PREP-ANCAComparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. | P4 | ANCA Associated Vasculitis (AAV) | 70 | Feb 2026 |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | P2 | Follicular Lymphoma | 100 | Jun 2023 |
| NCT06082102 | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma | P3 | Relapsed/Refractory Marginal Zone Lymphoma | 324 | Dec 2023 |
| NCT06846671 | CaDAnCe-302A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | P3 | CLL | 250 | Apr 2025 |
| NCT07448324 | Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL | P2 | Marginal Zone Lymphoma(MZL) | 50 | Apr 2025 |
| NCT07104032 | IGNITEIGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | P3 | Relapsed/Refractory Primary Central Nervous System Lymphoma | 132 | Jun 2026 |
| NCT07594899 | GUIDANCE-10AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | P2 | Large B-Cell Lymphoma (LBCL) | 178 | May 2026 |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | P2 | Primary Central Nervous System Lymphoma (PCNSL) | 50 | Feb 2026 |
| NCT07418190 | Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma | P2 | Relapsed/Refractory Follicular Lymphoma | 33 | Feb 2026 |
| NCT07051915 | The Holistic Study | P3 | Thrombocytopenia Purpura | 220 | Sep 2025 |
| NCT07139873 | TAI-SHAN6A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | P3 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 250 | Sep 2025 |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P3 | DLBCL | 244 | May 2024 |
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | P1 | B-cell Non-Hodgkin Lymphoma | 112 | Apr 2024 |
| NCT06190301 | RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma | N/A | Primary Ocular Adnexal MALT Lymphoma | 108 | Dec 2023 |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | P1/P2 | NHL | 128 | Oct 2023 |
| NCT05645718 | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | P2 | Leukemia | 27 | Jul 2023 |
| NCT06134284 | Clinical Study of OR for Second-line Treatment of Refractory MZL | P4 | OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | 39 | Jan 2023 |
| NCT04745728 | Different Immunosuppressive Treatment in iMN | P3 | Idiopathic Membranous Nephropathy | 200 | Apr 2021 |
| NCT07493148 | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | P2 | Diffuse Large B-Cell Lymphoma (DLBCL) | 50 | Apr 2026 |
| NCT07389356 | Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL | N/A | DLBCL - Diffuse Large B Cell Lymphoma | 70 | Feb 2026 |
| NCT06742502 | Si-RiSintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL | P2 | Primary Mediastinal Diffuse Large B-cell Lymphoma | 30 | Nov 2024 |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 134 | Jun 2025 |
| NCT06946407 | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | N/A | Primary Central Nervous System Lymphoma (PCNSL) | 41 | Dec 2022 |
| NCT04989491 | REPLYEvaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft | P4 | Epstein-Barr Virus Infections | 120 | Dec 2021 |
| NCT06970743 | CaDAnCe-303A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors | P3 | Chronic Lymphocytic Leukemia | 150 | May 2025 |
| NCT06091254 | OLYMPIA-1A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | P3 | Follicular Lymphoma (FL) | 822 | Dec 2023 |
| NCT06973811 | ZR-MTXZR-MTX for PIOL Phase II Trial | P2 | Primary Intraocular Lymphoma | 47 | May 2025 |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | P1/P2 | Diffuse Large B Cell Lymphoma (DLBCL) | 97 | Jul 2025 |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 43 | Apr 2026 |
| NCT07550855 | FLOURISHSonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma | P2 | Follicular Lymphoma (FL) | 52 | Sep 2026 |
| NCT07608731 | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | P1 | Large B-cell Lymphoma | 18 | Jun 2026 |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | P2 | Lymphoma | 41 | Apr 2023 |
| NCT06091865 | OLYMPIA-3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | P3 | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | Dec 2023 |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | P2 | Marginal Zone Lymphoma(MZL) | 51 | Mar 2025 |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | P1/P2 | PCNSL | 43 | Aug 2024 |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | P3 | Diffuse Large B-Cell Lymphoma | 100 | Jul 2024 |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | P2 | Non-Hodgkin's B-cell Lymphoma | 20 | Jul 2026 |
| NCT07185373 | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | P2/P3 | Primary Central Nervous System Lymphoma | 215 | Oct 2025 |
| NCT06504940 | MZLOptimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) | P2 | Marginal Zone Lymphoma | 69 | Jun 2024 |
| NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | P3 | Follicular Lymphoma (FL) | 93 | May 2026 |
| NCT07350850 | PRIME-PCNSLA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL | P2 | PCNSL | 77 | Dec 2025 |
| NCT06342544 | IMCOMGImmediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. | P3 | Ocular Myasthenia Gravis | 128 | Apr 2025 |
| NCT06792253 | Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 416 | Jan 2025 |
| NCT06564038 | Soundtrack-EA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | P1/P2 | Chronic Lymphocytic Leukaemia | 408 | Jan 2025 |
| NCT06942507 | BRZ-WMZanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia | N/A | Waldenström's Macroglobulinemia (WM) | 104 | May 2025 |
| NCT05952024 | ACRUEStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 80 | Jul 2024 |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | P2 | Diffuse Large B Cell Lymphoma | 528 | Oct 2024 |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | P3 | Primary Mediastinal Lymphoma | 100 | Apr 2022 |
| NCT04871191 | SATELITEStudy of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis | P3 | Granulomatosis With Polyangiitis | 42 | Jun 2025 |
| NCT06350318 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | P2 | Follicular Lymphoma | 43 | Apr 2024 |
| NCT05249959 | FIL_COLUMNConsolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. | P2 | Relapsed Mantle Cell Lymphoma | 49 | Mar 2022 |
| NCT03414502 | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response | P3 | Rheumatoid Arthritis | 400 | Dec 2007 |
| NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 53 | Oct 2025 |
| NCT07029139 | A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy | P2 | Primary Membranous Nephropathy | 156 | Jun 2025 |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | P3 | Follicular Lymphoma | 228 | Nov 2025 |
| NCT06983821 | SAFE-LOWSafe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) | P3 | Granulomatosis With Polyangiitis | 36 | Nov 2025 |
| NCT06149286 | OLYMPIA-5A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | P3 | Relapsed/Refractory Follicular Lymphoma | 470 | Dec 2023 |
| NCT06549231 | EVER-ILD 3Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis | P3 | Interstitial Lung Disease With Systemic Sclerosis | 102 | Jan 2025 |
| NCT03579875 | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders | P2 | Fanconi Anemia | 48 | Nov 2018 |
| NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | P2 | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | Apr 2026 |
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | P2 | Diffuse Large B-Cell Lymphoma (DLBCL) | 150 | Nov 2025 |
| NCT07002099 | Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study | P2 | Lymphomas | 26 | Jun 2025 |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 152 | Apr 2025 |
| NCT06581562 | IRIS-RD-01Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. | P1 | Rheumatoid Arthritis | 30 | May 2024 |
| NCT05998642 | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | P2 | Non-hodgkin Lymphoma | 30 | Feb 2024 |
| NCT06031233 | MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | Oncology | 776 | Sep 2023 |
| NCT05136976 | THERAMAGRituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders | P3 | Anti-MAG Neuropathy | 90 | Jun 2023 |
| NCT05207358 | GLUREDLUPMinimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis | P4 | Lupus Nephritis | 30 | Mar 2022 |
| NCT04784052 | Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab | P1/P2 | Fanconi Anemia | 18 | Dec 2021 |
| NCT04856137 | DLBLA Phase I/II Study of Diffuse Large B-cell Lymphoma | P1/P2 | Refractory Diffuse Large B-cell Lymphoma | 74 | May 2021 |
| NCT03500731 | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | P1/P2 | Idiopathic Pulmonary Fibrosis | 8 | Apr 2018 |
| NCT01419561 | KICSNatural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) | P2 | KSHV Inflammatory Cytokine Syndrome (KICS) | 140 | Sep 2011 |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | P2 | Diffuse Large B-Cell Lymphoma (DLBCL) | 58 | Jan 2026 |
| NCT07405255 | ZillionZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma | P2 | Central Nervous System Lymphoma | 19 | Jan 2026 |
| NCT07029737 | SOUND-MCLA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain | P2 | Mantle-cell Lymphoma | 55 | Sep 2025 |
| NCT06220032 | HO170DLBCLPrevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | P3 | DLBCL - Diffuse Large B Cell Lymphoma | 324 | Aug 2024 |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | P2 | Lymphoma | 65 | Nov 2025 |
| NCT05004064 | CARAMELAcalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 48 | Nov 2023 |
| NCT04323566 | Ra-P-OCDRituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement | P2 | Obsessive-Compulsive Disorder | 40 | May 2022 |
| NCT04884035 | CC-220Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | P1 | Lymphoma, B-Cell | 224 | Sep 2021 |
| NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma | P1/P2 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 51 | May 2026 |
| NCT07234019 | ITPRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 160 | Jan 2026 |
| NCT04627753 | Lemon-CStudy of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. | P2 | Primary CNS Lymphoma | 30 | Nov 2020 |
| NCT06714838 | ReCIXRituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy | P3 | CIDP | 100 | Oct 2024 |
| NCT05635162 | ZEBRAZanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 50 | May 2024 |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | P1/P2 | Relapsed/Refractory Non-Hodgkin Lymphoma | 308 | Dec 2023 |
| NCT06611696 | ARRIAAvacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis | P4 | ANCA Associated Vasculitis (AAV) | 160 | Nov 2024 |
| NCT06647732 | MALTZanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | P2 | Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | 42 | Oct 2024 |
| NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | P2 | Mantle Cell Lymphoma (MCL) | 25 | Sep 2025 |
| NCT07269639 | Go-Pro-DLBCLGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma | P1/P2 | Large B-Cell Lymphoma (LBCL) | 20 | Jan 2026 |
| NCT07169565 | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia | P1 | Waldenström Macroglobulinemia (WM) | 21 | Sep 2025 |
| NCT06554600 | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | Refractory or Relapsed Diffuse Large B Cell Lymphoma | 36 | Aug 2024 |
| NCT06319456 | APG-2575A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | P3 | CLL/SLL | 344 | Apr 2024 |
| NCT04989621 | RR FLOrelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) | P2 | Follicular Lymphoma | 32 | Aug 2021 |
| NCT04496037 | MOT-AMRMechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant | — | Transplant; Complication, Rejection | 170 | Sep 2020 |
| NCT04626791 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 45 | Aug 2021 |
| NCT07614282 | Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia | P1 | PTLD | 28 | Jul 2026 |
| NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma | P2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | 33 | Mar 2026 |
| NCT06738368 | DA-EPOCHEtoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia | P2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 30 | May 2026 |
| NCT07073833 | The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma | P1 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | 40 | Jul 2025 |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | P2 | Mantle Cell Lymphoma (MCL) | 45 | Jul 2025 |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | P1/P2 | Combination Therapy | 115 | Mar 2026 |
| NCT05018520 | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk | P3 | Diffuse Large B Cell Lymphoma | 640 | Sep 2021 |
| NCT06414148 | EpLCARTMRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma | P2 | Relapsed/Refractory Large B-cell Lymphoma | 40 | May 2024 |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | P2 | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma | 35 | Dec 2026 |
| NCT06468943 | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | P2 | Effects of Chemotherapy | 20 | Jul 2023 |
| NCT06954805 | PTLDDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) | P2 | Lymphoma | 30 | Apr 2025 |
| NCT07231952 | WMA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | P2 | Waldenstrom Macroglobulinemia | 40 | Nov 2025 |
| NCT07362238 | ITPDaratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 122 | Mar 2026 |
| NCT07041268 | Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab | P2 | Diabetes Mellitus, Type 1 | 116 | Apr 2024 |
| NCT06084936 | GLOBRYTEA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | P3 | Lymphoma | 182 | Oct 2023 |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | P2 | Lymphoplasmacytic Lymphoma | 92 | Jan 2022 |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | P2 | Lymphoma | 24 | Jun 2025 |
| NCT06530004 | Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children | — | Nephrotic Syndrome | 50 | Mar 2020 |
| NCT07168161 | BDB-001 Phase III Trial in ANCA-Associated Vasculitis | P3 | ANCA Associated Vasculitis (AAV) | 300 | Nov 2025 |
| NCT06832267 | RMTTRituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | N/A | Primary Central Nervous System Lymphoma | 44 | Feb 2025 |
| NCT05600686 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | P2 | Double-Expressor Lymphoma | 24 | May 2023 |
| NCT06929624 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | P3 | Diffuse Large B-cell Lymphoma | 280 | Apr 2025 |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | P2 | Diffuse Large B Cell Lymphoma (DLBCL) | 42 | Jan 2025 |
| NCT05615974 | A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | P1/P2 | Malignant Tumors | 139 | Jan 2023 |
| NCT03952637 | A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis | P1/P2 | Lysosomal Diseases | 54 | Aug 2019 |
| NCT07225439 | NHLRituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | P1 | Non Hodgkin Lymphoma | 15 | Dec 2025 |
| NCT06676631 | NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis | P1 | Refractory Systemic Lupus Erythematosus | 18 | Feb 2025 |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 152 | Dec 2024 |
| NCT06756308 | A Study of Enasidenib in People With T-Cell Lymphoma | P2 | T-cell Lymphoma | 25 | Dec 2024 |
| NCT06046248 | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease | P2 | Chronic Graft Versus Host Disease | 25 | Jan 2024 |
| NCT06003283 | RITUXERATapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis | P4 | Rheumatoid Arthritis | 134 | Jan 2024 |
| NCT05786768 | OBIRINSEfficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome | P2/P3 | Steroid-Dependent Nephrotic Syndrome | 88 | Oct 2023 |
| NCT05914155 | PRIMEClinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome | P3 | Glomerulonephritis, Membranous | 88 | Jun 2023 |
| NCT05786040 | Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder | P2 | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder | 28 | Mar 2023 |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | P2 | Primary Central Nervous System Lymphoma | 28 | Aug 2022 |
| NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | P1 | Advanced Solid Tumor | 480 | Mar 2022 |
| NCT00692939 | Autologous Stem Cell Transplantation for Crohn's Disease | P1/P2 | Crohn's Disease | 20 | Jun 2012 |
| NCT00977977 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | P2 | Nephrotic Syndrome | 30 | Dec 2010 |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | P2 | Follicular Lymphoma | 20 | Dec 2024 |
| NCT06254560 | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | P2 | Severe Aplastic Anemia | 20 | Feb 2023 |
| NCT04758975 | VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) | P2 | Chronic Lymphocytic Leukemia (CLL) | 55 | Sep 2022 |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | P1/P2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | 276 | Aug 2011 |
| NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial | P2 | Marginal Zone Lymphoma(MZL) | 90 | Dec 2024 |
| NCT06561347 | ZEBRAZanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | P2 | Waldenstrom Macroglobulinemia | 56 | Dec 2024 |
| NCT07297563 | ITPAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 160 | Jan 2026 |
| NCT07001540 | DLBCLEvaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation | P2 | Diffuse Large B-Cell Lymphoma | 130 | May 2025 |
| NCT05338190 | RITUX-PLUS 2Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia | P3 | Primary Immune Thrombocytopenia (ITP) | 132 | Nov 2022 |
| NCT06136351 | A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | Lymphoma, Mantle-Cell | 23 | Nov 2023 |
| NCT06952413 | Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | P2 | Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | 30 | Apr 2025 |
| NCT06351527 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | P1 | Mature B-cell Malignancies | 78 | Apr 2024 |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | P2 | Diffuse Large B Cell Lymphoma | 30 | Oct 2023 |
| NCT06064344 | RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma | N/A | Primary Ocular Adnexal MALT Lymphoma | 108 | Oct 2023 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | Rheumatic Disease | 80 | Sep 2025 |
| NCT05683171 | A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma | P1/P2 | Lymphoma | 60 | May 2023 |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | P2 | Richter Syndrome | 20 | Sep 2021 |
| NCT05139017 | MK-2140A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | P2/P3 | DLBCL | 290 | Jan 2022 |
| NCT06561360 | HCLA Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | P2 | Hairy Cell Leukemia | 86 | Sep 2024 |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | P1 | Acute Lymphoblastic Leukemia | 15 | May 2019 |
| NCT07444710 | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | P1 | Ann Arbor Stage II Mantle Cell Lymphoma | 16 | Aug 2026 |
| NCT07270835 | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | P4 | Hemophagocytic Lymphohistiocytosis | 40 | Nov 2025 |
| NCT04913103 | CLSGMCLPOLAStudy of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL | P2 | Lymphoma, Mantle-Cell | 21 | Sep 2021 |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | P3 | B Acute Lymphoblastic Leukemia | 310 | Sep 2017 |
| NCT04745949 | PACIFICPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | P2 | Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | 31 | May 2021 |
| NCT03653338 | SCDT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias | P1/P2 | Sickle Cell Anemia | 5 | Aug 2018 |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | P2 | Recurrent Acute Lymphoblastic Leukemia | 42 | Aug 2017 |
| NCT07206823 | Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | N/A | Primacy Immune Thrombocytopenia | 30 | Sep 2025 |
| NCT04022239 | Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant | P1/P2 | Hematopoietic and Lymphoid System Neoplasm | 25 | Mar 2020 |
| NCT06594640 | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P1/P2 | Diffuse Large B-cell Lymphoma | 108 | May 2024 |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | P3 | Lymphoma, Large B-Cell, Diffuse | 428 | Aug 2024 |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | P3 | Mantle Cell Lymphoma (MCL) | 78 | Jul 2024 |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | P1/P2 | Diffuse Large B-Cell Lymphoma | 35 | Jan 2023 |
| NCT07057778 | Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP | P2 | Immune Thrombocytopenia (ITP) | 120 | Jul 2025 |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | P1 | Lymphoma | 15 | Oct 2024 |
| NCT06362967 | The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT | P2 | High Titers of Anti-HLA Antibody (MFI ≥5000) | 30 | May 2024 |
| NCT06047171 | RENAL-F02Rescue of Nephrons With ALE.F02 (RENAL-F02) | P2 | Glomerulonephritis Rapidly Progressive | 80 | Sep 2023 |
| NCT00412594 | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia | P2 | Hairy Cell Leukemia | 150 | Jun 2004 |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | P1/P2 | Mantle Cell Lymphoma | 28 | Dec 2018 |
| NCT06478472 | ORProspective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy | N/A | Marginal Zone Lymphoma | 36 | Jun 2024 |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | P2 | Ann Arbor Stage II Follicular Lymphoma | 30 | Jul 2024 |
| NCT03758989 | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | P2 | DLBCL | 40 | May 2019 |
| NCT06489808 | Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL | P2 | Relapsed/Refractory Large B-Cell Lymphoma | 89 | May 2024 |
| NCT05834855 | Noisy RebelsNon-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | P3 | Multiple Sclerosis | 200 | Apr 2023 |
| NCT03899337 | STELLARA Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | P2 | Richter Syndrome | 105 | Jul 2019 |
| NCT02727803 | Personalized NK Cell Therapy in CBT | P2 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | 100 | May 2016 |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | P2 | Mantle-cell Lymphoma | 16 | Jan 2024 |
| NCT05583071 | MTR²Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | P2 | Non-Hodgkin Lymphoma | 20 | Aug 2024 |
| NCT07081022 | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma | P2 | B-cell Non-Hodgkin's Lymphoma | 180 | Aug 2025 |
| NCT04609046 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | P1 | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 47 | May 2021 |
| NCT07362199 | ITPAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 20 | Mar 2026 |
| NCT05618925 | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | P1 | Non Hodgkin's Lymphoma Refractory/Relapsed | 20 | Aug 2025 |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | P2 | Large B-Cell Lymphoma With IRF4 Rearrangement | 41 | Apr 2025 |
| NCT06921044 | A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 33 | Apr 2025 |
| NCT06263491 | PRPhase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | P2 | Mantle Cell Lymphoma | 50 | May 2024 |
| NCT06981988 | YY-20394A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL | P1/P2 | Relapsed/Refractory Indolent NHL | 80 | Jun 2025 |
| NCT05736419 | HCTA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | P2 | Sickle Cell Disease | 24 | Feb 2023 |
| NCT06572618 | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 27 | Jan 2025 |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | P1/P2 | Primary Central Nervous System Lymphoma | 37 | Aug 2020 |
| NCT05514015 | Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy | P4 | Primary Membranous Nephropathy | 78 | Mar 2024 |
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | P2 | Advanced Hepatocellular Carcinoma | 20 | Mar 2024 |
| NCT06410833 | BRRPJSBelimumab After Rituximab in Resistant Primary Juvenile SS | P4 | Sjogren's Syndrome | 15 | Mar 2024 |
| NCT06209619 | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | P1 | B-Cell Non-Hodgkin Lymphoma-Recurrent | 18 | Jan 2024 |
| NCT05698147 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | P1/P2 | Central Nervous System Lymphoma | 30 | Aug 2023 |
| NCT05280626 | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP | P2 | Diffuse Large B-Cell Lymphoma | 100 | Mar 2022 |
| NCT04432714 | Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement | P1/P2 | DLBCL | 81 | Jun 2020 |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | P2 | Blastic Plasmacytoid Dendritic Cell Neoplasm | 40 | May 2020 |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | — | Newly Diagnosed Mantle Cell Lymphoma | 100 | Aug 2022 |
| NCT05850546 | Rituximab in the First Episode of Paediatric Nephrotic Syndrome | P3 | Steroid-Sensitive Nephrotic Syndrome | 138 | Mar 2025 |
| NCT05946486 | TIM-DePisTEvaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity. | P3 | Mental Disorder | 174 | Oct 2023 |
| NCT05057468 | Second-line Treatment of Primary Autoimmune Hemolytic Anemia | P3 | Primary Autoimmune Hemolytic Anemia | 30 | Oct 2021 |
| NCT02877303 | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | P2 | B Acute Lymphoblastic Leukemia | 80 | Nov 2016 |
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial | P2 | Nodular Lymphocyte Predominant B-Cell Lymphoma | 70 | Jan 2024 |
| NCT06086197 | A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | P2 | Diffuse Large B-cell Lymphoma Recurrent | 41 | Oct 2023 |
| NCT05581030 | ALLCalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | P1 | Acute Lymphoblastic Leukemia | 7 | May 2023 |
| NCT05728658 | The Study of ICP-248 in Patients With Mature B-cell Malignancies | P1 | Hematological Malignancies | 191 | Mar 2023 |
| NCT06599307 | The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis | P2 | Secondary Progressive Multiple Sclerosis (SPMS) | 46 | Aug 2024 |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | P1/P2 | Indolent B-Cell Non-Hodgkin Lymphoma | 140 | May 2018 |
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL | N/A | Diffuse Large B-cell Lymphoma (DLBCL) | 30 | Sep 2024 |
| NCT06530511 | PROPolatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | P2 | Diffuse Large B Cell Lymphoma | 30 | Aug 2024 |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | N/A | Diffuse Large B-cell Lymphoma | 20 | Sep 2023 |
| NCT05690191 | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | — | Diffuse Large B-cell Lymphoma | 169 | Jun 2021 |
| NCT03630211 | SScAutologous Stem Cell Transplantation in Patients With Systemic Sclerosis | P2 | Systemic Sclerosis | 8 | Jul 2018 |
| NCT06906549 | RADAREvaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis | P4 | Rheumatoid Arthritis (RA) | 260 | Jul 2025 |
| NCT06977711 | DLBCLLoncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | P1 | Diffuse Large B-cell Lymphoma | 10 | Jun 2025 |
| NCT05734794 | STORMStudy of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial | P3 | Nephrotic Syndrome in Children | 80 | Feb 2023 |
| NCT05596786 | EvER-ILD2Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial | P3 | Lung Diseases | 126 | Jan 2023 |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | N/A | Diffuse Large B Cell Lymphoma | 35 | Jan 2023 |
| NCT05843968 | Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome | P2 | Nephrotic Syndrome in Children | 46 | Jan 2023 |
| NCT03274375 | IANMDARImmunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis | P2 | Anti-NMDAR Encephalitis | 20 | Jun 2021 |
| NCT03844061 | Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis | P2 | Systemic Sclerosis | 30 | Jul 2019 |
| NCT03697356 | BallondorR-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia | P2 | Waldenström's Macroglobulinemia | 54 | Mar 2019 |
| NCT06683885 | A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma | P1/P2 | Newly Diagnosed Diffuse Large B-cell Lymphoma | 80 | Nov 2024 |
| NCT04737889 | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | P2 | Primary Central Nervous System Lymphoma | 30 | Jan 2021 |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | P2 | DLBCL Germinal Center B-Cell Type | 50 | Jul 2022 |
| NCT04920968 | OVERALLObinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" | P2 | CD20-positive Acute Lymphoblastic Leukemia | 124 | Oct 2021 |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | P1/P2 | Chronic Lymphocytic Leukemia | 123 | Aug 2020 |
| NCT05914662 | ZBRZanubrutinib Plus BR in Newly Diagnosed Symptomatic WM | P2 | Waldenstrom Macroglobulinemia | 42 | Feb 2023 |
| NCT05868837 | REFINERituximab EfFicacy IN MyasthEnia Gravis (REFINE) | P3 | Myasthenia Gravis, Generalized | 40 | Feb 2022 |
Rituximab clinical trials by indication
Lymphoma (224)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06510309 | — | P2 | recruiting | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma |
| NCT01415752 | — | P2 | active not recruiting | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT05800366 | — | P2 | recruiting | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma |
| NCT07015242 | — | P2 | recruiting | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma |
| NCT06954805 | PTLD | P2 | recruiting | Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) |
| NCT06084936 | GLOBRYTE | P3 | recruiting | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma |
| NCT06557330 | — | P2 | not yet recruiting | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma |
| NCT05683171 | — | P1/P2 | recruiting | A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma |
| + 216 more, see All trials below. | ||||
Chronic Lymphocytic Leukemia (81)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06839053 | — | P2 | recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma |
| NCT06943872 | CELESTIAL-RRCLL | P3 | recruiting | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) |
| NCT05624554 | — | P3 | active not recruiting | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) |
| NCT02339922 | — | P2 | active not recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma |
| NCT04843904 | SAVE | P1 | active not recruiting | Safe Accelerated Venetoclax Escalation in CLL |
| NCT06970743 | CaDAnCe-303 | P3 | recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors |
| NCT05023980 | BRUIN CLL-313 | P3 | active not recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
| NCT04965493 | BRUIN CLL-322 | P3 | active not recruiting | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
| + 73 more, see All trials below. | ||||
Leukemia (69)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06644183 | IOA-244 | P1/P2 | recruiting | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) |
| NCT07294677 | CAVALRY | P1/P2 | recruiting | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL |
| NCT05645718 | — | P2 | recruiting | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia |
| NCT01446133 | CLL-SLL | P2 | active not recruiting | Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) |
| NCT01085617 | UKALL14 | N/A | completed | Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT01027000 | — | P2 | completed | Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT01319981 | — | P2 | completed | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia |
| NCT02423915 | GVHD | P1 | completed | Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention |
| + 61 more, see All trials below. | ||||
Rheumatoid Arthritis (68)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03414502 | — | P3 | recruiting | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response |
| NCT06581562 | IRIS-RD-01 | P1 | recruiting | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. |
| NCT06003283 | RITUXERA | P4 | recruiting | Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis |
| NCT06475495 | COMPARE | P1/P2 | active not recruiting | Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis |
| NCT06175338 | — | P1 | active not recruiting | Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis |
| NCT04680962 | MABRIDGE | P3 | withdrawn | MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis |
| NCT02304354 | LYRITUX | P3 | completed | Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX) |
| NCT02468791 | — | P3 | completed | MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis |
| + 60 more, see All trials below. | ||||
Non-Hodgkin's Lymphoma (64)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04002947 | — | P2 | recruiting | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma |
| NCT05191225 | — | P4 | unknown | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study |
| NCT02611323 | FL | P1/P2 | completed | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT01332968 | RO5072759 | P3 | completed | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) |
| NCT00712582 | — | P2 | completed | Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma |
| NCT01594229 | BR | P1 | completed | A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| NCT02453087 | — | P1 | completed | A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
| NCT02624986 | FL | P1/P2 | terminated | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants |
| + 56 more, see All trials below. | ||||
Follicular Lymphoma (59)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04669171 | SIDNEY | P1/P2 | recruiting | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma |
| NCT06284122 | MorningLyte | P3 | recruiting | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
| NCT03361852 | — | P1 | active not recruiting | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma |
| NCT05867030 | — | P1 | withdrawn | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma |
| NCT06792825 | HM2023-43 | P2 | recruiting | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL |
| NCT04998669 | — | P2 | recruiting | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma |
| NCT06911502 | GOLSEEK-4 | P3 | recruiting | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) |
| NCT05058404 | — | P3 | active not recruiting | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
| + 51 more, see All trials below. | ||||
Diffuse Large B-Cell Lymphoma (56)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06717347 | MK-2140 | P3 | recruiting | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) |
| NCT05578976 | EPCORE DLBCL-2 | P3 | active not recruiting | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT06522555 | — | P3 | recruiting | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma |
| NCT05952024 | ACRUE | P2 | recruiting | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL |
| NCT06803693 | — | P2 | recruiting | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL |
| NCT03984448 | — | P2/P3 | active not recruiting | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas |
| NCT06508658 | EPCORE DLBCL-4 | P3 | active not recruiting | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT06441097 | — | P2 | not yet recruiting | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL |
| + 48 more, see All trials below. | ||||
Mantle Cell Lymphoma (47)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06854003 | BRAZAN | P2 | recruiting | BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma |
| NCT05976763 | — | P3 | recruiting | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT04849715 | CITADEL-310 | P3 | withdrawn | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma |
| NCT06363994 | — | P3 | recruiting | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
| NCT01661881 | — | P2 | active not recruiting | Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma |
| NCT02682641 | — | P2 | active not recruiting | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL |
| NCT06522386 | GATE1 | P2 | active not recruiting | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT05004064 | CARAMEL | P2 | recruiting | Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma |
| + 39 more, see All trials below. | ||||
Diffuse Large B Cell Lymphoma (42)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05934097 | — | P1 | withdrawn | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma |
| NCT06516978 | — | P2 | not yet recruiting | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL |
| NCT05018520 | — | P3 | recruiting | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk |
| NCT06176729 | — | P2 | recruiting | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients |
| NCT04542824 | EPCORE™ NHL-3 | P1/P2 | active not recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) |
| NCT03943901 | — | P2 | active not recruiting | Split-Dose R-CHOP for Older Adults With DLBCL |
| NCT05221645 | P+R-ICE | P2 | active not recruiting | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT06530511 | PRO | P2 | recruiting | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL |
| + 34 more, see All trials below. | ||||
Diffuse Large B-cell Lymphoma (33)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06664411 | — | P2 | recruiting | Pola-ZR2P in Previously Untreated DLBCL |
| NCT06929624 | — | P3 | recruiting | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma |
| NCT04824092 | frontMIND | P3 | active not recruiting | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients |
| NCT06594640 | — | P1/P2 | recruiting | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma |
| NCT04404283 | ECHELON-3 | P3 | active not recruiting | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL |
| NCT05990985 | — | N/A | not yet recruiting | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. |
| NCT05690191 | — | N/A | enrolling by invitation | Chidamide in Patients With Recurrent and Refractory Diffuse Large b |
| NCT06977711 | DLBCL | P1 | recruiting | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) |
| + 25 more, see All trials below. | ||||
Lymphoma, Non-Hodgkin (30)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03930953 | — | P1/P2 | active not recruiting | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) |
| NCT03366272 | NIVEAU | P2/P3 | completed | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients |
| NCT01996865 | MAGNIFY | P3 | completed | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. |
| NCT02626455 | CHRONOS-4 | P3 | terminated | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) |
| NCT04074330 | — | P1/P2 | terminated | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma |
| NCT01938001 | AUGMENT | P3 | completed | Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) |
| NCT00324467 | LYTPET | P2 | unknown | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment |
| NCT02703272 | — | P3 | terminated | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma |
| + 22 more, see All trials below. | ||||
Lymphoma, Large B-Cell, Diffuse (19)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06890884 | MK-2140 | P2 | recruiting | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) |
| NCT05798156 | R-Pola-Glo | P2 | active not recruiting | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
| NCT06573645 | — | P3 | not yet recruiting | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL |
| NCT05186558 | — | P2 | unknown | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL |
| NCT05923879 | — | N/A | unknown | Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma |
| NCT04790903 | R | P1 | terminated | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT04021992 | — | P2 | unknown | GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL |
| NCT02031419 | — | P1 | terminated | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma |
| + 11 more, see All trials below. | ||||
Primary Central Nervous System Lymphoma (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07185373 | — | P2/P3 | not yet recruiting | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL |
| NCT04931368 | OptiMATe | P3 | active not recruiting | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma |
| NCT06541665 | — | P1 | active not recruiting | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL |
| NCT06832267 | RMTT | N/A | recruiting | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL |
| NCT05600660 | — | P2 | recruiting | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma |
| NCT02203526 | TEDDI-R | P1 | active not recruiting | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma |
| NCT04421560 | — | P1/P2 | recruiting | Pembrolizumab, Ibrutinib and Rituximab in PCNSL |
| NCT05549284 | RMO | P2 | unknown | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) |
| + 9 more, see All trials below. | ||||
Lymphocytic Leukemia, Chronic (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01292603 | — | P1 | completed | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia |
| NCT02053610 | CLL11 | P3 | completed | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) |
| NCT01998880 | CLL11 | P3 | completed | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) |
| NCT01010061 | CLL11 | P3 | completed | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) |
| NCT01263704 | — | P2 | completed | A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia |
| NCT01271010 | — | P4 | terminated | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status |
| NCT01283386 | — | P4 | terminated | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status |
| NCT01609023 | CaLLypso | N/A | completed | A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia |
| + 9 more, see All trials below. | ||||
Marginal Zone Lymphoma (14)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06390956 | PIONEER-MZL | P2 | recruiting | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) |
| NCT06006117 | — | P3 | recruiting | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
| NCT07233720 | — | N/A | recruiting | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma |
| NCT06504940 | MZL | P2 | recruiting | Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) |
| NCT03474744 | — | P2 | active not recruiting | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients |
| NCT06478472 | OR | N/A | recruiting | Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy |
| NCT03697512 | MALIBU | P2 | active not recruiting | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas |
| NCT04212013 | — | P3 | active not recruiting | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma |
| + 6 more, see All trials below. | ||||
Lymphoma, B-Cell (14)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04882163 | CC-220 | P1/P2 | withdrawn | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma |
| NCT04884035 | CC-220 | P1 | recruiting | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma |
| NCT04161248 | — | Early P1 | active not recruiting | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma |
| NCT04245722 | — | P1 | terminated | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies |
| NCT04246359 | RIPPLE | P2 | unknown | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma |
| NCT00577629 | — | P2 | completed | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma |
| NCT00634179 | — | P1/P2 | completed | A Phase I/II Trial of VR-CHOP in Lymphoma Patients |
| NCT01421667 | — | P2 | completed | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma |
| + 6 more, see All trials below. | ||||
Lymphoma, Follicular (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06425302 | GOLSEEK-2 | P2 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma |
| NCT00317096 | — | P3 | unknown | FCM Versus R-FCM Followed by R-Maintenance or Observation Only |
| NCT01234766 | Fol-BRITe | P2 | completed | Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma |
| NCT02472756 | REFLECT 2 | N/A | completed | A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma |
| NCT00510887 | — | P2 | terminated | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma |
| NCT02569996 | — | P3 | completed | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma |
| NCT00930514 | — | P1 | completed | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma |
| NCT00193492 | — | P2 | completed | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma |
| + 5 more, see All trials below. | ||||
Acute Lymphoblastic Leukemia (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03571321 | — | P1 | recruiting | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia |
| NCT02003222 | — | P3 | active not recruiting | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia |
| NCT05581030 | ALL | P1 | recruiting | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) |
| NCT05457556 | — | P3 | active not recruiting | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome |
| NCT03856216 | — | P2 | terminated | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation |
| NCT02881086 | — | P3 | completed | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment |
| NCT02960646 | — | P1 | completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT03023046 | — | P2 | completed | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| + 5 more, see All trials below. | ||||
Immune Thrombocytopenia (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07234019 | ITP | P2 | recruiting | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) |
| NCT07362238 | ITP | P2 | recruiting | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) |
| NCT07297563 | ITP | P2 | recruiting | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) |
| NCT07362199 | ITP | P2 | recruiting | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) |
| NCT04588194 | — | P2 | unknown | Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia |
| NCT03443570 | — | P3 | unknown | Rituximab Combining Bortezomib Versus Rituximab in Management of ITP |
| NCT03304288 | — | P2 | unknown | The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia |
| NCT03154385 | RITUX PLUS | N/A | completed | Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia |
| + 4 more, see All trials below. | ||||
Waldenstrom's Macroglobulinemia (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00492050 | — | P2 | active not recruiting | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia |
| NCT02371148 | FIL_BRB | P2 | completed | Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's |
| NCT02400437 | — | P2 | completed | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia |
| NCT01470196 | CaRD | P2 | completed | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia |
| NCT01078974 | — | P1 | terminated | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia |
| NCT01046006 | — | P2 | completed | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia |
| NCT00422799 | WM | P2 | completed | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) |
| NCT01125293 | — | P1/P2 | terminated | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia |
| + 4 more, see All trials below. | ||||
Non Hodgkin Lymphoma (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07222631 | — | P1/P2 | recruiting | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas |
| NCT02180711 | — | P1/P2 | active not recruiting | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma |
| NCT07225439 | NHL | P1 | not yet recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) |
| NCT04673617 | — | P1/P2 | completed | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT05200312 | ZR2-CHOP | P2 | unknown | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma |
| NCT03688451 | — | P2 | active not recruiting | Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma |
| NCT02953509 | — | P1/P2 | terminated | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma |
| NCT03169790 | NHL | P1/P2 | withdrawn | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL |
| + 3 more, see All trials below. | ||||
Waldenstrom Macroglobulinemia (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05099471 | VIWA-1 | P2 | recruiting | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia |
| NCT04624906 | BRAWM | P2 | active not recruiting | Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia |
| NCT04061512 | RAINBOW | P2/P3 | recruiting | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia |
| NCT07231952 | WM | P2 | recruiting | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) |
| NCT06561347 | ZEBRA | P2 | recruiting | Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM |
| NCT03620903 | — | P2 | active not recruiting | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia |
| NCT05914662 | ZBR | P2 | recruiting | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM |
| NCT03630042 | PembroWM | P2 | completed | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia |
| + 3 more, see All trials below. | ||||
Non-Hodgkin Lymphoma (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05283720 | SC | P2 | recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma |
| NCT05583071 | MTR² | P2 | recruiting | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL |
| NCT05171647 | SUNMO | P3 | active not recruiting | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
| NCT01796171 | LYMRIT-37-01 | P1/P2 | completed | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma |
| NCT02406092 | SC | P3 | completed | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A |
| NCT01939327 | R2 | P2 | completed | Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma |
| NCT01097057 | G-CSF | P2 | completed | Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells |
| NCT01181258 | NK | P2 | completed | Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies |
| + 3 more, see All trials below. | ||||
Multiple Sclerosis (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05758831 | TRIO | P3 | recruiting | RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. |
| NCT05834855 | Noisy Rebels | P3 | recruiting | Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS |
| NCT05078177 | — | P1 | unknown | Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis |
| NCT04640818 | — | N/A | unknown | Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy |
| NCT05762003 | CPE | N/A | completed | Czech Pharmaco-epidemiological Study on Disease Modifying Drugs |
| NCT02980042 | — | P3 | completed | Safety of Switching From Rituximab to Ocrelizumab in MS Patients |
| NCT01212094 | — | P1/P2 | terminated | Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) |
| NCT01569451 | GATEWAYII | P2 | completed | Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate |
| + 3 more, see All trials below. | ||||
DLBCL (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06521255 | — | P3 | recruiting | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT05139017 | MK-2140 | P2/P3 | recruiting | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) |
| NCT04974216 | — | P2 | active not recruiting | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older |
| NCT03758989 | — | P2 | recruiting | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma |
| NCT04432714 | — | P1/P2 | recruiting | Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement |
| NCT04594798 | — | P2 | active not recruiting | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL |
| NCT04994626 | — | P2 | unknown | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies |
| NCT04842487 | — | P2 | unknown | R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study |
| + 2 more, see All trials below. | ||||
Central Nervous System Lymphoma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06607549 | SOLAR | P1 | recruiting | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) |
| NCT07405255 | Zillion | P2 | not yet recruiting | Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma |
| NCT03684980 | — | Early P1 | active not recruiting | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma |
| NCT05698147 | — | P1/P2 | recruiting | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL |
| NCT04938297 | — | P2 | unknown | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma |
| NCT01011920 | CNS | P2 | completed | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma |
| NCT04516655 | C-R-HDMTX | P2 | unknown | A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients |
| NCT00293475 | — | P1/P2 | unknown | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma |
| + 1 more, see All trials below. | ||||
Lymphoma, Mantle-Cell (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06136351 | — | P2 | recruiting | A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma |
| NCT04913103 | CLSGMCLPOLA | P2 | not yet recruiting | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL |
| NCT05564052 | VEGA | P2 | completed | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma |
| NCT00209209 | MCLelderly | P3 | unknown | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL |
| NCT00490529 | — | P2 | completed | Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL |
| NCT00209222 | — | P3 | unknown | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL |
| NCT00992134 | R-BAC | P2 | completed | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma |
| NCT00038623 | — | P2 | completed | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma |
| + 1 more, see All trials below. | ||||
Chronic Lymphocytic Leukemia (CLL) (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04758975 | VALUABLE | P2 | recruiting | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) |
| NCT04285567 | CRISTALLO | P3 | completed | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation |
| NCT03788291 | — | P2 | completed | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma |
| NCT02914938 | — | P1 | terminated | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma |
| NCT01723839 | FCR | P2 | completed | Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide |
| NCT01203930 | — | P2 | terminated | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL |
| NCT01466153 | CLL | P2 | completed | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
| NCT01754870 | CLL | P2 | withdrawn | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) |
| + 1 more, see All trials below. | ||||
Non-Hodgkins Lymphoma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00856245 | — | P2 | completed | Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma |
| NCT01290549 | — | P1 | completed | A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma |
| NCT00807196 | — | P1/P2 | unknown | Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma |
| NCT00574730 | — | N/A | completed | CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma |
| NCT00193479 | — | P2 | completed | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma |
| NCT00193440 | — | P2 | completed | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma |
| NCT00193466 | — | P2 | completed | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT00301301 | GEM-P | N/A | completed | A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) |
| + 1 more, see All trials below. | ||||
Follicular Lymphoma (FL) (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06191744 | EPCORE™FL-2 | P3 | recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT05888493 | LEDA | P3 | active not recruiting | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma |
| NCT05409066 | EPCORE FL-1 | P3 | active not recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma |
| NCT06091254 | OLYMPIA-1 | P3 | recruiting | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT07550855 | FLOURISH | P2 | not yet recruiting | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma |
| NCT06097364 | OLYMPIA-2 | P3 | active not recruiting | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma |
| NCT07562022 | — | P3 | not yet recruiting | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma |
| NCT04745832 | ME-401 | P3 | terminated | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) |
B-cell Lymphoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07520006 | — | P1/P2 | not yet recruiting | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies |
| NCT05270057 | LONCA | P1 | active not recruiting | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies |
| NCT05379647 | NK | P1 | unknown | Natural Killer (NK) Cell Therapy for B-Cell Malignancies |
| NCT03424122 | CITADEL-112 | P1 | completed | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) |
| NCT02741388 | SELINDA | P1 | completed | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP |
| NCT02933320 | — | P1/P2 | completed | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia |
| NCT00895661 | — | P2 | completed | High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas |
| NCT00486759 | — | P3 | terminated | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma |
Recurrent Diffuse Large B-Cell Lymphoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06905509 | — | P2 | recruiting | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma |
| NCT03321643 | — | P1 | active not recruiting | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma |
| NCT02446457 | — | P2 | active not recruiting | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma |
| NCT05052528 | — | P1 | unknown | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT03259503 | — | P1 | completed | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant |
| NCT03401853 | — | P2 | terminated | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma |
| NCT03440567 | — | P1 | completed | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma |
| NCT02366663 | SPINOZA | P3 | terminated | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL |
Idiopathic Membranous Nephropathy (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04745728 | — | P3 | recruiting | Different Immunosuppressive Treatment in iMN |
| NCT04743739 | — | P3 | terminated | Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN |
| NCT03804359 | PMMN | P2 | completed | Personalized Medicine for Membranous Nephropathy |
| NCT05667909 | — | N/A | unknown | Prognostic Model of Rituximab in the Treatment of MN |
| NCT05782933 | — | N/A | unknown | Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy |
| NCT04154787 | — | P2 | terminated | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy |
| NCT01180036 | MENTOR | P2/P3 | completed | MEmbranous Nephropathy Trial Of Rituximab |
| NCT01508468 | GEMRITUX | P3 | completed | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy |
Nephrotic Syndrome (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06530004 | — | N/A | recruiting | Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children |
| NCT00977977 | — | P2 | recruiting | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy |
| NCT03501459 | — | P3 | unknown | Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome |
| NCT05704400 | — | P2 | unknown | Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome |
| NCT02382575 | — | P4 | unknown | Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome |
| NCT02394119 | — | P2 | completed | Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome |
| NCT02438982 | — | P3 | completed | Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome |
| NCT00981838 | NEMO | P3 | completed | Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) |
Hairy Cell Leukemia (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06965114 | — | P1/P2 | recruiting | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia |
| NCT00923013 | — | P2 | active not recruiting | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia |
| NCT01059786 | — | P2 | active not recruiting | Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia |
| NCT06561360 | HCL | P2 | recruiting | A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) |
| NCT00412594 | — | P2 | recruiting | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia |
| NCT03805932 | TM | P1 | active not recruiting | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia |
| NCT05388123 | — | P2 | completed | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia |
Granulomatosis With Polyangiitis (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04871191 | SATELITE | P3 | recruiting | Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis |
| NCT06983821 | SAFE-LOW | P3 | recruiting | Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) |
| NCT05376319 | — | P2 | terminated | PR3-AAV Resilient Remission or PRRR |
| NCT01750697 | — | P2 | completed | A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis |
| NCT02169219 | SCOUT | P4 | completed | Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis |
| NCT01613599 | — | N/A | completed | An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis |
| NCT01731561 | MAINRITSAN 2 | P3 | completed | Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis |
Pemphigus (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05898308 | RITUX4 | P4 | recruiting | Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus |
| NCT04400994 | — | P2 | active not recruiting | IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus |
| NCT01974518 | — | P3 | unknown | Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus |
| NCT01299857 | Suiviritux | P3 | completed | Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab |
| NCT01338103 | — | N/A | unknown | Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex |
| NCT00960713 | RITAI | N/A | completed | The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders |
| NCT00656656 | — | P2 | completed | Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus |
Leukemia, Lymphocytic, Chronic, B-Cell (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05947851 | VR | P3 | recruiting | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). |
| NCT06205290 | — | P3 | withdrawn | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies |
| NCT06364423 | — | P1/P2 | recruiting | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias |
| NCT00545714 | CLL | P2 | completed | A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) |
| NCT01373229 | CLL | P1 | completed | Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) |
| NCT00738829 | — | P1/P2 | completed | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL |
| NCT01005979 | CR2 | P1 | terminated | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) |
Lupus Nephritis (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05207358 | GLUREDLUP | P4 | recruiting | Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis |
| NCT03791827 | — | N/A | unknown | Multicenter Registry of Pediatric Lupus Nephritis in China |
| NCT02260934 | CALIBRATE | P2 | completed | Rituximab and Belimumab for Lupus Nephritis |
| NCT01765842 | RITULUP | P3 | terminated | Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy |
| NCT00282347 | LUNAR | P3 | completed | A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis |
| NCT00908986 | — | N/A | withdrawn | Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis |
| NCT00404157 | — | P3 | withdrawn | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02073097 | — | P1/P2 | completed | Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma |
| NCT00736450 | — | Early P1 | terminated | Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma |
| NCT01539174 | — | P2 | withdrawn | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma |
| NCT00088881 | — | P2 | terminated | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma |
| NCT00121199 | — | P2 | completed | Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma |
| NCT00080847 | — | P2 | terminated | S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
| NCT00017381 | — | Early P1 | completed | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01479842 | — | P1 | active not recruiting | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma |
| NCT02049541 | — | P1 | completed | Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma |
| NCT01812005 | — | P2 | terminated | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT01238146 | — | P1/P2 | withdrawn | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
| NCT00012298 | — | P1/P2 | terminated | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| NCT00068315 | — | P1 | completed | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
| NCT00026182 | — | P2 | completed | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma |
B-cell Chronic Lymphocytic Leukemia (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00119392 | — | P2 | completed | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| NCT01269385 | — | P1/P2 | completed | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia |
| NCT00098670 | — | P2 | completed | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia |
| NCT00845104 | — | P2 | withdrawn | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment |
| NCT00612612 | — | P1 | terminated | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia |
| NCT00098488 | — | P1 | terminated | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia |
| NCT00058227 | — | P1 | completed | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma |
Diffuse Large B-Cell Lymphoma (DLBCL) (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07493148 | — | P2 | recruiting | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL |
| NCT07189065 | — | P2 | recruiting | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma |
| NCT07397832 | — | P2 | recruiting | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL |
| NCT05364424 | — | P1 | completed | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma |
| NCT00001337 | — | P2 | completed | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma |
| NCT00400478 | — | P3 | completed | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 |
Mantle Cell Lymphoma (MCL) (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06846489 | — | P2 | recruiting | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma |
| NCT07285590 | IMCL-2023 | P2 | recruiting | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma |
| NCT05951959 | TrAVeRse | P2 | active not recruiting | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma |
| NCT07272499 | — | P2 | recruiting | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease |
| NCT07199296 | — | P2 | recruiting | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment |
| NCT06496308 | — | P3 | recruiting | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment |
Diffuse Large Cell Lymphoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05389423 | — | P1 | recruiting | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas |
| NCT01859819 | REBOOT | P2 | completed | Treatment for Advanced B-Cell Lymphoma |
| NCT00591630 | — | P2 | completed | Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation |
| NCT00169195 | R-GEMOX | P2 | completed | Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma |
| NCT00144807 | — | P2 | completed | ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma |
| NCT00140660 | — | P3 | terminated | ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma |
Systemic Lupus Erythematosus (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05828147 | — | P4 | unknown | Anti-CD20 Antibodies for Treatment of SLE-PAH |
| NCT05659407 | PREDICT | N/A | unknown | BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis |
| NCT03312907 | SLE | P3 | completed | A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE |
| NCT00556192 | — | P2 | completed | Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus |
| NCT00230035 | LIST | P2 | withdrawn | Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) |
| NCT00293072 | SLE | P2 | completed | Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis |
Burkitt Lymphoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04933617 | — | P1 | terminated | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas |
| NCT03864419 | — | P1 | terminated | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda |
| NCT01290120 | B-ALL | P2 | completed | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma |
| NCT00126191 | — | P2 | terminated | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma |
| NCT00180882 | — | P3 | unknown | LMBA02 Protocol for Patients With a Burkitt Lymphoma |
| NCT00180895 | — | P2 | terminated | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL |
Diffuse, Large B-Cell, Lymphoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04236141 | — | P3 | terminated | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). |
| NCT02871869 | — | P2/P3 | unknown | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma |
| NCT00599170 | — | P2 | completed | Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma |
| NCT02867566 | — | P3 | completed | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients |
| NCT01848132 | — | P2 | completed | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. |
| NCT02855359 | SGN-CD19A | P2 | terminated | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma |
Thrombotic Thrombocytopenic Purpura (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04074187 | — | P2/P3 | completed | A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) |
| NCT01554514 | — | P2 | completed | Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura |
| NCT00907751 | PTTritux | P2 | completed | Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura |
| NCT00531089 | — | P2 | unknown | Rituximab in Patients With Relapsed or Refractory TTP-HUS |
| NCT00799773 | STAR | P3 | terminated | Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) |
| NCT00251277 | — | P1/P2 | withdrawn | Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura |
B-Cell Lymphoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03467373 | CHOP | P1 | completed | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL |
| NCT02945215 | IBI301 | P1 | completed | A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients |
| NCT03003039 | — | P1 | completed | A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma |
| NCT00299494 | NHL | P1/P2 | completed | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) |
| NCT00965289 | — | P2 | completed | High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma |
| NCT00085696 | — | P2 | completed | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma |
Lupus Erythematosus, Systemic (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02284984 | SYNBIoSe | P2 | completed | Synergetic B-cell Immodulation in SLE |
| NCT00076752 | — | P2 | completed | Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus |
| NCT00381810 | VOYAGER | P3 | terminated | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus |
| NCT01702038 | — | P2 | withdrawn | Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE |
| NCT00137969 | EXPLORER | P2/P3 | completed | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus |
| NCT00036491 | — | P1/P2 | completed | Anti-CD20 in Systemic Lupus Erythematosus |
Kidney Transplantation (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01136395 | — | P2 | completed | Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation |
| NCT00476164 | RituxiCAN-C4 | P4 | completed | Study of Rituximab to Treat Chronic Renal Transplant Rejection |
| NCT00565331 | — | P2/P3 | completed | Rituximab for Prevention of Rejection After Renal Transplantation |
| NCT00801632 | — | P2 | completed | Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection |
| NCT00371904 | RAPTURE | P2 | unknown | Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients |
| NCT00697996 | — | P2/P3 | completed | Rituximab for Pediatric Renal Transplant Rejection |
Systemic Sclerosis (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07335562 | Breakfree-SSc | P3 | recruiting | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis |
| NCT03630211 | SSc | P2 | recruiting | Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis |
| NCT03844061 | — | P2 | recruiting | Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis |
| NCT03593902 | CAST | P2/P3 | terminated | Cardiac Safe Transplants for Systemic Sclerosis |
| NCT01748084 | RECOVER | P2/P3 | completed | Rituximab in Systemic Sclerosis |
Lymphoma, Non-Hodgkin's (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07226843 | — | P1 | recruiting | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers |
| NCT00363636 | NHL | P3 | terminated | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) |
| NCT00384150 | NHL | P3 | terminated | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) |
| NCT00143871 | — | P2 | completed | Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma |
| NCT00141700 | — | P2 | terminated | Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma |
Relapsed/Refractory Follicular Lymphoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05371093 | ZUMA-22 | P3 | active not recruiting | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma |
| NCT05100862 | MAHOGANY | P3 | recruiting | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
| NCT07418190 | — | P2 | recruiting | Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma |
| NCT04224493 | SYMPHONY-1 | P3 | active not recruiting | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
| NCT06149286 | OLYMPIA-5 | P3 | recruiting | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma |
Marginal Zone Lymphoma(MZL) (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07208981 | — | P2 | recruiting | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL |
| NCT07299331 | — | N/A | not yet recruiting | Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma |
| NCT07448324 | — | P2 | recruiting | Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL |
| NCT07022223 | — | P2 | recruiting | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma |
| NCT06700798 | — | P2 | recruiting | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial |
Hematologic Malignancies (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01810588 | — | P2 | active not recruiting | Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation |
| NCT07200583 | PAIA-Haplo | N/A | completed | Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients |
| NCT02663518 | TTI-621 | P1 | terminated | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors |
| NCT00824135 | — | P1 | completed | Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies |
| NCT00496340 | Pento & tBU | P2 | completed | Phase II Trial of Pentostatin and Targeted Busulfan |
Diffuse Large B-cell Lymphoma (DLBCL) (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06091865 | OLYMPIA-3 | P3 | recruiting | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma |
| NCT06832228 | — | N/A | recruiting | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL |
| NCT02957019 | DLBCL | P1/P2 | terminated | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT02983097 | R²-DHAP | P1/P2 | terminated | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP |
| NCT01054781 | DLBCL | P2 | completed | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) |
B Acute Lymphoblastic Leukemia (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05303792 | — | P2 | active not recruiting | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma |
| NCT04872790 | — | P1 | active not recruiting | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia |
| NCT03150693 | — | P3 | recruiting | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia |
| NCT02877303 | — | P2 | recruiting | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia |
| NCT02538926 | — | P2 | withdrawn | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
Recurrent B-Cell Non-Hodgkin Lymphoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04447716 | — | P1 | active not recruiting | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment |
| NCT01695941 | — | P1 | active not recruiting | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma |
| NCT02628405 | — | P1/P2 | active not recruiting | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma |
| NCT04659044 | — | P2 | terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| NCT00764517 | — | P2 | completed | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma |
Multiple Myeloma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03524235 | — | P1 | completed | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL |
| NCT04136756 | — | P1 | completed | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma |
| NCT04045028 | PK | P1 | terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT00505895 | — | P2 | completed | FM 140 vs FM100 Study in Patients With Multiple Myeloma |
| NCT00427557 | — | P2 | completed | Cellular Therapy With Cord Blood Cells |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01424982 | — | P2 | active not recruiting | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia |
| NCT02727803 | — | P2 | recruiting | Personalized NK Cell Therapy in CBT |
| NCT03147612 | — | P2 | active not recruiting | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia |
| NCT03096782 | — | P2 | completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma |
| NCT01619761 | — | P1 | unknown | NK Cells in Cord Blood Transplantation |
B-cell Adult Acute Lymphoblastic Leukemia (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01670084 | — | P2 | withdrawn | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia |
| NCT02281279 | — | P1/P2 | withdrawn | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT00867529 | — | P2 | completed | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
| NCT02168907 | CPI-613 | P1 | terminated | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT00010192 | — | P1 | completed | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer |
CD20 Positive (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01959698 | — | P1 | active not recruiting | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma |
| NCT00880815 | — | P1 | completed | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant |
| NCT00439556 | — | P2 | completed | Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant |
| NCT01729806 | — | P1 | completed | Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma |
| NCT02219737 | — | P1 | completed | Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma |
Graft Versus Host Disease (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00577278 | — | P2 | completed | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan |
| NCT01810926 | — | P2 | unknown | T&B Depletion Non Malignant |
| NCT01309997 | — | P2 | completed | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease |
| NCT01135641 | R-GVHD | P2 | completed | Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD) |
| NCT01066598 | — | P2 | terminated | A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD) |
Post-transplant Lymphoproliferative Disorder (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06040320 | R | P1/P2 | recruiting | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) |
| NCT07573436 | PLUTO | P1/P2 | not yet recruiting | Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) |
| NCT04337827 | — | P2 | terminated | Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder |
| NCT00064246 | — | P1/P2 | completed | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder |
Large B-cell Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06045247 | — | P2 | recruiting | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma |
| NCT06356129 | GOLSEEK-1 | P3 | active not recruiting | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma |
| NCT07608731 | — | P1 | not yet recruiting | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas |
| NCT05929716 | — | P2 | withdrawn | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma |
DLBCL - Diffuse Large B Cell Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07255963 | — | P2 | recruiting | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL |
| NCT07389356 | — | N/A | not yet recruiting | Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL |
| NCT07034508 | — | P2 | not yet recruiting | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 |
| NCT06220032 | HO170DLBCL | P3 | recruiting | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma |
Primary Central Nervous System Lymphoma (PCNSL) (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07410520 | — | P2 | recruiting | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. |
| NCT06946407 | — | N/A | recruiting | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma |
| NCT03703167 | — | P1 | completed | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) |
| NCT04688151 | RAD | P1 | active not recruiting | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. |
PCNSL (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06554561 | — | P1/P2 | recruiting | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma |
| NCT07350850 | PRIME-PCNSL | P2 | recruiting | A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL |
| NCT05896007 | — | P2 | unknown | Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT |
| NCT04481815 | — | P2 | unknown | Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma |
Membranous Nephropathy (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06341205 | iRITUX | P3 | recruiting | Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) |
| NCT03949855 | REBOOT | P2 | recruiting | Belimumab With Rituximab for Primary Membranous Nephropathy |
| NCT00405340 | — | Early P1 | completed | Rituximab in the Treatment of Idiopathic Membranous Nephropathy |
| NCT00425217 | — | P2/P3 | completed | Rituximab in Membranous Nephropathy |
Chronic Lymphocytic Leukaemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06564038 | Soundtrack-E | P1/P2 | recruiting | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies |
| NCT03582098 | RETRO-idel | N/A | completed | Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland |
| NCT01446900 | — | P2 | terminated | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma |
| NCT00504491 | R-CHOP | P2 | withdrawn | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia |
Sjogren's Syndrome (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06410833 | BRRPJS | P4 | recruiting | Belimumab After Rituximab in Resistant Primary Juvenile SS |
| NCT02631538 | — | P2 | completed | Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome |
| NCT00101829 | — | P1 | completed | Anti-CD20 Antibody Therapy for Sjogren's Syndrome |
| NCT00363350 | — | P1/P2 | completed | Rituximab Treatment in Sjogren's Syndrome |
Waldenström's Macroglobulinemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03697356 | Ballondor | P2 | recruiting | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia |
| NCT05979948 | CZ-WM01 | P2 | unknown | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia |
| NCT01788020 | — | P3 | completed | Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia |
| NCT02165397 | — | P3 | completed | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia |
Hodgkin Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06201507 | — | P2 | unknown | BV-AVD-R Treatment Children Hodgkin's Lymphoma |
| NCT02398240 | — | P2 | completed | Brentuximab for Newly Diagnosed Hodgkin Disease |
| NCT01030900 | DA-EPOCH-R | P2 | completed | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas |
| NCT00992030 | — | P3 | terminated | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma |
Aggressive Non-Hodgkin Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04231877 | — | P1 | recruiting | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma |
| NCT03749018 | — | P2 | active not recruiting | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma |
| NCT03704714 | — | P1/P2 | suspended | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma |
| NCT03161054 | — | P2 | completed | Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas |
B Cell Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02898259 | — | P1/P2 | terminated | Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma |
| NCT03670888 | — | P1 | terminated | A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients |
| NCT00841945 | — | P3 | terminated | Treatment of Aggressive Localized Lymphoma |
| NCT00169468 | — | P2 | completed | Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma |
Purpura, Thrombocytopenic, Idiopathic (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03010202 | — | P3 | unknown | The PROLONG Trial - Rituximab Maintenance Therapy in ITP |
| NCT03258866 | — | P4 | completed | The Study of Different Dose Rituximab in the Treatment of ITP |
| NCT00372892 | ITP | P2 | completed | Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) |
| NCT00005652 | — | P2 | completed | Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura |
Lymphoma, Large-Cell, Diffuse (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01014208 | ORCHARRD | P3 | completed | Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma |
| NCT00561379 | — | N/A | completed | Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab |
| NCT00135499 | — | P3 | terminated | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma |
| NCT00137995 | — | P3 | completed | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma |
Graft vs Host Disease (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00350545 | — | N/A | completed | A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease |
| NCT01042509 | LowAR | N/A | completed | Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease |
| NCT00136396 | — | P1/P2 | completed | Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease |
| NCT00578591 | Rituximab GVHD | P2 | withdrawn | Rituximab for GVHD |
Brain and Central Nervous System Tumors (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00068250 | — | P1/P2 | completed | Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma |
| NCT00416819 | — | N/A | completed | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma |
| NCT00734773 | — | Early P1 | withdrawn | Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL |
| NCT00416923 | — | P1 | completed | Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma |
Idiopathic Thrombocytopenic Purpura (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00909077 | ITP | P3 | completed | The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) |
| NCT00475423 | — | P2 | completed | A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. |
| NCT00749112 | — | P2/P3 | completed | Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias |
| NCT00770562 | ITP | P3 | completed | A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) |
Multiple Myeloma and Plasma Cell Neoplasm (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00477815 | — | P1 | completed | Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma |
| NCT00567229 | — | P2 | terminated | Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma |
| NCT00258206 | — | P2 | completed | Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma |
| NCT00003554 | — | P2 | completed | Rituximab in Treating Patients With Multiple Myeloma |
Hematological Malignancies (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07137481 | — | P2 | not yet recruiting | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies |
| NCT05728658 | — | P1 | recruiting | The Study of ICP-248 in Patients With Mature B-cell Malignancies |
| NCT00379587 | — | P1/P2 | completed | Rituximab for Prevention of Chronic GVHD |
Recurrent Mantle Cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07578077 | — | P1/P2 | not yet recruiting | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma |
| NCT04047797 | — | P2 | terminated | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
| NCT00109967 | — | P2 | completed | CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
PTLD (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07614282 | — | P1 | not yet recruiting | Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia |
| NCT04138875 | — | P2 | withdrawn | A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) |
| NCT00590447 | PTLD-1/3 | P2 | completed | Risk Stratified Sequential Treatment for CD20-positive PTLD |
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05453500 | — | P2 | active not recruiting | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia |
| NCT06918431 | — | P2 | recruiting | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT06738368 | DA-EPOCH | P2 | recruiting | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia |
Richter Syndrome (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07220187 | — | P3 | not yet recruiting | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial |
| NCT04679012 | — | P2 | recruiting | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation |
| NCT03899337 | STELLAR | P2 | recruiting | A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome |
ANCA Associated Vasculitis (AAV) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07451847 | PREP-ANCA | P4 | not yet recruiting | Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. |
| NCT06611696 | ARRIA | P4 | recruiting | Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis |
| NCT07168161 | — | P3 | recruiting | BDB-001 Phase III Trial in ANCA-Associated Vasculitis |
B-Cell Non-Hodgkin Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07097363 | EPOCH-R | P2 | recruiting | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma |
| NCT03505762 | — | P2 | active not recruiting | Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment |
| NCT05201248 | SC | P1/P2 | active not recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma |
Mantle-cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07029737 | SOUND-MCL | P2 | recruiting | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain |
| NCT05868395 | — | P2 | recruiting | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma |
| NCT02267915 | MAN2 | P2 | unknown | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT |
Primary Membranous Nephropathy (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07029139 | — | P2 | not yet recruiting | A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy |
| NCT05514015 | — | P4 | recruiting | Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy |
| NCT05696613 | — | P3 | unknown | A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy |
Type 1 Diabetes Mellitus (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03929601 | TN25 | P2 | active not recruiting | Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
| NCT00468442 | — | P2 | terminated | B-Lymphocyte Immunotherapy in Islet Transplantation |
| NCT00279305 | TN05 | P2 | completed | Rituximab in New Onset Type 1 Diabetes |
NHL (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06119685 | — | P1/P2 | recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers |
| NCT04555811 | — | P1 | completed | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL |
| NCT03527147 | PRISM | P1 | completed | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) |
Nephrotic Syndrome in Children (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05734794 | STORM | P3 | recruiting | Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial |
| NCT05843968 | — | P2 | recruiting | Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome |
| NCT07049172 | — | N/A | completed | Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome |
Multiple Sclerosis, Relapsing-Remitting (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05482542 | — | N/A | withdrawn | Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis |
| NCT03979456 | RIDOSE-MS | P3 | unknown | RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS |
| NCT02746744 | RIFUND-MS | P3 | completed | RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. |
Primary CNS Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04627753 | Lemon-C | P2 | recruiting | Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. |
| NCT05425654 | — | P2 | unknown | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL |
| NCT03569995 | — | P2 | unknown | [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma |
Relapsed Diffuse Large B-Cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04384484 | LOTIS 5 | P3 | active not recruiting | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT02077166 | — | P1/P2 | completed | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT03136497 | — | P1 | terminated | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Autoimmune Diseases (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05586737 | — | P2 | completed | Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency |
| NCT04127747 | — | P4 | unknown | Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus |
| NCT03790293 | LTFURITUX3 | P3 | completed | Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial |
IgA Nephropathy (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04525729 | RITA | P4 | completed | Rituximab and RASi in Patients with IgAN |
| NCT05824390 | — | P4 | unknown | A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy |
| NCT00498368 | — | P4 | completed | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02749292 | MAINTANCAVAS | P4 | terminated | Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing |
| NCT02198248 | LoVAS | P4 | unknown | Low-dose Glucocorticoid Vasculitis Induction Study |
| NCT01697267 | RITAZAREM | P3 | completed | Rituximab Vasculitis Maintenance Study |
Indolent Non-Hodgkin's Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02576275 | BRAVURA | P3 | withdrawn | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) |
| NCT01889797 | PrE0401 | P2 | terminated | Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma |
| NCT01088048 | — | P1 | completed | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia |
B-cell Non Hodgkin's Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02787239 | — | P3 | completed | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL |
| NCT02456207 | — | P2 | unknown | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma |
| NCT02584920 | — | P1/P2 | completed | A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma |
Lymphoma, B-cell (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02592876 | SGN-CD19A | P2 | terminated | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma |
| NCT01925612 | DLBCL | P2 | terminated | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT00482053 | — | P2 | terminated | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT |
Pompe Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02525172 | — | P4 | unknown | Immune Modulation Therapy for Pompe Disease |
| NCT01451879 | — | N/A | completed | Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies |
| NCT00701129 | — | P4 | completed | An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease |
B-Cell Chronic Lymphocytic Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01576588 | — | P2 | completed | Rituximab in Pretreated Elderly or Unfit B-CLL Patients |
| NCT02315118 | — | P1/P2 | unknown | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies |
| NCT00254163 | — | P3 | completed | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients |
Immune Thrombocytopenic Purpura (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01719692 | ITP | N/A | completed | Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia |
| NCT01107951 | — | P2 | completed | Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP |
| NCT00774202 | — | P2/P3 | completed | Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP |
Purpura (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01525836 | — | P3 | completed | rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP |
| NCT01506414 | ITP | P3 | completed | Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) |
| NCT01734057 | ITP | P3 | withdrawn | Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) |
Adult Nasal Type Extranodal NK/T-cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00072514 | — | P2 | completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
| NCT01419795 | — | P2 | terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant |
| NCT00601718 | — | P1/P2 | completed | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
Recurrent Grade 1 Follicular Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01318317 | — | P1/P2 | active not recruiting | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma |
| NCT00096460 | BMT CTN 0202 | P2/P3 | terminated | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) |
| NCT00079443 | — | P2 | terminated | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma |
Chronic Fatigue Syndrome (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01156922 | — | P2 | terminated | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome |
| NCT01156909 | — | P2 | completed | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome |
| NCT00848692 | KTS-1-2008 | P2/P3 | completed | Drug Intervention in Chronic Fatigue Syndrome |
Chronic Myeloproliferative Disorders (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00691015 | — | P2 | completed | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant |
| NCT01116232 | — | P2 | terminated | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation |
| NCT00080925 | — | P1 | completed | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies |
Lymphoproliferative Disorder (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00092222 | — | P2 | active not recruiting | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity |
| NCT00869323 | — | P2 | terminated | Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders |
| NCT00066469 | — | P2 | completed | Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation |
Large B-Cell Lymphoma (LBCL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07594899 | GUIDANCE-10 | P2 | not yet recruiting | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL |
| NCT07269639 | Go-Pro-DLBCL | P1/P2 | not yet recruiting | Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Relapsing-remitting Multiple Sclerosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07517185 | HiHat | P2 | not yet recruiting | The HIt HArd and hiT Early in Multiple Sclerosis Trial |
| NCT03193866 | COMBAT-MS | N/A | completed | COMparison Between All immunoTherapies for Multiple Sclerosis. |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07224100 | — | P2 | recruiting | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma |
| NCT01371630 | — | P1/P2 | recruiting | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia |
Waldenström Macroglobulinemia (WM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07259122 | ZBR in WM | P2 | not yet recruiting | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia |
| NCT07169565 | — | P1 | not yet recruiting | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia |
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07139873 | TAI-SHAN6 | P3 | recruiting | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) |
| NCT04458610 | — | P2 | active not recruiting | Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Diffuse Large B Cell Lymphoma (DLBCL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07124936 | — | P1/P2 | recruiting | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma |
| NCT06765317 | — | P2 | recruiting | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma |
Immune Thrombocytopenia (ITP) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07057778 | — | P2 | not yet recruiting | Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP |
| NCT00344149 | — | P3 | completed | Rituximab as Second Line Treatment for ITP |
Lymphomas (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07002099 | — | P2 | recruiting | Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study |
| NCT00980304 | — | P2 | unknown | R Retreatment in 1st Relapsed DLBCL |
Primary Intraocular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06973811 | ZR-MTX | P2 | not yet recruiting | ZR-MTX for PIOL Phase II Trial |
| NCT03746223 | — | P2 | unknown | Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma |
CNS Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06730542 | — | P1 | recruiting | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma |
| NCT05926427 | — | P2 | unknown | Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement |
CLL (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06846671 | CaDAnCe-302 | P3 | recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors |
| NCT05209308 | CORAL | P2 | withdrawn | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL |
Diffuse Large B Cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06835530 | FIL_RICCO | P2 | recruiting | A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) |
| NCT02141451 | — | P1/P2 | completed | ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL |
Steroid-Sensitive Nephrotic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05850546 | — | P3 | not yet recruiting | Rituximab in the First Episode of Paediatric Nephrotic Syndrome |
| NCT04783675 | RTXFIRPedINS | P2 | completed | Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome |
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06792253 | — | P3 | recruiting | Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT06164327 | — | P1 | unknown | Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Ann Arbor Stage II Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06471738 | — | P2 | recruiting | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma |
| NCT02532257 | — | P2 | completed | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma |
Severe Aplastic Anemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06412497 | MT2023-20 | P2 | recruiting | MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. |
| NCT06254560 | — | P2 | recruiting | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness |
B-cell Non Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05991388 | Glo-BNHL | P2/P3 | recruiting | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
| NCT01516580 | — | P3 | completed | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients |
Diabetes Mellitus, Type 1 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07041268 | — | P2 | recruiting | Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab |
| NCT00798785 | — | P1/P2 | unknown | Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients |
B-cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06251180 | — | P1 | recruiting | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma |
| NCT03671018 | BTCT4465A | P1/P2 | active not recruiting | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma |
Relapsed or Refractory Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06313996 | — | P3 | withdrawn | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma |
| NCT04712097 | Celestimo | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma |
Non-hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05998642 | — | P2 | recruiting | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma |
| NCT04502706 | — | P1 | terminated | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma |
Primary Ocular Adnexal MALT Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06190301 | — | N/A | recruiting | RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma |
| NCT06064344 | — | N/A | not yet recruiting | RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma |
Steroid-Dependent Nephrotic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05786768 | OBIRINS | P2/P3 | recruiting | Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome |
| NCT03899103 | RITURNS II | P3 | completed | Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome |
Kidney Failure (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05900401 | — | P1/P2 | active not recruiting | Delayed Tolerance Through Mixed Chimerism |
| NCT00986947 | — | P2 | terminated | Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates |
Diffuse Large B-cell Lymphoma Recurrent (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06086197 | — | P2 | recruiting | A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL |
| NCT03795571 | R2-GOD | P1 | unknown | Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL |
Relapsed Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05848765 | REFRACT | P2 | recruiting | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy |
| NCT00715208 | — | P2 | completed | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma |
Glomerulonephritis, Membranous (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05914155 | PRIME | P3 | recruiting | Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome |
| NCT03018535 | RI-CYCLO | P3 | unknown | Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy |
Schizophrenia Spectrum and Other Psychotic Disorders (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05622201 | RCT-RITS | P2 | active not recruiting | A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults |
| NCT03983018 | RITS-PS-2019 | P2 | completed | Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) |
Polymyalgia Rheumatica (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05533164 | REDUCE-PMR-2 | P3 | active not recruiting | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse |
| NCT05533125 | REDUCE-PMR-1 | P3 | completed | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed |
Sickle Cell Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05736419 | HCT | P2 | recruiting | A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) |
| NCT01279616 | SCT | P2 | terminated | A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease |
Primary Immune Thrombocytopenia (ITP) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04518475 | ITP | P4 | recruiting | Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults |
| NCT05338190 | RITUX-PLUS 2 | P3 | recruiting | Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia |
Antiphospholipid Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05644210 | — | N/A | unknown | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE |
| NCT00537290 | RITAPS | P2 | completed | A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome |
Treatment (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07071246 | — | N/A | active not recruiting | Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis |
| NCT02971982 | — | P1/P2 | unknown | PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia |
Obsessive-Compulsive Disorder (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04323566 | Ra-P-OCD | P2 | enrolling by invitation | Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement |
| NCT03983031 | RITS-PO-2019 | P1 | completed | Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019) |
Stem Cell Transplantation (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05293509 | PTIS | P2 | withdrawn | Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders |
| NCT00972101 | — | P1 | withdrawn | Infusion of Expanded Cord Blood T Cells |
Fanconi Anemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03579875 | — | P2 | recruiting | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders |
| NCT04784052 | — | P1/P2 | recruiting | Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab |
Interstitial Lung Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05963048 | — | P2/P3 | completed | Rituxmab Versus IL-6 in Treating ILD |
| NCT01862926 | RECITAL | P2/P3 | completed | Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD |
Epstein-Barr Virus Infections (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04989491 | REPLY | P4 | recruiting | Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft |
| NCT04507477 | — | P1/P2 | unknown | Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial |
Recurrent Aggressive Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03003546 | — | P1 | completed | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial |
| NCT04220008 | — | P2 | withdrawn | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma |
Relapsing Remitting Multiple Sclerosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04688788 | DanNORMS | P3 | active not recruiting | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis |
| NCT04578639 | OVERLORD-MS | P3 | active not recruiting | Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease |
Hematopoietic and Lymphoid Cell Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04752163 | — | P1/P2 | terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| NCT01664910 | — | P1/P2 | completed | CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies |
Diffuse Large B-Cell Lymphoma Unclassifiable (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665765 | — | P2 | active not recruiting | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT02636322 | — | P2 | completed | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib |
Nephrotic Syndrome Steroid-Dependent (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04585152 | RTXvsMMF | P2 | unknown | Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome. |
| NCT04402580 | — | P2 | terminated | Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome |
Refractory Myasthenia Gravis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05332587 | — | P3 | unknown | Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis |
| NCT00619671 | — | P1/P2 | completed | A Pilot Trial of Rituxan in Refractory Myasthenia Gravis |
Untreated Mantle Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05504603 | ZR | P2 | unknown | Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma |
| NCT00401817 | — | P2 | completed | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma |
Ann Arbor Stage III Grade 1 Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04404088 | — | P2 | active not recruiting | Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma |
| NCT00695786 | — | P2 | completed | Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma |
Indolent Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04431635 | — | P1 | terminated | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma |
| NCT00954005 | R-GO | P1/P2 | terminated | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04323956 | — | P1 | active not recruiting | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma |
| NCT01856192 | — | P2 | active not recruiting | Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma |
Lymphoid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01754857 | — | P2 | completed | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL |
| NCT04155840 | — | P2 | terminated | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Neuromyelitis Optica (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03829566 | ATTEND | P2/P3 | withdrawn | Autologous Transplant To End NMO Spectrum Disorder |
| NCT00501748 | — | P1 | completed | Safety and Tolerability of Rituximab in Neuromyelitis Optica |
CCND1 Positive (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01880567 | — | P2 | active not recruiting | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma |
| NCT03232307 | — | P2 | withdrawn | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06325943 | CIDPRIT | P3 | completed | Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
| NCT05877040 | — | P2 | unknown | A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy |
ANCA Associated Vasculitis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03942887 | ENDURRANCE-1 | P3 | unknown | Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis |
| NCT03967925 | COMBIVAS | P2 | unknown | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis |
Recurrent B Acute Lymphoblastic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03808610 | — | P1/P2 | terminated | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia |
| NCT02420717 | — | P2 | terminated | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia |
Renal Transplant (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04033276 | — | P4 | completed | IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies |
| NCT00820469 | PK-rituximab | P4 | completed | Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab |
Relapsed Non Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03892421 | — | P1/P2 | completed | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma |
| NCT03778619 | — | P1/P2 | unknown | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin |
Acquired Hemophilia A (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03384277 | — | P4 | completed | Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab |
| NCT03700229 | — | P2 | unknown | Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A |
Idiopathic Nephrotic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03298698 | — | P3 | unknown | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome |
| NCT04494438 | — | P3 | completed | Rituximab for Idiopathic Nephrotic Syndrome |
Sickle Cell Anemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03653338 | SCD | P1/P2 | recruiting | T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias |
| NCT01350232 | — | N/A | terminated | Treatment of Sickle Cell Anemia With Stem Cell Transplant |
Idiopathic Pulmonary Fibrosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03500731 | — | P1/P2 | recruiting | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure |
| NCT01524068 | — | P2 | withdrawn | A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations |
Mature B-cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02405676 | BNHL-2015 | P2/P3 | active not recruiting | BNHL-2015 for Children or Adolescents in China |
| NCT03206671 | B-NHL 2013 | P3 | active not recruiting | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents |
Lymphoma, Mantle Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02972840 | — | P3 | active not recruiting | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL |
| NCT00114738 | — | P2 | completed | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma |
Bullous Pemphigoid (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04128176 | — | P3 | withdrawn | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid |
| NCT00286325 | — | P1/P2 | completed | Rituximab in the Treatment of Patients With Bullous Pemphigoid |
B-Cell Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02018861 | CITADEL-101 | P1/P2 | completed | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) |
| NCT01775631 | — | P1 | completed | Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma |
Acute Lymphoblastic Leukemia (ALL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02790515 | — | P2 | active not recruiting | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation |
| NCT02259348 | — | P2 | terminated | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation |
Large B Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00118209 | — | P3 | completed | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
| NCT03188198 | — | P2 | unknown | Risk Adapted Therapy in Diffuse Large B Cell Lymphoma |
AIDS-Related Burkitt Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02337985 | — | P1 | active not recruiting | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
| NCT02199184 | — | P2 | completed | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia |
Neuromyelitis Optica Spectrum Disorder (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04256252 | RESCUE | P4 | completed | Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) |
| NCT03002038 | — | P2/P3 | completed | Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients |
Renal Transplant Rejection (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02500251 | — | P1/P2 | completed | Belimumab Impacting Transplant Eligibility |
| NCT00695097 | — | N/A | completed | The Effect of Rituximab on the Development of Anti-Donor Antibodies |
Marginal Zone B-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02853370 | — | P2 | completed | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma |
| NCT02433795 | BR | P2 | completed | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) |
Kidney Failure, Chronic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02314403 | — | P1 | completed | Renal Allograft Tolerance Through Mixed Chimerism (Belatacept) |
| NCT00446251 | MMF | P2 | completed | Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant |
Ann Arbor Stage I Grade 1 Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01473628 | — | P1/P2 | active not recruiting | Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma |
| NCT02320292 | — | P3 | terminated | Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma |
Adult Grade III Lymphomatoid Granulomatosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02213913 | DA-EPOCH-R | P1/P2 | completed | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
| NCT01805037 | — | P1/P2 | terminated | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
Stage I Chronic Lymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01886872 | — | P3 | active not recruiting | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia |
| NCT00602459 | — | P2 | completed | Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia |
Prolymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02007044 | — | P2 | active not recruiting | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia |
| NCT00281931 | — | P2 | terminated | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia |
Lymphoma, Non Hodgkin (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01992653 | — | P1/P2 | completed | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma |
| NCT01987505 | — | P3 | completed | MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma |
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01829568 | — | P1 | active not recruiting | Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma |
| NCT01145495 | — | P2 | completed | Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma |
End Stage Renal Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01780454 | — | P1/P2 | completed | Renal Allograft Tolerance Through Mixed Chimerism |
| NCT00167791 | — | N/A | withdrawn | Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant |
Cold Agglutinin Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02689986 | CAD5 | P2 | completed | Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease |
| NCT00373594 | — | P2 | completed | Therapy for Chronic Cold Agglutinin Disease |
Indolent Non-Hodgkin's Lymphomas (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01732913 | Yosemite | P3 | terminated | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas |
| NCT01732926 | Bridalveil | P3 | terminated | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas |
Anaplastic Large Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01686165 | — | P2 | completed | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL |
| NCT00720135 | — | P1 | completed | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
Aggressive Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01686321 | B-R-ENDA | P2 | completed | Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma |
| NCT01562977 | RGemOx | P2 | completed | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL |
Acquired Haemophilia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01808911 | CREHA | P3 | completed | Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study) |
| NCT01403740 | EHEM | N/A | unknown | Turkish Acquired Haemophilia Registry |
Acute Rejection (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01117662 | RIACT | P3 | terminated | Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients |
| NCT00579592 | — | N/A | terminated | Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation |
Mantle-Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00878254 | — | P2 | completed | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT01497275 | — | P2 | terminated | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma |
Contiguous Stage II Mantle Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01267812 | — | P2 | completed | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation |
| NCT00433537 | — | P2 | completed | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma |
Recurrent Adult Diffuse Large Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01165112 | TREC | P1/P2 | completed | Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma |
| NCT00086944 | — | P1/P2 | completed | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma |
Adult Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00438880 | — | P1/P2 | completed | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma |
| NCT01045928 | — | P1 | terminated | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
Primary Non Hodgkin Lymphoma of the Central Nervous System (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00647049 | — | P2 | unknown | Freiburg ZNS-NHL Study |
| NCT00989352 | PRIMAIN | P2 | unknown | Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma |
Hodgkin's Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00667615 | DLBCL | P1/P2 | completed | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT00648037 | EBV | N/A | completed | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT |
Lymphoma, Small Lymphocytic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00636155 | — | P2 | terminated | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT00143065 | — | P2 | completed | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Myositis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00774462 | FORCE | P2 | completed | Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis |
| NCT00106184 | DM | P2 | completed | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) |
Myelodysplastic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00520130 | — | P1/P2 | completed | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System |
| NCT00498316 | — | P1 | completed | Cord Blood Expansion on Mesenchymal Stem Cells |
Lymphoma, Large Cell, Diffuse (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00689169 | ZBEAM2 | P2 | completed | Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma |
| NCT00436280 | — | P2 | completed | Chemotherapy for Participants With Lymphoma |
Contiguous Stage II Grade 1 Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01682044 | — | P2 | completed | Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma |
| NCT00244855 | — | P2 | completed | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma |
Stage III Grade 1 Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00301795 | — | P2 | terminated | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma |
| NCT00003204 | — | P3 | completed | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma |
Kidney Transplant (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00307125 | — | P2 | completed | Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies |
| NCT00642655 | IVIG | P1/P2 | completed | Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation |
Lymphoma, Low-Grade (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00311129 | — | P2 | completed | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL |
| NCT00060684 | — | P1 | completed | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma |
Renal Transplantation (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00255593 | — | P1 | completed | Safety and Efficacy Study of Rituximab in Renal Transplantation |
| NCT00214266 | — | P2 | completed | A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation |
Neuroblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00790413 | — | Early P1 | unknown | Haploidentical Stem Cell Transplantation in Neuroblastoma |
| NCT00202930 | — | P2 | terminated | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma |
Wegener's Granulomatosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00307593 | RATTRAP | N/A | completed | RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides |
| NCT00072592 | — | P1 | completed | An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies |
Adult Acute Lymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00198978 | — | P4 | completed | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| NCT00199004 | — | P4 | completed | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab |
Idiopathic Thrombocytopenic Purpura (ITP) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01713738 | ITP | P1/P2 | completed | Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
| NCT00161564 | — | P2 | withdrawn | A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone |
Burkitt's Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00669877 | — | P2 | completed | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma |
| NCT00199082 | — | P4 | completed | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults |
Lymphoma, B Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00210379 | — | P2 | completed | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma |
| NCT00210340 | — | P1 | withdrawn | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis |
AIDS Related Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00001563 | — | P2 | completed | EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma |
| NCT00126243 | CHOP | P2 | terminated | Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma |
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07583810 | — | P2 | not yet recruiting | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma |
Ann Arbor Stage II Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07444710 | — | P1 | not yet recruiting | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma |
Hypophosphatasia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06015750 | RESTORE | P4 | withdrawn | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia |
Non-Hodgkin's B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07588698 | — | P2 | not yet recruiting | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma |
Relapsed/Refractory Primary Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07104032 | IGNITE | P3 | recruiting | IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) |
NMOSD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07010302 | BEST-NMOSD | P4 | not yet recruiting | Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD |
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07601607 | — | P1/P2 | not yet recruiting | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma |
Relapsed B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07477366 | — | P2 | not yet recruiting | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma |
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07365306 | — | P2 | recruiting | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Phase 2 Study (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07257055 | — | P2 | recruiting | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study |
Double Expressor DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07415980 | — | P1/P2 | not yet recruiting | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL |
Combination Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07432022 | — | P1/P2 | not yet recruiting | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma |
Autoimmune Prematur Ovarian Insuffience (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07509840 | REFINE | P3 | recruiting | Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency |
Hemophagocytic Lymphohistiocytosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07270835 | — | P4 | recruiting | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma |
Rheumatic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07138898 | — | P2 | not yet recruiting | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Relapsing-Remitting Multiple Sclerosis (RRMS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07189325 | DESIRE MS | P3 | not yet recruiting | A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis |
Marginal Zone Lymphoma of Ocular Adnexal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07247383 | — | P2 | active not recruiting | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma |
Thrombocytopenia Purpura (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07051915 | — | P3 | not yet recruiting | The Holistic Study |
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06824701 | TARZAN | P1 | suspended | Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
Primacy Immune Thrombocytopenia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07206823 | — | N/A | recruiting | Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia |
Relapsed or Refractory Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06788964 | CORAL | P2 | recruiting | Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) |
Non Hodgkin's Lymphoma Refractory/Relapsed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05618925 | — | P1 | recruiting | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma |
B-cell Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07081022 | — | P2 | recruiting | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma |
Crohn Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06986382 | — | P1/P2 | not yet recruiting | Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease |
Chronic Inflammatory Demyelinating Polyneuropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04480450 | — | P2 | withdrawn | Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy |
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07073833 | — | P1 | recruiting | The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06973096 | — | P1 | recruiting | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy |
Rheumatoid Arthritis (RA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06906549 | RADAR | P4 | recruiting | Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis |
Relapsed/Refractory Indolent NHL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06981988 | YY-20394 | P1/P2 | not yet recruiting | A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL |
Waldenström's Macroglobulinemia (WM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06942507 | BRZ-WM | N/A | not yet recruiting | Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia |
Acute Demyelinating Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05545384 | IDAR | P3 | recruiting | Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial |
Ocular Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06342544 | IMCOMG | P3 | recruiting | Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. |
Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06952413 | — | P2 | recruiting | Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
Large B-Cell Lymphoma With IRF4 Rearrangement (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06834373 | — | P2 | recruiting | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy |
Presymptomatic Diabetes Type 1 (Stage 1) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06688331 | PreTreg | P2 | recruiting | Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody |
Refractory Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06676631 | — | P1 | recruiting | NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis |
T-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06756308 | — | P2 | recruiting | A Study of Enasidenib in People With T-Cell Lymphoma |
Graft-versus-host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06682169 | — | P3 | recruiting | Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
Newly Diagnosed Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06683885 | — | P1/P2 | recruiting | A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma |
Interstitial Lung Disease With Systemic Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06549231 | EVER-ILD 3 | P3 | recruiting | Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis |
Primary Mediastinal Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06742502 | Si-Ri | P2 | recruiting | Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL |
Mucosa-associated Lymphoid Tissue Lymphoma (MALT) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06647732 | MALT | P2 | recruiting | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) |
Scleroderma, Diffuse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06655896 | — | P2 | recruiting | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis |
Classic Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06337318 | — | P3 | recruiting | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma |
CIDP (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06714838 | ReCIX | P3 | recruiting | Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy |
Refractory or Relapsed Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06554600 | — | P2 | recruiting | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06388941 | — | P2 | active not recruiting | Iptacopan in Patients With ANCA Associated Vasculitis |
Secondary Progressive Multiple Sclerosis (SPMS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06599307 | — | P2 | recruiting | The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis |
Relapsed/Refractory Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06489808 | — | P2 | recruiting | Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL |
Splenic Marginal Zone Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05735834 | RITZ | P3 | active not recruiting | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
Relapsed/Refractory Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06414148 | EpLCART | P2 | recruiting | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma |
High Titers of Anti-HLA Antibody (MFI ≥5000) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06362967 | — | P2 | recruiting | The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT |
Mature B-cell Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06351527 | — | P1 | recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies |
Tophaceous Gout (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06186219 | — | P1 | completed | Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout |
CLL/SLL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06319456 | APG-2575 | P3 | recruiting | A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
Lupus Nephritis - WHO Class III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06265220 | — | P1 | active not recruiting | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus |
Recurrent Transformed Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06247540 | — | P2 | withdrawn | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Advanced Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06301399 | — | P2 | recruiting | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study |
B-Cell Non-Hodgkin Lymphoma (B-NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06230224 | OLYMPIA-4 | P3 | active not recruiting | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma |
Chronic Graft Versus Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06046248 | — | P2 | recruiting | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease |
B-Cell Non-Hodgkin Lymphoma-Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06209619 | — | P1 | recruiting | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma |
Nodular Lymphocyte Predominant B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05886036 | — | P2 | recruiting | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial |
Relapsed/Refractory Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06090539 | — | P1/P2 | recruiting | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas |
Relapsed/Refractory Marginal Zone Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06082102 | — | P3 | recruiting | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma |
Relapsed/Refractory B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05950334 | FT522-101 | P1 | completed | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) |
Neuromyelitis Optica Spectrum Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06068829 | — | N/A | unknown | Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders |
Mental Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05946486 | TIM-DePisT | P3 | not yet recruiting | Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity. |
Mild Cognitive Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06245707 | — | N/A | unknown | the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy |
Anemia, Sickle Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06078696 | CD2 SCD | P1/P2 | terminated | Siplizumab for Sickle Cell Disease Transplant |
Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06047080 | — | P3 | active not recruiting | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma |
Glomerulonephritis Rapidly Progressive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06047171 | RENAL-F02 | P2 | recruiting | Rescue of Nephrons With ALE.F02 (RENAL-F02) |
Mantle Cell Lymphoma Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05864742 | — | P2 | active not recruiting | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma |
Oncology (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06031233 | MINUTE | P4 | recruiting | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie |
Follicular Lymphoma Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05788081 | TOP-FLOR | P2 | active not recruiting | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. |
Effects of Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06468943 | — | P2 | enrolling by invitation | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
Anti-MAG Neuropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05136976 | THERAMAG | P3 | recruiting | Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders |
Hypersenstivity Pneumonitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07035561 | — | P2 | completed | Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis |
Double-Expressor Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05600686 | — | P2 | recruiting | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma |
Hematologic Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05735717 | — | P2 | recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies |
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05786040 | — | P2 | recruiting | Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder |
Peripheral T-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05821192 | — | N/A | unknown | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. |
Mucopolysaccharidosis (MPS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05494593 | — | P4 | withdrawn | A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
Double Express Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05527912 | — | P2 | unknown | A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy |
High-risk Large B-cell Lymphoma (LBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05605899 | ZUMA-23 | P3 | active not recruiting | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma |
Lung Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05596786 | EvER-ILD2 | P3 | recruiting | Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial |
Malignant Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05615974 | — | P1/P2 | recruiting | A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors |
SIOD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05508009 | — | P1/P2 | recruiting | Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor |
Rheumatic Heart Disease in Children (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05682196 | AGRAF-2 | P2 | suspended | Rituximab in Patients With Acute Rheumatic Fever |
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06134284 | — | P4 | recruiting | Clinical Study of OR for Second-line Treatment of Refractory MZL |
Follicular Lymphoma ( FL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04796922 | FL | P3 | withdrawn | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) |
Mature B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05533775 | iMATRIX GLO | P1/P2 | recruiting | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma |
Pharmacological Action (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05553496 | — | P2/P3 | unknown | Assessment of Rituximab Therapeutic Response Versus Conventional Treatment |
Efficacy and Safety (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05532111 | — | N/A | unknown | Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial |
Newly Diagnosed Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05506410 | — | N/A | recruiting | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma |
DLBCL Germinal Center B-Cell Type (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05422066 | — | P2 | recruiting | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05406401 | waveLINE-007 | P2 | active not recruiting | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) |
Transplant Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05156710 | SAR445088 | P2 | active not recruiting | BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) |
Relapsed or Refractory DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05115409 | PCR | P2 | unknown | Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) |
Overall Survival (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05392257 | — | P2 | unknown | Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial |
Relapsed Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05267054 | BGB-A1217 | P1/P2 | completed | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab |
Advanced Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05245916 | — | P1 | withdrawn | IBI397 or Combination Therapies in Patients With Advanced Malignancies |
Rituximab (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05324917 | — | N/A | unknown | Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases |
Primary Mediastinal Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06188676 | — | P3 | recruiting | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05279300 | — | P1 | recruiting | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas |
Relapsed Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05249959 | FIL_COLUMN | P2 | recruiting | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
IgA Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05329090 | RIGA | P3 | completed | Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis |
Myasthenia Gravis, Generalized (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05868837 | REFINE | P3 | recruiting | Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) |
Recurrent Adult Lymphoblastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05032183 | — | P1/P2 | terminated | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
Secondary Hemophagocytic Lymphohistiocytosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05384743 | — | P3 | unknown | Rituximab Monotherapy for EBV-HLH and CAEBV |
Lymphoplasmacytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04840602 | — | P2 | recruiting | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma |
Inert Non Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05073250 | — | P2 | unknown | IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. |
MCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05214183 | ALTAMIRA | P2 | active not recruiting | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma |
IgM MGUS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05065554 | — | P2 | active not recruiting | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy |
Primary Autoimmune Hemolytic Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05057468 | — | P3 | recruiting | Second-line Treatment of Primary Autoimmune Hemolytic Anemia |
Aggressive B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05025800 | ALX148 | P1/P2 | active not recruiting | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma |
Primary Mediastinal Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04759586 | — | P3 | active not recruiting | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma |
CD20-positive Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04920968 | OVERALL | P2 | recruiting | Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" |
Autoimmune Hemolytic Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05057481 | — | P3 | unknown | Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus |
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04981912 | — | P1 | active not recruiting | Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients |
Renal Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04540380 | — | P1 | active not recruiting | Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH |
Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04113226 | Relyage | P2 | completed | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma |
Giant Cell Arteritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05168475 | BIOVAS | P2 | terminated | Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis |
Anti-NMDAR Encephalitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03274375 | IANMDAR | P2 | recruiting | Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis |
Multicentric Castleman Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04585893 | — | P2 | active not recruiting | Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi |
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04609046 | — | P1 | recruiting | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma |
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04799275 | — | P2/P3 | active not recruiting | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma |
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04745949 | PACIFIC | P2 | recruiting | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy |
Refractory Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04856137 | DLBL | P1/P2 | not yet recruiting | A Phase I/II Study of Diffuse Large B-cell Lymphoma |
Non-GCB/ABC Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04835870 | — | P2 | unknown | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
Intravascular Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04899570 | — | P2 | unknown | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma |
Secondary Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05398224 | — | P2 | unknown | R-MTX-zanbrutinib in Secondary CNS Lymphoma |
Heart Failure With Reduced Ejection Fraction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03332888 | ICFEr-RITU2 | P2 | unknown | Safety of HMA-CD20 in Patients With HFrEF |
Frequently Relapsing Nephrotic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04531865 | — | P3 | withdrawn | Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment |
Beta Thalassemia Major (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04776850 | — | Early P1 | withdrawn | Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies |
Relapsed/Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04623541 | EPCORE™ CLL-1 | P1/P2 | active not recruiting | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome |
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04607772 | RR | P1/P2 | withdrawn | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
Microscopic Polyangiitis (MPA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03920722 | RITUXGOPRO | P3 | completed | Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis |
Inflammatory Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03651518 | PIMOC | P2 | completed | Personalized Therapies in Inflammatory Complex Disease |
Refractory Epilepsy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04542629 | — | P4 | unknown | Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children |
Immune-related Adverse Events (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04375228 | — | P2 | active not recruiting | Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) |
HBV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04519710 | HepB20 | N/A | completed | Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies |
Interstitial Lymphocytic Lung Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04572620 | — | N/A | unknown | Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies. |
Relapsed/Refractory Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04442022 | R-GDP | P2/P3 | active not recruiting | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Transplant; Complication, Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04496037 | MOT-AMR | N/A | not yet recruiting | Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant |
Primary Vitreoretinal Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04899453 | — | P2 | unknown | Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL |
AML/MDS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04318678 | CATCHAML | P1 | recruiting | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) |
Minimal Change Nephrotic Syndrome (MCNS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03970577 | RIFIREINS | P2 | unknown | RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome |
Large-B-cell Diffuse Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03804372 | CLL1818 | P2 | terminated | The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
Glioma of Spinal Cord (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04196413 | DIPG | P1 | recruiting | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) |
Blastic Plasmacytoid Dendritic Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04216524 | — | P2 | recruiting | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm |
High Grade B-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04285268 | — | P2 | withdrawn | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
Immune Thrombocytopenia Purpura (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05861297 | — | P4 | unknown | Immune Thrombocytopenia Management in Adults |
Grade 3b Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04156828 | — | P1 | terminated | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma |
Oncology Patients Receiving Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04189588 | versus | P2 | completed | Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine |
Angioimmunoblastic T-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04319601 | AITL | N/A | unknown | Rituximab Combined With Chidamide and Lenalidomide for r/r AITL |
Hematopoietic and Lymphoid System Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04022239 | — | P1/P2 | recruiting | Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant |
B Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06336395 | — | P2 | recruiting | Ma-Spore ALL 2020 Study |
Untreated Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04075292 | — | P3 | active not recruiting | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia |
Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04129710 | PCNSL | P2 | unknown | A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) |
Graft Vs Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04235036 | — | P2 | terminated | Ibrutinib and Rituxan for Chronic GVHD |
Liver Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04115631 | — | P2 | active not recruiting | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma |
Refractory Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04002401 | ZUMA-14 | P2 | completed | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma |
Relapsing Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04121403 | NOR-MS | P3 | completed | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) |
Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03997968 | — | P1/P2 | completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors |
Acute Myelogenous Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04023071 | — | P1 | terminated | FT516 in Subjects With Advanced Hematologic Malignancies |
CD19 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03579927 | — | P1/P2 | withdrawn | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma |
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04002297 | MANGROVE | P3 | active not recruiting | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation |
Lysosomal Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03952637 | — | P1/P2 | recruiting | A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis |
HTLV-1-associated Myelopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04004819 | — | P2 | unknown | Rituximab for HTLV-1-associated Myelopathy |
Kidney Transplant Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03994783 | TAR:GET-1 | P3 | terminated | Transplant Antibody-Mediated Rejection: Guiding Effective Treatments |
Severe Forms of Mucous Membrane Pemphigoid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03295383 | RITUX-MMP | P3 | active not recruiting | Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid |
Focal Segmental Glomerulosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03763643 | PRI-VENT FSGS | Early P1 | completed | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant |
Cutaneous Melanoma, Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03719131 | — | P2 | active not recruiting | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy |
Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03934814 | — | P1 | completed | Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma |
Chronic Graft-versus-host-disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03689894 | — | P1/P2 | terminated | Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT |
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03864185 | RECIPE | P2 | completed | The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies |
Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03783403 | — | P1 | terminated | A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers |
EBV-Positive DLBCL, Nos (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04181489 | — | P2 | unknown | Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS |
CD20 Positive B Cell NHL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03980379 | — | P1 | unknown | Pharmacokinetics, Efficacy and Safety of the 304 Injection |
CD20-positive Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03578198 | MG4101 | P2 | terminated | Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) |
Chronic Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03455517 | VeRitAs | P2 | completed | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia |
Relapsed or Refractory Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04279938 | — | P1 | withdrawn | A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL |
Acute Lymphoblastic Leukemia, in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04224571 | — | P2 | completed | CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children |
Acute Lymphoid Leukemia (ALL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03615105 | — | P2 | terminated | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors |
End-stage Renal Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03507348 | — | N/A | terminated | Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates |
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03576547 | — | P1/P2 | terminated | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia |
Recurrent Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03558750 | — | P1 | terminated | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma |
Indolent B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03571568 | — | P1/P2 | recruiting | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL |
Membranous Nephropathy - PLA2R Induced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05679336 | — | N/A | unknown | Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy |
Philadelphia Chromosome Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03518112 | — | P2 | terminated | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia |
Acute Lymphoblastic Leukemia in Remission (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03488225 | — | P2 | terminated | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia |
Breast Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03432741 | — | P1 | terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer |
Clonal Cytopenia of Undetermined Significance (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03418038 | — | P2 | recruiting | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia |
AIDS-Related Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03220022 | — | P1 | active not recruiting | Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas |
Eosinophilic Granulomatosis With Polyangiitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03164473 | MAINRITSEG | P3 | completed | Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. |
Invasive Pneumococcal Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03069703 | PNEUMOVAS | P2 | completed | Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy |
Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03372837 | — | P3 | completed | Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma |
Scleroderma, Systemic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04274257 | DesiReS | P2/P3 | completed | A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis |
Secondary Progressive Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03315923 | — | P2/P3 | completed | Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients |
Psychosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03194815 | SINAPPS2 | P2 | active not recruiting | IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 |
Diffuse B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03283202 | CC-122 | P1 | completed | Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors |
Systemic Lupus Erythematosus Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03054259 | ROOTS | P2 | unknown | Rituximab Objective Outcome Measures Trial in SLE |
Recurrent Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03136146 | — | P2 | recruiting | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia |
Primary Effusion Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02911142 | EPOCH-R2 | P1/P2 | active not recruiting | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma |
Membranoproliferative Glomerulonephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03180723 | — | P3 | unknown | Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis |
Graft-versus-host Disease (GVHD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03112603 | BAT | P3 | completed | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) |
Diffuse Large B-cell-lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03064867 | — | P1/P2 | active not recruiting | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Ischemic Heart Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03072199 | RITA-MI | P1/P2 | completed | Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study |
Non-hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03456466 | — | P1/P2 | unknown | Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma |
Cognitive Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03530462 | — | N/A | completed | To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI |
EBV-Related Post-Transplant Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02900976 | — | P2 | completed | Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder |
ANCA-Associated Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02994927 | ADVOCATE | P3 | completed | A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis |
Metastatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03013218 | ALX148 | P1 | completed | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) |
Lung Disease, Interstitial (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02990286 | EvER-ILD | P3 | completed | Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases |
Eosinophilic Granulomatosis With Polyangiitis (EGPA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02807103 | REOVAS | P3 | completed | Rituximab in Eosinophilic Granulomatosis With Polyangiitis |
Generalized Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02950155 | Rinomax | P3 | completed | A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis |
Diffuse Large B-cells Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02955823 | — | P2 | completed | A Phase II Study of the FIL on Elderly Frail Patients With DLBCL |
Renal Insufficiency, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02966717 | CKD | P2 | unknown | Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD) |
B-cell Lymphoma Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02843061 | — | P1/P2 | completed | Combination of Rituximab and NK Immunotherapy for B Lymphoma |
Waldenström Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02844322 | BDH-WM01 | P4 | completed | The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia |
Arthritis, Rheumatoid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02792699 | RA | P3 | completed | Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab |
Granulomatous and Lymphocytic Interstitial Lung Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02789397 | — | P2 | withdrawn | Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency |
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02670616 | — | P2 | completed | Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma |
Immunoglobulin G Subclass 4 Related Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02705638 | TIGR2 | P1 | completed | Treatment of IgG4-Related Disease With Revlimid and Rituximab |
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02600897 | FL | P1/P2 | completed | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Follicular Low Grade Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02501473 | — | P1/P2 | terminated | Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) |
Hemophilia A With Inhibitor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03598725 | HA-LD-ITI | P4 | unknown | Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China |
Granulomatosis With Polyangiitis (Wegener's Granulomatosis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02626845 | RENTGPA | P4 | terminated | Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis |
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02596971 | CHOP | P1/P2 | completed | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) |
Off-Label Use (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02654379 | — | N/A | completed | Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe |
Contiguous Stage II Adult Lymphoblastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02293109 | — | P1 | completed | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma |
Multiple Sclerosis, Chronic Progressive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02545959 | EFFRITE | P2 | completed | Intrathecal Rituximab in Progressive Multiple Sclerosis |
Composite Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02541565 | — | P1 | completed | Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma |
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02594384 | LAM-002A/NHL | P1 | completed | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma |
Diffuse Large B-cell Lymphoma Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02594163 | — | P2 | terminated | Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma |
Adult Burkitt Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02481310 | — | P1/P2 | unknown | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma |
Myelodysplastic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02356159 | — | P1/P2 | completed | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation |
Lymphoma,Non-Hodgkin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02367040 | CHRONOS-3 | P3 | completed | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) |
Cryoglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02556866 | ESBAM | P2 | terminated | Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis |
Wegener's Granulomatosis or Microscopic Polyangiitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02115997 | — | P4 | completed | A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis |
Hematologic Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02484053 | — | Early P1 | completed | Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders |
Blastoid Variant Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02427620 | — | P2 | active not recruiting | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma |
Pemphigus Vulgaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02383589 | MMF | P3 | completed | A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) |
Systemic Lupus Erythematosus, Lupus Nephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01773616 | RITUXILUP | P3 | terminated | Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis |
Relapsed/Refractory Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02460276 | PHILEMON | P2 | completed | A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma |
Refractory Diffuse Large B Cell Lymphoma (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02348216 | ZUMA-1 | P1/P2 | completed | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma |
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02384954 | — | P1/P2 | terminated | QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab |
ANCA-associated Vasculitides (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02433522 | MAINRITSAN3 | P3 | completed | Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab |
Hematologic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02367196 | — | P1 | completed | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers |
Chronic Lymphocyte Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02232386 | LLC1114 | P2 | completed | Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia |
ANCA-associated Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02222155 | — | P2 | completed | Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis |
Posttransplant Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02042391 | PTLD-2 | P2 | completed | Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy |
Frequent Relapsing Nephrotic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02390362 | RAMP | P3 | terminated | Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome |
Lung Transplant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02266888 | — | P2 | completed | B Cell Induction in Pediatric Lung Transplantation |
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02086175 | — | P2 | completed | A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma |
Transplants and Implants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02442648 | — | P1 | unknown | B-Cell Targeted Carfilzomib Desensitization |
CD20+ Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02391545 | CONTEMPO | P1/P2 | terminated | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) |
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02315326 | BTK | P1/P2 | completed | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) |
Fibrillary Glomerulonephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02197767 | — | P2 | completed | Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis |
Primary Progressive Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02253264 | — | P1 | completed | A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients |
Acute Bilineal Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02135874 | — | P2 | completed | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia |
Lung Diseases, Interstitial (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02251964 | RITUX-IP | P2/P3 | completed | Rituximab in Interstitial Pneumonitis |
Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02229942 | RituxME | P3 | completed | B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. |
Non-Hodgkin Lymphoma (NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02265731 | — | P1/P2 | completed | Study Evaluating Venetoclax in Subjects With Hematological Malignancies |
Macular Degeneration (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02332941 | Rituximab | P1 | completed | Treatment -Resistant Neovascular Age-Related Macular Degeneration |
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02228512 | — | P1/P2 | withdrawn | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02205333 | MEDI6469 | P1/P2 | terminated | A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies |
B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02044822 | — | P2 | terminated | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion |
Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02059239 | — | P1/P2 | completed | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma |
Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02110706 | — | P2 | completed | BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis |
Recurrent Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02160015 | — | P1 | active not recruiting | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery |
Pulmonary Alveolar Proteinosis (PAP) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01842386 | — | P1 | completed | Rituximab for Anti-cytokine Autoantibody-Associated Diseases |
Primary Central Nervous System Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01973062 | — | P2 | terminated | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma |
Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02048813 | — | P3 | active not recruiting | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
MEMBRANOUS NEPHROPATHY (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01955187 | STARMEN | P3 | completed | Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy |
Acute Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02043587 | — | P2 | terminated | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma |
Ambulatory IPF (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01969409 | ART-IPF | P2 | completed | Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis |
Mature B-Cell Leukemia Burkitt Type (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05049473 | BL | P2 | unknown | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. |
MALT Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01808599 | — | P2 | active not recruiting | Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma |
Advanced Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01983969 | — | P1/P2 | completed | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma |
Primary Focal Segmental Glomerulosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01573533 | — | P2 | completed | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS |
Follicular Lymphoma (FL/Indolent NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01994382 | — | P1/P2 | completed | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL |
Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01804712 | — | Early P1 | completed | Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy |
Head and Neck Squamous Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04361409 | — | P1 | completed | Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Non Hodgkin Lymphoma (NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01829958 | — | N/A | active not recruiting | Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy |
Opsoclonus Myoclonus Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01868269 | — | P3 | completed | Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) |
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01700946 | — | P2 | completed | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma |
Refractory Non Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01811368 | — | P2 | unknown | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
Waldenstrom's Macroglobulinaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01592981 | R2W | P2 | completed | Randomised Trial in Waldenstrom's Macroglobulinaemia |
Leukemia Lymphocytic Chronic B-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01744626 | — | P1 | completed | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01724021 | — | P3 | completed | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a |
Recurrent/Refractory CNS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01542918 | — | P1 | completed | Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma |
Fatigue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02376335 | RITPBC | P2 | completed | B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis |
Hematopoietic Cell Transplantation Recipient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01701986 | — | P1/P2 | completed | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
Diffuse Large B Cell Lymphoma CD20 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01659099 | GAINED | P3 | terminated | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma |
CD20+, B-cell Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01665768 | — | P2 | completed | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma |
Steroid Resistant Nephrotic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01716442 | RTX2012 | P2/P3 | unknown | Rituximab Trial for Pediatric Nephrotic Syndrome |
Heart Transplantation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01556347 | — | P2 | terminated | Multi-Drug Desensitization Protocol for Heart Transplant Candidates |
Small Lymphocytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01682616 | — | P1 | completed | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
Blood And Marrow Transplantation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01471067 | — | P1 | completed | Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies |
Relapsed or Refractory Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01676558 | DLBCL | P2 | unknown | A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) |
Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01678417 | — | P2 | unknown | 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma |
Crohn's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00692939 | — | P1/P2 | recruiting | Autologous Stem Cell Transplantation for Crohn's Disease |
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01611259 | — | P2 | completed | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue |
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01429025 | — | P1 | completed | Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma |
Retroperitoneal Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01584388 | — | P1/P2 | completed | Rituximab in IgG4-RD: A Phase 1-2 Trial |
Primary Mediastinal Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01516567 | — | P2 | completed | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation |
FSGS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01164098 | — | P3 | terminated | Rituximab to Prevent Recurrence of Proteinuria |
Recurrent IgA Nephropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02571842 | — | P4 | unknown | Rituximab in Recurrent IgA Nephropathy |
Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01509300 | — | P1/P2 | unknown | HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors |
Ophthalmopathy, Thyroid-Associated (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02378298 | RTX | P4 | completed | Rituximab (RTX) Therapy in Patients With Active TAO |
Non-Hodgkin's Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01567475 | (RAD001-R) | P1 | completed | The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas |
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01514344 | IRIS | P2 | completed | Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01429610 | RADICAL | P2 | unknown | Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia |
Post-transplant Lymphoproliferative Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01058239 | — | P2 | completed | Bortezomib Plus Rituximab for EBV+ PTLD |
Low-grade B Cell Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01718691 | — | P2 | completed | Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
CD20+ Aggressive B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01478542 | OPTIMAL>60 | P3 | completed | OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine |
Post-Transplant Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01434472 | — | P2 | terminated | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma |
Indolent Cutaneous B Cell Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02867553 | RADIO-LYMPH | P3 | unknown | Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions |
Relapsed or Refractory Marginal Zone B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01678404 | — | P2 | unknown | 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma |
Chemotherapeutic Agent Toxicity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01399372 | — | P2 | completed | Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma |
Cardiac Allograft Vasculopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01278745 | — | P2 | terminated | Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation |
Follicular Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01701232 | — | P3 | completed | Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma |
KSHV Inflammatory Cytokine Syndrome (KICS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01419561 | KICS | P2 | recruiting | Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) |
Large B Cell Diffuse Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01448096 | — | P2 | completed | Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma |
Aplastic Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01408342 | — | N/A | withdrawn | Alemtuzumab and Rituximab in Aplastic Anemia |
Adult B Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01326702 | — | P1/P2 | completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
Renal Transplant Recipients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01318915 | RESTARRT | Early P1 | terminated | Research Study of ATG and Rituximab in Renal Transplantation |
Recurrent Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01381692 | — | P1/P2 | completed | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma |
Lymphoma, Diffuse Large-Cell B-cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01415765 | — | P1/P2 | withdrawn | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma |
Systemic Sclerosis-Associated PAH (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01086540 | — | P2 | completed | Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) |
B-cell Chronic Lymphocytic Leukemia CLL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01370772 | — | P2 | completed | Intensified Rituimab Prephase Before FCR in Untreated B-CLL |
B-cell Small Lymphocytic Lymphoma Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01317901 | — | P1 | completed | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma |
Renal Insufficiency (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01312064 | — | P4 | terminated | De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction |
Chronic Graft-versus-host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01161628 | GVHD | P2 | completed | Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) |
IPF (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01266317 | — | P1/P2 | completed | Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations |
Warm Autoimmune Hemolytic Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01181154 | RAHIA | P3 | completed | Rituximab in Auto-Immune Hemolytic Anemia |
Non Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01316523 | — | P2 | terminated | Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma |
Childhood Idiopathic Nephrotic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01268033 | NEPHRUTIX | P2/P3 | completed | Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood |
Function of Renal Transplant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01095172 | ReMIND | P4 | unknown | RituxiMab INDuction in Renal Transplantation |
Ann Arbor Stage II Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00972478 | — | P1/P2 | active not recruiting | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma |
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01209130 | — | P1 | completed | A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma |
Indolent or Intermediate Grade B-cell Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01206777 | — | P2 | completed | Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies |
AIDS-Related Plasmablastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01193842 | — | P1/P2 | completed | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas |
Adult Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00992446 | — | P2 | completed | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
Lymphoma, Large B-cell, Diffuse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01181999 | — | P2 | unknown | Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma |
DMARD Resistant Rheumatoid Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01593332 | — | P4 | completed | Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis |
Type 1 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01280682 | — | P4 | completed | Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes |
B-cell Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00983619 | — | P1/P2 | completed | A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies |
Autoimmune Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01086631 | — | P1 | completed | Rituximab for Autoimmune Retinopathy |
Accelerated Phase Chronic Myelogenous Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01044745 | — | P2 | terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer |
Progressive Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01719159 | ITT-PMS | P2 | completed | Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis |
Anaplastic Large Cell Lymphoma, ALK-Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01035463 | — | P1/P2 | completed | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma |
Blood Stem Cell Transplant Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01010217 | — | P2 | completed | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide |
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00931918 | — | P2 | completed | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients |
Devic's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00787722 | — | P1/P2 | completed | Hematopoietic Stem Cell Transplant in Devic's Disease |
Large B-cell Diffuse Lymphoma of Testis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00945724 | IELSG30 | P2 | completed | Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis |
Active Chronic Graft Versus Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01001780 | PCR | P2 | withdrawn | Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease |
Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line. (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01127841 | RB | P2 | unknown | Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line |
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05063513 | ASTIL | P2/P3 | withdrawn | Autologous Stem Cell Transplantation: International Lupus Trial |
Pemphigus Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00784589 | Rituximab 3 | P3 | completed | Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus |
Sarcoidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00855205 | RIPS | P2 | completed | Rituximab for Pulmonary Sarcoidosis |
CD20-Positive Lymphoid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00788684 | — | P1 | completed | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers |
Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00936546 | — | P2 | completed | A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy |
MALT LYMPHOMA (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01015248 | MALT | P2 | completed | Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma |
HLA Sensitization (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00908583 | — | P4 | completed | Desensitization in Kidney Transplantation |
Advanced Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00892827 | — | P2 | unknown | Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia |
Indolent Non Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01830478 | R | P2 | unknown | Lenalidomide Plus Rituximab (R) in Non Follicular NHL |
Epstein Barr Virus Associated Non Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01964755 | — | P2 | terminated | Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma |
Follicular Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00877214 | MAINTAIN | P3 | active not recruiting | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas |
Leukemia, Lymphocytic, Acute (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00905034 | MOAD | P2 | completed | Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage |
High Risk Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00994643 | — | P2 | completed | Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma |
Autoimmune Hemolytic Disease (Cold Type) (Warm Type) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01345708 | — | P2 | completed | A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia |
T-Cell Peripheral Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01445535 | — | P1 | completed | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas |
Wegener Granulomatosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00748644 | MAINRITSAN | P3 | completed | Efficacy Study of Two Treatments in the Remission of Vasculitis |
Graft Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00771875 | — | P2 | completed | Randomized Trial for Mixed Acute Rejection |
No Hodgkin B Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00849355 | CV | P2 | unknown | Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk |
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00711828 | — | P2 | completed | Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma |
Hodgkins Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00515554 | — | P3 | completed | HD18 for Advanced Stages in Hodgkins Lymphoma |
Lymphoma of Mucosa-Associated Lymphoid Tissue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00656812 | MALT | P2 | completed | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma |
Thyroid-associated Ophthalmopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00595335 | — | P2/P3 | completed | Trial of Rituximab for Graves' Ophthalmopathy |
Lymphoma, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00509184 | MIR | P2 | completed | Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma |
Sjogren's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00740948 | TEARS | P2/P3 | completed | Tolerance and Efficacy of Rituximab in Sjogren's Disease |
Classic Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00654732 | — | P2 | completed | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma |
Focal Segmental Glomerulosclerosis (FSGS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00550342 | — | P2 | withdrawn | Rituximab Treatment of Focal Segmental Glomerulosclerosis |
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00617929 | — | P2 | terminated | Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant |
Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00609869 | — | P2 | completed | Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab |
Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01032122 | — | P1 | terminated | Rituximab in Metastatic Melanoma |
Chronic B-Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00558181 | LT-CLL-001 | P2 | completed | High-dose Methylprednisolone and Rituximab in High Risk B-CLL |
Churg-Strauss Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00424749 | — | P2 | terminated | Rituxan in Churg Strauss Syndrome With Renal Involvement |
Steroid-Refractory Chronic GVHD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00472225 | — | P2 | unknown | Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease |
Richter's Transformation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00472849 | — | P1/P2 | completed | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias |
Kidney Insufficiency (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00476515 | — | P1 | withdrawn | Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor |
Ankylosing Spondylitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00432653 | — | P2/P3 | unknown | Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis |
Scleritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00415506 | — | P1/P2 | completed | Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation |
Primary Sjögren's Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00426543 | — | P2 | completed | Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome |
Primary Biliary Cirrhosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00364819 | — | P1/P2 | completed | Initial Study of Rituximab to Treat Primary Biliary Cirrhosis |
Pulmonary Alveolar Proteinosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00552461 | PAP | P2 | completed | Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis |
Nonneoplastic Condition (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00486421 | — | Early P1 | completed | Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura |
Graves' Dysthyroid Ophthalmopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00424151 | — | P1/P2 | completed | Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy |
Psoriatic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00509678 | — | P1 | completed | Rituxan With or Without Methotrexate in Psoriatic Arthritis |
Early and Severe Systemic Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00379431 | — | P2 | completed | A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab |
Waldenstroms Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00832234 | BDR-WM | P2 | completed | Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia |
AIDS-Related-Primary Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00267865 | — | P2 | completed | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma |
Non Hodgkin's Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01830465 | — | P2 | completed | VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma |
Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00366418 | — | P1 | completed | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia |
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00346684 | RIPL | P2 | completed | Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) |
Hemophilia A (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00331006 | RICH | P2 | completed | Rituximab to Treat Severe Hemophilia A |
Leukemia, Lymphocytic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00327678 | ALL | P3 | completed | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults |
Behcet's Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00664599 | — | P2 | completed | Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease |
Polyneuropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00259974 | — | P3 | completed | RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy |
Leukemia, Lymphocytic, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00290407 | CLL | P2 | terminated | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) |
Thrombotic Thrombocytopenic Purpura (TTP) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00937131 | TTP | P2 | completed | The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) |
AIDS-related Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00310128 | — | P2 | withdrawn | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma |
Ocular Cicatricial Pemphigoid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00584935 | — | P1/P2 | completed | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid |
Urticaria (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00216762 | — | P1/P2 | terminated | Safety Study of Rituximab (Rituxan®) in Chronic Urticaria |
Non-Hodgkin's Lymphoma (CD20+) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00280878 | — | P2 | completed | Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma |
Chronic Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00261547 | — | P1/P2 | withdrawn | Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients |
Dermatitis, Atopic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00267826 | — | N/A | completed | Immunopharmacological Effects of Rituximab in Atopic Dermatitis |
Untreated T-cell Angioimmunoblastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00169156 | — | P2 | completed | A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma |
Glomerulonephritis, Membranoproliferative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00275613 | — | P1 | completed | Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis |
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00288067 | — | P1/P2 | terminated | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
Relapsed or Refractory Chronic Lymphoproliferative Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01224769 | — | N/A | completed | Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders |
Anemia, Aplastic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00229619 | — | P2 | completed | Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia |
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02486952 | — | N/A | completed | MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma |
Leukemia, Mast-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00186628 | — | P2 | completed | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD |
Opsoclonus-myoclonus Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00244361 | — | P1/P2 | completed | Effectiveness of Rituximab in Pediatric OMS Patients. |
Immunocytoma/Morbus Waldenström (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00927797 | PERLL | P2 | unknown | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) |
Precancerous Condition (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00588822 | — | P2 | terminated | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance |
Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00104299 | RAVE | P2/P3 | completed | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis |
Chronic Focal Encephalitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00259805 | — | P1 | completed | A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis |
Relapsed or Refractory Mantle Cell Lymphoma (MCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00656084 | — | P2 | completed | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell |
Stiff Person Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00091897 | — | P2 | completed | Rituximab to Treat Stiff Person Syndrome |
Lymphoma, High-Grade (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00385125 | — | P2 | unknown | Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL |
Hairy Cell Leukemia (HCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02157181 | — | P2 | completed | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab |
Childhood Burkitt Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00057811 | — | P2 | completed | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma |
Untreated CD20-positive Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00169143 | — | P2 | completed | Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma |
Ulcerative Colitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00261118 | — | P2/P3 | completed | Rituximab in Active Ulcerative Colitis |
Follicular T-NHL Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01560117 | — | P2 | completed | Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma |
Diffuse Large-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00140595 | — | P3 | completed | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 |
B-cell Childhood Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00058461 | — | P2 | terminated | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
Refractory Aggressive Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01538641 | GROC | P2 | completed | Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas |
Graves´ Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00150111 | — | P1/P2 | completed | Rituximab in the Treatment of Graves' Disease |
HIV Infections (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00127569 | — | P2 | terminated | Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy |
Primary Gastric Diffuse-Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00204659 | CHOP | P2 | completed | Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
Non-Hodgkin's Lymphoma (NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00129090 | — | P3 | completed | Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma |
AIDS-related Diffuse Large Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00049036 | — | P2 | completed | Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma |
Elderly Patients (>65 Years) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01148446 | ANZINTER3 | P3 | completed | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL |
Cutaneous B-cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00054639 | — | P2 | completed | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
Lymphoma, Mucosa-Associated Lymphoid Tissue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00210353 | — | P3 | completed | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma |
Post-transplantation Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01458548 | PTLD | P2 | terminated | Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) |
Polyneuropathies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00050245 | — | P2 | completed | Rituximab to Treat Neuropathy With Anti-MAG Antibodies |
Aggressive Non-Hodgkin's Lymphoma in the Elderly. (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00244127 | — | P2 | unknown | Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL. |
B-Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00201721 | — | P2 | completed | Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia |
CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01933711 | — | P3 | unknown | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma |
AIDS-related Peripheral/Systemic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00036855 | — | P1 | terminated | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma |
Post-transplant Lymphoproliferative Disease (PTLD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01088724 | FCD-R | P4 | completed | Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) |
Hepatitis C (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00029107 | — | P2 | completed | Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis |
Relapsed Non-Hodgkin-Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02099292 | Mz-135 | P2 | completed | Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma |
Lymphoma, AIDS-related (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00006436 | — | P2 | completed | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection |
CD20-Positive Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00169169 | — | P3 | terminated | Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma |
Breast Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00001805 | — | P2 | completed | A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab |
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00168740 | — | P3 | completed | Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) |
Systemic Scleroderma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01047072 | — | P2 | withdrawn | Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis |
Rituximab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| RITUX4 | NCT05898308 | P4 | recruiting | Pemphigus | 133 | — |
| ITP | NCT04518475 | P4 | recruiting | Primary Immune Thrombocytopenia (ITP) | 224 | — |
| BEST-NMOSD | NCT07010302 | P4 | not yet recruiting | NMOSD | 540 | PMID 36007339 |
| RESTORE | NCT06015750 | P4 | withdrawn | Hypophosphatasia | 0 | — |
| PREP-ANCA | NCT07451847 | P4 | not yet recruiting | ANCA Associated Vasculitis (AAV) | 70 | — |
| REPLY | NCT04989491 | P4 | recruiting | Epstein-Barr Virus Infections | 120 | — |
| MINUTE | NCT06031233 | P4 | recruiting | Oncology | 776 | — |
| GLUREDLUP | NCT05207358 | P4 | recruiting | Lupus Nephritis | 30 | PMID 33572385 |
| ARRIA | NCT06611696 | P4 | recruiting | ANCA Associated Vasculitis (AAV) | 160 | PMID 35110332 |
| RITUXERA | NCT06003283 | P4 | recruiting | Rheumatoid Arthritis | 134 | PMID 39407334 |
| BRRPJS | NCT06410833 | P4 | recruiting | Sjogren's Syndrome | 15 | — |
| RADAR | NCT06906549 | P4 | recruiting | Rheumatoid Arthritis (RA) | 260 | — |
| RITA | NCT04525729 | P4 | completed | IgA Nephropathy | 116 | PMID 38299639 |
| BDH-WM01 | NCT02844322 | P4 | completed | Waldenström Macroglobulinemia | 35 | PMID 38205507 |
| ReMIND | NCT01095172 | P4 | unknown | Function of Renal Transplant | 100 | — |
| MAINTANCAVAS | NCT02749292 | P4 | terminated | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 115 | PMID 38123922 |
| LoVAS | NCT02198248 | P4 | unknown | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 140 | PMID 33164993 |
| HA-LD-ITI | NCT03598725 | P4 | unknown | Hemophilia A With Inhibitor | 55 | PMID 40286913 |
| BDH-MCL01 | NCT02858804 | P4 | completed | Mantle Cell Lymphoma | 55 | — |
| RESCUE | NCT04256252 | P4 | completed | Neuromyelitis Optica Spectrum Disorder | 108 | — |
| RTX | NCT02378298 | P4 | completed | Ophthalmopathy, Thyroid-Associated | 38 | — |
| SCOUT | NCT02169219 | P4 | completed | Granulomatosis With Polyangiitis | 20 | — |
| RENTGPA | NCT02626845 | P4 | terminated | Granulomatosis With Polyangiitis (Wegener's Granulomatosis) | 3 | PMID 22627727 |
| RituxiCAN-C4 | NCT00476164 | P4 | completed | Kidney Transplantation | 62 | PMID 32117242 |
| SWITCH | NCT01295151 | P4 | completed | Rheumatoid Arthritis | 122 | PMID 32859608 |
| ORBIT | NCT01021735 | P4 | completed | Rheumatoid Arthritis | 302 | PMID 27197690 |
| SEWORRA | NCT01765374 | P4 | completed | Rheumatoid Arthritis | 30 | PMID 36377584 |
| ROC | NCT01000441 | P4 | completed | Rheumatoid Arthritis | 300 | PMID 27654603 |
| RATE-RA | NCT01382940 | P4 | completed | Rheumatoid Arthritis | 351 | — |
| PARIS | NCT02731560 | P4 | completed | Rheumatoid Arthritis | 74 | — |
| RESONAR | NCT01117129 | P4 | terminated | Rheumatoid Arthritis | 2 | — |
| FCD-R | NCT01088724 | P4 | completed | Post-transplant Lymphoproliferative Disease (PTLD) | 4 | — |
| PK-rituximab | NCT00820469 | P4 | completed | Renal Transplant | 20 | PMID 23432476 |
| RFC | NCT01124526 | P4 | completed | Non Hodgkin Lymphoma | 75 | — |
| EPCORE™FL-2 | NCT06191744 | P3 | recruiting | Follicular Lymphoma (FL) | 1,095 | — |
| VR | NCT05947851 | P3 | recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 735 | — |
| CITADEL-310 | NCT04849715 | P3 | withdrawn | Mantle Cell Lymphoma | 0 | — |
| MorningLyte | NCT06284122 | P3 | recruiting | Follicular Lymphoma | 790 | — |
| FL | NCT04796922 | P3 | withdrawn | Follicular Lymphoma ( FL) | 0 | — |
| MK-2140 | NCT06717347 | P3 | recruiting | Diffuse Large B-Cell Lymphoma | 1,046 | — |
| REFINE | NCT07509840 | P3 | recruiting | Autoimmune Prematur Ovarian Insuffience | 40 | — |
| CELESTIAL-RRCLL | NCT06943872 | P3 | recruiting | Chronic Lymphocytic Leukemia | 630 | — |
| iRITUX | NCT06341205 | P3 | recruiting | Membranous Nephropathy | 120 | PMID 40180405 |
| MANGROVE | NCT04002297 | P3 | active not recruiting | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | 510 | PMID 32985902 |
| ZUMA-23 | NCT05605899 | P3 | active not recruiting | High-risk Large B-cell Lymphoma (LBCL) | 300 | — |
| LEDA | NCT05888493 | P3 | active not recruiting | Follicular Lymphoma (FL) | 109 | — |
| Breakfree-SSc | NCT07335562 | P3 | recruiting | Systemic Sclerosis | 92 | — |
| ZUMA-22 | NCT05371093 | P3 | active not recruiting | Relapsed/Refractory Follicular Lymphoma | 231 | — |
| DESIRE MS | NCT07189325 | P3 | not yet recruiting | Relapsing-Remitting Multiple Sclerosis (RRMS) | 250 | — |
| GOLSEEK-4 | NCT06911502 | P3 | recruiting | Follicular Lymphoma | 400 | — |
| MAHOGANY | NCT05100862 | P3 | recruiting | Relapsed/Refractory Follicular Lymphoma | 780 | — |
| TRIO | NCT05758831 | P3 | recruiting | Multiple Sclerosis | 386 | — |
| IDAR | NCT05545384 | P3 | recruiting | Acute Demyelinating Syndrome | 86 | — |
| CaDAnCe-302 | NCT06846671 | P3 | recruiting | CLL | 250 | — |
| IGNITE | NCT07104032 | P3 | recruiting | Relapsed/Refractory Primary Central Nervous System Lymphoma | 132 | — |
| TAI-SHAN6 | NCT07139873 | P3 | recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 250 | — |
| EPCORE DLBCL-2 | NCT05578976 | P3 | active not recruiting | Diffuse Large B-Cell Lymphoma | 900 | — |
| EPCORE FL-1 | NCT05409066 | P3 | active not recruiting | Follicular Lymphoma (FL) | 549 | PMID 41371238 |
| Celestimo | NCT04712097 | P3 | active not recruiting | Relapsed or Refractory Follicular Lymphoma | 478 | — |
| CaDAnCe-303 | NCT06970743 | P3 | recruiting | Chronic Lymphocytic Leukemia | 150 | — |
| GOLSEEK-1 | NCT06356129 | P3 | active not recruiting | Large B-cell Lymphoma | 850 | — |
| OLYMPIA-1 | NCT06091254 | P3 | recruiting | Follicular Lymphoma (FL) | 822 | — |
| OLYMPIA-3 | NCT06091865 | P3 | recruiting | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | — |
| OLYMPIA-2 | NCT06097364 | P3 | active not recruiting | Follicular Lymphoma (FL) | 733 | — |
| IMCOMG | NCT06342544 | P3 | recruiting | Ocular Myasthenia Gravis | 128 | — |
| DanNORMS | NCT04688788 | P3 | active not recruiting | Relapsing Remitting Multiple Sclerosis | 600 | — |
| RITZ | NCT05735834 | P3 | active not recruiting | Splenic Marginal Zone Lymphoma | 122 | — |
| OLYMPIA-4 | NCT06230224 | P3 | active not recruiting | B-Cell Non-Hodgkin Lymphoma (B-NHL) | 216 | — |
| SATELITE | NCT04871191 | P3 | recruiting | Granulomatosis With Polyangiitis | 42 | PMID 27338776 |
| SYMPHONY-1 | NCT04224493 | P3 | active not recruiting | Relapsed/Refractory Follicular Lymphoma | 599 | PMID 40896460 |
| SAFE-LOW | NCT06983821 | P3 | recruiting | Granulomatosis With Polyangiitis | 36 | — |
| OLYMPIA-5 | NCT06149286 | P3 | recruiting | Relapsed/Refractory Follicular Lymphoma | 470 | — |
| EVER-ILD 3 | NCT06549231 | P3 | recruiting | Interstitial Lung Disease With Systemic Sclerosis | 102 | — |
| THERAMAG | NCT05136976 | P3 | recruiting | Anti-MAG Neuropathy | 90 | — |
| HO170DLBCL | NCT06220032 | P3 | recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 324 | PMID 39875951 |
| OptiMATe | NCT04931368 | P3 | active not recruiting | Primary Central Nervous System Lymphoma | 331 | — |
| ReCIX | NCT06714838 | P3 | recruiting | CIDP | 100 | — |
| APG-2575 | NCT06319456 | P3 | recruiting | CLL/SLL | 344 | — |
| InMIND | NCT04680052 | P3 | active not recruiting | Follicular Lymphoma | 654 | PMID 41360064 |
| LOTIS 5 | NCT04384484 | P3 | active not recruiting | Relapsed Diffuse Large B-Cell Lymphoma | 440 | — |
| EPCORE DLBCL-4 | NCT06508658 | P3 | active not recruiting | Diffuse Large B-Cell Lymphoma | 379 | — |
| GLOBRYTE | NCT06084936 | P3 | recruiting | Lymphoma | 182 | — |
| REDUCE-PMR-2 | NCT05533164 | P3 | active not recruiting | Polymyalgia Rheumatica | 174 | PMID 39400109 |
| PRIME | NCT05914155 | P3 | recruiting | Glomerulonephritis, Membranous | 88 | PMID 40100934 |
| RITUX-PLUS 2 | NCT05338190 | P3 | recruiting | Primary Immune Thrombocytopenia (ITP) | 132 | — |
| frontMIND | NCT04824092 | P3 | active not recruiting | Diffuse Large B-cell Lymphoma | 899 | PMID 40993016 |
| BRUIN CLL-313 | NCT05023980 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 309 | PMID 41363773 |
| BRUIN CLL-322 | NCT04965493 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 600 | — |
| SEQUOIA | NCT03336333 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 590 | PMID 33054121 |
| B-NHL 2013 | NCT03206671 | P3 | active not recruiting | Mature B-cell Non-Hodgkin Lymphoma | 650 | — |
| Noisy Rebels | NCT05834855 | P3 | recruiting | Multiple Sclerosis | 200 | — |
| BRUIN CLL-321 | NCT04666038 | P3 | active not recruiting | Chronic Lymphocytic Leukemia | 238 | PMID 40479620 |
| RITUX-MMP | NCT03295383 | P3 | active not recruiting | Severe Forms of Mucous Membrane Pemphigoid | 92 | — |
| SUNMO | NCT05171647 | P3 | active not recruiting | Non-Hodgkin Lymphoma | 208 | PMID 41037766 |
| ESCALADE | NCT04529772 | P3 | active not recruiting | Diffuse Large B-Cell Lymphoma | 611 | — |
| ECHELON-3 | NCT04404283 | P3 | active not recruiting | Diffuse Large B-cell Lymphoma | 239 | PMID 34780623 |
| TIM-DePisT | NCT05946486 | P3 | not yet recruiting | Mental Disorder | 174 | — |
| STORM | NCT05734794 | P3 | recruiting | Nephrotic Syndrome in Children | 80 | PMID 32872709 |
| EvER-ILD2 | NCT05596786 | P3 | recruiting | Lung Diseases | 126 | PMID 39693827 |
| POLARIX | NCT03274492 | P3 | completed | Diffuse Large B-Cell Lymphoma | 1,000 | PMID 35726803 |
| RIGA | NCT05329090 | P3 | completed | IgA Vasculitis | 75 | — |
| REDUCE-PMR-1 | NCT05533125 | P3 | completed | Polymyalgia Rheumatica | 114 | — |
| OVERLORD-MS | NCT04578639 | P3 | active not recruiting | Relapsing Remitting Multiple Sclerosis | 214 | — |
| REFINE | NCT05868837 | P3 | recruiting | Myasthenia Gravis, Generalized | 40 | — |
| DEB | NCT04231448 | P3 | completed | Diffuse Large B-cell Lymphoma | 423 | PMID 42018318 |
| RIDOSE-MS | NCT03979456 | P3 | unknown | Multiple Sclerosis, Relapsing-Remitting | 200 | — |
| ENDURRANCE-1 | NCT03942887 | P3 | unknown | ANCA Associated Vasculitis | 100 | PMID 36130755 |
| CRISTALLO | NCT04285567 | P3 | completed | Chronic Lymphocytic Leukemia (CLL) | 166 | — |
| MAINTAIN | NCT00877214 | P3 | active not recruiting | Follicular Lymphomas | 1,272 | — |
| POLARGO | NCT04182204 | P3 | completed | Diffuse Large B-Cell Lymphoma | 270 | — |
| CHRONOS-3 | NCT02367040 | P3 | completed | Lymphoma,Non-Hodgkin | 458 | PMID 33848462 |
| MAINRITSEG | NCT03164473 | P3 | completed | Eosinophilic Granulomatosis With Polyangiitis | 98 | — |
| MAGNIFY | NCT01996865 | P3 | completed | Lymphoma, Non-Hodgkin | 503 | PMID 30919940 |
| NOR-MS | NCT04121403 | P3 | completed | Relapsing Multiple Sclerosis | 267 | — |
| ILyAD | NCT03078855 | P3 | completed | Follicular Lymphoma | 211 | PMID 39677358 |
| RELEVANCE | NCT01650701 | P3 | completed | Follicular Lymphoma | 1,030 | PMID 35947804 |
| RELEVANCE | NCT01476787 | P3 | completed | Follicular Lymphoma | 1,030 | PMID 24122387 |
| GAIA | NCT02950051 | P3 | completed | Chronic Lymphocytic Leukemia | 926 | PMID 38821083 |
| OPTIMAL>60 | NCT01478542 | P3 | completed | CD20+ Aggressive B-Cell Lymphoma | 1,152 | PMID 33928400 |
| RITURNS II | NCT03899103 | P3 | completed | Steroid-Dependent Nephrotic Syndrome | 100 | PMID 36456193 |
| CIDPRIT | NCT06325943 | P3 | completed | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 37 | PMID 39658326 |
| CHRONOS-4 | NCT02626455 | P3 | terminated | Lymphoma, Non-Hodgkin | 551 | PMID 39058951 |
| RITUXGOPRO | NCT03920722 | P3 | completed | Microscopic Polyangiitis (MPA) | 8 | PMID 24161361 |
| MABRIDGE | NCT04680962 | P3 | withdrawn | Rheumatoid Arthritis | 0 | — |
| SELENE | NCT01974440 | P3 | completed | Lymphoma | 403 | PMID 37722354 |
| PACIFICO | NCT01303887 | P3 | completed | Follicular Lymphoma | 680 | — |
| BLOCAGE-01 | NCT02313389 | P3 | unknown | Primary Central Nervous System Lymphoma | 428 | PMID 38366824 |
| ME-401 | NCT04745832 | P3 | terminated | Follicular Lymphoma (FL) | 82 | — |
| FLINTER | NCT03976102 | P3 | completed | Follicular Lymphoma | 317 | PMID 40421128 |
| TAR:GET-1 | NCT03994783 | P3 | terminated | Kidney Transplant Rejection | 3 | — |
| BAT | NCT03112603 | P3 | completed | Graft-versus-host Disease (GVHD) | 330 | PMID 40561385 |
| MURANO | NCT02005471 | P3 | completed | Chronic Lymphocytic Leukemia | 389 | PMID 35605176 |
| ROBUST | NCT02285062 | P3 | completed | Lymphoma, Large B-Cell, Diffuse | 570 | PMID 33621109 |
| Rinomax | NCT02950155 | P3 | completed | Generalized Myasthenia Gravis | 47 | PMID 36121672 |
| AUGMENT | NCT01938001 | P3 | completed | Lymphoma, Non-Hodgkin | 358 | PMID 30897038 |
| RIFUND-MS | NCT02746744 | P3 | completed | Multiple Sclerosis, Relapsing-Remitting | 200 | PMID 35841908 |
| RO5072759 | NCT01332968 | P3 | completed | Non-Hodgkin's Lymphoma | 1,401 | PMID 30309758 |
| SLE | NCT03312907 | P3 | completed | Systemic Lupus Erythematosus | 292 | PMID 30898822 |
| SC | NCT02406092 | P3 | completed | Non-Hodgkin Lymphoma | 139 | — |
| FLIRT | NCT02303119 | P3 | completed | Follicular Lymphoma | 221 | PMID 37071836 |
| BRiF | NCT02423837 | P3 | unknown | Follicular Lymphoma | 200 | — |
| CREHA | NCT01808911 | P3 | completed | Acquired Haemophilia | 110 | PMID 38555718 |
| DLBCL | NCT03777085 | P3 | unknown | Diffuse Large B-cell Lymphoma | 230 | — |
| REOVAS | NCT02807103 | P3 | completed | Eosinophilic Granulomatosis With Polyangiitis (EGPA) | 107 | PMID 40720835 |
| EvER-ILD | NCT02990286 | P3 | completed | Lung Disease, Interstitial | 122 | PMID 37230499 |
| RI-CYCLO | NCT03018535 | P3 | unknown | Glomerulonephritis, Membranous | 76 | PMID 33649098 |
| LYRITUX | NCT02304354 | P3 | completed | Rheumatoid Arthritis | 70 | PMID 23918413 |
| Javelin DLBCL | NCT02951156 | P3 | terminated | Diffuse Large B-Cell Lymphoma | 29 | PMID 34687398 |
| RITAZAREM | NCT01697267 | P3 | completed | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 188 | PMID 36958796 |
| ADVOCATE | NCT02994927 | P3 | completed | ANCA-Associated Vasculitis | 331 | PMID 35167187 |
| MMF | NCT02383589 | P3 | completed | Pemphigus Vulgaris | 135 | PMID 34097368 |
| JASMINE | NCT02747043 | P3 | completed | Lymphoma, Non-Hodgkin | 256 | PMID 33044684 |
| STARMEN | NCT01955187 | P3 | completed | MEMBRANOUS NEPHROPATHY | 86 | PMID 34778952 |
| Tugela | NCT01569295 | P3 | completed | Chronic Lymphocytic Leukemia | 416 | PMID 31729982 |
| DLBCL | NCT01889069 | P3 | completed | Lymphoma | 159 | — |
| LTFURITUX3 | NCT03790293 | P3 | completed | Autoimmune Diseases | 80 | PMID 28342637 |
| RADIO-LYMPH | NCT02867553 | P3 | unknown | Indolent Cutaneous B Cell Lymphomas | 36 | — |
| (R-HAD) | NCT01449344 | P3 | unknown | Mantle Cell Lymphoma | 128 | PMID 38678093 |
| MCLelderly | NCT00209209 | P3 | unknown | Lymphoma, Mantle-Cell | 570 | PMID 22873532 |
| RA | NCT02792699 | P3 | completed | Arthritis, Rheumatoid | 311 | PMID 32627420 |
| PIX-R | NCT01321541 | P3 | completed | Diffuse Large B-cell Lymphoma | 312 | PMID 31879945 |
| MAINRITSAN3 | NCT02433522 | P3 | completed | ANCA-associated Vasculitides | 97 | PMID 32479166 |
| MabCute | NCT01461928 | P3 | completed | Non-Hodgkin's Lymphoma | 692 | PMID 24720836 |
| MADILYM | NCT02617485 | P3 | completed | Diffuse Large B-Cell Lymphoma | 143 | — |
| GOYA | NCT01287741 | P3 | terminated | Diffuse Large B-Cell Lymphoma | 1,418 | PMID 38498084 |
| ASSIST_FL | NCT01419665 | P3 | completed | Follicular Lymphoma | 629 | PMID 28712941 |
| RITUXILUP | NCT01773616 | P3 | terminated | Systemic Lupus Erythematosus, Lupus Nephritis | 24 | — |
| GAINED | NCT01659099 | P3 | terminated | Diffuse Large B Cell Lymphoma CD20 Positive | 671 | PMID 33211799 |
| RituxME | NCT02229942 | P3 | completed | Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) | 151 | PMID 30934066 |
| SC | NCT01200758 | P3 | completed | Non-Hodgkin's Lymphoma | 410 | PMID 24521993 |
| FND | NCT00577993 | P3 | completed | Lymphoma | 210 | — |
| CLL11 | NCT02053610 | P3 | completed | Lymphocytic Leukemia, Chronic | 787 | PMID 29255066 |
| CLL11 | NCT01998880 | P3 | completed | Lymphocytic Leukemia, Chronic | 787 | — |
| CLL11 | NCT01010061 | P3 | completed | Lymphocytic Leukemia, Chronic | 787 | PMID 33131249 |
| ITP | NCT00909077 | P3 | completed | Idiopathic Thrombocytopenic Purpura | 155 | — |
| LLC2007SA | NCT00645606 | P3 | completed | Leukemia | 542 | PMID 29275118 |
| PLRG4 | NCT00801281 | P3 | completed | Follicular Lymphoma | 250 | — |
| DYNAMO + R | NCT02204982 | P3 | terminated | Follicular Lymphoma | 13 | — |
| RAMP | NCT02390362 | P3 | terminated | Frequent Relapsing Nephrotic Syndrome | 3 | — |
| Rituximab 3 | NCT00784589 | P3 | completed | Pemphigus Disease | 90 | PMID 32186656 |
| HOMER | NCT01200589 | P3 | terminated | Non-Hodgkin's Lymphoma | 438 | PMID 32810220 |
| BRAVURA | NCT02576275 | P3 | withdrawn | Indolent Non-Hodgkin's Lymphoma | 0 | — |
| ASSIST-RT | NCT02514772 | P3 | completed | Rheumatoid Arthritis | 107 | PMID 30295429 |
| SPINOZA | NCT02366663 | P3 | terminated | Recurrent Diffuse Large B-Cell Lymphoma | 3 | — |
| GEMRITUX | NCT01508468 | P3 | completed | Idiopathic Membranous Nephropathy | 80 | PMID 31340979 |
| RIACT | NCT01117662 | P3 | terminated | Acute Rejection | 13 | PMID 23101480 |
| Yosemite | NCT01732913 | P3 | terminated | Indolent Non-Hodgkin's Lymphomas | 295 | — |
| Bridalveil | NCT01732926 | P3 | terminated | Indolent Non-Hodgkin's Lymphomas | 475 | — |
| MAINRITSAN 2 | NCT01731561 | P3 | completed | Granulomatosis With Polyangiitis | 166 | PMID 29695500 |
| RAHIA | NCT01181154 | P3 | completed | Warm Autoimmune Hemolytic Anemia | 32 | — |
| RITULUP | NCT01765842 | P3 | terminated | Lupus Nephritis | 9 | — |
| CLL | NCT00718549 | P3 | completed | Lymphocytic Leukemia, Chronic | 128 | — |
| BIORA | NCT01759030 | P3 | completed | Rheumatoid Arthritis | 181 | — |
| ORCHARRD | NCT01014208 | P3 | completed | Lymphoma, Large-Cell, Diffuse | 447 | — |
| PET | NCT01510184 | P3 | terminated | Diffuse Large B-cell Lymphoma | 79 | — |
| CLL | NCT01539512 | P3 | completed | Chronic Lymphocytic Leukemia | 220 | PMID 32599655 |
| ALL | NCT00327678 | P3 | completed | Leukemia, Lymphocytic | 1,080 | PMID 24166518 |
| IDEC-C2B8 | NCT00064116 | P3 | completed | Lymphoma | 824 | PMID 16648042 |
| ITP | NCT01506414 | P3 | completed | Purpura | 91 | — |
| ITP | NCT01734057 | P3 | withdrawn | Purpura | 0 | PMID 19005182 |
| DLCL04 | NCT00499018 | P3 | unknown | Diffuse Large B-Cell Lymphoma | 399 | PMID 28668386 |
| IMAGE | NCT00299104 | P3 | completed | Rheumatoid Arthritis | 755 | PMID 20937671 |
| SERENE | NCT00299130 | P3 | completed | Rheumatoid Arthritis | 511 | PMID 20488885 |
| MAINRITSAN | NCT00748644 | P3 | completed | Wegener Granulomatosis | 117 | PMID 27049404 |
| SCORE | NCT00578305 | P3 | completed | Rheumatoid Arthritis | 185 | PMID 25355728 |
| DMARD | NCT00503425 | P3 | completed | Rheumatoid Arthritis | 215 | — |
| RA | NCT00422383 | P3 | completed | Rheumatoid Arthritis | 378 | PMID 20463186 |
| SUNDIAL | NCT00443651 | P3 | completed | Rheumatoid Arthritis | 578 | PMID 23547218 |
| LUNAR | NCT00282347 | P3 | completed | Lupus Nephritis | 144 | PMID 26867033 |
| Suiviritux | NCT01299857 | P3 | completed | Pemphigus | 22 | — |
| NHL | NCT01073163 | P3 | completed | Non-Hodgkin's Lymphoma | 54 | — |
| CLL | NCT00090051 | P3 | completed | Chronic Lymphocytic Leukemia | 552 | PMID 23525797 |
| BR | NCT00877006 | P3 | completed | Non-Hodgkin's Lymphoma | 447 | PMID 24591201 |
| VOYAGER | NCT00381810 | P3 | terminated | Lupus Erythematosus, Systemic | 31 | — |
| CLL-8 | NCT00281918 | P3 | completed | Leukemia | 817 | PMID 24916506 |
| NHL | NCT01144364 | P3 | completed | Non-Hodgkin's Lymphoma | 234 | PMID 23960180 |
| RATE | NCT00719472 | P3 | completed | Non-Hodgkin's Lymphoma | 451 | — |
| NEMO | NCT00981838 | P3 | completed | Nephrotic Syndrome | 24 | PMID 24480824 |
| NHL | NCT00562965 | P3 | terminated | Lymphoma, Follicular | 29 | — |
| NHL | NCT00088530 | P3 | completed | Lymphoma, Non-Hodgkin | 140 | PMID 22652183 |
| NHL | NCT00363636 | P3 | terminated | Lymphoma, Non-Hodgkin's | 340 | — |
| STAR | NCT00799773 | P3 | terminated | Thrombotic Thrombocytopenic Purpura | 3 | — |
| NHL | NCT00384150 | P3 | terminated | Lymphoma, Non-Hodgkin's | 16 | — |
| RESET | NCT01272908 | P3 | completed | Rheumatoid Arthritis | 120 | — |
| ITP | NCT00770562 | P3 | completed | Idiopathic Thrombocytopenic Purpura | 103 | PMID 20130241 |
| SUNRISE | NCT00266227 | P3 | completed | Rheumatoid Arthritis | 559 | — |
| ANZINTER3 | NCT01148446 | P3 | completed | Elderly Patients (>65 Years) | 226 | PMID 29975624 |
| BRAZAN | NCT06854003 | P2 | recruiting | Mantle Cell Lymphoma | 60 | — |
| MT2023-20 | NCT06412497 | P2 | recruiting | Severe Aplastic Anemia | 60 | — |
| VIWA-1 | NCT05099471 | P2 | recruiting | Waldenstrom Macroglobulinemia | 80 | PMID 37348018 |
| IMCL-2023 | NCT07285590 | P2 | recruiting | Mantle Cell Lymphoma (MCL) | 50 | — |
| PreTreg | NCT06688331 | P2 | recruiting | Presymptomatic Diabetes Type 1 (Stage 1) | 150 | — |
| PIONEER-MZL | NCT06390956 | P2 | recruiting | Marginal Zone Lymphoma | 23 | — |
| MK-2140 | NCT06890884 | P2 | recruiting | Lymphoma, Large B-Cell, Diffuse | 594 | — |
| SC | NCT05283720 | P2 | recruiting | Non-Hodgkin Lymphoma | 496 | — |
| ZBR in WM | NCT07259122 | P2 | not yet recruiting | Waldenström Macroglobulinemia (WM) | 43 | — |
| REFRACT | NCT05848765 | P2 | recruiting | Relapsed Follicular Lymphoma | 284 | PMID 38528445 |
| HM2023-43 | NCT06792825 | P2 | recruiting | Follicular Lymphoma | 65 | — |
| HiHat | NCT07517185 | P2 | not yet recruiting | Relapsing-remitting Multiple Sclerosis | 60 | — |
| EPOCH-R | NCT07097363 | P2 | recruiting | B-Cell Non-Hodgkin Lymphoma | 18 | — |
| FIL_RICCO | NCT06835530 | P2 | recruiting | Diffuse Large B Cell Non-Hodgkin Lymphoma | 47 | — |
| CORAL | NCT06788964 | P2 | recruiting | Relapsed or Refractory Large B-cell Lymphoma | 29 | — |
| BRAWM | NCT04624906 | P2 | active not recruiting | Waldenstrom Macroglobulinemia | 63 | — |
| REBOOT | NCT03949855 | P2 | recruiting | Membranous Nephropathy | 58 | PMID 33311560 |
| GUIDANCE-10 | NCT07594899 | P2 | not yet recruiting | Large B-Cell Lymphoma (LBCL) | 178 | — |
| Si-Ri | NCT06742502 | P2 | recruiting | Primary Mediastinal Diffuse Large B-cell Lymphoma | 30 | — |
| ZR-MTX | NCT06973811 | P2 | not yet recruiting | Primary Intraocular Lymphoma | 47 | — |
| FLOURISH | NCT07550855 | P2 | not yet recruiting | Follicular Lymphoma (FL) | 52 | — |
| MZL | NCT06504940 | P2 | recruiting | Marginal Zone Lymphoma | 69 | — |
| PRIME-PCNSL | NCT07350850 | P2 | recruiting | PCNSL | 77 | — |
| waveLINE-007 | NCT05406401 | P2 | active not recruiting | Lymphoma, Large B-Cell, Diffuse (DLBCL) | 60 | — |
| ACRUE | NCT05952024 | P2 | recruiting | Diffuse Large B-Cell Lymphoma | 80 | — |
| TN25 | NCT03929601 | P2 | active not recruiting | Type 1 Diabetes Mellitus | 74 | PMID 39735417 |
| FIL_COLUMN | NCT05249959 | P2 | recruiting | Relapsed Mantle Cell Lymphoma | 49 | — |
| GATE1 | NCT06522386 | P2 | active not recruiting | Mantle Cell Lymphoma | 50 | — |
| KICS | NCT01419561 | P2 | recruiting | KSHV Inflammatory Cytokine Syndrome (KICS) | 140 | PMID 40763275 |
| Zillion | NCT07405255 | P2 | not yet recruiting | Central Nervous System Lymphoma | 19 | — |
| SOUND-MCL | NCT07029737 | P2 | recruiting | Mantle-cell Lymphoma | 55 | — |
| CARAMEL | NCT05004064 | P2 | recruiting | Mantle Cell Lymphoma | 48 | — |
| Ra-P-OCD | NCT04323566 | P2 | enrolling by invitation | Obsessive-Compulsive Disorder | 40 | PMID 27037228 |
| ITP | NCT07234019 | P2 | recruiting | Immune Thrombocytopenia | 160 | — |
| GOLSEEK-2 | NCT06425302 | P2 | active not recruiting | Lymphoma, Follicular | 90 | — |
| Lemon-C | NCT04627753 | P2 | recruiting | Primary CNS Lymphoma | 30 | — |
| ZEBRA | NCT05635162 | P2 | recruiting | Mantle Cell Lymphoma | 50 | — |
| TrAVeRse | NCT05951959 | P2 | active not recruiting | Mantle Cell Lymphoma (MCL) | 108 | — |
| MALT | NCT06647732 | P2 | recruiting | Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | 42 | — |
| RR FL | NCT04989621 | P2 | recruiting | Follicular Lymphoma | 32 | — |
| DA-EPOCH | NCT06738368 | P2 | recruiting | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 30 | — |
| EpLCART | NCT06414148 | P2 | recruiting | Relapsed/Refractory Large B-cell Lymphoma | 40 | — |
| PTLD | NCT06954805 | P2 | recruiting | Lymphoma | 30 | — |
| WM | NCT07231952 | P2 | recruiting | Waldenstrom Macroglobulinemia | 40 | — |
| ITP | NCT07362238 | P2 | recruiting | Immune Thrombocytopenia | 122 | — |
| R-Pola-Glo | NCT05798156 | P2 | active not recruiting | Lymphoma, Large B-Cell, Diffuse | 125 | — |
| VALUABLE | NCT04758975 | P2 | recruiting | Chronic Lymphocytic Leukemia (CLL) | 55 | — |
| ZEBRA | NCT06561347 | P2 | recruiting | Waldenstrom Macroglobulinemia | 56 | — |
| ITP | NCT07297563 | P2 | recruiting | Immune Thrombocytopenia | 160 | — |
| DLBCL | NCT07001540 | P2 | recruiting | Diffuse Large B-Cell Lymphoma | 130 | — |
| HCL | NCT06561360 | P2 | recruiting | Hairy Cell Leukemia | 86 | — |
| CLSGMCLPOLA | NCT04913103 | P2 | not yet recruiting | Lymphoma, Mantle-Cell | 21 | — |
| PACIFIC | NCT04745949 | P2 | recruiting | Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | 31 | — |
| RENAL-F02 | NCT06047171 | P2 | recruiting | Glomerulonephritis Rapidly Progressive | 80 | — |
| MALIBU | NCT03697512 | P2 | active not recruiting | Marginal Zone Lymphoma | 175 | PMID 40550489 |
| TOP-FLOR | NCT05788081 | P2 | active not recruiting | Follicular Lymphoma Stage II | 40 | — |
| STELLAR | NCT03899337 | P2 | recruiting | Richter Syndrome | 105 | PMID 33206936 |
| MTR² | NCT05583071 | P2 | recruiting | Non-Hodgkin Lymphoma | 20 | — |
| SINAPPS2 | NCT03194815 | P2 | active not recruiting | Psychosis | 70 | PMID 31174586 |
| ITP | NCT07362199 | P2 | recruiting | Immune Thrombocytopenia | 20 | — |
| PR | NCT06263491 | P2 | recruiting | Mantle Cell Lymphoma | 50 | — |
| HCT | NCT05736419 | P2 | recruiting | Sickle Cell Disease | 24 | — |
| ALTAMIRA | NCT05214183 | P2 | active not recruiting | MCL | 81 | — |
| iFCR | NCT02251548 | P2 | active not recruiting | Chronic Lymphocytic Leukemia | 85 | PMID 38163317 |
| RCT-RITS | NCT05622201 | P2 | active not recruiting | Schizophrenia Spectrum and Other Psychotic Disorders | 123 | PMID 37872497 |
| P+R-ICE | NCT05221645 | P2 | active not recruiting | Diffuse Large B Cell Lymphoma | 65 | — |
| SAR445088 | NCT05156710 | P2 | active not recruiting | Transplant Rejection | 48 | PMID 35332298 |
| R | NCT04980222 | P2 | active not recruiting | Lymphoma | 46 | PMID 41979332 |
| PRO | NCT06530511 | P2 | recruiting | Diffuse Large B Cell Lymphoma | 30 | — |
| SSc | NCT03630211 | P2 | recruiting | Systemic Sclerosis | 8 | — |
| IANMDAR | NCT03274375 | P2 | recruiting | Anti-NMDAR Encephalitis | 20 | — |
| Ballondor | NCT03697356 | P2 | recruiting | Waldenström's Macroglobulinemia | 54 | — |
| CLL-SLL | NCT01446133 | P2 | active not recruiting | Leukemia | 120 | PMID 31076409 |
| RMO | NCT05549284 | P2 | unknown | Primary Central Nervous System Lymphoma | 36 | — |
| POR | NCT05390749 | P2 | unknown | Primary Central Nervous System Lymphoma | 50 | — |
| OVERALL | NCT04920968 | P2 | recruiting | CD20-positive Acute Lymphoblastic Leukemia | 124 | — |
| PCNSL | NCT04129710 | P2 | unknown | Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) | 120 | — |
| BV mini CHP | NCT02734771 | P2 | active not recruiting | Diffuse Large B-Cell Lymphoma | 24 | — |
| ZBR | NCT05914662 | P2 | recruiting | Waldenstrom Macroglobulinemia | 42 | PMID 32698195 |
| CZ-WM01 | NCT05979948 | P2 | unknown | Waldenström's Macroglobulinemia | 60 | — |
| ZR2 | NCT04460248 | P2 | active not recruiting | Diffuse Large B Cell Lymphoma | 40 | PMID 40829156 |
| PIMOC | NCT03651518 | P2 | completed | Inflammatory Disease | 32 | — |
| ZR | NCT05504603 | P2 | unknown | Untreated Mantle Cell Lymphoma | 20 | — |
| AGRAF-2 | NCT05682196 | P2 | suspended | Rheumatic Heart Disease in Children | 234 | — |
| ZR2-CHOP | NCT05200312 | P2 | unknown | Non Hodgkin Lymphoma | 36 | PMID 41136989 |
| PCR | NCT05115409 | P2 | unknown | Relapsed or Refractory DLBCL | 27 | — |
| CNS | NCT01011920 | P2 | completed | Central Nervous System Lymphoma | 227 | PMID 27132696 |
| FIORELLA | NCT03495960 | P2 | completed | Primary Central Nervous System Lymphoma | 72 | — |
| ZFCR/ZBR | NCT05287984 | P2 | unknown | Chronic Lymphocytic Leukemia | 63 | PMID 31208944 |
| PMMN | NCT03804359 | P2 | completed | Idiopathic Membranous Nephropathy | 68 | PMID 25457107 |
| VEGA | NCT05564052 | P2 | completed | Lymphoma, Mantle-Cell | 36 | — |
| PrE0405 | NCT03834688 | P2 | completed | Mantle Cell Lymphoma | 33 | — |
| Relyage | NCT04113226 | P2 | completed | Chemotherapy | 1 | — |
| CLL1818 | NCT03804372 | P2 | terminated | Large-B-cell Diffuse Lymphoma | 5 | PMID 33559286 |
| LLC1114 | NCT02232386 | P2 | completed | Chronic Lymphocyte Leukemia | 156 | PMID 35913400 |
| PembroWM | NCT03630042 | P2 | completed | Waldenstrom Macroglobulinemia | 17 | — |
| BL | NCT05049473 | P2 | unknown | Mature B-Cell Leukemia Burkitt Type | 100 | PMID 37560813 |
| LOTIS-9 | NCT05144009 | P2 | terminated | Diffuse Large B-cell Lymphoma | 41 | — |
| COMBIVAS | NCT03967925 | P2 | unknown | ANCA Associated Vasculitis | 31 | PMID 36906660 |
| BIOVAS | NCT05168475 | P2 | terminated | Giant Cell Arteritis | 22 | — |
| RIFIREINS | NCT03970577 | P2 | unknown | Minimal Change Nephrotic Syndrome (MCNS) | 148 | PMID 41563842 |
| RTXvsMMF | NCT04585152 | P2 | unknown | Nephrotic Syndrome Steroid-Dependent | 160 | PMID 34845071 |
| IELSG30 | NCT00945724 | P2 | completed | Large B-cell Diffuse Lymphoma of Testis | 54 | PMID 38181782 |
| PTIS | NCT05293509 | P2 | withdrawn | Stem Cell Transplantation | 0 | — |
| PTLD | NCT02753062 | P2 | unknown | Diffuse Large B Cell Lymphoma | 22 | — |
| LEGEND | NCT02060656 | P2 | unknown | Diffuse Large B-Cell Lymphoma | 92 | — |
| C-R-HDMTX | NCT04516655 | P2 | unknown | Central Nervous System Lymphoma | 51 | PMID 30008379 |
| VeRitAs | NCT03455517 | P2 | completed | Chronic Myeloid Leukemia | 77 | PMID 36632738 |
| R2DLBCL80 | NCT04622579 | P2 | unknown | Diffuse Large B Cell Lymphoma | 20 | — |
| CORAL | NCT05209308 | P2 | withdrawn | CLL | 0 | — |
| WM | NCT04062448 | P2 | completed | Waldenstrom Macroglobulinemia | 16 | — |
| ZUMA-14 | NCT04002401 | P2 | completed | Refractory Large B-cell Lymphoma | 27 | PMID 41492094 |
| RTXFIRPedINS | NCT04783675 | P2 | completed | Steroid-Sensitive Nephrotic Syndrome | 44 | — |
| RIPPLE | NCT04246359 | P2 | unknown | Lymphoma, B-Cell | 52 | — |
| PK | NCT04660799 | P2 | completed | Lymphoma, Large B-Cell, Diffuse | 50 | PMID 39773004 |
| CLL | NCT01199575 | P2 | completed | Chronic Lymphocytic Leukemia | 30 | — |
| PTLD-2 | NCT02042391 | P2 | completed | Posttransplant Lymphoproliferative Disorder | 60 | PMID 35974101 |
| MG4101 | NCT03578198 | P2 | terminated | CD20-positive Non-Hodgkin Lymphoma | 12 | — |
| RITS-PS-2019 | NCT03983018 | P2 | completed | Schizophrenia Spectrum and Other Psychotic Disorders | 9 | PMID 39350952 |
| INCA | NCT01679119 | P2 | completed | Diffuse Large B Cell Lymphoma | 129 | — |
| SYMPHONY-2 | NCT04762160 | P2 | terminated | Follicular Lymphoma | 5 | — |
| LYTPET | NCT00324467 | P2 | unknown | Lymphoma, Non-Hodgkin | 150 | PMID 15266320 |
| PNEUMOVAS | NCT03069703 | P2 | completed | Invasive Pneumococcal Infection | 96 | PMID 23851398 |
| ARGO | NCT03422523 | P2 | terminated | Diffuse Large B Cell Lymphoma | 53 | — |
| CKD | NCT02966717 | P2 | unknown | Renal Insufficiency, Chronic | 116 | — |
| DA-EPOCH-R | NCT01030900 | P2 | completed | Hodgkin Lymphoma | 50 | — |
| ICFEr-RITU2 | NCT03332888 | P2 | unknown | Heart Failure With Reduced Ejection Fraction | 10 | PMID 30918029 |
| REBOOT | NCT01859819 | P2 | completed | Diffuse Large Cell Lymphoma | 45 | PMID 33941850 |
| FCR | NCT01723839 | P2 | completed | Chronic Lymphocytic Leukemia (CLL) | 21 | PMID 16357183 |
| RECIPE | NCT03864185 | P2 | completed | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 25 | PMID 32234705 |
| Fol-BRITe | NCT01234766 | P2 | completed | Lymphoma, Follicular | 39 | — |
| Lymvac-2 | NCT02677155 | P2 | completed | Follicular Lymphoma | 10 | — |
| R-FND | NCT00290511 | P2 | completed | Lymphoma | 49 | — |
| OAML | NCT01427114 | P2 | completed | Lymphoma | 33 | PMID 28978139 |
| ThRiL | NCT01125176 | P2 | completed | Chronic Lymphocytic Leukemia | 15 | — |
| versus | NCT04189588 | P2 | completed | Oncology Patients Receiving Chemotherapy | 34 | PMID 34555839 |
| ART-IPF | NCT01969409 | P2 | completed | Ambulatory IPF | 58 | — |
| R2W | NCT01592981 | P2 | completed | Waldenstrom's Macroglobulinaemia | 60 | — |
| FIL_BRB | NCT02371148 | P2 | completed | Waldenstrom's Macroglobulinemia | 38 | — |
| CLL | NCT00759798 | P2 | completed | Chronic Lymphocytic Leukemia | 289 | PMID 24705492 |
| ROOTS | NCT03054259 | P2 | unknown | Systemic Lupus Erythematosus Arthritis | 30 | — |
| MAN2 | NCT02267915 | P2 | unknown | Mantle-cell Lymphoma | 36 | — |
| TORCH | NCT02752204 | P2 | completed | Diffuse Large B-Cell Lymphoma | 36 | — |
| R2 | NCT01939327 | P2 | completed | Non-Hodgkin Lymphoma | 34 | — |
| PHILEMON | NCT02460276 | P2 | completed | Relapsed/Refractory Mantle Cell Lymphoma | 50 | PMID 29396091 |
| ICORG | NCT00812669 | P2 | completed | Leukemia | 52 | PMID 28925785 |
| BR | NCT02433795 | P2 | completed | Marginal Zone B-cell Lymphoma | 27 | — |
| IRIS | NCT01514344 | P2 | completed | Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | 20 | PMID 32182364 |
| EFFRITE | NCT02545959 | P2 | completed | Multiple Sclerosis, Chronic Progressive | 10 | PMID 24417802 |
| CLL | NCT02481297 | P2 | completed | Leukemia | 7 | — |
| SCT | NCT01490723 | P2 | completed | Leukemia | 20 | — |
| CALIBRATE | NCT02260934 | P2 | completed | Lupus Nephritis | 43 | PMID 32755035 |
| RADICAL | NCT01429610 | P2 | unknown | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 78 | PMID 37334511 |
| CyBeR-Lymph | NCT02758925 | P2 | unknown | Diffuse Large B Cell Lymphoma | 78 | PMID 23753028 |
| SYNBIoSe | NCT02284984 | P2 | completed | Lupus Erythematosus, Systemic | 16 | PMID 29636274 |
| WM | NCT01813227 | P2 | completed | Waldenstrom Macroglobulinemia | 7 | — |
| ESHAP | NCT00732498 | P2 | completed | Lymphoma | 28 | — |
| CLL | NCT00899431 | P2 | terminated | Chronic Lymphocytic Leukemia | 39 | — |
| VCR | NCT00980395 | P2 | completed | Lymphoma | 24 | PMID 29056470 |
| B-R-ENDA | NCT01686321 | P2 | completed | Aggressive Lymphoma | 68 | — |
| STORM | NCT01653067 | P2 | unknown | Diffuse Large B-Cell Lymphoma | 88 | PMID 23799873 |
| ESBAM | NCT02556866 | P2 | terminated | Cryoglobulinemia | 14 | — |
| SGN-CD19A | NCT02855359 | P2 | terminated | Diffuse, Large B-Cell, Lymphoma | 24 | — |
| SGN-CD19A | NCT02592876 | P2 | terminated | Lymphoma, B-cell | 81 | — |
| ALL | NCT01134575 | P2 | completed | Acute Lymphoblastic Leukemia | 90 | PMID 38551807 |
| GDC-0199 | NCT02187861 | P2 | completed | Follicular Lymphoma | 163 | PMID 32785666 |
| Hi-CHOP | NCT03485118 | P2 | completed | Diffuse Large B-cell Lymphoma | 137 | — |
| REVRI | NCT01956695 | P2 | completed | Lymphoma | 45 | PMID 30698644 |
| BRIEF | NCT01313611 | P2 | terminated | Follicular Lymphoma | 62 | PMID 30117149 |
| G-CSF | NCT01097057 | P2 | completed | Non-Hodgkin Lymphoma | 20 | — |
| ZAR2007 | NCT00662948 | P2 | completed | Lymphoma | 149 | PMID 34459702 |
| CLL | NCT00254410 | P2 | completed | Chronic Lymphocytic Leukemia | 30 | — |
| FIL-RBAC500 | NCT01662050 | P2 | completed | Mantle Cell Lymphoma | 57 | PMID 27927586 |
| DLBCL | NCT01676558 | P2 | unknown | Relapsed or Refractory Diffuse Large B Cell Lymphoma | 24 | — |
| S-BR | NCT02623920 | P2 | withdrawn | Diffuse Large B Cell Lymphoma | 0 | — |
| DLBCL | NCT01925612 | P2 | terminated | Lymphoma, B-cell | 87 | — |
| R2-B | NCT01737177 | P2 | completed | Mantle Cell Lymphoma | 42 | — |
| GM-CSF | NCT00940342 | P2 | completed | Leukemia | 130 | — |
| CAD5 | NCT02689986 | P2 | completed | Cold Agglutinin Disease | 43 | PMID 28533306 |
| LBH589 | NCT01238692 | P2 | completed | Diffuse Large B Cell Lymphoma | 42 | PMID 27166360 |
| FRESCO | NCT02605694 | P2 | withdrawn | Lymphoma | 0 | — |
| RITPBC | NCT02376335 | P2 | completed | Fatigue | 71 | PMID 29790196 |
| CaRD | NCT01470196 | P2 | completed | Waldenstrom's Macroglobulinemia | 31 | PMID 24859363 |
| PrE0401 | NCT01889797 | P2 | terminated | Indolent Non-Hodgkin's Lymphoma | 32 | PMID 20194898 |
| DLBCL | NCT02531308 | P2 | terminated | Diffuse Large B-Cell Lymphoma | 5 | — |
| NK | NCT01181258 | P2 | completed | Non-Hodgkin Lymphoma | 16 | PMID 29218366 |
| DLBCL | NCT01453205 | P2 | completed | Diffuse Large B-Cell Lymphoma | 187 | — |
| ITT-PMS | NCT01719159 | P2 | completed | Progressive Multiple Sclerosis | 23 | PMID 27536708 |
| R-CHOP | NCT00450385 | P2 | terminated | Lymphoma | 57 | — |
| CLL | NCT00545714 | P2 | completed | Leukemia, Lymphocytic, Chronic, B-Cell | 86 | PMID 30890600 |
| CNS | NCT02113007 | P2 | terminated | Primary Central Nervous System Lymphoma | 2 | — |
| BMR | NCT00901927 | P2 | terminated | Follicular Lymphoma | 14 | — |
| CLL | NCT01466153 | P2 | completed | Chronic Lymphocytic Leukemia (CLL) | 183 | — |
| RB | NCT01127841 | P2 | unknown | Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line. | 60 | — |
| FIZZ | NCT01493479 | P2 | completed | Follicular Lymphoma | 76 | PMID 24297953 |
| WM | NCT00422799 | P2 | completed | Waldenstrom's Macroglobulinemia | 63 | PMID 20142586 |
| MZL | NCT01213095 | P2 | completed | Lymphoma | 48 | PMID 31619290 |
| ManteauRiBVD | NCT00740415 | P2 | completed | Lymphoma | 39 | — |
| CLL | NCT02420938 | P2 | withdrawn | Leukemia | 0 | — |
| GVHD | NCT01161628 | P2 | completed | Chronic Graft-versus-host Disease | 25 | PMID 10929168 |
| PTLD-1/3 | NCT00590447 | P2 | completed | PTLD | 152 | PMID 27992268 |
| LLCRlowdoz | NCT01521689 | P2 | unknown | Chronic Lymphocytic Leukemia | 35 | — |
| HYDRIC | NCT01625741 | P2 | terminated | Chronic Lymphocytic Leukemia | 6 | — |
| GATEWAYII | NCT01569451 | P2 | completed | Multiple Sclerosis | 53 | PMID 30635477 |
| RGemOx | NCT01562977 | P2 | completed | Aggressive Lymphoma | 82 | — |
| MOAD | NCT00905034 | P2 | completed | Leukemia, Lymphocytic, Acute | 37 | — |
| SCT | NCT01279616 | P2 | terminated | Sickle Cell Disease | 8 | — |
| FLE09 | NCT01523860 | P2 | completed | Follicular Lymphoma | 76 | PMID 33476434 |
| FRAIL-06 | NCT00911183 | P2 | completed | Lymphoma | 67 | — |
| GM-CSF | NCT00381004 | P2 | completed | Chronic Lymphocytic Leukemia | 60 | — |
| CLL | NCT02533401 | P2 | completed | Lymphocytic Leukemia, Chronic | 34 | — |
| Lymvac-1 | NCT01926639 | P2 | completed | Follicular Lymphoma | 14 | PMID 25293773 |
| R | NCT01830478 | P2 | unknown | Indolent Non Hodgkin Lymphoma | 44 | — |
| CLL | NCT00448019 | P2 | completed | Chronic Lymphocytic Leukemia | 64 | PMID 25043749 |
| CLL | NCT01754870 | P2 | withdrawn | Chronic Lymphocytic Leukemia (CLL) | 0 | — |
| B-ALL | NCT01290120 | P2 | completed | Burkitt Lymphoma | 182 | PMID 23753030 |
| THRiL for WM | NCT01779167 | P2 | terminated | Waldenstrom Macroglobulinemia | 4 | — |
| R-GVHD | NCT01135641 | P2 | completed | Graft Versus Host Disease | 25 | PMID 28864814 |
| Mz-135 | NCT02099292 | P2 | completed | Relapsed Non-Hodgkin-Lymphoma | 103 | — |
| NAVIGATE | NCT01423539 | P2 | withdrawn | Diffuse Large B-Cell Lymphoma | 0 | — |
| ZBEAM2 | NCT00689169 | P2 | completed | Lymphoma, Large Cell, Diffuse | 75 | PMID 25072780 |
| MALT | NCT01015248 | P2 | completed | MALT LYMPHOMA | 60 | PMID 27029228 |
| 904 | NCT00831597 | P2 | completed | Diffuse Large B-Cell Lymphoma | 61 | PMID 23955074 |
| PTTritux | NCT00907751 | P2 | completed | Thrombotic Thrombocytopenic Purpura | 12 | PMID 27643485 |
| Pento & tBU | NCT00496340 | P2 | completed | Hematologic Malignancies | 42 | — |
| BDR-WM | NCT00832234 | P2 | completed | Waldenstroms Macroglobulinemia | 59 | — |
| MIR | NCT00509184 | P2 | completed | Lymphoma, Malignant | 85 | PMID 31723798 |
| RO5072759 | NCT00576758 | P2 | completed | Non-Hodgkin's Lymphoma | 175 | PMID 26282650 |
| RITAPS | NCT00537290 | P2 | completed | Antiphospholipid Syndrome | 19 | PMID 23124321 |
| RIPS | NCT00855205 | P2 | completed | Sarcoidosis | 10 | PMID 24488568 |
| RA | NCT02093026 | P2 | completed | Rheumatoid Arthritis | 465 | — |
| R-GEMOX | NCT00169195 | P2 | completed | Diffuse Large Cell Lymphoma | 49 | PMID 10907954 |
| CMC-544 | NCT00867087 | P2 | completed | Lymphoma, B-Cell | 64 | — |
| CLL | NCT02013817 | P2 | completed | Lymphocytic Leukemia, Chronic | 43 | — |
| CLL | NCT01087151 | P2 | completed | Chronic Lymphocytic Leukemia | 118 | — |
| R-BAC | NCT00992134 | P2 | completed | Lymphoma, Mantle-Cell | 41 | PMID 23401442 |
| Z-BEAM LDGGB | NCT00646750 | P2 | completed | Non-Hodgkin's Lymphoma | 31 | — |
| R-CHOP | NCT00504491 | P2 | withdrawn | Chronic Lymphocytic Leukaemia | 0 | — |
| R-COMP | NCT01009970 | P2 | unknown | Diffuse Large B-Cell Lymphoma | 50 | — |
| SIERRA | NCT00282308 | P2 | completed | Rheumatoid Arthritis | 103 | PMID 20039397 |
| FR | NCT00860457 | P2 | completed | Chronic Lymphocytic Leukemia | 22 | — |
| NHL-14 | NCT00575406 | P2 | completed | Diffuse Large B-Cell Lymphoma | 94 | — |
| RICH | NCT00331006 | P2 | completed | Hemophilia A | 23 | — |
| PERLL | NCT00927797 | P2 | unknown | Immunocytoma/Morbus Waldenström | 185 | — |
| DLBCL | NCT00968331 | P2 | terminated | Diffuse Large B-cell Lymphoma | 25 | — |
| FORCE | NCT00774462 | P2 | completed | Myositis | 30 | PMID 26539981 |
| PAP | NCT00552461 | P2 | completed | Pulmonary Alveolar Proteinosis | 10 | PMID 21478218 |
| PTLD | NCT01458548 | P2 | terminated | Post-transplantation Lymphoproliferative Disorder | 70 | PMID 22173060 |
| PRIMAIN | NCT00989352 | P2 | unknown | Primary Non Hodgkin Lymphoma of the Central Nervous System | 56 | PMID 27843136 |
| MALT | NCT00656812 | P2 | completed | Lymphoma of Mucosa-Associated Lymphoid Tissue | 40 | — |
| CLL | NCT00628238 | P2 | unknown | Chronic Lymphocytic Leukemia | 80 | PMID 16750498 |
| ITP | NCT00372892 | P2 | completed | Purpura, Thrombocytopenic, Idiopathic | 60 | PMID 22223819 |
| CLL | NCT00309881 | P2 | completed | Chronic Lymphocytic Leukemia | 75 | PMID 25196783 |
| PCR | NCT01001780 | P2 | withdrawn | Active Chronic Graft Versus Host Disease | 0 | — |
| LYM-2023 | NCT00509379 | P2 | completed | Lymphoma | 48 | — |
| VRCD | NCT00413959 | P2 | terminated | Lymphoma, Non-Hodgkin | 12 | — |
| CFAR | NCT01082939 | P2 | completed | Chronic Lymphocytic Leukemia | 80 | — |
| DLBCL | NCT00568815 | P2 | completed | Lymphoma | 31 | — |
| CV | NCT00849355 | P2 | unknown | No Hodgkin B Lymphoma | 44 | — |
| NK | NCT00536978 | P2 | completed | Lymphoma | 22 | — |
| August III | NCT00664521 | P2 | completed | Rheumatoid Arthritis | 27 | PMID 26137975 |
| DM | NCT00106184 | P2 | completed | Myositis | 200 | PMID 23124935 |
| CLL | NCT00758693 | P2 | withdrawn | Chronic Lymphocytic Leukemia | 0 | — |
| TTP | NCT00937131 | P2 | completed | Thrombotic Thrombocytopenic Purpura (TTP) | 40 | PMID 21636861 |
| RA | NCT00422942 | P2 | terminated | Rheumatoid Arthritis | 3 | — |
| VERTICAL | NCT00636792 | P2 | completed | Follicular Lymphoma | 73 | — |
| CLL | NCT00290407 | P2 | terminated | Leukemia, Lymphocytic, Chronic | 2 | — |
| LT-CLL-001 | NCT00558181 | P2 | completed | Chronic B-Lymphocytic Leukemia | 29 | — |
| TN05 | NCT00279305 | P2 | completed | Type 1 Diabetes Mellitus | 87 | PMID 19940299 |
| BVR | NCT00547534 | P2 | completed | Non-Hodgkin's Lymphoma | 31 | PMID 21239695 |
| GX15-070MS | NCT00427856 | P2 | completed | Lymphoma, Follicular | 7 | — |
| PREMIER | NCT00308087 | P2 | terminated | Lymphoma, Follicular | 75 | — |
| NHL | NCT00444912 | P2 | completed | Non-Hodgkin Lymphoma | 30 | — |
| GM-CSF | NCT00896519 | P2 | unknown | Lymphoma | 30 | — |
| RUMBA | NCT00243412 | P2 | completed | Rheumatoid Arthritis | 42 | — |
| DLBCL | NCT01054781 | P2 | completed | Diffuse Large B-cell Lymphoma (DLBCL) | 91 | PMID 36996864 |
| RAPTURE | NCT00371904 | P2 | unknown | Kidney Transplantation | 192 | — |
| MMF | NCT00446251 | P2 | completed | Kidney Failure, Chronic | 14 | PMID 11549905 |
| GROC | NCT01538641 | P2 | completed | Refractory Aggressive Non-Hodgkin's Lymphoma | 43 | — |
| S0629 | NCT00723658 | P2 | withdrawn | Lymphoma | 0 | — |
| CHOP | NCT00204659 | P2 | completed | Primary Gastric Diffuse-Large B-Cell Lymphoma | 30 | — |
| NHL | NCT00076349 | P2 | completed | Non-Hodgkin's Lymphoma | 66 | — |
| R-ESHAP | NCT00367497 | P2 | terminated | Lymphoma, Non-Hodgkin | 5 | — |
| CLL | NCT00086203 | P2 | completed | Chronic Lymphocytic Leukemia | 0 | — |
| IL-2 | NCT00250861 | P2 | terminated | Non-Hodgkin's Lymphoma | 110 | — |
| Rituximab GVHD | NCT00578591 | P2 | withdrawn | Graft vs Host Disease | 0 | — |
| BORID | NCT00261612 | P2 | unknown | Lymphoma, Mantle-Cell | 16 | PMID 21486866 |
| DLBCL | NCT00556127 | P2 | completed | Diffuse Large B-Cell Lymphoma | 94 | — |
| RIPL | NCT00346684 | P2 | completed | Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) | 0 | PMID 31636342 |
| NHL | NCT00333008 | P2 | unknown | Diffuse Large B Cell Lymphoma | 27 | — |
| LIST | NCT00230035 | P2 | withdrawn | Systemic Lupus Erythematosus | 0 | PMID 12428232 |
| SLE | NCT00293072 | P2 | completed | Systemic Lupus Erythematosus | 20 | — |
| IL-2 | NCT00100737 | P2 | terminated | Non-Hodgkin Lymphoma | 300 | — |
| CHOP | NCT00126243 | P2 | terminated | AIDS Related Lymphoma | 60 | — |
Terminated and withdrawn Rituximab trials (374)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05934097withdrawnFT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- NCT04849715withdrawnA Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- NCT05867030withdrawnParsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
- NCT06824701suspendedTazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- NCT04796922withdrawnTo Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- NCT06247540withdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- NCT06313996withdrawnA Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- NCT06205290withdrawnA Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
- NCT06015750withdrawnMitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
- NCT04882163withdrawnStudy to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- NCT05929716withdrawnAn Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
- NCT05482542withdrawnOptimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
- NCT04974996withdrawnA Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
- NCT04850495suspendedZanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- NCT03808610terminatedLow-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- NCT03349346withdrawnIdelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
- NCT04607772withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04668365suspendedZanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- NCT06078696terminatedSiplizumab for Sickle Cell Disease Transplant
- NCT03829566withdrawnAutologous Transplant To End NMO Spectrum Disorder
- NCT03856216terminatedInotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- NCT05498220terminatedPolatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT04480450withdrawnRituximab in Chronic Inflammatory Demyelinating Polyneuropathy
- NCT05494593withdrawnA Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
- NCT03704714suspendedNivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
- NCT04047797terminatedIxazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- NCT05682196suspendedRituximab in Patients With Acute Rheumatic Fever
- NCT04464798terminatedA Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- NCT05265975terminatedA Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
- NCT04743739terminatedRituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
- NCT04268277terminatedPembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
- NCT04285268withdrawnRituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT03401853terminatedPembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
- NCT03783403terminatedA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
- NCT05032183terminatedTagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT03576547terminatedVenetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
- NCT03804372terminatedThe Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
- NCT04790903terminatedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT05376319terminatedPR3-AAV Resilient Remission or PRRR
- NCT03919175terminatedUmbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
- NCT00848328terminatedLenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
- NCT01316523terminatedLenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
- NCT04659044terminatedPolatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- NCT02953509terminatedTrial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- NCT03615105terminatedDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
- NCT05144009terminatedA Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
- NCT04138875withdrawnA Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
- NCT02031419terminatedNovel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
- NCT04933617terminatedCopanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
- NCT05168475terminatedBiologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
- NCT03492125terminatedA Study Of The Selective PKC-β Inhibitor MS- 553
- NCT04128176withdrawnEfficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
- NCT04431635terminatedDose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
- NCT02626455terminatedStudy of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
- NCT02320292terminatedRituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
- NCT04752163terminatedDS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- NCT04023071terminatedFT516 in Subjects With Advanced Hematologic Malignancies
- NCT02957019terminatedA Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- NCT04245722terminatedFT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
- NCT05293509withdrawnPharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- NCT05245916withdrawnIBI397 or Combination Therapies in Patients With Advanced Malignancies
- NCT03121677terminatedPersonalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
- NCT04680962withdrawnMabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
- NCT03636503terminatedRituximab + Immunotherapy in Follicular Lymphoma
- NCT03864419terminatedRituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
- NCT02451111terminatedRituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
- NCT04156828terminatedCopanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
- NCT04517435terminatedME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
- NCT04074330terminatedA Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
- NCT02914938terminatedA Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- NCT04045028terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- NCT04745832terminatedPhase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- NCT05209308withdrawnRituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- NCT01307605terminatedRituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
- NCT04154787terminatedEfficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
- NCT03994783terminatedTransplant Antibody-Mediated Rejection: Guiding Effective Treatments
- NCT04235036terminatedIbrutinib and Rituxan for Chronic GVHD
- NCT04337827terminatedRituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
- NCT04776850withdrawnPre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- NCT02663518terminatedA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
- NCT03432741terminatedDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- NCT04531865withdrawnRandomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment
- NCT02898259terminatedLenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
- NCT02043587terminatedChemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
- NCT03578198terminatedRituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
- NCT04502706terminatedStudy of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
- NCT04762160terminatedSYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- NCT04189952terminatedAcalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
- NCT04236141terminatedA Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
- NCT02749292terminatedMaintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
- NCT03169790withdrawnQUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
- NCT03422523terminatedAtezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
- NCT04220008withdrawnVorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
- NCT03689894terminatedIbrutinib Plus Rituximab for cGVHD Following Allo-SCT
- NCT04419389terminatedAPR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
- NCT02538926withdrawnEtoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT03232307withdrawnIbrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
- NCT02961816withdrawnPanobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
- NCT02703272terminatedA Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- NCT03518112terminatedLow-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
- NCT01644253terminatedPhase 1b Safety and Efficacy Study of TRU-016
- NCT04155840terminatedBendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- NCT04279938withdrawnA Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
- NCT02420717terminatedRuxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- NCT02384954terminatedQUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
- NCT03136497terminatedA Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT03189836terminatedStudy of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
- NCT04402580terminatedEfficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
- NCT02954406terminatedA Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- NCT01434472terminatedHigh-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
- NCT03135262terminatedA Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT03488225terminatedCombination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- NCT02951156terminatedAvelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- NCT03507348terminatedEvaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates
- NCT03225924terminatedStudy of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
- NCT03593902terminatedCardiac Safe Transplants for Systemic Sclerosis
- NCT03579927withdrawnCAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
- NCT02501473terminatedStudy of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
- NCT02624986terminatedA Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
- NCT03558750terminatedRituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
- NCT02589145terminatedLenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- NCT00992030terminatedR-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
- NCT03670888terminatedA Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
- NCT01253460terminatedSapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
- NCT01805037terminatedBrentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
- NCT03269552terminatedCarfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
- NCT00899431terminatedNonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
- NCT01729104terminatedPhase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
- NCT01964755terminatedChemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
- NCT02556866terminatedRituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
- NCT02855359terminatedDenintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
- NCT02592876terminatedTreatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
- NCT02789397withdrawnTreatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency
- NCT01287741terminatedA Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
- NCT01773616terminatedTrial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
- NCT01659099terminatedGA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
- NCT01313611terminatedBRIEF Bendamustine and Rituximab In Elderly Follicular
- NCT01446900terminatedR-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
- NCT01044745terminatedRituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
- NCT02594163terminatedStudy of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
- NCT01670084withdrawnNilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- NCT01318915terminatedResearch Study of ATG and Rituximab in Renal Transplantation
- NCT00074490terminatedDonor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
- NCT02200848terminatedPhase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- NCT02626845terminatedRituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
- NCT01900496terminatedStudy of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
- NCT05063513withdrawnAutologous Stem Cell Transplantation: International Lupus Trial
- NCT02194374withdrawnAutologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
- NCT02419469terminatedAugmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT02391545terminatedA Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
- NCT02623920withdrawnBrentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- NCT01925612terminatedStudy of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
- NCT01812005terminatedAlisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- NCT02204982terminatedStudy of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
- NCT00481832terminatedAutologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
- NCT01596127terminatedIntrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
- NCT00022971terminatedCombination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
- NCT00841945terminatedTreatment of Aggressive Localized Lymphoma
- NCT02390362terminatedRandomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
- NCT00869323terminatedBortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
- NCT01200589terminatedSingle Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
- NCT02649504withdrawnRituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
- NCT02605694withdrawnDuvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
- NCT02576275withdrawnA Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- NCT02281279withdrawnRituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- NCT02366663terminatedBEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
- NCT01164098terminatedRituximab to Prevent Recurrence of Proteinuria
- NCT01889797terminatedPhase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
- NCT01117662terminatedEfficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
- NCT02531308terminatedMetformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
- NCT01524068withdrawnA MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
- NCT01203930terminatedA Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
- NCT00513747terminatedEarly or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
- NCT01980888terminatedEfficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- NCT02735876withdrawnA Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- NCT01556347terminatedMulti-Drug Desensitization Protocol for Heart Transplant Candidates
- NCT00450385terminatedGenes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
- NCT01732913terminatedEfficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- NCT02044822terminatedEfficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
- NCT01732926terminatedEfficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- NCT01271010terminatedA Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
- NCT02258529terminatedIdelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
- NCT01156922terminatedB-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
- NCT02205333terminatedA Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
- NCT02259348terminatedRepeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
- NCT01078974terminatedPomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
- NCT01283386terminatedA Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
- NCT02113007terminatedStudy of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
- NCT02137681withdrawnA Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
- NCT00901927terminatedBendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
- NCT02532192withdrawnA Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- NCT02417129terminatedBI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
- NCT01765842terminatedComparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
- NCT01598558withdrawnAssessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
- NCT01212094terminatedDouble Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
- NCT02408042withdrawnStudy of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
- NCT01278745terminatedPrevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
- NCT00617929terminatedAntithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
- NCT02420938withdrawnUrelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
- NCT00335140terminatedRituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
- NCT01973062terminatedYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
- NCT01625741terminatedPhase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
- NCT01549886terminatedPhase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
- NCT02228512withdrawnStudy of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
- NCT02983097terminatedTherapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
- NCT01013961terminatedRituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
- NCT00110149terminatedRituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
- NCT02168907terminatedCPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- NCT01279616terminatedA Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
- NCT01173679terminatedDasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
- NCT00637832terminatedRituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
- NCT01510184terminatedStudy of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
- NCT01754870withdrawnPhase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
- NCT01282476terminatedPanobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
- NCT01144403terminatedA Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
- NCT01125293terminatedEverolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
- NCT01497275terminatedZevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
- NCT00250718terminatedStudy: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
- NCT01779167terminatedThalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
- NCT01390441terminatedA Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
- NCT00809341terminatedR-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- NCT01232556terminatedA Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
- NCT01423539withdrawnA Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
- NCT01408342withdrawnAlemtuzumab and Rituximab in Aplastic Anemia
- NCT01415765withdrawnMLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
- NCT01734057withdrawnRecombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
- NCT01186458terminatedFludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
- NCT00510887terminatedBortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
- NCT00288067terminatedFenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- NCT00946023terminatedOptimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
- NCT00372905terminatedPhase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
- NCT01116232terminatedSirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
- NCT00845832terminatedA Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
- NCT00582166terminatedIbritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
- NCT01662102terminatedRituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
- NCT01534949terminatedProvide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial
- NCT00543114terminatedDose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
- NCT01230788terminatedRituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
- NCT00881387withdrawnRituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
- NCT00736450terminatedOblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
- NCT00248534terminatedRituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
- NCT00060346terminatedRituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
- NCT00577161withdrawnFludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
- NCT00504491withdrawnR-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
- NCT00954005terminatedStudy With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
- NCT01419795terminatedLenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
- NCT00636155terminatedEL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- NCT01312064terminatedDe Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
- NCT00949988terminatedA Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
- NCT01144754terminatedObservational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
- NCT01300793terminatedStudy of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
- NCT00140660terminatedACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
- NCT01045928terminatedLenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- NCT00818961terminatedDonor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
- NCT00381810terminatedA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
- NCT01539174withdrawnRituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
- NCT00968331terminatedStudy of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- NCT00486759terminatedA Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
- NCT00515138terminatedA Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
- NCT00850499terminatedPhase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
- NCT01458548terminatedSequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
- NCT00972101withdrawnInfusion of Expanded Cord Blood T Cells
- NCT00851552terminatedBortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- NCT00468442terminatedB-Lymphocyte Immunotherapy in Islet Transplantation
- NCT00208975terminatedPhase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
- NCT01066598terminatedA Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
- NCT01350232terminatedTreatment of Sickle Cell Anemia With Stem Cell Transplant
- NCT00986947terminatedDesensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
- NCT00455897terminatedCHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
- NCT00298272terminatedSafety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
- NCT00126191terminatedIntensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- NCT01032122terminatedRituximab in Metastatic Melanoma
- NCT00529503terminatedA Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
- NCT00562965terminatedStudy Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- NCT00983944withdrawnRituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
- NCT00493454terminatedIbritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
- NCT00088881terminatedRituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
- NCT00772668terminatedRituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
- NCT00588822terminatedRituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
- NCT01001780withdrawnPentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease
- NCT00413959terminatedVELCADE,Rituximab,Cyclophosphamide and Decadron
- NCT00771602terminatedAlemtuzumab + Rituximab Consolidation in CLL
- NCT01238146withdrawnObatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- NCT00939328withdrawnS0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
- NCT01005979terminatedA Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
- NCT00758693withdrawnFrontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
- NCT01117129terminatedA Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)
- NCT00788606terminatedR-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
- NCT00422942terminatedA Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
- NCT00072449terminatedRituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
- NCT00482053terminatedPhase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
- NCT01076556terminatedCyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- NCT00625729terminatedDonor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
- NCT00363636terminatedA Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
- NCT01103388terminatedRituximab Maintenance After Autologous Transplantation
- NCT00012298terminatedRadiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- NCT00135499terminatedR-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
- NCT00799773terminatedEvaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
- NCT00384150terminatedRetreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
- NCT00290407terminatedRituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT01047072withdrawnLow-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
- NCT00550342withdrawnRituximab Treatment of Focal Segmental Glomerulosclerosis
- NCT00908986withdrawnOpen Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
- NCT00473551terminatedAnti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
- NCT01702038withdrawnDetermining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
- NCT00424749terminatedRituxan in Churg Strauss Syndrome With Renal Involvement
- NCT00396812terminatedRituximab for the Treatment of Early Rheumatoid Arthritis (RA)
- NCT00308087terminatedComparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
- NCT00033423terminatedRadiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- NCT00691652terminatedClofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
- NCT00251277withdrawnUse of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
- NCT00517699terminatedA Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
- NCT00096460terminatedAutologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
- NCT00833534withdrawnLenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
- NCT00567229terminatedLenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
- NCT00202930terminatedUse of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
- NCT00829205withdrawnSe-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- NCT00845104withdrawnFludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
- NCT00734773withdrawnPilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
- NCT00723658withdrawnS0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- NCT00087009terminatedBeta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
- NCT00361621terminatedPh II CHOP+Velcade in Mediastinal LBCL
- NCT00142168terminatedCC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
- NCT00167791withdrawnRituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
- NCT00176475terminatedIrradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
- NCT00612612terminatedObatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
- NCT00261547withdrawnRituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
- NCT00367497terminatedSafety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
- NCT00476515withdrawnRituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor
- NCT00551239withdrawnFludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- NCT01902862terminatedAn Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
- NCT00250861terminatedTrial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
- NCT00578591withdrawnRituximab for GVHD
- NCT00343447withdrawnCyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
- NCT00216762terminatedSafety Study of Rituximab (Rituxan®) in Chronic Urticaria
- NCT00579592terminatedCampath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
- NCT00216164terminatedRituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT00183989terminatedCombination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
- NCT00006708terminatedS0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- NCT00404157withdrawnA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
- NCT00281931terminatedFludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
- NCT00120198terminatedPegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
- NCT00400764terminatedA Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
- NCT00324831suspendedGM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- NCT00301795terminatedRituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
- NCT00265915terminatedRituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
- NCT00310128withdrawnCombination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
- NCT00183976terminatedPegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
- NCT00060671terminatedComparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
- NCT00127569terminatedRituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
- NCT00141700terminatedStudy of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
- NCT00265928terminatedBortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- NCT00230035withdrawnLupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
- NCT00210340withdrawnA Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
- NCT00169169terminatedEfficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
- NCT00098488terminated17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
- NCT00100737terminatedComparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
- NCT00110006withdrawnPositron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
- NCT00089115terminatedVaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
- NCT00180895terminatedRituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
- NCT00057447terminatedSafety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
- NCT00080847terminatedS0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- NCT00161564withdrawnA Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
- NCT00079443terminatedFR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
- NCT00058461terminatedCombination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
- NCT00126243terminatedEfficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
- NCT00060294terminatedYttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
- NCT00057343terminatedSafety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
- NCT00036855terminatedRadiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
- NCT00006669withdrawnRituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
- NCT00004039withdrawnCombination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
- NCT00003663withdrawnRituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
- NCT00003605withdrawnRituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
- NCT00004040withdrawnMonoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
All Rituximab trials (2053)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04196413 | DIPG | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) | P1 | recruiting | 97 | Stanford University | Jun 2020 |
| NCT06973096 | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | P1 | recruiting | 9 | University of Pennsylvania | Jul 2025 | |
| NCT06986382 | Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease | P1/P2 | not yet recruiting | 14 | Stanford University | Jul 2025 | |
| NCT06854003 | BRAZAN | BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma | P2 | recruiting | 60 | Christine Ryan | Apr 2025 |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | P1 | withdrawn | 0 | Fate Therapeutics | Dec 2022 | |
| NCT05976763 | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | P3 | recruiting | 421 | Alliance for Clinical Trials in Oncology | Oct 2023 | |
| NCT06191744 | EPCORE™FL-2 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | P3 | recruiting | 1,095 | Genmab | Feb 2024 |
| NCT07220187 | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial | P3 | not yet recruiting | 102 | SWOG Cancer Research Network | Aug 2026 | |
| NCT06412497 | MT2023-20 | MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. | P2 | recruiting | 60 | Masonic Cancer Center, University of Minnesota | Jun 2024 |
| NCT05947851 | VR | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | P3 | recruiting | 735 | Merck Sharp & Dohme LLC | Aug 2023 |
| NCT05508009 | Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor | P1/P2 | recruiting | 12 | Alice Bertaina | Jan 2023 | |
| NCT04849715 | CITADEL-310 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | P3 | withdrawn | 0 | Incyte Corporation | Mar 2022 |
| NCT04669171 | SIDNEY | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma | P1/P2 | recruiting | 80 | Enterome | Jul 2021 |
| NCT06284122 | MorningLyte | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | P3 | recruiting | 790 | The Lymphoma Academic Research Organisation | Jun 2024 |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | P1 | active not recruiting | 20 | Dana-Farber Cancer Institute | Mar 2022 | |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | P2 | recruiting | 80 | Mayo Clinic | Mar 2018 | |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | P1/P2 | not yet recruiting | 150 | Nurix Therapeutics, Inc. | May 2026 | |
| NCT05991388 | Glo-BNHL | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | P2/P3 | recruiting | 210 | University of Birmingham | May 2024 |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | P1 | withdrawn | 0 | Innovent Biologics (Suzhou) Co. Ltd. | Jul 2023 | |
| NCT05099471 | VIWA-1 | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | P2 | recruiting | 80 | Christian Buske | Mar 2025 |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | P1/P2 | recruiting | 48 | University of California, San Diego | Feb 2026 | |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | P2 | recruiting | 50 | Sun Yat-sen University | Apr 2025 | |
| NCT06824701 | TARZAN | Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | suspended | 24 | University of Utah | Sep 2025 |
| NCT07285590 | IMCL-2023 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma | P2 | recruiting | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Sep 2025 |
| NCT06688331 | PreTreg | Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody | P2 | recruiting | 150 | PolTREG S.A. | Mar 2025 |
| NCT06390956 | PIONEER-MZL | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | P2 | recruiting | 23 | University of Utah | Feb 2025 |
| NCT06890884 | MK-2140 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | P2 | recruiting | 594 | Merck Sharp & Dohme LLC | Apr 2025 |
| NCT05533775 | iMATRIX GLO | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | P1/P2 | recruiting | 65 | Hoffmann-La Roche | Nov 2022 |
| NCT05283720 | SC | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | P2 | recruiting | 496 | Genmab | Jun 2022 |
| NCT06644183 | IOA-244 | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | P1/P2 | recruiting | 64 | Jennifer R. Brown, MD, PhD | Mar 2025 |
| NCT06006117 | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | P3 | recruiting | 260 | The Lymphoma Academic Research Organisation | Sep 2023 | |
| NCT06655896 | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | P2 | recruiting | 96 | Novartis Pharmaceuticals | Oct 2024 | |
| NCT04796922 | FL | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | P3 | withdrawn | 0 | Incyte Corporation | Dec 2022 |
| NCT07137481 | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies | P2 | not yet recruiting | 70 | M.D. Anderson Cancer Center | Feb 2027 | |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | P2 | recruiting | 30 | Fred Hutchinson Cancer Center | Jun 2025 | |
| NCT07259122 | ZBR in WM | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia | P2 | not yet recruiting | 43 | Institute of Hematology & Blood Diseases Hospital, China | Dec 2025 |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | P3 | recruiting | 476 | InnoCare Pharma Inc. | May 2024 | |
| NCT05389423 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | P1 | recruiting | 25 | National Cancer Institute (NCI) | Jun 2023 | |
| NCT06040320 | R | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) | P1/P2 | recruiting | 12 | Washington University School of Medicine | Oct 2023 |
| NCT05898308 | RITUX4 | Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus | P4 | recruiting | 133 | University Hospital, Rouen | Dec 2024 |
| NCT07294677 | CAVALRY | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | P1/P2 | recruiting | 104 | University of Chicago | Mar 2026 |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | P3 | recruiting | 600 | National Cancer Institute (NCI) | Oct 2024 | |
| NCT06717347 | MK-2140 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | P3 | recruiting | 1,046 | Merck Sharp & Dohme LLC | Jan 2025 |
| NCT07509840 | REFINE | Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency | P3 | recruiting | 40 | Angelica Lindén Hirschberg | Feb 2026 |
| NCT06943872 | CELESTIAL-RRCLL | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | P3 | recruiting | 630 | BeOne Medicines | Jun 2025 |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | withdrawn | 0 | Northwestern University | Mar 2024 | |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | P1 | recruiting | 56 | University of Washington | Oct 2020 | |
| NCT05848765 | REFRACT | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | P2 | recruiting | 284 | University of Birmingham | Sep 2023 |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | P3 | withdrawn | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Mar 2024 | |
| NCT06205290 | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | P3 | withdrawn | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Jan 2024 | |
| NCT06510309 | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma | P2 | recruiting | 33 | Gottfried von Keudell, MD PhD | Feb 2026 | |
| NCT06341205 | iRITUX | Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) | P3 | recruiting | 120 | Centre Hospitalier Universitaire de Nice | Feb 2025 |
| NCT04002297 | MANGROVE | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | P3 | active not recruiting | 510 | BeOne Medicines | Aug 2019 |
| NCT01415752 | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 373 | Eastern Cooperative Oncology Group | Aug 2012 | |
| NCT06792825 | HM2023-43 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | P2 | recruiting | 65 | Masonic Cancer Center, University of Minnesota | Aug 2025 |
| NCT07573436 | PLUTO | Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) | P1/P2 | not yet recruiting | 23 | University of Utah | Jun 2026 |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | P2 | recruiting | 169 | The First Affiliated Hospital with Nanjing Medical University | Aug 2025 | |
| NCT05453500 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | P2 | active not recruiting | 32 | University of Washington | Mar 2023 | |
| NCT07299331 | Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma | N/A | not yet recruiting | 50 | Zhengzhou University | Jan 2026 | |
| NCT07415980 | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL | P1/P2 | not yet recruiting | 68 | Sun Yat-sen University | Apr 2026 | |
| NCT05605899 | ZUMA-23 | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | P3 | active not recruiting | 300 | Kite, A Gilead Company | Feb 2023 |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | P2 | recruiting | 132 | National Cancer Institute (NCI) | Aug 2019 | |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | P3 | active not recruiting | 300 | Merck Sharp & Dohme LLC | Mar 2023 | |
| NCT05888493 | LEDA | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma | P3 | active not recruiting | 109 | Novartis Pharmaceuticals | Oct 2023 |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | P2 | active not recruiting | 33 | University of Washington | May 2016 | |
| NCT07517185 | HiHat | The HIt HArd and hiT Early in Multiple Sclerosis Trial | P2 | not yet recruiting | 60 | Uppsala University | Apr 2026 |
| NCT06682169 | Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease | P3 | recruiting | 182 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nov 2024 | |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | P2 | recruiting | 80 | Navy General Hospital, Beijing | Sep 2024 | |
| NCT05900401 | Delayed Tolerance Through Mixed Chimerism | P1/P2 | active not recruiting | 20 | Massachusetts General Hospital | Oct 2023 | |
| NCT06607549 | SOLAR | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) | P1 | recruiting | 12 | University of Utah | Mar 2025 |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | P2 | recruiting | 70 | Masonic Cancer Center, University of Minnesota | May 2023 | |
| NCT07257055 | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study | P2 | recruiting | 30 | M.D. Anderson Cancer Center | Apr 2026 | |
| NCT07335562 | Breakfree-SSc | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis | P3 | recruiting | 92 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Aug 2026 |
| NCT05371093 | ZUMA-22 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | P3 | active not recruiting | 231 | Kite, A Gilead Company | Sep 2022 |
| NCT06047080 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | P3 | active not recruiting | 1,130 | Hoffmann-La Roche | Sep 2023 | |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | P2 | recruiting | 29 | The First Affiliated Hospital of Soochow University | Nov 2025 | |
| NCT07189325 | DESIRE MS | A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis | P3 | not yet recruiting | 250 | University Hospital, Montpellier | Sep 2025 |
| NCT04518475 | ITP | Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults | P4 | recruiting | 224 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2020 |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | P2 | recruiting | 25 | Joseph Tuscano | Jul 2025 | |
| NCT04998669 | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | P2 | recruiting | 100 | Juan P. Alderuccio, MD | Feb 2022 | |
| NCT06911502 | GOLSEEK-4 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | P3 | recruiting | 400 | Celgene | Jul 2025 |
| NCT06045247 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | recruiting | 40 | M.D. Anderson Cancer Center | Jan 2024 | |
| NCT05058404 | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma | P3 | active not recruiting | 605 | Fondazione Italiana Linfomi - ETS | Dec 2021 | |
| NCT04318678 | CATCHAML | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | P1 | recruiting | 108 | St. Jude Children's Research Hospital | Jul 2020 |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | P1/P2 | recruiting | 132 | National Cancer Institute (NCI) | Sep 2024 | |
| NCT07233720 | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma | — | recruiting | 30 | Henan Cancer Hospital | Nov 2025 | |
| NCT05100862 | MAHOGANY | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | P3 | recruiting | 780 | BeOne Medicines | Mar 2022 |
| NCT04843904 | SAVE | Safe Accelerated Venetoclax Escalation in CLL | P1 | active not recruiting | 40 | Dana-Farber Cancer Institute | Apr 2021 |
| NCT07010302 | BEST-NMOSD | Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | P4 | not yet recruiting | 540 | Massachusetts General Hospital | May 2026 |
| NCT07097363 | EPOCH-R | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | P2 | recruiting | 18 | University of Washington | Dec 2025 |
| NCT05758831 | TRIO | RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. | P3 | recruiting | 386 | Rennes University Hospital | Jun 2023 |
| NCT05545384 | IDAR | Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial | P3 | recruiting | 86 | Assistance Publique - Hôpitaux de Paris | Apr 2025 |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | P1 | recruiting | 20 | Juan P. Alderuccio, MD | Apr 2025 | |
| NCT06835530 | FIL_RICCO | A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) | P2 | recruiting | 47 | Fondazione Italiana Linfomi - ETS | Apr 2025 |
| NCT01661881 | Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | P2 | active not recruiting | 23 | Christine Ryan | Aug 2012 | |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | P1/P2 | not yet recruiting | 58 | City of Hope Medical Center | Dec 2026 | |
| NCT06788964 | CORAL | Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) | P2 | recruiting | 29 | University of Utah | Aug 2025 |
| NCT04624906 | BRAWM | Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | P2 | active not recruiting | 63 | Sunnybrook Health Sciences Centre | Mar 2021 |
| NCT06336395 | Ma-Spore ALL 2020 Study | P2 | recruiting | 500 | National University Hospital, Singapore | Mar 2020 | |
| NCT04061512 | RAINBOW | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia | P2/P3 | recruiting | 148 | University College, London | Feb 2020 |
| NCT06015750 | RESTORE | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia | P4 | withdrawn | 0 | Alexion Pharmaceuticals, Inc. | Jul 2026 |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | P1/P2 | recruiting | 84 | National Cancer Institute (NCI) | May 2026 | |
| NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | P2 | recruiting | 45 | Reid Merryman, MD | Jan 2025 | |
| NCT03949855 | REBOOT | Belimumab With Rituximab for Primary Membranous Nephropathy | P2 | recruiting | 58 | National Institute of Allergy and Infectious Diseases (NIAID) | Mar 2020 |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | P1 | recruiting | 460 | Eli Lilly and Company | Apr 2026 | |
| NCT07451847 | PREP-ANCA | Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. | P4 | not yet recruiting | 70 | Assistance Publique - Hôpitaux de Paris | Feb 2026 |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | P2 | recruiting | 100 | Reid Merryman, MD | Jun 2023 | |
| NCT06082102 | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma | P3 | recruiting | 324 | Beijing InnoCare Pharma Tech Co., Ltd. | Dec 2023 | |
| NCT06846671 | CaDAnCe-302 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | P3 | recruiting | 250 | BeOne Medicines | Apr 2025 |
| NCT00923013 | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | P2 | active not recruiting | 175 | National Cancer Institute (NCI) | Oct 2008 | |
| NCT07448324 | Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL | P2 | recruiting | 50 | The First Affiliated Hospital with Nanjing Medical University | Apr 2025 | |
| NCT07104032 | IGNITE | IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | P3 | recruiting | 132 | Ono Pharmaceutical Co., Ltd. | Jun 2026 |
| NCT07594899 | GUIDANCE-10 | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | P2 | not yet recruiting | 178 | Ruijin Hospital | May 2026 |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | P2 | recruiting | 50 | The First Affiliated Hospital with Nanjing Medical University | Feb 2026 | |
| NCT07418190 | Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma | P2 | recruiting | 33 | The First Affiliated Hospital with Nanjing Medical University | Feb 2026 | |
| NCT07051915 | The Holistic Study | P3 | not yet recruiting | 220 | Ostfold Hospital Trust | Sep 2025 | |
| NCT07139873 | TAI-SHAN6 | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | P3 | recruiting | 250 | Dizal Pharmaceuticals | Sep 2025 |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P3 | recruiting | 244 | Beijing InnoCare Pharma Tech Co., Ltd. | May 2024 | |
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | P1 | recruiting | 112 | Guangzhou Lupeng Pharmaceutical Company LTD. | Apr 2024 | |
| NCT06190301 | RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma | N/A | recruiting | 108 | Zhongshan Ophthalmic Center, Sun Yat-sen University | Dec 2023 | |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | P1/P2 | recruiting | 128 | Indapta Therapeutics, INC. | Oct 2023 | |
| NCT05645718 | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | P2 | recruiting | 27 | M.D. Anderson Cancer Center | Jul 2023 | |
| NCT05578976 | EPCORE DLBCL-2 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | P3 | active not recruiting | 900 | Genmab | Feb 2023 |
| NCT06134284 | Clinical Study of OR for Second-line Treatment of Refractory MZL | P4 | recruiting | 39 | Lixia Sheng | Jan 2023 | |
| NCT05409066 | EPCORE FL-1 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | P3 | active not recruiting | 549 | Genmab | Sep 2022 |
| NCT04712097 | Celestimo | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma | P3 | active not recruiting | 478 | Hoffmann-La Roche | Oct 2021 |
| NCT04745728 | Different Immunosuppressive Treatment in iMN | P3 | recruiting | 200 | Peking Union Medical College Hospital | Apr 2021 | |
| NCT02682641 | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL | P2 | active not recruiting | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | May 2016 | |
| NCT02405676 | BNHL-2015 | BNHL-2015 for Children or Adolescents in China | P2/P3 | active not recruiting | 200 | Children's Cancer Group, China | Jan 2015 |
| NCT07493148 | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | P2 | recruiting | 50 | Ou Bai, MD/PHD | Apr 2026 | |
| NCT07389356 | Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL | N/A | not yet recruiting | 70 | The First Affiliated Hospital with Nanjing Medical University | Feb 2026 | |
| NCT06742502 | Si-Ri | Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL | P2 | recruiting | 30 | Sun Yat-sen University | Nov 2024 |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | P2 | not yet recruiting | 134 | Institute of Hematology & Blood Diseases Hospital, China | Jun 2025 | |
| NCT06946407 | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | N/A | recruiting | 41 | FengYan Jin | Dec 2022 | |
| NCT04989491 | REPLY | Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft | P4 | recruiting | 120 | University Hospital, Strasbourg, France | Dec 2021 |
| NCT06970743 | CaDAnCe-303 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors | P3 | recruiting | 150 | BeOne Medicines | May 2025 |
| NCT06356129 | GOLSEEK-1 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | P3 | active not recruiting | 850 | Celgene | Jun 2024 |
| NCT06091254 | OLYMPIA-1 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | P3 | recruiting | 822 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT06973811 | ZR-MTX | ZR-MTX for PIOL Phase II Trial | P2 | not yet recruiting | 47 | Peking Union Medical College Hospital | May 2025 |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | P1/P2 | recruiting | 97 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Jul 2025 | |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | recruiting | 43 | City of Hope Medical Center | Apr 2026 | |
| NCT07550855 | FLOURISH | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma | P2 | not yet recruiting | 52 | Sun Yat-sen University | Sep 2026 |
| NCT07608731 | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | P1 | not yet recruiting | 18 | Allison Winter | Jun 2026 | |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | P2 | recruiting | 41 | Jennifer Crombie, MD | Apr 2023 | |
| NCT06091865 | OLYMPIA-3 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | P3 | recruiting | 904 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | P2 | recruiting | 51 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Mar 2025 | |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | P1/P2 | recruiting | 43 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2024 | |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | P3 | recruiting | 100 | Ruijin Hospital | Jul 2024 | |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | P2 | not yet recruiting | 20 | Mwanasha Merrill, MD | Jul 2026 | |
| NCT07185373 | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | P2/P3 | not yet recruiting | 215 | Huashan Hospital | Oct 2025 | |
| NCT06097364 | OLYMPIA-2 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | P3 | active not recruiting | 733 | Regeneron Pharmaceuticals | Nov 2023 |
| NCT06504940 | MZL | Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) | P2 | recruiting | 69 | First Affiliated Hospital of Zhejiang University | Jun 2024 |
| NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | P3 | not yet recruiting | 93 | Sinocelltech Ltd. | May 2026 | |
| NCT07350850 | PRIME-PCNSL | A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL | P2 | recruiting | 77 | Tongji Hospital | Dec 2025 |
| NCT06342544 | IMCOMG | Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. | P3 | recruiting | 128 | Fondation Ophtalmologique Adolphe de Rothschild | Apr 2025 |
| NCT06792253 | Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P3 | recruiting | 416 | BeBetter Med Inc | Jan 2025 | |
| NCT06564038 | Soundtrack-E | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | P1/P2 | recruiting | 408 | AstraZeneca | Jan 2025 |
| NCT04688788 | DanNORMS | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | P3 | active not recruiting | 600 | Rigshospitalet, Denmark | Apr 2021 |
| NCT05864742 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | P2 | active not recruiting | 40 | Peter MacCallum Cancer Centre, Australia | Sep 2023 | |
| NCT05735834 | RITZ | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients | P3 | active not recruiting | 122 | International Extranodal Lymphoma Study Group (IELSG) | May 2024 |
| NCT05303792 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | P2 | active not recruiting | 68 | Alliance for Clinical Trials in Oncology | Jun 2023 | |
| NCT06230224 | OLYMPIA-4 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | P3 | active not recruiting | 216 | Regeneron Pharmaceuticals | Feb 2024 |
| NCT06942507 | BRZ-WM | Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia | N/A | not yet recruiting | 104 | Peking Union Medical College Hospital | May 2025 |
| NCT05406401 | waveLINE-007 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | P2 | active not recruiting | 60 | Merck Sharp & Dohme LLC | Jul 2022 |
| NCT05952024 | ACRUE | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | P2 | recruiting | 80 | AstraZeneca | Jul 2024 |
| NCT04882163 | CC-220 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | P1/P2 | withdrawn | 0 | Celgene | Oct 2021 |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | P2 | not yet recruiting | 528 | The First Affiliated Hospital with Nanjing Medical University | Oct 2024 | |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | P3 | recruiting | 100 | National Research Center for Hematology, Russia | Apr 2022 | |
| NCT04871191 | SATELITE | Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis | P3 | recruiting | 42 | Assistance Publique - Hôpitaux de Paris | Jun 2025 |
| NCT06350318 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | P2 | recruiting | 43 | H. Lee Moffitt Cancer Center and Research Institute | Apr 2024 | |
| NCT03929601 | TN25 | Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes | P2 | active not recruiting | 74 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Oct 2023 |
| NCT05249959 | FIL_COLUMN | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. | P2 | recruiting | 49 | Fondazione Italiana Linfomi - ETS | Mar 2022 |
| NCT03414502 | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response | P3 | recruiting | 400 | University of Nebraska | Dec 2007 | |
| NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | recruiting | 53 | City of Hope Medical Center | Oct 2025 | |
| NCT07029139 | A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy | P2 | not yet recruiting | 156 | Shanghai JMT-Bio Inc. | Jun 2025 | |
| NCT04224493 | SYMPHONY-1 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | P3 | active not recruiting | 599 | Epizyme, Inc. | Jun 2020 |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | P3 | not yet recruiting | 228 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Nov 2025 | |
| NCT06983821 | SAFE-LOW | Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) | P3 | recruiting | 36 | Ottawa Hospital Research Institute | Nov 2025 |
| NCT06522386 | GATE1 | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Jan 2025 |
| NCT06149286 | OLYMPIA-5 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | P3 | recruiting | 470 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT06549231 | EVER-ILD 3 | Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis | P3 | recruiting | 102 | University Hospital, Tours | Jan 2025 |
| NCT03579875 | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders | P2 | recruiting | 48 | Masonic Cancer Center, University of Minnesota | Nov 2018 | |
| NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | P2 | not yet recruiting | 20 | ImmunityBio, Inc. | Apr 2026 | |
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | P2 | recruiting | 150 | Guangzhou Lupeng Pharmaceutical Company LTD. | Nov 2025 | |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | P2 | active not recruiting | 39 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Sep 2025 | |
| NCT07002099 | Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study | P2 | recruiting | 26 | Second Affiliated Hospital of Soochow University | Jun 2025 | |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | recruiting | 152 | Ruijin Hospital | Apr 2025 | |
| NCT06581562 | IRIS-RD-01 | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. | P1 | recruiting | 30 | IRIS Research and Development, LLC | May 2024 |
| NCT05998642 | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | P2 | recruiting | 30 | Canadian Cancer Trials Group | Feb 2024 | |
| NCT06031233 | MINUTE | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | recruiting | 776 | Isala | Sep 2023 |
| NCT05136976 | THERAMAG | Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders | P3 | recruiting | 90 | Centre Hospitalier Universitaire de Saint Etienne | Jun 2023 |
| NCT05207358 | GLUREDLUP | Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis | P4 | recruiting | 30 | Institutul Clinic Fundeni | Mar 2022 |
| NCT04784052 | Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab | P1/P2 | recruiting | 18 | Porteus, Matthew, MD | Dec 2021 | |
| NCT04856137 | DLBL | A Phase I/II Study of Diffuse Large B-cell Lymphoma | P1/P2 | not yet recruiting | 74 | National Health Research Institutes, Taiwan | May 2021 |
| NCT03500731 | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | P1/P2 | recruiting | 8 | Paul Szabolcs | Apr 2018 | |
| NCT01419561 | KICS | Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) | P2 | recruiting | 140 | National Cancer Institute (NCI) | Sep 2011 |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | P2 | recruiting | 58 | Tianjin Medical University Cancer Institute and Hospital | Jan 2026 | |
| NCT07405255 | Zillion | Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma | P2 | not yet recruiting | 19 | Ruijin Hospital | Jan 2026 |
| NCT02180711 | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 113 | Acerta Pharma BV | Dec 2014 | |
| NCT07029737 | SOUND-MCL | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain | P2 | recruiting | 55 | AstraZeneca | Sep 2025 |
| NCT06220032 | HO170DLBCL | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | P3 | recruiting | 324 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Aug 2024 |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | P2 | recruiting | 65 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Nov 2025 | |
| NCT05004064 | CARAMEL | Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | P2 | recruiting | 48 | University College, London | Nov 2023 |
| NCT04323566 | Ra-P-OCD | Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement | P2 | enrolling by invitation | 40 | Uppsala University Hospital | May 2022 |
| NCT04884035 | CC-220 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | P1 | recruiting | 224 | Celgene | Sep 2021 |
| NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma | P1/P2 | not yet recruiting | 51 | Sun Yat-sen University | May 2026 | |
| NCT07234019 | ITP | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 160 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2026 |
| NCT04931368 | OptiMATe | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma | P3 | active not recruiting | 331 | Klinikum Stuttgart | Jun 2021 |
| NCT06425302 | GOLSEEK-2 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | P2 | active not recruiting | 90 | Celgene | Aug 2024 |
| NCT04627753 | Lemon-C | Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. | P2 | recruiting | 30 | Kim, Seok Jin | Nov 2020 |
| NCT06714838 | ReCIX | Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy | P3 | recruiting | 100 | Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC) | Oct 2024 |
| NCT05635162 | ZEBRA | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | P2 | recruiting | 50 | University College, London | May 2024 |
| NCT05951959 | TrAVeRse | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma | P2 | active not recruiting | 108 | AstraZeneca | Dec 2023 |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | P1/P2 | recruiting | 308 | Bristol-Myers Squibb | Dec 2023 | |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | P2 | active not recruiting | 12 | Shayna Sarosiek, MD | Nov 2021 | |
| NCT06611696 | ARRIA | Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis | P4 | recruiting | 160 | Chiba University | Nov 2024 |
| NCT06647732 | MALT | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | P2 | recruiting | 42 | Sun Yat-sen University | Oct 2024 |
| NCT01808599 | Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma | P2 | active not recruiting | 112 | International Extranodal Lymphoma Study Group (IELSG) | Dec 2013 | |
| NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | P2 | recruiting | 25 | Ruijin Hospital | Sep 2025 | |
| NCT07269639 | Go-Pro-DLBCL | Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma | P1/P2 | not yet recruiting | 20 | Seoul National University Hospital | Jan 2026 |
| NCT07169565 | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia | P1 | not yet recruiting | 21 | Institute of Hematology & Blood Diseases Hospital, China | Sep 2025 | |
| NCT06554600 | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | recruiting | 36 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2024 | |
| NCT06541665 | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | P1 | active not recruiting | 20 | Ono Pharmaceutical Co., Ltd. | May 2024 | |
| NCT06319456 | APG-2575 | A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | P3 | recruiting | 344 | Ascentage Pharma Group Inc. | Apr 2024 |
| NCT04989621 | RR FL | Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) | P2 | recruiting | 32 | Sun Yat-sen University | Aug 2021 |
| NCT04496037 | MOT-AMR | Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant | — | not yet recruiting | 170 | Imperial College London | Sep 2020 |
| NCT04680052 | InMIND | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | P3 | active not recruiting | 654 | Incyte Corporation | Apr 2021 |
| NCT04626791 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | P2 | recruiting | 45 | Academic and Community Cancer Research United | Aug 2021 | |
| NCT07614282 | Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia | P1 | not yet recruiting | 28 | Jennifer Amengual | Jul 2026 | |
| NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma | P2 | recruiting | 33 | University of Washington | Mar 2026 | |
| NCT06738368 | DA-EPOCH | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia | P2 | recruiting | 30 | University of Washington | May 2026 |
| NCT07073833 | The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma | P1 | recruiting | 40 | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Jul 2025 | |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | P2 | recruiting | 45 | Ruijin Hospital | Jul 2025 | |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | P1/P2 | not yet recruiting | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Mar 2026 | |
| NCT05018520 | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk | P3 | recruiting | 640 | Ruijin Hospital | Sep 2021 | |
| NCT04384484 | LOTIS 5 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P3 | active not recruiting | 440 | ADC Therapeutics S.A. | Sep 2020 |
| NCT06414148 | EpLCART | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma | P2 | recruiting | 40 | Peter MacCallum Cancer Centre, Australia | May 2024 |
| NCT03863184 | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | P2 | active not recruiting | 37 | Weill Medical College of Cornell University | Oct 2019 | |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | P1 | active not recruiting | 50 | Mayo Clinic | Jun 2020 | |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | P2 | not yet recruiting | 35 | City of Hope Medical Center | Dec 2026 | |
| NCT06468943 | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | P2 | enrolling by invitation | 20 | The First Affiliated Hospital of Soochow University | Jul 2023 | |
| NCT01810588 | Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | P2 | active not recruiting | 270 | Weill Medical College of Cornell University | Oct 2012 | |
| NCT06954805 | PTLD | Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) | P2 | recruiting | 30 | Jennifer Amengual | Apr 2025 |
| NCT07231952 | WM | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | P2 | recruiting | 40 | Memorial Sloan Kettering Cancer Center | Nov 2025 |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | P2/P3 | active not recruiting | 363 | National Cancer Institute (NCI) | Oct 2019 | |
| NCT07362238 | ITP | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 122 | Institute of Hematology & Blood Diseases Hospital, China | Mar 2026 |
| NCT06508658 | EPCORE DLBCL-4 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P3 | active not recruiting | 379 | Genmab | Aug 2024 |
| NCT07041268 | Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab | P2 | recruiting | 116 | Pirogov Russian National Research Medical University | Apr 2024 | |
| NCT06084936 | GLOBRYTE | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | P3 | recruiting | 182 | Hoffmann-La Roche | Oct 2023 |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | P2 | recruiting | 92 | National Cancer Institute (NCI) | Jan 2022 | |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | P2 | not yet recruiting | 24 | Fox Chase Cancer Center | Jun 2025 | |
| NCT05025800 | ALX148 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 47 | M.D. Anderson Cancer Center | Oct 2021 |
| NCT05929716 | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Sep 2023 | |
| NCT04404088 | Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma | P2 | active not recruiting | 60 | M.D. Anderson Cancer Center | Jul 2020 | |
| NCT06530004 | Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children | — | recruiting | 50 | The First Affiliated Hospital of Xiamen University | Mar 2020 | |
| NCT07168161 | BDB-001 Phase III Trial in ANCA-Associated Vasculitis | P3 | recruiting | 300 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Nov 2025 | |
| NCT04623541 | EPCORE™ CLL-1 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | P1/P2 | active not recruiting | 194 | Genmab | Nov 2020 |
| NCT05798156 | R-Pola-Glo | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP | P2 | active not recruiting | 125 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Mar 2023 |
| NCT06832267 | RMTT | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | N/A | recruiting | 44 | Zhejiang Cancer Hospital | Feb 2025 |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | P1/P2 | active not recruiting | 438 | Celgene | May 2019 | |
| NCT05600686 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | P2 | recruiting | 24 | Joseph Tuscano | May 2023 | |
| NCT06929624 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | P3 | recruiting | 280 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Apr 2025 | |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | P2 | recruiting | 42 | Memorial Sloan Kettering Cancer Center | Jan 2025 | |
| NCT05533164 | REDUCE-PMR-2 | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse | P3 | active not recruiting | 174 | Sint Maartenskliniek | Feb 2023 |
| NCT05615974 | A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | P1/P2 | recruiting | 139 | LaNova Medicines Limited | Jan 2023 | |
| NCT03952637 | A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis | P1/P2 | recruiting | 54 | National Human Genome Research Institute (NHGRI) | Aug 2019 | |
| NCT07225439 | NHL | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | P1 | not yet recruiting | 15 | Paolo Caimi, MD | Dec 2025 |
| NCT06676631 | NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis | P1 | recruiting | 18 | Guangdong Provincial People's Hospital | Feb 2025 | |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | not yet recruiting | 152 | Ruijin Hospital | Dec 2024 | |
| NCT06756308 | A Study of Enasidenib in People With T-Cell Lymphoma | P2 | recruiting | 25 | Memorial Sloan Kettering Cancer Center | Dec 2024 | |
| NCT06046248 | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease | P2 | recruiting | 25 | Northside Hospital, Inc. | Jan 2024 | |
| NCT06003283 | RITUXERA | Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis | P4 | recruiting | 134 | Universitaire Ziekenhuizen KU Leuven | Jan 2024 |
| NCT05786768 | OBIRINS | Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome | P2/P3 | recruiting | 88 | Assistance Publique - Hôpitaux de Paris | Oct 2023 |
| NCT05914155 | PRIME | Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome | P3 | recruiting | 88 | Shoichi Maruyama MD PhD | Jun 2023 |
| NCT05786040 | Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder | P2 | recruiting | 28 | Timothy Voorhees | Mar 2023 | |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | P2 | recruiting | 28 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2022 | |
| NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | P1 | recruiting | 480 | CStone Pharmaceuticals | Mar 2022 | |
| NCT03474744 | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | P2 | active not recruiting | 36 | Christian Buske | Dec 2019 | |
| NCT00692939 | Autologous Stem Cell Transplantation for Crohn's Disease | P1/P2 | recruiting | 20 | Paul Szabolcs | Jun 2012 | |
| NCT00977977 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | P2 | recruiting | 30 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Dec 2010 | |
| NCT01059786 | Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | P2 | active not recruiting | 69 | National Cancer Institute (NCI) | Jul 2010 | |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | P2 | recruiting | 20 | Tianjin Medical University Cancer Institute and Hospital | Dec 2024 | |
| NCT06254560 | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | P2 | recruiting | 20 | Institute of Hematology & Blood Diseases Hospital, China | Feb 2023 | |
| NCT04758975 | VALUABLE | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) | P2 | recruiting | 55 | Paolo Ghia | Sep 2022 |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | P1/P2 | recruiting | 276 | M.D. Anderson Cancer Center | Aug 2011 | |
| NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial | P2 | recruiting | 90 | Fei Li | Dec 2024 | |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | P1 | active not recruiting | 20 | OHSU Knight Cancer Institute | Sep 2022 | |
| NCT06561347 | ZEBRA | Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | P2 | recruiting | 56 | Massachusetts General Hospital | Dec 2024 |
| NCT02203526 | TEDDI-R | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | P1 | active not recruiting | 68 | National Cancer Institute (NCI) | Aug 2014 |
| NCT07297563 | ITP | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 160 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2026 |
| NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | Early P1 | active not recruiting | 58 | Memorial Sloan Kettering Cancer Center | Nov 2018 | |
| NCT07001540 | DLBCL | Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation | P2 | recruiting | 130 | Fudan University | May 2025 |
| NCT05338190 | RITUX-PLUS 2 | Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia | P3 | recruiting | 132 | Assistance Publique - Hôpitaux de Paris | Nov 2022 |
| NCT06136351 | A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | recruiting | 23 | Ruijin Hospital | Nov 2023 | |
| NCT04824092 | frontMIND | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | P3 | active not recruiting | 899 | Incyte Corporation | May 2021 |
| NCT06952413 | Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | P2 | recruiting | 30 | National Center of Neurology and Psychiatry, Japan | Apr 2025 | |
| NCT05023980 | BRUIN CLL-313 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | P3 | active not recruiting | 309 | Loxo Oncology, Inc. | Sep 2021 |
| NCT04965493 | BRUIN CLL-322 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | P3 | active not recruiting | 600 | Loxo Oncology, Inc. | Sep 2021 |
| NCT03336333 | SEQUOIA | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | P3 | active not recruiting | 590 | BeiGene | Oct 2017 |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | P2 | active not recruiting | 88 | M.D. Anderson Cancer Center | Oct 2011 | |
| NCT06351527 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | P1 | recruiting | 78 | InnoCare Pharma Inc. | Apr 2024 | |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | P2 | recruiting | 30 | Yan Zhang, MD | Oct 2023 | |
| NCT05270057 | LONCA | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | P1 | active not recruiting | 11 | Medical College of Wisconsin | Jan 2023 |
| NCT06064344 | RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma | N/A | not yet recruiting | 108 | Zhongshan Ophthalmic Center, Sun Yat-sen University | Oct 2023 | |
| NCT02911142 | EPOCH-R2 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | P1/P2 | active not recruiting | 17 | National Cancer Institute (NCI) | Jul 2017 |
| NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | P3 | active not recruiting | 310 | Acerta Pharma BV | Feb 2017 | |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | not yet recruiting | 80 | NYU Langone Health | Sep 2025 | |
| NCT05683171 | A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma | P1/P2 | recruiting | 60 | M.D. Anderson Cancer Center | May 2023 | |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | P2 | recruiting | 20 | Weill Medical College of Cornell University | Sep 2021 | |
| NCT04663347 | EPCORE™ NHL-2 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | P1/P2 | active not recruiting | 543 | Genmab | Nov 2020 |
| NCT04542824 | EPCORE™ NHL-3 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | P1/P2 | active not recruiting | 78 | Genmab | Aug 2020 |
| NCT05139017 | MK-2140 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | P2/P3 | recruiting | 290 | Merck Sharp & Dohme LLC | Jan 2022 |
| NCT06561360 | HCL | A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | P2 | recruiting | 86 | Memorial Sloan Kettering Cancer Center | Sep 2024 |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | P1 | recruiting | 15 | University of Chicago | May 2019 | |
| NCT07444710 | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | P1 | not yet recruiting | 16 | National Cancer Institute (NCI) | Aug 2026 | |
| NCT07270835 | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | P4 | recruiting | 40 | The First Affiliated Hospital of Soochow University | Nov 2025 | |
| NCT06265220 | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | P1 | active not recruiting | 51 | Artiva Biotherapeutics, Inc. | Apr 2024 | |
| NCT04913103 | CLSGMCLPOLA | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL | P2 | not yet recruiting | 21 | Czech Lymphoma Study Group | Sep 2021 |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | P3 | recruiting | 310 | Alliance for Clinical Trials in Oncology | Sep 2017 | |
| NCT04745949 | PACIFIC | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | P2 | recruiting | 31 | M.D. Anderson Cancer Center | May 2021 |
| NCT03653338 | SCD | T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias | P1/P2 | recruiting | 5 | Paul Szabolcs | Aug 2018 |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | P2 | recruiting | 42 | M.D. Anderson Cancer Center | Aug 2017 | |
| NCT07206823 | Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | N/A | recruiting | 30 | The First Affiliated Hospital of Soochow University | Sep 2025 | |
| NCT07071246 | Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis | N/A | active not recruiting | 30 | Tang-Du Hospital | Aug 2022 | |
| NCT04022239 | Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant | P1/P2 | recruiting | 25 | M.D. Anderson Cancer Center | Mar 2020 | |
| NCT06594640 | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P1/P2 | recruiting | 108 | Institute of Hematology & Blood Diseases Hospital, China | May 2024 | |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | P3 | not yet recruiting | 428 | Xia Yi | Aug 2024 | |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | P3 | recruiting | 78 | Ruijin Hospital | Jul 2024 | |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | P1/P2 | recruiting | 35 | University of Washington | Jan 2023 | |
| NCT07057778 | Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP | P2 | not yet recruiting | 120 | Peking University People's Hospital | Jul 2025 | |
| NCT05482542 | Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis | N/A | withdrawn | 0 | Scripps Health | Jan 2023 | |
| NCT06475495 | COMPARE | Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis | P1/P2 | active not recruiting | 13 | Charite University, Berlin, Germany | Dec 2024 |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | P1 | recruiting | 15 | Dana-Farber Cancer Institute | Oct 2024 | |
| NCT06362967 | The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT | P2 | recruiting | 30 | Anhui Provincial Hospital | May 2024 | |
| NCT06047171 | RENAL-F02 | Rescue of Nephrons With ALE.F02 (RENAL-F02) | P2 | recruiting | 80 | Alentis Therapeutics AG | Sep 2023 |
| NCT04974216 | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | P2 | active not recruiting | 71 | The Lymphoma Academic Research Organisation | Dec 2021 | |
| NCT04540380 | Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH | P1 | active not recruiting | 20 | Massachusetts General Hospital | Sep 2021 | |
| NCT03321643 | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma | P1 | active not recruiting | 24 | National Cancer Institute (NCI) | Sep 2018 | |
| NCT03206671 | B-NHL 2013 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | P3 | active not recruiting | 650 | University Hospital Muenster | Aug 2017 |
| NCT02427620 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | active not recruiting | 131 | M.D. Anderson Cancer Center | Jun 2015 | |
| NCT00412594 | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia | P2 | recruiting | 150 | M.D. Anderson Cancer Center | Jun 2004 | |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | P1/P2 | recruiting | 28 | City of Hope Medical Center | Dec 2018 | |
| NCT06478472 | OR | Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy | N/A | recruiting | 36 | The First Affiliated Hospital of Xiamen University | Jun 2024 |
| NCT03697512 | MALIBU | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas | P2 | active not recruiting | 175 | International Extranodal Lymphoma Study Group (IELSG) | Sep 2019 |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | P2 | recruiting | 30 | Chinese PLA General Hospital | Jul 2024 | |
| NCT05788081 | TOP-FLOR | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. | P2 | active not recruiting | 40 | Olivia Newton-John Cancer Research Institute | Aug 2023 |
| NCT03758989 | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | P2 | recruiting | 40 | University of Rochester | May 2019 | |
| NCT06489808 | Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL | P2 | recruiting | 89 | Institute of Hematology & Blood Diseases Hospital, China | May 2024 | |
| NCT05834855 | Noisy Rebels | Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | P3 | recruiting | 200 | Amsterdam UMC, location VUmc | Apr 2023 |
| NCT05551936 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | P1/P2 | active not recruiting | 42 | Vaishalee Kenkre | Jan 2023 | |
| NCT04666038 | BRUIN CLL-321 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | P3 | active not recruiting | 238 | Loxo Oncology, Inc. | Mar 2021 |
| NCT03899337 | STELLAR | A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | P2 | recruiting | 105 | University of Birmingham | Jul 2019 |
| NCT02727803 | Personalized NK Cell Therapy in CBT | P2 | recruiting | 100 | M.D. Anderson Cancer Center | May 2016 | |
| NCT04458610 | Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | active not recruiting | 60 | M.D. Anderson Cancer Center | May 2020 | |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | P2 | recruiting | 16 | Medical University of Vienna | Jan 2024 | |
| NCT01473628 | Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | P1/P2 | active not recruiting | 81 | M.D. Anderson Cancer Center | May 2013 | |
| NCT04974996 | LOTIS-8 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | P1 | withdrawn | 0 | ADC Therapeutics S.A. | Feb 2022 |
| NCT05583071 | MTR² | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | P2 | recruiting | 20 | University of Cologne | Aug 2024 |
| NCT04447716 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | P1 | active not recruiting | 4 | Thomas Jefferson University | Oct 2020 | |
| NCT03194815 | SINAPPS2 | IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 | P2 | active not recruiting | 70 | University of Cambridge | Nov 2017 |
| NCT01829958 | Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | N/A | active not recruiting | 201 | Memorial Sloan Kettering Cancer Center | Apr 2013 | |
| NCT07081022 | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma | P2 | recruiting | 180 | Shanghai Junshi Bioscience Co., Ltd. | Aug 2025 | |
| NCT04609046 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | P1 | recruiting | 47 | National Cancer Institute (NCI) | May 2021 | |
| NCT07362199 | ITP | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 20 | Institute of Hematology & Blood Diseases Hospital, China | Mar 2026 |
| NCT05495464 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Early P1 | active not recruiting | 22 | M.D. Anderson Cancer Center | Nov 2022 | |
| NCT03295383 | RITUX-MMP | Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | P3 | active not recruiting | 92 | University Hospital, Rouen | Jul 2019 |
| NCT03710772 | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | active not recruiting | 51 | M.D. Anderson Cancer Center | May 2019 | |
| NCT04212013 | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | P3 | active not recruiting | 23 | Memorial Sloan Kettering Cancer Center | Dec 2019 | |
| NCT05618925 | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | P1 | recruiting | 20 | ImmunityBio, Inc. | Aug 2025 | |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | P1/P2 | active not recruiting | 83 | National Cancer Institute (NCI) | Nov 2010 | |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | P2 | recruiting | 41 | Mayo Clinic | Apr 2025 | |
| NCT01695941 | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | P1 | active not recruiting | 24 | National Cancer Institute (NCI) | Aug 2012 | |
| NCT06921044 | A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL | P2 | not yet recruiting | 33 | Xiaohui He | Apr 2025 | |
| NCT06263491 | PR | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | P2 | recruiting | 50 | M.D. Anderson Cancer Center | May 2024 |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | P2/P3 | active not recruiting | 422 | National Cancer Institute (NCI) | May 2021 | |
| NCT06981988 | YY-20394 | A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL | P1/P2 | not yet recruiting | 80 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2025 |
| NCT05171647 | SUNMO | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | P3 | active not recruiting | 208 | Hoffmann-La Roche | Apr 2022 |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | P2 | active not recruiting | 27 | University of Wisconsin, Madison | Feb 2021 | |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | P2 | active not recruiting | 53 | Christian Buske | Sep 2019 | |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | P2 | active not recruiting | 22 | M.D. Anderson Cancer Center | Feb 2018 | |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | P3 | active not recruiting | 488 | National Cancer Institute (NCI) | May 2014 | |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 8 | City of Hope Medical Center | Sep 2011 | |
| NCT04529772 | ESCALADE | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | P3 | active not recruiting | 611 | Acerta Pharma BV | Oct 2020 |
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | P3 | active not recruiting | 635 | Acerta Pharma BV | Apr 2017 | |
| NCT05736419 | HCT | A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | P2 | recruiting | 24 | Memorial Sloan Kettering Cancer Center | Feb 2023 |
| NCT05214183 | ALTAMIRA | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 81 | Nordic Lymphoma Group | Dec 2021 |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | P3 | active not recruiting | 689 | ECOG-ACRIN Cancer Research Group | Nov 2017 | |
| NCT02251548 | iFCR | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | P2 | active not recruiting | 85 | Dana-Farber Cancer Institute | Oct 2014 |
| NCT04978584 | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | P2 | active not recruiting | 62 | M.D. Anderson Cancer Center | Mar 2022 | |
| NCT06572618 | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma | P2 | recruiting | 27 | City of Hope Medical Center | Jan 2025 | |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | P1/P2 | recruiting | 37 | Dana-Farber Cancer Institute | Aug 2020 | |
| NCT04075292 | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | P3 | active not recruiting | 155 | AstraZeneca | Jan 2020 | |
| NCT03789240 | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | P2 | active not recruiting | 33 | National Cancer Institute (NCI) | Aug 2019 | |
| NCT05514015 | Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy | P4 | recruiting | 78 | First Affiliated Hospital, Sun Yat-Sen University | Mar 2024 | |
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | P2 | recruiting | 20 | Tianjin Medical University Cancer Institute and Hospital | Mar 2024 | |
| NCT06410833 | BRRPJS | Belimumab After Rituximab in Resistant Primary Juvenile SS | P4 | recruiting | 15 | Peking Union Medical College Hospital | Mar 2024 |
| NCT06209619 | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | P1 | recruiting | 18 | Nathan Denlinger | Jan 2024 | |
| NCT05698147 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | P1/P2 | recruiting | 30 | Tong Chen, MD | Aug 2023 | |
| NCT05622201 | RCT-RITS | A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults | P2 | active not recruiting | 123 | Region Örebro County | Mar 2023 |
| NCT05221645 | P+R-ICE | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | active not recruiting | 65 | University of Southampton | Jun 2022 |
| NCT05280626 | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP | P2 | not yet recruiting | 100 | Innovent Biologics (Suzhou) Co. Ltd. | Mar 2022 | |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | P3 | active not recruiting | 244 | National Cancer Institute (NCI) | Oct 2021 | |
| NCT04624958 | Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL | P2 | active not recruiting | 42 | Sun Yat-sen University | Dec 2020 | |
| NCT04375228 | Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) | P2 | active not recruiting | 8 | Columbia University | Sep 2020 | |
| NCT04442022 | R-GDP | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2/P3 | active not recruiting | 501 | Karyopharm Therapeutics Inc | Sep 2020 |
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Early P1 | active not recruiting | 40 | Canadian Cancer Trials Group | Sep 2020 | |
| NCT04404283 | ECHELON-3 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | P3 | active not recruiting | 239 | Seagen, a wholly owned subsidiary of Pfizer | Aug 2020 |
| NCT04432714 | Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement | P1/P2 | recruiting | 81 | The First Affiliated Hospital with Nanjing Medical University | Jun 2020 | |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | P2 | recruiting | 40 | M.D. Anderson Cancer Center | May 2020 | |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | active not recruiting | 360 | ECOG-ACRIN Cancer Research Group | Dec 2019 | |
| NCT03749018 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | P2 | active not recruiting | 30 | David Bond, MD | Jan 2019 | |
| NCT03467867 | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | P2 | active not recruiting | 25 | Georgetown University | Apr 2018 | |
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | P2 | active not recruiting | 129 | Canadian Cancer Trials Group | Oct 2015 | |
| NCT01856192 | Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma | P2 | active not recruiting | 349 | National Cancer Institute (NCI) | Aug 2013 | |
| NCT06388941 | Iptacopan in Patients With ANCA Associated Vasculitis | P2 | active not recruiting | 84 | Novartis Pharmaceuticals | Aug 2024 | |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | — | recruiting | 100 | Zhengzhou University | Aug 2022 | |
| NCT05850546 | Rituximab in the First Episode of Paediatric Nephrotic Syndrome | P3 | not yet recruiting | 138 | Children's Hospital of Fudan University | Mar 2025 | |
| NCT05946486 | TIM-DePisT | Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity. | P3 | not yet recruiting | 174 | University Hospital, Bordeaux | Oct 2023 |
| NCT04850495 | Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | P1 | suspended | 38 | Yazeed Sawalha | Nov 2021 | |
| NCT01959698 | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | P1 | active not recruiting | 29 | Roswell Park Cancer Institute | Apr 2014 | |
| NCT05057468 | Second-line Treatment of Primary Autoimmune Hemolytic Anemia | P3 | recruiting | 30 | Assiut University | Oct 2021 | |
| NCT03352765 | A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients | P1 | active not recruiting | 28 | Memorial Sloan Kettering Cancer Center | Nov 2017 | |
| NCT02877303 | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | P2 | recruiting | 80 | M.D. Anderson Cancer Center | Nov 2016 | |
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial | P2 | recruiting | 70 | National Cancer Institute (NCI) | Jan 2024 | |
| NCT06086197 | A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | P2 | recruiting | 41 | Zhejiang Cancer Hospital | Oct 2023 | |
| NCT05581030 | ALL | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | P1 | recruiting | 7 | H. Lee Moffitt Cancer Center and Research Institute | May 2023 |
| NCT05728658 | The Study of ICP-248 in Patients With Mature B-cell Malignancies | P1 | recruiting | 191 | Beijing InnoCare Pharma Tech Co., Ltd. | Mar 2023 | |
| NCT05156710 | SAR445088 | BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) | P2 | active not recruiting | 48 | Sanofi | Jun 2022 |
| NCT02048813 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P3 | active not recruiting | 529 | National Cancer Institute (NCI) | Mar 2014 | |
| NCT00092222 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | P2 | active not recruiting | 75 | National Cancer Institute (NCI) | Oct 2004 | |
| NCT06599307 | The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis | P2 | recruiting | 46 | Cairo University | Aug 2024 | |
| NCT04980222 | R | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 46 | Hoffmann-La Roche | Mar 2022 |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | P1/P2 | recruiting | 140 | BioInvent International AB | May 2018 | |
| NCT02337985 | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | P1 | active not recruiting | 10 | City of Hope Medical Center | Nov 2015 | |
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL | N/A | recruiting | 30 | Zhejiang Cancer Hospital | Sep 2024 | |
| NCT01479842 | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | P1 | active not recruiting | 48 | Kami Maddocks, MD | Mar 2014 | |
| NCT04765111 | Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | P2 | active not recruiting | 53 | M.D. Anderson Cancer Center | Jun 2021 | |
| NCT02160015 | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | P1 | active not recruiting | 12 | National Cancer Institute (NCI) | May 2014 | |
| NCT06530511 | PRO | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | P2 | recruiting | 30 | Affiliated Hospital of Nantong University | Aug 2024 |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | N/A | not yet recruiting | 20 | The First Hospital of Jilin University | Sep 2023 | |
| NCT05690191 | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | — | enrolling by invitation | 169 | Second Affiliated Hospital of Soochow University | Jun 2021 | |
| NCT03630211 | SSc | Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis | P2 | recruiting | 8 | Paul Szabolcs | Jul 2018 |
| NCT06906549 | RADAR | Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis | P4 | recruiting | 260 | University Hospital, Strasbourg, France | Jul 2025 |
| NCT06977711 | DLBCL | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | P1 | recruiting | 10 | The University of Texas Health Science Center at San Antonio | Jun 2025 |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | P2 | active not recruiting | 39 | University of Rochester | Sep 2021 | |
| NCT02446236 | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | P1 | active not recruiting | 27 | Hackensack Meridian Health | Jun 2015 | |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | P1/P2 | active not recruiting | 32 | Dana-Farber Cancer Institute | Jun 2014 | |
| NCT01880567 | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | active not recruiting | 113 | M.D. Anderson Cancer Center | Jul 2013 | |
| NCT05734794 | STORM | Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial | P3 | recruiting | 80 | The Children's Hospital of Zhejiang University School of Medicine | Feb 2023 |
| NCT04981912 | Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients | P1 | active not recruiting | 4 | University of California, San Diego | Sep 2021 | |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | P2 | active not recruiting | 8 | Barbara Ann Karmanos Cancer Institute | Aug 2020 | |
| NCT05596786 | EvER-ILD2 | Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial | P3 | recruiting | 126 | University Hospital, Tours | Jan 2023 |
| NCT03220022 | Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | P1 | active not recruiting | 46 | National Cancer Institute (NCI) | Mar 2018 | |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | N/A | recruiting | 35 | The First Affiliated Hospital of Soochow University | Jan 2023 | |
| NCT05843968 | Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome | P2 | recruiting | 46 | Children's Hospital of Chongqing Medical University | Jan 2023 | |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 41 | City of Hope Medical Center | Jan 2021 | |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | P2 | active not recruiting | 170 | St. Jude Children's Research Hospital | Jul 2016 | |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | P3 | active not recruiting | 435 | Children's Oncology Group | Mar 2023 | |
| NCT03274375 | IANMDAR | Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis | P2 | recruiting | 20 | Assistance Publique - Hôpitaux de Paris | Jun 2021 |
| NCT04416451 | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma | P2 | active not recruiting | 6 | Memorial Sloan Kettering Cancer Center | May 2021 | |
| NCT04400994 | IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus | P2 | active not recruiting | 20 | The University of Hong Kong | Jun 2020 | |
| NCT03805932 | TM | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia | P1 | active not recruiting | 18 | National Cancer Institute (NCI) | Oct 2019 |
| NCT03844061 | Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis | P2 | recruiting | 30 | Hospital for Special Surgery, New York | Jul 2019 | |
| NCT03719131 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | P2 | active not recruiting | 15 | Emory University | Jun 2019 | |
| NCT03697356 | Ballondor | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia | P2 | recruiting | 54 | Kosin University Gospel Hospital | Mar 2019 |
| NCT02007044 | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | P2 | active not recruiting | 66 | M.D. Anderson Cancer Center | Dec 2013 | |
| NCT01446133 | CLL-SLL | Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) | P2 | active not recruiting | 120 | M.D. Anderson Cancer Center | Dec 2011 |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | P2 | active not recruiting | 46 | M.D. Anderson Cancer Center | Aug 2006 | |
| NCT04585893 | Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi | P2 | active not recruiting | 15 | UNC Lineberger Comprehensive Cancer Center | Jun 2021 | |
| NCT01886872 | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | P3 | active not recruiting | 547 | National Cancer Institute (NCI) | Jan 2014 | |
| NCT01829568 | Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma | P1 | active not recruiting | 33 | National Cancer Institute (NCI) | Jun 2013 | |
| NCT05351346 | Genotype-guided Treatment in DLBCL | P3 | unknown | 1,100 | Ruijin Hospital | Jun 2022 | |
| NCT05737628 | First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | P1 | active not recruiting | 17 | Byondis B.V. | Mar 2024 | |
| NCT05425654 | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL | P2 | unknown | 30 | National Research Center for Hematology, Russia | May 2021 | |
| NCT05549284 | RMO | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) | P2 | unknown | 36 | Affiliated Hospital to Academy of Military Medical Sciences | Jun 2022 |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | P1/P2 | terminated | 53 | M.D. Anderson Cancer Center | Apr 2019 | |
| NCT06683885 | A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma | P1/P2 | recruiting | 80 | Mingzhi Zhang | Nov 2024 | |
| NCT05926427 | Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement | P2 | unknown | 25 | Ruijin Hospital | Aug 2023 | |
| NCT03274492 | POLARIX | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | P3 | completed | 1,000 | Hoffmann-La Roche | Nov 2017 |
| NCT02889523 | Epi-RCHOP | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | P1/P2 | active not recruiting | 214 | The Lymphoma Academic Research Organisation | Oct 2016 |
| NCT02446457 | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 53 | M.D. Anderson Cancer Center | Jul 2015 | |
| NCT05390749 | POR | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | P2 | unknown | 50 | Peking Union Medical College Hospital | Apr 2022 |
| NCT05388123 | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | P2 | completed | 15 | Scripps Health | Mar 2022 | |
| NCT05828147 | Anti-CD20 Antibodies for Treatment of SLE-PAH | P4 | unknown | 50 | Chinese SLE Treatment And Research Group | May 2023 | |
| NCT04433156 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | P2 | completed | 26 | Henan Cancer Hospital | Apr 2020 | |
| NCT05696613 | A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy | P3 | unknown | 148 | Cerium Pharmaceuticals, Inc. | Mar 2023 | |
| NCT03349346 | RICE | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | P1 | withdrawn | 0 | Gilead Sciences | Jun 2019 |
| NCT05186558 | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | P2 | unknown | 54 | The First Affiliated Hospital with Nanjing Medical University | May 2022 | |
| NCT02315326 | BTK | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | P1/P2 | completed | 93 | Memorial Sloan Kettering Cancer Center | Dec 2014 |
| NCT03609593 | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | P2 | completed | 42 | Nicole Lamanna | Nov 2018 | |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | P1 | completed | 25 | Memorial Sloan Kettering Cancer Center | Jan 2019 | |
| NCT05329090 | RIGA | Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis | P3 | completed | 75 | Hopital Foch | Mar 2022 |
| NCT04737889 | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | P2 | recruiting | 30 | Henan Cancer Hospital | Jan 2021 | |
| NCT00584935 | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | P1/P2 | completed | 3 | University of Alabama at Birmingham | Jan 2006 | |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | P2 | unknown | 30 | Peng Liu | Jul 2023 | |
| NCT05896007 | Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT | P2 | unknown | 29 | Ruijin Hospital | Jul 2023 | |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | P2 | unknown | 44 | Beijing Children's Hospital | Oct 2022 | |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | P2 | recruiting | 50 | Li Zhiming | Jul 2022 | |
| NCT04920968 | OVERALL | Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" | P2 | recruiting | 124 | Maria Sklodowska-Curie National Research Institute of Oncology | Oct 2021 |
| NCT04938297 | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | P2 | unknown | 100 | Henan Cancer Hospital | May 2021 | |
| NCT04688151 | RAD | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. | P1 | active not recruiting | 22 | National Health Research Institutes, Taiwan | Feb 2021 |
| NCT04607772 | RR | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | withdrawn | 0 | Karyopharm Therapeutics Inc | Nov 2020 |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | P1/P2 | recruiting | 123 | Ascentage Pharma Group Inc. | Aug 2020 | |
| NCT04129710 | PCNSL | A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | P2 | unknown | 120 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jan 2020 |
| NCT02900976 | Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder | P2 | completed | 18 | Children's Oncology Group | Mar 2017 | |
| NCT02734771 | BV mini CHP | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | P2 | active not recruiting | 24 | Patrick Reagan | Jun 2016 |
| NCT03501459 | Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome | P3 | unknown | 100 | National University Health System, Singapore | Jun 2008 | |
| NCT00006721 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | P3 | completed | 571 | SWOG Cancer Research Network | Mar 2001 | |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | unknown | 35 | Peng Liu | Jul 2023 | |
| NCT05644210 | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE | — | unknown | 80 | Qilu Hospital of Shandong University | Oct 2022 | |
| NCT04481815 | Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | P2 | unknown | 240 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Oct 2020 | |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | P1/P2 | unknown | 140 | Huiqiang Huang | Apr 2020 | |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | P3 | unknown | 280 | Ruijin Hospital | Mar 2022 | |
| NCT04668365 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma | P2 | suspended | 59 | Henan Cancer Hospital | Dec 2020 | |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | P1/P2 | completed | 803 | Loxo Oncology, Inc. | Mar 2019 | |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | P1/P2 | active not recruiting | 30 | Academic and Community Cancer Research United | May 2016 | |
| NCT05914662 | ZBR | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM | P2 | recruiting | 42 | Institute of Hematology & Blood Diseases Hospital, China | Feb 2023 |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P1 | unknown | 36 | Mehrdad Abedi, MD | Sep 2021 | |
| NCT06078696 | CD2 SCD | Siplizumab for Sickle Cell Disease Transplant | P1/P2 | terminated | 1 | Columbia University | Sep 2023 |
| NCT05979948 | CZ-WM01 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia | P2 | unknown | 60 | Shanghai Changzheng Hospital | Aug 2023 |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | P2 | unknown | 31 | Zhejiang Cancer Hospital | Oct 2021 | |
| NCT04460248 | ZR2 | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | P2 | active not recruiting | 40 | Ruijin Hospital | Aug 2020 |
| NCT03505762 | Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment | P2 | active not recruiting | 80 | Wake Forest University Health Sciences | Jul 2018 | |
| NCT03829566 | ATTEND | Autologous Transplant To End NMO Spectrum Disorder | P2/P3 | withdrawn | 0 | Northwestern University | Nov 2019 |
| NCT03651518 | PIMOC | Personalized Therapies in Inflammatory Complex Disease | P2 | completed | 32 | Assistance Publique - Hôpitaux de Paris | Oct 2020 |
| NCT06164327 | Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P1 | unknown | 75 | BeBetter Med Inc | Dec 2023 | |
| NCT03259503 | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | P1 | completed | 50 | M.D. Anderson Cancer Center | Sep 2019 | |
| NCT05575973 | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | P2 | unknown | 55 | Jianfeng Zhou | Oct 2022 | |
| NCT05533125 | REDUCE-PMR-1 | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed | P3 | completed | 114 | Sint Maartenskliniek | Feb 2023 |
| NCT02296918 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | P1 | completed | 69 | Acerta Pharma BV | Dec 2014 | |
| NCT05364424 | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma | P1 | completed | 43 | Hoffmann-La Roche | Nov 2022 | |
| NCT03746223 | Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma | P2 | unknown | 42 | Peking Union Medical College Hospital | Nov 2018 | |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | P2 | terminated | 15 | M.D. Anderson Cancer Center | Oct 2019 | |
| NCT04673617 | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | P1/P2 | completed | 45 | Artiva Biotherapeutics, Inc. | Mar 2021 | |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | terminated | 5 | UNC Lineberger Comprehensive Cancer Center | Feb 2023 | |
| NCT04835870 | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | P2 | unknown | 78 | The First Affiliated Hospital of Soochow University | Apr 2021 | |
| NCT04480450 | Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy | P2 | withdrawn | 0 | University of Kansas Medical Center | Jul 2025 | |
| NCT06245707 | the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy | N/A | unknown | 2 | Beijing Friendship Hospital | Oct 2023 | |
| NCT05036577 | ORMD2021 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL | P1 | active not recruiting | 15 | Huashan Hospital | Oct 2021 |
| NCT04578639 | OVERLORD-MS | Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease | P3 | active not recruiting | 214 | Haukeland University Hospital | Nov 2020 |
| NCT07200583 | PAIA-Haplo | Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients | — | completed | 50 | Ting YANG | May 2025 |
| NCT05494593 | A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) | P4 | withdrawn | 0 | Takeda | Feb 2023 | |
| NCT05887726 | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | P2 | unknown | 30 | Liaoning Cancer Hospital & Institute | Aug 2023 | |
| NCT05868837 | REFINE | Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) | P3 | recruiting | 40 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Feb 2022 |
| NCT04914741 | COALITION | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | P1/P2 | active not recruiting | 80 | Peter MacCallum Cancer Centre, Australia | Jun 2021 |
| NCT05504603 | ZR | Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma | P2 | unknown | 20 | The First Affiliated Hospital of Soochow University | Jul 2020 |
| NCT03671018 | BTCT4465A | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 422 | Hoffmann-La Roche | Sep 2018 |
| NCT03013218 | ALX148 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | P1 | completed | 174 | ALX Oncology Inc. | Feb 2017 |
| NCT04994626 | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies | P2 | unknown | 20 | Chinese Academy of Medical Sciences | Oct 2021 | |
| NCT05950334 | FT522-101 | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | P1 | completed | 20 | Fate Therapeutics | Nov 2023 |
| NCT06068829 | Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders | — | unknown | 80 | Feng Jinzhou | Oct 2023 | |
| NCT05923879 | Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma | — | unknown | 30 | Ruijin Hospital | Jun 2023 | |
| NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | P2 | unknown | 150 | First Affiliated Hospital of Wenzhou Medical University | Jun 2022 | |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | P3 | unknown | 218 | Beijing InnoCare Pharma Tech Co., Ltd. | Jan 2021 | |
| NCT03569995 | [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma | P2 | unknown | 35 | Won Seog Kim | Nov 2018 | |
| NCT04231448 | DEB | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL | P3 | completed | 423 | Chipscreen Biosciences, Ltd. | May 2020 |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | P1/P2 | suspended | 30 | Northwestern University | Nov 2018 | |
| NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | P3 | completed | 445 | Pharmacyclics LLC. | Jan 2017 | |
| NCT03979456 | RIDOSE-MS | RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS | P3 | unknown | 200 | Karolinska Institutet | Jul 2018 |
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | P2 | completed | 25 | University of Miami | Mar 2009 | |
| NCT06175338 | Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis | P1 | active not recruiting | 208 | Mabscale, LLC | Jun 2023 | |
| NCT05201248 | SC | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 49 | Genmab | Mar 2022 |
| NCT04214626 | R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma | P2 | completed | 60 | Henan Cancer Hospital | Jan 2020 | |
| NCT03623373 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | P2 | completed | 13 | Washington University School of Medicine | Nov 2018 | |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | P2 | terminated | 3 | M.D. Anderson Cancer Center | Aug 2019 | |
| NCT04899570 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | P2 | unknown | 20 | Peking Union Medical College Hospital | Apr 2021 | |
| NCT03942887 | ENDURRANCE-1 | Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis | P3 | unknown | 100 | Leiden University Medical Center | May 2019 |
| NCT02356159 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | P1/P2 | completed | 34 | National Cancer Institute (NCI) | Sep 2015 | |
| NCT04285567 | CRISTALLO | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | P3 | completed | 166 | Hoffmann-La Roche | May 2020 |
| NCT06790420 | RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study | — | completed | 2,703 | Pfizer | Jan 2025 | |
| NCT05704400 | Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome | P2 | unknown | 20 | Istituto Giannina Gaslini | Mar 2023 | |
| NCT01085617 | UKALL14 | Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia | — | completed | 0 | University College, London | Dec 2010 |
| NCT03763643 | PRI-VENT FSGS | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | Early P1 | completed | 21 | University of Minnesota | Jul 2019 |
| NCT00788684 | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | P1 | completed | 29 | AbbVie | Jul 2009 | |
| NCT05682196 | AGRAF-2 | Rituximab in Patients With Acute Rheumatic Fever | P2 | suspended | 234 | African Academy of Methodology and Statistics | Jan 2023 |
| NCT05200312 | ZR2-CHOP | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma | P2 | unknown | 36 | The First Affiliated Hospital with Nanjing Medical University | Feb 2022 |
| NCT07035561 | Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis | P2 | completed | 30 | Shereen Medhat Mohammed Elsayed Nassar | Jun 2023 | |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | P3 | completed | 623 | The Lymphoma Academic Research Organisation | Nov 2013 | |
| NCT01868269 | Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) | P3 | completed | 102 | Institut Curie | Apr 2013 | |
| NCT03366272 | NIVEAU | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients | P2/P3 | completed | 348 | Universität des Saarlandes | Dec 2017 |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | P1 | terminated | 62 | Celgene | Nov 2020 | |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | N/A | unknown | 60 | The First Affiliated Hospital with Nanjing Medical University | Apr 2023 | |
| NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | P2 | unknown | 46 | The First Affiliated Hospital of Soochow University | Jul 2022 | |
| NCT05821192 | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. | N/A | unknown | 34 | Ou Bai, MD/PHD | Mar 2023 | |
| NCT05115409 | PCR | Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) | P2 | unknown | 27 | Sun Yat-sen University | Jun 2022 |
| NCT05265975 | SWATCH | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL | P1/P2 | terminated | 54 | Antengene Corporation | Apr 2022 |
| NCT05379647 | NK | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | P1 | unknown | 24 | Zhejiang University | Nov 2021 |
| NCT03010202 | The PROLONG Trial - Rituximab Maintenance Therapy in ITP | P3 | unknown | 136 | Ostfold Hospital Trust | Dec 2016 | |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | P3 | completed | 1,023 | Goethe University | Aug 2016 | |
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | P4 | unknown | 290 | Ruijin Hospital | Jun 2016 | |
| NCT00877214 | MAINTAIN | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas | P3 | active not recruiting | 1,272 | Jurgen Barth | Apr 2009 |
| NCT05078177 | Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis | P1 | unknown | 40 | St. Petersburg State Pavlov Medical University | Dec 2020 | |
| NCT04743739 | Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN | P3 | terminated | 12 | Peking Union Medical College Hospital | Apr 2021 | |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | P1/P2 | completed | 169 | Cyteir Therapeutics, Inc. | Oct 2019 | |
| NCT01011920 | CNS | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | P2 | completed | 227 | International Extranodal Lymphoma Study Group (IELSG) | Nov 2009 |
| NCT05586737 | Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency | P2 | completed | 15 | Angelica Lindén Hirschberg | Apr 2019 | |
| NCT03495960 | FIORELLA | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System | P2 | completed | 72 | International Extranodal Lymphoma Study Group (IELSG) | Jun 2019 |
| NCT04268277 | Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY | P2 | terminated | 22 | University of Ulm | Mar 2022 | |
| NCT03467373 | CHOP | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | P1 | completed | 111 | Hoffmann-La Roche | Mar 2018 |
| NCT05527912 | A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy | P2 | unknown | 45 | Sun Yat-sen University | Feb 2023 | |
| NCT03791827 | Multicenter Registry of Pediatric Lupus Nephritis in China | — | unknown | 1,200 | Xiqiang Dang | Dec 2018 | |
| NCT05287984 | ZFCR/ZBR | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL | P2 | unknown | 63 | Institute of Hematology & Blood Diseases Hospital, China | Mar 2022 |
| NCT04182204 | POLARGO | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P3 | completed | 270 | Hoffmann-La Roche | Feb 2020 |
| NCT06186219 | Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout | P1 | completed | 2 | University of California, Los Angeles | Apr 2024 | |
| NCT02367040 | CHRONOS-3 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) | P3 | completed | 458 | Bayer | Aug 2015 |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | P1 | completed | 20 | Noah Merin | Jul 2018 | |
| NCT03804359 | PMMN | Personalized Medicine for Membranous Nephropathy | P2 | completed | 68 | Centre Hospitalier Universitaire de Nice | Jan 2020 |
| NCT05073250 | IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. | P2 | unknown | 40 | Chinese PLA General Hospital | Dec 2021 | |
| NCT02213913 | DA-EPOCH-R | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | P1/P2 | completed | 55 | University of Chicago | Jul 2014 |
| NCT00670358 | Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma | P1/P2 | completed | 138 | Mayo Clinic | Aug 2008 | |
| NCT03688451 | Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma | P2 | active not recruiting | 20 | Tahir Latif | Oct 2018 | |
| NCT05532111 | Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial | N/A | unknown | 60 | RenJi Hospital | Sep 2022 | |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P2 | withdrawn | 0 | Rutgers, The State University of New Jersey | May 2020 | |
| NCT05564052 | VEGA | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | P2 | completed | 36 | Janssen Research & Development, LLC | Dec 2022 |
| NCT03164473 | MAINRITSEG | Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. | P3 | completed | 98 | Assistance Publique - Hôpitaux de Paris | Mar 2018 |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | P2 | terminated | 18 | University of Washington | Mar 2018 | |
| NCT01996865 | MAGNIFY | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. | P3 | completed | 503 | Celgene | Apr 2014 |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | P2 | unknown | 118 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2019 | |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | N/A | unknown | 30 | The First Affiliated Hospital with Nanjing Medical University | Mar 2023 | |
| NCT04121403 | NOR-MS | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) | P3 | completed | 267 | Oslo University Hospital | Oct 2019 |
| NCT04120350 | REMLA | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL:a Multicenter Phase Ib/II Stuty | P1/P2 | unknown | 47 | Peking Union Medical College Hospital | Aug 2019 |
| NCT05679336 | Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy | N/A | unknown | 40 | St. Petersburg State Pavlov Medical University | May 2018 | |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | P1/P2 | unknown | 12 | Emory University | Mar 2016 | |
| NCT05267054 | BGB-A1217 | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab | P1/P2 | completed | 53 | BeiGene | Apr 2022 |
| NCT03783403 | A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | P1 | terminated | 206 | Celgene | Mar 2019 | |
| NCT04899453 | Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL | P2 | unknown | 42 | Peking Union Medical College Hospital | Aug 2020 | |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P1/P2 | terminated | 4 | M.D. Anderson Cancer Center | Feb 2022 | |
| NCT04004819 | Rituximab for HTLV-1-associated Myelopathy | P2 | unknown | 100 | First Affiliated Hospital of Fujian Medical University | Aug 2019 | |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | P1/P2 | unknown | 38 | Northwestern University | Oct 2015 | |
| NCT03834688 | PrE0405 | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age | P2 | completed | 33 | PrECOG, LLC. | Jan 2020 |
| NCT03078855 | ILyAD | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma | P3 | completed | 211 | Jonathan Friedberg | Sep 2017 |
| NCT03440567 | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | P1 | completed | 16 | City of Hope Medical Center | Apr 2018 | |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | P3 | completed | 523 | Janssen Research & Development, LLC | May 2013 | |
| NCT02763319 | B-MIND | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | P2/P3 | completed | 453 | Incyte Corporation | Nov 2016 |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | P1/P2 | terminated | 9 | M.D. Anderson Cancer Center | Jun 2018 | |
| NCT01701986 | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | P1/P2 | completed | 64 | M.D. Anderson Cancer Center | Oct 2012 | |
| NCT04113226 | Relyage | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma | P2 | completed | 1 | Centre Hospitalier Universitaire, Amiens | Nov 2021 |
| NCT05398224 | R-MTX-zanbrutinib in Secondary CNS Lymphoma | P2 | unknown | 45 | Peking University | Feb 2021 | |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | P2 | completed | 348 | National Cancer Institute (NCI) | May 1993 | |
| NCT03804372 | CLL1818 | The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide | P2 | terminated | 5 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Jul 2020 |
| NCT04790903 | R | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | P1 | terminated | 50 | Hoffmann-La Roche | Jul 2021 |
| NCT05376319 | PR3-AAV Resilient Remission or PRRR | P2 | terminated | 6 | Mayo Clinic | Jun 2023 | |
| NCT03919175 | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | P2 | terminated | 18 | Massachusetts General Hospital | Sep 2019 | |
| NCT05392257 | Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial | P2 | unknown | 20 | Qingdao Central Hospital | May 2022 | |
| NCT01788020 | Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | P3 | completed | 202 | University of Ulm | Nov 2013 | |
| NCT01650701 | RELEVANCE | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | P3 | completed | 1,030 | The Lymphoma Academic Research Organisation | Feb 2012 |
| NCT01476787 | RELEVANCE | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | P3 | completed | 1,030 | Celgene | Dec 2011 |
| NCT02232386 | LLC1114 | Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia | P2 | completed | 156 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Mar 2015 |
| NCT00848328 | Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma | P2 | terminated | 30 | University of California, Davis | Aug 2008 | |
| NCT01316523 | Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma | P2 | terminated | 30 | University of California, Davis | Dec 2010 | |
| NCT05861297 | Immune Thrombocytopenia Management in Adults | P4 | unknown | 467 | Nahda University | May 2020 | |
| NCT05384743 | Rituximab Monotherapy for EBV-HLH and CAEBV | P3 | unknown | 30 | Beijing Friendship Hospital | Feb 2022 | |
| NCT04083066 | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | P4 | unknown | 20 | Mingzhi Zhang | Sep 2019 | |
| NCT04525729 | RITA | Rituximab and RASi in Patients with IgAN | P4 | completed | 116 | Nan Chen,MD | Jul 2020 |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | terminated | 3 | Academic and Community Cancer Research United | Apr 2021 | |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | P1/P2 | terminated | 178 | Gilead Sciences | Nov 2016 | |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | P2 | completed | 79 | International Extranodal Lymphoma Study Group (IELSG) | Dec 2014 | |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | P2 | terminated | 9 | Memorial Sloan Kettering Cancer Center | Jul 2018 | |
| NCT02950051 | GAIA | Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation | P3 | completed | 926 | German CLL Study Group | Dec 2016 |
| NCT03630042 | PembroWM | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia | P2 | completed | 17 | University College, London | Sep 2019 |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | P1 | completed | 12 | Northwestern University | Mar 2019 | |
| NCT05049473 | BL | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | P2 | unknown | 100 | PETHEMA Foundation | Jan 2014 |
| NCT05144009 | LOTIS-9 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | P2 | terminated | 41 | ADC Therapeutics S.A. | Jun 2022 |
| NCT03295240 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | Early P1 | completed | 10 | Memorial Sloan Kettering Cancer Center | Sep 2017 | |
| NCT01478542 | OPTIMAL>60 | OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine | P3 | completed | 1,152 | Universität des Saarlandes | Nov 2011 |
| NCT00006436 | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | P2 | completed | 68 | National Cancer Institute (NCI) | Jan 2001 | |
| NCT05667909 | Prognostic Model of Rituximab in the Treatment of MN | — | unknown | 50 | Qianfoshan Hospital | Jun 2023 | |
| NCT04138875 | A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) | P2 | withdrawn | 0 | Yale University | Jan 2022 | |
| NCT07049172 | Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome | N/A | completed | 91 | Wuhan Children's Hospital | Jan 2021 | |
| NCT02382575 | Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome | P4 | unknown | 120 | Nilratan Sircar Medical College | Mar 2015 | |
| NCT01811368 | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | P2 | unknown | 20 | Joseph Tuscano | Mar 2013 | |
| NCT01359592 | S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | P2 | completed | 159 | SWOG Cancer Research Network | Sep 2011 | |
| NCT04842487 | R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study | P2 | unknown | 80 | Sun Yat-sen University | Apr 2021 | |
| NCT04181489 | Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS | P2 | unknown | 55 | The First Affiliated Hospital with Nanjing Medical University | Jan 2019 | |
| NCT03899103 | RITURNS II | Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome | P3 | completed | 100 | Nilratan Sircar Medical College | May 2019 |
| NCT04021992 | GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL | P2 | unknown | 48 | Sun Yat-sen University | Jul 2019 | |
| NCT00577278 | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | P2 | completed | 41 | City of Hope Medical Center | Oct 2007 | |
| NCT02031419 | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma | P1 | terminated | 174 | Celgene | Dec 2013 | |
| NCT05782933 | Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy | N/A | unknown | 2 | Beijing Friendship Hospital | Aug 2022 | |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | P1 | terminated | 8 | National Cancer Institute (NCI) | Mar 2022 | |
| NCT04555811 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | P1 | completed | 7 | Masonic Cancer Center, University of Minnesota | Sep 2020 | |
| NCT06325943 | CIDPRIT | Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy | P3 | completed | 37 | Istituto Clinico Humanitas | Apr 2019 |
| NCT03967925 | COMBIVAS | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis | P2 | unknown | 31 | Rachel Jones | Feb 2019 |
| NCT05168475 | BIOVAS | Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis | P2 | terminated | 22 | Cambridge University Hospitals NHS Foundation Trust | Jul 2021 |
| NCT03970577 | RIFIREINS | RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome | P2 | unknown | 148 | Assistance Publique - Hôpitaux de Paris | Jul 2020 |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | P1/P2 | terminated | 60 | MingSight Pharmaceuticals, Inc | May 2018 | |
| NCT04128176 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | P3 | withdrawn | 0 | University of California, Davis | Mar 2017 | |
| NCT04431635 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | P1 | terminated | 6 | University of Michigan Rogel Cancer Center | Jun 2020 | |
| NCT02626455 | CHRONOS-4 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | P3 | terminated | 551 | Bayer | Jan 2016 |
| NCT02320292 | Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma | P3 | terminated | 20 | Mayo Clinic | Feb 2015 | |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | P1/P2 | terminated | 17 | M.D. Anderson Cancer Center | Mar 2021 | |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | P1 | terminated | 72 | Fate Therapeutics | Oct 2019 | |
| NCT05076097 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | P2 | unknown | 29 | Tianjin Medical University Cancer Institute and Hospital | Sep 2021 | |
| NCT04519710 | HepB20 | Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies | N/A | completed | 60 | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Sep 2020 |
| NCT05553496 | Assessment of Rituximab Therapeutic Response Versus Conventional Treatment | P2/P3 | unknown | 40 | Ain Shams University | Sep 2022 | |
| NCT05824390 | A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy | P4 | unknown | 116 | XIEJINGYUAN | Jun 2020 | |
| NCT04585152 | RTXvsMMF | Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome. | P2 | unknown | 160 | Istituto Giannina Gaslini | Oct 2020 |
| NCT03736616 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | P2 | unknown | 47 | Swedish Medical Center | Aug 2019 | |
| NCT05877040 | A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy | P2 | unknown | 20 | Istituto Clinico Humanitas | Jun 2019 | |
| NCT02957019 | DLBCL | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | P1/P2 | terminated | 6 | Philogen S.p.A. | Jul 2013 |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | P1 | terminated | 98 | Fate Therapeutics | Mar 2020 | |
| NCT00945724 | IELSG30 | Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis | P2 | completed | 54 | International Extranodal Lymphoma Study Group (IELSG) | Sep 2009 |
| NCT05293509 | PTIS | Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Mar 2022 |
| NCT00112931 | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | P3 | completed | 462 | University College, London | Sep 2004 | |
| NCT03920722 | RITUXGOPRO | Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis | P3 | completed | 8 | Assistance Publique - Hôpitaux de Paris | Oct 2020 |
| NCT02753062 | PTLD | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma | P2 | unknown | 22 | Asan Medical Center | Aug 2015 |
| NCT02060656 | LEGEND | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) | P2 | unknown | 92 | Royal Marsden NHS Foundation Trust | Sep 2013 |
| NCT04516655 | C-R-HDMTX | A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients | P2 | unknown | 51 | Fudan University | Sep 2020 |
| NCT05245916 | IBI397 or Combination Therapies in Patients With Advanced Malignancies | P1 | withdrawn | 0 | Innovent Biologics (Suzhou) Co. Ltd. | Apr 2022 | |
| NCT02728531 | Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | P1 | completed | 18 | Washington University School of Medicine | Apr 2016 | |
| NCT02532257 | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | P2 | completed | 48 | M.D. Anderson Cancer Center | Apr 2016 | |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P1/P2 | active not recruiting | 65 | Molly Gallogly | Jun 2017 | |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | P1 | terminated | 4 | Washington University School of Medicine | Oct 2018 | |
| NCT04680962 | MABRIDGE | MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis | P3 | withdrawn | 0 | Mabion SA | Aug 2023 |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | P1 | terminated | 24 | Dana-Farber Cancer Institute | Oct 2018 | |
| NCT01472562 | Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma | P2 | completed | 38 | Weill Medical College of Cornell University | Jul 2011 | |
| NCT02348216 | ZUMA-1 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | P1/P2 | completed | 307 | Kite, A Gilead Company | Apr 2015 |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | P1 | terminated | 18 | Fred Hutchinson Cancer Center | Oct 2019 | |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | P2 | terminated | 190 | Swiss Cancer Institute | Nov 2015 | |
| NCT04127747 | Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus | P4 | unknown | 110 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2020 | |
| NCT02073097 | Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma | P1/P2 | completed | 48 | Case Comprehensive Cancer Center | Jan 2015 | |
| NCT01664910 | CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies | P1/P2 | completed | 27 | M.D. Anderson Cancer Center | Oct 2012 | |
| NCT01974440 | SELENE | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | P3 | completed | 403 | Janssen Research & Development, LLC | Jan 2014 |
| NCT00863369 | Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma | P1/P2 | completed | 33 | City of Hope Medical Center | Jun 2005 | |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | P1 | terminated | 12 | University of Washington | Mar 2020 | |
| NCT05963048 | Rituxmab Versus IL-6 in Treating ILD | P2/P3 | completed | 60 | Assiut University | Dec 2021 | |
| NCT04025593 | Biomarker Guided Treatment in DLBCL | P2 | unknown | 128 | Ruijin Hospital | Jul 2019 | |
| NCT02844322 | BDH-WM01 | The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia | P4 | completed | 35 | Institute of Hematology & Blood Diseases Hospital, China | May 2016 |
| NCT03788291 | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | P2 | completed | 39 | University of Rochester | Mar 2019 | |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | P1/P2 | terminated | 13 | Deepa Jagadeesh | Apr 2021 | |
| NCT03003546 | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial | P1 | completed | 9 | Mayo Clinic | Apr 2019 | |
| NCT03455517 | VeRitAs | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia | P2 | completed | 77 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Oct 2018 |
| NCT01303887 | PACIFICO | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients | P3 | completed | 680 | University of Liverpool | Oct 2009 |
| NCT02313389 | BLOCAGE-01 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma | P3 | unknown | 428 | Assistance Publique - Hôpitaux de Paris | Sep 2015 |
| NCT01027000 | Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 68 | Alliance for Clinical Trials in Oncology | Feb 2010 | |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | P1/P2 | terminated | 38 | Takeda | Oct 2019 | |
| NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | P1 | completed | 30 | Nektar Therapeutics | Oct 2019 | |
| NCT00602459 | Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | P2 | completed | 418 | National Cancer Institute (NCI) | Jan 2008 | |
| NCT05324917 | Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases | — | unknown | 20 | The Affiliated Hospital of Qingdao University | Apr 2022 | |
| NCT04622579 | R2DLBCL80 | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years | P2 | unknown | 20 | Guangdong Provincial People's Hospital | Oct 2020 |
| NCT02594384 | LAM-002A/NHL | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma | P1 | completed | 62 | OrphAI Therapeutics | Oct 2015 |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | P1 | terminated | 97 | MEI Pharma, Inc. | Oct 2016 | |
| NCT04045028 | PK | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | terminated | 41 | Genentech, Inc. | Jul 2019 |
| NCT04745832 | ME-401 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | P3 | terminated | 82 | MEI Pharma, Inc. | Aug 2021 |
| NCT05209308 | CORAL | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL | P2 | withdrawn | 0 | MEI Pharma, Inc. | Nov 2022 |
| NCT04022005 | Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL | P2 | completed | 54 | Sun Yat-sen University | Jun 2019 | |
| NCT04062448 | WM | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | P2 | completed | 16 | Janssen Pharmaceutical K.K. | Sep 2019 |
| NCT03976102 | FLINTER | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma | P3 | completed | 317 | Dr. Reddy's Laboratories Limited | May 2019 |
| NCT02135874 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | P2 | completed | 16 | M.D. Anderson Cancer Center | Oct 2014 | |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | P2 | completed | 14 | M.D. Anderson Cancer Center | Jan 2015 | |
| NCT04224571 | CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children | P2 | completed | 208 | Chinese University of Hong Kong | Sep 2018 | |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | P1 | completed | 11 | M.D. Anderson Cancer Center | Jan 2017 | |
| NCT04507477 | Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial | P1/P2 | unknown | 10 | University Health Network, Toronto | Jul 2020 | |
| NCT05659407 | PREDICT | BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis | — | unknown | 60 | University of Cagliari | Jul 2020 |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | P1/P2 | unknown | 81 | OHSU Knight Cancer Institute | Oct 2005 | |
| NCT04002401 | ZUMA-14 | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | P2 | completed | 27 | Kite, A Gilead Company | Nov 2019 |
| NCT01307605 | Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | P2 | terminated | 154 | Swiss Cancer Institute | Feb 2011 | |
| NCT04154787 | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | P2 | terminated | 37 | Novartis Pharmaceuticals | Nov 2019 | |
| NCT04783675 | RTXFIRPedINS | Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome | P2 | completed | 44 | Children's Hospital of Fudan University | Apr 2021 |
| NCT04246359 | RIPPLE | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma | P2 | unknown | 52 | Huiqiang Huang | Jan 2020 |
| NCT05057481 | Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus | P3 | unknown | 30 | Assiut University | Sep 2021 | |
| NCT03934814 | Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | P1 | completed | 98 | I-Mab Biopharma US Limited | Apr 2019 | |
| NCT03994783 | TAR:GET-1 | Transplant Antibody-Mediated Rejection: Guiding Effective Treatments | P3 | terminated | 3 | Imperial College London | Jul 2019 |
| NCT05191225 | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study | P4 | unknown | 48 | Laida Cuevas Palomares | Sep 2021 | |
| NCT04425824 | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma | P2 | unknown | 20 | Chinese Academy of Medical Sciences | Jun 2020 | |
| NCT04319601 | AITL | Rituximab Combined With Chidamide and Lenalidomide for r/r AITL | N/A | unknown | 26 | Zhejiang Cancer Hospital | Mar 2020 |
| NCT02398240 | Brentuximab for Newly Diagnosed Hodgkin Disease | P2 | completed | 40 | Mitchell Cairo | May 2015 | |
| NCT00790413 | Haploidentical Stem Cell Transplantation in Neuroblastoma | Early P1 | unknown | 15 | Lund University Hospital | Aug 2005 | |
| NCT04235036 | Ibrutinib and Rituxan for Chronic GVHD | P2 | terminated | 15 | Northside Hospital, Inc. | Dec 2019 | |
| NCT04337827 | Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder | P2 | terminated | 6 | Deepa Jagadeesh | Sep 2020 | |
| NCT03112603 | BAT | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | P3 | completed | 330 | Incyte Corporation | Jun 2017 |
| NCT04776850 | Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies | Early P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Dec 2020 | |
| NCT02955823 | A Phase II Study of the FIL on Elderly Frail Patients With DLBCL | P2 | completed | 68 | Fondazione Italiana Linfomi - ETS | Sep 2016 | |
| NCT02663518 | TTI-621 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | P1 | terminated | 249 | Pfizer | Jan 2016 |
| NCT01516567 | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | P2 | completed | 47 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2012 | |
| NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | P3 | completed | 482 | Gustave Roussy, Cancer Campus, Grand Paris | Dec 2011 | |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | P2 | completed | 17 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jan 2020 | |
| NCT04588194 | Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia | P2 | unknown | 12 | David Gomez Almaguer | Nov 2020 | |
| NCT04640818 | Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy | — | unknown | 45 | Claudio Gobbi | Dec 2020 | |
| NCT01095172 | ReMIND | RituxiMab INDuction in Renal Transplantation | P4 | unknown | 100 | Guy's and St Thomas' NHS Foundation Trust | Nov 2010 |
| NCT01796171 | LYMRIT-37-01 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma | P1/P2 | completed | 191 | Nordic Nanovector | Dec 2012 |
| NCT02636322 | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | P2 | completed | 60 | M.D. Anderson Cancer Center | Mar 2016 | |
| NCT04660799 | PK | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) | P2 | completed | 50 | Hoffmann-La Roche | Feb 2021 |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | P1 | terminated | 17 | Mayo Clinic | Mar 2018 | |
| NCT04531865 | Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment | P3 | withdrawn | 0 | Children's Hospital of Fudan University | Jan 2021 | |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | P2 | completed | 6 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT02733042 | FUSION NHL 001 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | P1/P2 | completed | 106 | Celgene | May 2016 |
| NCT04542629 | Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children | P4 | unknown | 140 | Assiut University | Oct 2020 | |
| NCT00493467 | Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | P2 | completed | 31 | M.D. Anderson Cancer Center | Jun 2006 | |
| NCT00114738 | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | P2 | completed | 53 | National Cancer Institute (NCI) | Jun 2005 | |
| NCT02611323 | FL | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 133 | Hoffmann-La Roche | Mar 2016 |
| NCT02005471 | MURANO | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P3 | completed | 389 | Hoffmann-La Roche | Mar 2014 |
| NCT02285062 | ROBUST | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma | P3 | completed | 570 | Celgene | Feb 2015 |
| NCT01199575 | CLL | Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 30 | University of California, San Diego | Aug 2010 |
| NCT02042391 | PTLD-2 | Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy | P2 | completed | 60 | Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH | Feb 2015 |
| NCT03384277 | Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab | P4 | completed | 66 | Institute of Hematology & Blood Diseases Hospital, China | Dec 2017 | |
| NCT05332587 | Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis | P3 | unknown | 50 | First Affiliated Hospital, Sun Yat-Sen University | Aug 2020 | |
| NCT01754857 | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | P2 | completed | 36 | University of Wisconsin, Madison | Nov 2013 | |
| NCT03424122 | CITADEL-112 | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | P1 | completed | 50 | Incyte Corporation | Jul 2018 |
| NCT01682616 | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | P1 | completed | 49 | AbbVie | Jul 2012 | |
| NCT02115997 | A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis | P4 | completed | 30 | Hoffmann-La Roche | Jul 2015 | |
| NCT02898259 | Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | P1/P2 | terminated | 19 | Brian Hill | Feb 2017 | |
| NCT03949062 | Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | P2 | unknown | 30 | Ruijin Hospital | Mar 2019 | |
| NCT04361279 | A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | P3 | completed | 421 | Shanghai Institute Of Biological Products | Jul 2019 | |
| NCT01399372 | Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | P2 | completed | 91 | Radiation Therapy Oncology Group | Sep 2011 | |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | P1/P2 | completed | 107 | National Cancer Institute (NCI) | Oct 2010 | |
| NCT04033276 | IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies | P4 | completed | 50 | Seoul National University Hospital | Jan 2019 | |
| NCT03023046 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | completed | 54 | University of Washington | Feb 2017 | |
| NCT03003520 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | P2 | completed | 46 | Celgene | Feb 2017 | |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | P2 | terminated | 31 | University of California, San Diego | Jan 2014 | |
| NCT03578198 | MG4101 | Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) | P2 | terminated | 12 | Seoul National University Hospital | Nov 2018 |
| NCT04502706 | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | P1 | terminated | 9 | Gilead Sciences | Nov 2020 | |
| NCT03983031 | RITS-PO-2019 | Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019) | P1 | completed | 11 | Region Örebro County | Aug 2019 |
| NCT03983018 | RITS-PS-2019 | Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) | P2 | completed | 9 | Region Örebro County | Aug 2019 |
| NCT03193866 | COMBAT-MS | COMparison Between All immunoTherapies for Multiple Sclerosis. | — | completed | 3,526 | Karolinska Institutet | Jun 2017 |
| NCT01679119 | INCA | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy | P2 | completed | 129 | University College, London | Oct 2013 |
| NCT04762160 | SYMPHONY-2 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | P2 | terminated | 5 | Epizyme, Inc. | Dec 2020 |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | P2 | terminated | 2 | University of Miami | Sep 2020 | |
| NCT00667329 | Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | P1 | completed | 14 | M.D. Anderson Cancer Center | Jul 1999 | |
| NCT04236141 | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). | P3 | terminated | 42 | Hoffmann-La Roche | Jul 2020 | |
| NCT02950155 | Rinomax | A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis | P3 | completed | 47 | Fredrik Piehl | Oct 2016 |
| NCT02749292 | MAINTANCAVAS | Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing | P4 | terminated | 115 | Massachusetts General Hospital | Jun 2016 |
| NCT01938001 | AUGMENT | Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) | P3 | completed | 358 | Celgene | Nov 2013 |
| NCT03298698 | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome | P3 | unknown | 40 | Radboud University Medical Center | Aug 2018 | |
| NCT01145495 | Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | P2 | completed | 66 | National Cancer Institute (NCI) | Jun 2010 | |
| NCT05762003 | CPE | Czech Pharmaco-epidemiological Study on Disease Modifying Drugs | — | completed | 17,478 | IMPULS Endowment Fund | Jan 2019 |
| NCT02871869 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | P2/P3 | unknown | 316 | Xinjiang Medical University | Sep 2016 | |
| NCT00324467 | LYTPET | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | P2 | unknown | 150 | British Columbia Cancer Agency | Aug 2006 |
| NCT03169790 | NHL | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | P1/P2 | withdrawn | 0 | ImmunityBio, Inc. | Dec 2017 |
| NCT02600897 | FL | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 114 | Hoffmann-La Roche | Mar 2016 |
| NCT01619761 | NK Cells in Cord Blood Transplantation | P1 | unknown | 13 | M.D. Anderson Cancer Center | May 2013 | |
| NCT03069703 | PNEUMOVAS | Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy | P2 | completed | 96 | Assistance Publique - Hôpitaux de Paris | Feb 2018 |
| NCT03422523 | ARGO | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | P2 | terminated | 53 | University Hospital Southampton NHS Foundation Trust | May 2018 |
| NCT00118209 | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P3 | completed | 524 | Alliance for Clinical Trials in Oncology | May 2005 | |
| NCT03036904 | V+DA-EPOCH-R | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | P1 | completed | 31 | Weill Medical College of Cornell University | Feb 2017 |
| NCT02966717 | CKD | Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD) | P2 | unknown | 116 | Zhujiang Hospital | Aug 2016 |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2021 | |
| NCT02257567 | DCDS4501A | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | P1/P2 | completed | 331 | Hoffmann-La Roche | Oct 2014 |
| NCT02471911 | KPT-330+RICE | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | P1 | completed | 22 | Weill Medical College of Cornell University | Dec 2015 |
| NCT04572620 | Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies. | — | unknown | 30 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Sep 2020 | |
| NCT02442648 | B-Cell Targeted Carfilzomib Desensitization | P1 | unknown | 32 | E. Steve Woodle | Dec 2014 | |
| NCT02741388 | SELINDA | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | P1 | completed | 39 | The Lymphoma Academic Research Organisation | Oct 2016 |
| NCT03689894 | Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT | P1/P2 | terminated | 2 | Dartmouth-Hitchcock Medical Center | Apr 2019 | |
| NCT02652468 | TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma | N/A | completed | 11 | University of Wisconsin, Madison | Mar 2016 | |
| NCT01381692 | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | P1/P2 | completed | 9 | National Cancer Institute (NCI) | Jul 2011 | |
| NCT02746744 | RIFUND-MS | RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. | P3 | completed | 200 | Anders Svenningsson | May 2016 |
| NCT00075946 | Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | P3 | completed | 545 | Eastern Cooperative Oncology Group | Jan 2004 | |
| NCT04419389 | R/R | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | P1/P2 | terminated | 1 | Aprea Therapeutics | Mar 2021 |
| NCT03019640 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 22 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT01030900 | DA-EPOCH-R | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | P2 | completed | 50 | National Cancer Institute (NCI) | Oct 2009 |
| NCT02314403 | Renal Allograft Tolerance Through Mixed Chimerism (Belatacept) | P1 | completed | 2 | Massachusetts General Hospital | Feb 2015 | |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | withdrawn | 0 | University of Washington | Jul 2018 | |
| NCT01332968 | RO5072759 | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | P3 | completed | 1,401 | Hoffmann-La Roche | Jul 2011 |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | P2 | completed | 80 | St. Jude Children's Research Hospital | Apr 2013 | |
| NCT03332888 | ICFEr-RITU2 | Safety of HMA-CD20 in Patients With HFrEF | P2 | unknown | 10 | Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud | Jan 2021 |
| NCT03312907 | SLE | A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE | P3 | completed | 292 | GlaxoSmithKline | Mar 2018 |
| NCT03232307 | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Jul 2019 | |
| NCT02961816 | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT02406092 | SC | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | P3 | completed | 139 | Hoffmann-La Roche | Oct 2015 |
| NCT02198248 | LoVAS | Low-dose Glucocorticoid Vasculitis Induction Study | P4 | unknown | 140 | Chiba University | Oct 2014 |
| NCT01859819 | REBOOT | Treatment for Advanced B-Cell Lymphoma | P2 | completed | 45 | New York Medical College | Jan 2013 |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | P3 | unknown | 319 | Ludwig-Maximilians - University of Munich | Nov 1998 | |
| NCT02303119 | FLIRT | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) | P3 | completed | 221 | The Lymphoma Academic Research Organisation | Feb 2015 |
| NCT02564744 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | P2 | completed | 100 | Debiopharm International SA | Jun 2016 | |
| NCT03161054 | Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas | P2 | completed | 21 | Fondazione Italiana Linfomi - ETS | Sep 2017 | |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | P3 | terminated | 72 | Janssen Research & Development, LLC | Jul 2016 | |
| NCT01723839 | FCR | Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | P2 | completed | 21 | Hackensack Meridian Health | Feb 2012 |
| NCT03864185 | RECIPE | The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies | P2 | completed | 25 | Nagoya University | Mar 2019 |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia | P2 | terminated | 6 | M.D. Anderson Cancer Center | Apr 2018 | |
| NCT04074187 | A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | P2/P3 | completed | 21 | Sanofi | Oct 2019 | |
| NCT01842386 | Rituximab for Anti-cytokine Autoantibody-Associated Diseases | P1 | completed | 7 | National Institute of Allergy and Infectious Diseases (NIAID) | Apr 2014 | |
| NCT03072199 | RITA-MI | Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study | P1/P2 | completed | 24 | Papworth Hospital NHS Foundation Trust | Jun 2017 |
| NCT03892421 | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma | P1/P2 | completed | 22 | La Raza Medical Center | Apr 2018 | |
| NCT02423837 | BRiF | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma | P3 | unknown | 200 | National Research Center for Hematology, Russia | Dec 2013 |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | P1 | terminated | 87 | Aptevo Therapeutics | Sep 2012 | |
| NCT02018861 | CITADEL-101 | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) | P1/P2 | completed | 88 | Incyte Corporation | Sep 2016 |
| NCT01234766 | Fol-BRITe | Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma | P2 | completed | 39 | Dartmouth-Hitchcock Medical Center | Oct 2010 |
| NCT03527147 | PRISM | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) | P1 | completed | 30 | Acerta Pharma BV | Jun 2018 |
| NCT02187133 | Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | P1 | completed | 10 | University of California, San Francisco | May 2015 | |
| NCT01412879 | S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma | P2 | completed | 53 | SWOG Cancer Research Network | Nov 2011 | |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | terminated | 1 | University of Washington | Jan 2020 | |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | P1/P2 | completed | 38 | AbbVie | Sep 2014 | |
| NCT00712582 | Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma | P2 | completed | 96 | Memorial Sloan Kettering Cancer Center | Jul 2008 | |
| NCT03443570 | Rituximab Combining Bortezomib Versus Rituximab in Management of ITP | P3 | unknown | 200 | Shandong University | Mar 2018 | |
| NCT03304288 | The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia | P2 | unknown | 168 | Peking University People's Hospital | Oct 2017 | |
| NCT02677155 | Lymvac-2 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | P2 | completed | 10 | Oslo University Hospital | Jan 2016 |
| NCT00290511 | R-FND | Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | P2 | completed | 49 | M.D. Anderson Cancer Center | Jun 2004 |
| NCT02086175 | A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma | P2 | completed | 25 | Dana-Farber Cancer Institute | Dec 2014 | |
| NCT04279938 | A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL | P1 | withdrawn | 0 | Royal Marsden NHS Foundation Trust | Sep 2018 | |
| NCT03018626 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | P3 | unknown | 402 | Nanfang Hospital, Southern Medical University | Jul 2017 | |
| NCT01862926 | RECITAL | Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD | P2/P3 | completed | 104 | Royal Brompton & Harefield NHS Foundation Trust | Nov 2014 |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | P3 | completed | 250 | The Lymphoma Academic Research Organisation | Aug 2014 | |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | P2 | terminated | 11 | M.D. Anderson Cancer Center | Jul 2015 | |
| NCT02692248 | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT | P2 | completed | 64 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Apr 2016 | |
| NCT01808911 | CREHA | Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study) | P3 | completed | 110 | University Hospital, Rouen | May 2012 |
| NCT00599170 | Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | P2 | completed | 52 | University of Southern California | Jan 2008 | |
| NCT01427114 | OAML | R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) | P2 | completed | 33 | Konkuk University Medical Center | Jul 2011 |
| NCT02767674 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | P3 | unknown | 258 | The First Affiliated Hospital with Nanjing Medical University | May 2016 | |
| NCT02853370 | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma | P2 | completed | 78 | International Extranodal Lymphoma Study Group (IELSG) | Jul 2012 | |
| NCT03777085 | DLBCL | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | P3 | unknown | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Jan 2019 |
| NCT01125176 | ThRiL | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL | P2 | completed | 15 | Weill Medical College of Cornell University | Mar 2012 |
| NCT02367196 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | P1 | completed | 60 | Celgene | Mar 2015 | |
| NCT04189588 | versus | Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine | P2 | completed | 34 | TerSera Therapeutics LLC | Mar 2020 |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P1/P2 | completed | 138 | Pharmacyclics LLC. | Mar 2014 | |
| NCT03283202 | CC-122 | Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors | P1 | completed | 35 | Celgene | Oct 2017 |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | P1/P2 | completed | 260 | Alexion Pharmaceuticals, Inc. | Aug 2013 | |
| NCT02384954 | QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab | P1/P2 | terminated | 43 | Altor BioScience | Apr 2015 | |
| NCT03598725 | HA-LD-ITI | Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China | P4 | unknown | 55 | Beijing Children's Hospital | Jan 2016 |
| NCT01969409 | ART-IPF | Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis | P2 | completed | 58 | University of Alabama at Birmingham | Jan 2014 |
| NCT00783367 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | P2 | completed | 50 | Abramson Cancer Center at Penn Medicine | Jul 2008 | |
| NCT02257242 | BRiM | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | P1 | completed | 11 | Brown University | May 2017 |
| NCT01319981 | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | P2 | completed | 31 | M.D. Anderson Cancer Center | Mar 2013 | |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | P1 | terminated | 10 | Hackensack Meridian Health | Sep 2017 | |
| NCT01267812 | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation | P2 | completed | 23 | City of Hope Medical Center | Oct 2011 | |
| NCT02951728 | DR-CHOP | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma | P1/P2 | unknown | 58 | Ruijin Hospital | Oct 2016 |
| NCT02670616 | Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | P2 | completed | 24 | Samsung Medical Center | May 2016 | |
| NCT03778619 | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin | P1/P2 | unknown | 9 | GC Cell Corporation | Nov 2018 | |
| NCT03545035 | LLC178 | Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study | — | completed | 104 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Feb 2019 |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | P1/P2 | completed | 107 | M.D. Anderson Cancer Center | Apr 2007 | |
| NCT01445535 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | P1 | completed | 15 | National Cancer Institute (NCI) | Jan 2009 | |
| NCT02807103 | REOVAS | Rituximab in Eosinophilic Granulomatosis With Polyangiitis | P3 | completed | 107 | Assistance Publique - Hôpitaux de Paris | Dec 2016 |
| NCT01742988 | CUDC-907 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | P1 | completed | 106 | Curis, Inc. | Dec 2012 |
| NCT02423915 | GVHD | Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | P1 | completed | 5 | M.D. Anderson Cancer Center | Jul 2015 |
| NCT03189836 | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | P1 | terminated | 26 | Cogent Biosciences, Inc. | Oct 2017 | |
| NCT04402580 | Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome | P2 | terminated | 30 | Istituto Giannina Gaslini | Jul 2019 | |
| NCT01665768 | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma | P2 | completed | 56 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2012 | |
| NCT01439750 | VELCADE | Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) | P1 | unknown | 13 | Milton S. Hershey Medical Center | May 2012 |
| NCT03520920 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | P2 | completed | 41 | BeiGene | Jan 2018 | |
| NCT01671904 | CLL | A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | P1 | completed | 84 | Genentech, Inc. | Jan 2014 |
| NCT01804712 | Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy | Early P1 | completed | 8 | Christopher Kane | Jul 2013 | |
| NCT01592981 | R2W | Randomised Trial in Waldenstrom's Macroglobulinaemia | P2 | completed | 60 | University College, London | Jan 2013 |
| NCT02525172 | Immune Modulation Therapy for Pompe Disease | P4 | unknown | 8 | National Taiwan University Hospital | Aug 2015 | |
| NCT00515554 | HD18 for Advanced Stages in Hodgkins Lymphoma | P3 | completed | 1,500 | University of Cologne | May 2008 | |
| NCT02954406 | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | P1 | terminated | 43 | Millennium Pharmaceuticals, Inc. | Mar 2017 | |
| NCT02371148 | FIL_BRB | Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's | P2 | completed | 38 | Fondazione Italiana Linfomi - ETS | Jun 2014 |
| NCT00759798 | CLL | Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 289 | M.D. Anderson Cancer Center | Aug 2008 |
| NCT01594229 | BR | A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | P1 | completed | 60 | AbbVie | May 2012 |
| NCT00695786 | Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma | P2 | completed | 156 | M.D. Anderson Cancer Center | Jun 2008 | |
| NCT02858804 | BDH-MCL01 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL | P4 | completed | 55 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2016 |
| NCT04256252 | RESCUE | Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) | P4 | completed | 108 | Tang-Du Hospital | Apr 2014 |
| NCT01780454 | Renal Allograft Tolerance Through Mixed Chimerism | P1/P2 | completed | 2 | Massachusetts General Hospital | Mar 2013 | |
| NCT02631538 | Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome | P2 | completed | 86 | GlaxoSmithKline | Feb 2016 | |
| NCT02059239 | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | P1/P2 | completed | 34 | Weill Medical College of Cornell University | Jun 2014 | |
| NCT02428751 | R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | P3 | unknown | 216 | Wenqi Jiang | Sep 2015 | |
| NCT02596971 | CHOP | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 91 | Hoffmann-La Roche | Dec 2015 |
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma | P2 | terminated | 20 | Fred Hutchinson Cancer Center | Nov 2011 | |
| NCT03135262 | FL | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | terminated | 29 | Hoffmann-La Roche | Jun 2017 |
| NCT03700229 | Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A | P2 | unknown | 22 | Peking Union Medical College Hospital | Oct 2018 | |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | P2 | terminated | 4 | M.D. Anderson Cancer Center | Mar 2018 | |
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | P1/P2 | completed | 14 | Cancer Research UK | Oct 2016 | |
| NCT00591630 | Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | P2 | completed | 30 | M.D. Anderson Cancer Center | Nov 2007 | |
| NCT03054259 | ROOTS | Rituximab Objective Outcome Measures Trial in SLE | P2 | unknown | 30 | University of Leeds | Sep 2017 |
| NCT02267915 | MAN2 | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT | P2 | unknown | 36 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Mar 2015 |
| NCT02990286 | EvER-ILD | Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases | P3 | completed | 122 | University Hospital, Tours | Jan 2017 |
| NCT01554514 | Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura | P2 | completed | 19 | Washington University School of Medicine | Aug 2012 | |
| NCT02776813 | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | P1 | completed | 34 | Cogent Biosciences, Inc. | Aug 2016 | |
| NCT02752204 | TORCH | An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma | P2 | completed | 36 | University of Birmingham | Oct 2015 |
| NCT02378298 | RTX | Rituximab (RTX) Therapy in Patients With Active TAO | P4 | completed | 38 | Göteborg University | Dec 2011 |
| NCT01939327 | R2 | Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma | P2 | completed | 34 | Institut Paoli-Calmettes | Sep 2013 |
| NCT02343536 | CC-486 | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | P1 | completed | 59 | Celgene | Apr 2015 |
| NCT03259529 | BeGeRN | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | P1/P2 | completed | 30 | St. Petersburg State Pavlov Medical University | Mar 2017 |
| NCT03795571 | R2-GOD | Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL | P1 | unknown | 12 | The First Affiliated Hospital with Nanjing Medical University | Jan 2019 |
| NCT03372837 | Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma | P3 | completed | 40 | SymBio Pharmaceuticals | Jan 2018 | |
| NCT03180723 | Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis | P3 | unknown | 30 | Assiut University | Jul 2017 | |
| NCT02772822 | A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients | P3 | unknown | 330 | Sinocelltech Ltd. | Jun 2016 | |
| NCT02460276 | PHILEMON | A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma | P2 | completed | 50 | Lund University Hospital | Apr 2015 |
| NCT03018535 | RI-CYCLO | Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy | P3 | unknown | 76 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Jan 2012 |
| NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | P3 | completed | 420 | Innovent Biologics (Suzhou) Co. Ltd. | Aug 2016 | |
| NCT02304354 | LYRITUX | Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX) | P3 | completed | 70 | University Hospital, Tours | Mar 2015 |
| NCT01086540 | Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) | P2 | completed | 57 | National Institute of Allergy and Infectious Diseases (NIAID) | Jun 2011 | |
| NCT02951156 | Javelin DLBCL | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | P3 | terminated | 29 | Pfizer | Dec 2016 |
| NCT01216683 | Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | P2 | completed | 289 | ECOG-ACRIN Cancer Research Group | Feb 2011 | |
| NCT02400437 | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia | P2 | completed | 26 | Dana-Farber Cancer Institute | Apr 2015 | |
| NCT03507348 | Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates | N/A | terminated | 8 | University Hospital, Grenoble | Jul 2018 | |
| NCT01697267 | RITAZAREM | Rituximab Vasculitis Maintenance Study | P3 | completed | 188 | Cambridge University Hospitals NHS Foundation Trust | Apr 2013 |
| NCT00812669 | ICORG | CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | P2 | completed | 52 | Cancer Trials Ireland | Aug 2008 |
| NCT00058422 | Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | P2 | completed | 65 | Memorial Sloan Kettering Cancer Center | Feb 2003 | |
| NCT03154385 | RITUX PLUS | Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia | N/A | completed | 15 | Assistance Publique - Hôpitaux de Paris | Mar 2017 |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | P3 | completed | 181 | Pharmacyclics LLC. | Jul 2014 | |
| NCT04274257 | DesiReS | A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis | P2/P3 | completed | 56 | Tokyo University | Dec 2017 |
| NCT02994927 | ADVOCATE | A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis | P3 | completed | 331 | Amgen | Mar 2017 |
| NCT03980379 | Pharmacokinetics, Efficacy and Safety of the 304 Injection | P1 | unknown | 60 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dec 2018 | |
| NCT02433795 | BR | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | P2 | completed | 27 | Seoul National University Hospital | May 2015 |
| NCT01514344 | IRIS | Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma | P2 | completed | 20 | Andres J. M. Ferreri | Dec 2011 |
| NCT02383589 | MMF | A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) | P3 | completed | 135 | Hoffmann-La Roche | May 2015 |
| NCT00992446 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | P2 | completed | 27 | Fred Hutchinson Cancer Center | Sep 2010 | |
| NCT03225924 | ENTO | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | P1/P2 | terminated | 25 | The Lymphoma Academic Research Organisation | Jul 2017 |
| NCT02945215 | IBI301 | A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients | P1 | completed | 181 | Innovent Biologics (Suzhou) Co. Ltd. | Dec 2016 |
| NCT03593902 | CAST | Cardiac Safe Transplants for Systemic Sclerosis | P2/P3 | terminated | 9 | Northwestern University | May 2018 |
| NCT02729896 | FL | A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 36 | Hoffmann-La Roche | Nov 2016 |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2019 | |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | P2 | completed | 12 | National Cancer Institute (NCI) | Sep 2006 | |
| NCT02545959 | EFFRITE | Intrathecal Rituximab in Progressive Multiple Sclerosis | P2 | completed | 10 | Centre Hospitalier de PAU | Nov 2015 |
| NCT00770224 | S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | P2 | completed | 87 | SWOG Cancer Research Network | Apr 2009 | |
| NCT02481297 | CLL | Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | P2 | completed | 7 | M.D. Anderson Cancer Center | Jun 2015 |
| NCT02501473 | Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) | P1/P2 | terminated | 52 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Feb 2016 | |
| NCT01118234 | Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) | P3 | completed | 256 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Dec 2009 | |
| NCT00383994 | Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation | P1 | completed | 6 | M.D. Anderson Cancer Center | Sep 2006 | |
| NCT02453087 | A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | P1 | completed | 66 | Hoffmann-La Roche | Aug 2015 | |
| NCT01448096 | Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma | P2 | completed | 33 | Chonbuk National University Hospital | Aug 2011 | |
| NCT02280525 | NK | Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | P1 | completed | 8 | M.D. Anderson Cancer Center | Mar 2015 |
| NCT03255096 | A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 | P1 | completed | 39 | Hoffmann-La Roche | Aug 2017 | |
| NCT02843061 | Combination of Rituximab and NK Immunotherapy for B Lymphoma | P1/P2 | completed | 30 | Fuda Cancer Hospital, Guangzhou | Jul 2016 | |
| NCT01429025 | Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma | P1 | completed | 26 | Alliance for Clinical Trials in Oncology | May 2012 | |
| NCT02266888 | B Cell Induction in Pediatric Lung Transplantation | P2 | completed | 45 | National Institute of Allergy and Infectious Diseases (NIAID) | Jan 2015 | |
| NCT02141451 | ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL | P1/P2 | completed | 30 | Masonic Cancer Center, University of Minnesota | May 2014 | |
| NCT01576588 | Rituximab in Pretreated Elderly or Unfit B-CLL Patients | P2 | completed | 25 | Prof. Dr. Med. Laimonas Griskevicius | Oct 2011 | |
| NCT02747043 | JASMINE | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab | P3 | completed | 256 | Amgen | May 2016 |
| NCT02055820 | NHL | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | P1/P2 | completed | 267 | Hoffmann-La Roche | Nov 2013 |
| NCT01955187 | STARMEN | Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy | P3 | completed | 86 | Hospital Universitario 12 de Octubre | Jan 2014 |
| NCT01136395 | Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation | P2 | completed | 85 | University of Giessen | Jan 2010 | |
| NCT01569295 | Tugela | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | P3 | completed | 416 | Gilead Sciences | Jun 2012 |
| NCT03188198 | Risk Adapted Therapy in Diffuse Large B Cell Lymphoma | P2 | unknown | 60 | Mansoura University | Jun 2016 | |
| NCT02394119 | Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome | P2 | completed | 140 | Istituto Giannina Gaslini | Jun 2015 | |
| NCT01889069 | DLBCL | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) | P3 | completed | 159 | Hoffmann-La Roche | Jul 2013 |
| NCT00880815 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | P1 | completed | 60 | M.D. Anderson Cancer Center | Feb 2009 | |
| NCT03003039 | A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | P1 | completed | 85 | Nanjing Yoko Biomedical Co., Ltd. | Jun 2017 | |
| NCT02624986 | FL | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | P1/P2 | terminated | 25 | Hoffmann-La Roche | Dec 2015 |
| NCT02705638 | TIGR2 | Treatment of IgG4-Related Disease With Revlimid and Rituximab | P1 | completed | 6 | Mayo Clinic | Apr 2016 |
| NCT02753647 | Chidamide Plus R-CHOP in Elderly DLBCL | P2 | unknown | 49 | Ruijin Hospital | Apr 2016 | |
| NCT01490723 | SCT | Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) | P2 | completed | 20 | M.D. Anderson Cancer Center | Jan 2013 |
| NCT03790293 | LTFURITUX3 | Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial | P3 | completed | 80 | University Hospital, Rouen | Nov 2018 |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | P1 | terminated | 6 | Vanderbilt-Ingram Cancer Center | Jun 2018 | |
| NCT02049541 | Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | P1 | completed | 18 | Kami Maddocks, MD | Jul 2014 | |
| NCT02589145 | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | P1/P2 | terminated | 8 | M.D. Anderson Cancer Center | Jun 2016 | |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | P3 | completed | 838 | Janssen Research & Development, LLC | Sep 2013 | |
| NCT00992030 | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma | P3 | terminated | 112 | Fondazione Michelangelo | Sep 2009 | |
| NCT00274924 | Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 100 | Eastern Cooperative Oncology Group | Sep 2006 | |
| NCT03582098 | RETRO-idel | Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | — | completed | 112 | Gilead Sciences | Sep 2018 |
| NCT00983619 | A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies | P1/P2 | completed | 136 | MedImmune LLC | Apr 2010 | |
| NCT03670888 | A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients | P1 | terminated | 1 | JHL Biotech, Inc. | Nov 2018 | |
| NCT02980042 | Safety of Switching From Rituximab to Ocrelizumab in MS Patients | P3 | completed | 200 | University of Colorado, Denver | Jan 2017 | |
| NCT03315923 | Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients | P2/P3 | completed | 84 | Isfahan University of Medical Sciences | Dec 2017 | |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | P1 | completed | 190 | Pfizer | Jun 2011 | |
| NCT01253460 | Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | P2 | terminated | 18 | M.D. Anderson Cancer Center | Aug 2011 | |
| NCT02260934 | CALIBRATE | Rituximab and Belimumab for Lupus Nephritis | P2 | completed | 43 | National Institute of Allergy and Infectious Diseases (NIAID) | Jul 2015 |
| NCT01691898 | ROMULUS | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | P1/P2 | completed | 231 | Genentech, Inc. | Sep 2012 |
| NCT02867553 | RADIO-LYMPH | Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions | P3 | unknown | 36 | CHU de Reims | Oct 2011 |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P3 | completed | 578 | Janssen Research & Development, LLC | Sep 2012 | |
| NCT01429610 | RADICAL | Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia | P2 | unknown | 78 | Asan Medical Center | Nov 2011 |
| NCT02971982 | PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia | P1/P2 | unknown | 40 | The First Affiliated Hospital of Soochow University | Oct 2016 | |
| NCT02758925 | CyBeR-Lymph | CyBeR Association in Relapsed/Refractory DLBCL | P2 | unknown | 78 | University Hospital, Caen | Jun 2016 |
| NCT02757196 | Treatment of ITP With Rituximab and / or Accutane | P2 | unknown | 112 | Peking University People's Hospital | May 2016 | |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | P1/P2 | unknown | 18 | National University Hospital, Singapore | Dec 2014 | |
| NCT02381899 | Observational Study in CLL Patients Receiving BR | — | completed | 83 | Czech CLL Study Group | Sep 2014 | |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | P1/P2 | terminated | 20 | Northwestern University | Mar 2013 | |
| NCT01280682 | Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes | P4 | completed | 120 | Yang Tao | Jul 2010 | |
| NCT01449344 | (R-HAD) | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | P3 | unknown | 128 | Prof. Dr. M. Dreyling (co-chairman) | May 2009 |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | P1/P2 | completed | 92 | National Cancer Institute (NCI) | Oct 2007 | |
| NCT00209209 | MCLelderly | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL | P3 | unknown | 570 | European Mantle Cell Lymphoma Network | Jan 2004 |
| NCT00078949 | Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | P3 | completed | 849 | NCIC Clinical Trials Group | Aug 2003 | |
| NCT01933711 | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | P3 | unknown | 328 | University Hospital Heidelberg | Jul 2002 | |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma | P2 | terminated | 4 | University of Washington | Dec 2017 | |
| NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | P1/P2 | completed | 85 | Genentech, Inc. | Nov 2013 | |
| NCT02541565 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma | P1 | completed | 30 | University of Washington | Nov 2015 | |
| NCT00787722 | Hematopoietic Stem Cell Transplant in Devic's Disease | P1/P2 | completed | 13 | Northwestern University | Oct 2009 | |
| NCT01573533 | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS | P2 | completed | 9 | Mayo Clinic | Oct 2013 | |
| NCT02284984 | SYNBIoSe | Synergetic B-cell Immodulation in SLE | P2 | completed | 16 | Leiden University Medical Center | Mar 2014 |
| NCT01813227 | WM | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 | P2 | completed | 7 | Hackensack Meridian Health | Apr 2013 |
| NCT00732498 | ESHAP | Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL | P2 | completed | 28 | University of Arizona | May 2006 |
| NCT02792699 | RA | Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab | P3 | completed | 311 | Amgen | May 2016 |
| NCT00899431 | CLL | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | P2 | terminated | 39 | M.D. Anderson Cancer Center | May 2009 |
| NCT01729104 | Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | P1 | terminated | 18 | M.D. Anderson Cancer Center | Apr 2013 | |
| NCT02779283 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | P1 | completed | 7 | OHSU Knight Cancer Institute | Jan 2016 | |
| NCT01321541 | PIX-R | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant | P3 | completed | 312 | CTI BioPharma | Apr 2011 |
| NCT00654732 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | P2 | completed | 58 | M.D. Anderson Cancer Center | Mar 2008 | |
| NCT02500251 | Belimumab Impacting Transplant Eligibility | P1/P2 | completed | 11 | E. Steve Woodle | Jun 2015 | |
| NCT01848132 | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. | P2 | completed | 121 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Oct 2013 | |
| NCT00278421 | Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | P3 | completed | 592 | German High-Grade Non-Hodgkin's Lymphoma Study Group | Nov 2005 | |
| NCT00115700 | Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma | P3 | completed | 150 | Trans Tasman Radiation Oncology Group | Feb 2000 | |
| NCT02433522 | MAINRITSAN3 | Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab | P3 | completed | 97 | Assistance Publique - Hôpitaux de Paris | Mar 2015 |
| NCT00980395 | VCR | Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | P2 | completed | 24 | University of Arizona | Jul 2009 |
| NCT01520519 | Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients | P2 | completed | 40 | M.D. Anderson Cancer Center | Feb 2012 | |
| NCT01686321 | B-R-ENDA | Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma | P2 | completed | 68 | University of Göttingen | Jul 2012 |
| NCT01653067 | STORM | STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma | P2 | unknown | 88 | Mathias Witzens-Harig | Sep 2012 |
| NCT01035463 | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma | P1/P2 | completed | 74 | University of Nebraska | Nov 2009 | |
| NCT03456466 | Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma | P1/P2 | unknown | 122 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | May 2017 | |
| NCT01964755 | Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma | P2 | terminated | 6 | University of Miami | Apr 2009 | |
| NCT00439556 | Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant | P2 | completed | 40 | M.D. Anderson Cancer Center | Feb 2007 | |
| NCT01461928 | MabCute | A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab | P3 | completed | 692 | Hoffmann-La Roche | Dec 2011 |
| NCT02787239 | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | P3 | completed | 407 | Shanghai Henlius Biotech | Oct 2015 | |
| NCT02556866 | ESBAM | Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis | P2 | terminated | 14 | Assistance Publique - Hôpitaux de Paris | Jul 2015 |
| NCT02110706 | BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis | P2 | completed | 52 | Yale University | May 2014 | |
| NCT02855359 | SGN-CD19A | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | P2 | terminated | 24 | Seagen Inc. | Aug 2016 |
| NCT01750697 | A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | P2 | completed | 25 | Hoffmann-La Roche | May 2013 | |
| NCT00477815 | Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma | P1 | completed | 30 | Mayo Clinic | May 2005 | |
| NCT00074282 | Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL | P2 | completed | 102 | Eastern Cooperative Oncology Group | Apr 2005 | |
| NCT02592876 | SGN-CD19A | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | P2 | terminated | 81 | Seagen Inc. | Oct 2015 |
| NCT01134575 | ALL | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | P2 | completed | 90 | M.D. Anderson Cancer Center | Jun 2010 |
| NCT00711828 | Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma | P2 | completed | 21 | Mayo Clinic | Aug 2008 | |
| NCT01197560 | DLBCL | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | P2/P3 | completed | 111 | Celgene | Sep 2010 |
| NCT01622439 | VALFRID | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma | P1/P2 | completed | 50 | Lund University Hospital | Jun 2012 |
| NCT01729806 | Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | P1 | completed | 32 | National Cancer Institute (NCI) | Nov 2012 | |
| NCT00104858 | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 66 | Fred Hutchinson Cancer Center | Dec 2004 | |
| NCT02624492 | To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL | P2 | completed | 21 | Boehringer Ingelheim | Jan 2016 | |
| NCT02187861 | GDC-0199 | A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) | P2 | completed | 163 | Hoffmann-La Roche | Dec 2014 |
| NCT00295932 | Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | P1/P2 | completed | 79 | Memorial Sloan Kettering Cancer Center | Dec 2005 | |
| NCT02789397 | Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency | P2 | withdrawn | 0 | Medical College of Wisconsin | May 2016 | |
| NCT03530462 | To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI | — | completed | 22 | First Affiliated Hospital of Zhejiang University | Apr 2017 | |
| NCT02251964 | RITUX-IP | Rituximab in Interstitial Pneumonitis | P2/P3 | completed | 20 | Human Adams | Sep 2014 |
| NCT00278408 | Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | P3 | completed | 700 | German High-Grade Non-Hodgkin's Lymphoma Study Group | Jan 2006 | |
| NCT02617485 | MADILYM | MabionCD20 Compared to MabThera in Lymphoma Patients | P3 | completed | 143 | Mabion SA | Dec 2015 |
| NCT01400685 | Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | P1 | completed | 34 | Massachusetts General Hospital | Dec 2012 | |
| NCT01287741 | GOYA | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | P3 | terminated | 1,418 | Hoffmann-La Roche | Jul 2011 |
| NCT00769522 | FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | P3 | completed | 564 | German CLL Study Group | Oct 2008 | |
| NCT01419665 | ASSIST_FL | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) | P3 | completed | 629 | Sandoz | Dec 2011 |
| NCT03485118 | Hi-CHOP | RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | P2 | completed | 137 | Zhejiang Hisun Pharmaceutical Co. Ltd. | May 2016 |
| NCT02293109 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | P1 | completed | 10 | Mehrdad Abedi, MD | Dec 2015 | |
| NCT01956695 | REVRI | Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma | P2 | completed | 45 | Institut Curie | Sep 2013 |
| NCT01773616 | RITUXILUP | Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis | P3 | terminated | 24 | Imperial College London | Apr 2015 |
| NCT01659099 | GAINED | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | P3 | terminated | 671 | The Lymphoma Academic Research Organisation | Sep 2012 |
| NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | P2 | unknown | 57 | Pusan National University Hospital | Aug 2012 | |
| NCT01313611 | BRIEF | BRIEF Bendamustine and Rituximab In Elderly Follicular | P2 | terminated | 62 | The Lymphoma Academic Research Organisation | Feb 2011 |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | P2 | terminated | 25 | European Institute of Oncology | Jan 2011 | |
| NCT01097057 | G-CSF | Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells | P2 | completed | 20 | Fred Hutchinson Cancer Center | Nov 2010 |
| NCT00227695 | Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma | P3 | completed | 270 | Swiss Cancer Institute | Jun 2004 | |
| NCT00490529 | Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL | P2 | completed | 59 | Ronald Levy | Aug 2009 | |
| NCT02229942 | RituxME | B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. | P3 | completed | 151 | Haukeland University Hospital | Sep 2014 |
| NCT01980654 | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | P2 | completed | 80 | Pharmacyclics LLC. | Dec 2013 | |
| NCT01058239 | Bortezomib Plus Rituximab for EBV+ PTLD | P2 | completed | 7 | Massachusetts General Hospital | Nov 2011 | |
| NCT01684865 | An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma | — | completed | 22 | Hoffmann-La Roche | Oct 2012 | |
| NCT01983969 | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | P1/P2 | completed | 61 | M.D. Anderson Cancer Center | Nov 2013 | |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | P1 | completed | 240 | Hoffmann-La Roche | Apr 2011 | |
| NCT01686165 | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | P2 | completed | 5 | University of Arizona | Aug 2012 | |
| NCT02169219 | SCOUT | Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis | P4 | completed | 20 | Massachusetts General Hospital | Jun 2014 |
| NCT02468791 | MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis | P3 | completed | 709 | Mabion SA | May 2013 | |
| NCT01200758 | SC | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | P3 | completed | 410 | Hoffmann-La Roche | Feb 2011 |
| NCT01451879 | Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies | — | completed | 11 | University of Florida | Oct 2008 | |
| NCT00129090 | Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma | P3 | completed | 450 | German High-Grade Non-Hodgkin's Lymphoma Study Group | Mar 2003 | |
| NCT00662948 | ZAR2007 | ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) | P2 | completed | 149 | PETHEMA Foundation | Dec 2008 |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | P2 | terminated | 20 | University of Nebraska | Dec 2009 | |
| NCT01010217 | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | P2 | completed | 176 | M.D. Anderson Cancer Center | Nov 2009 | |
| NCT01180036 | MENTOR | MEmbranous Nephropathy Trial Of Rituximab | P2/P3 | completed | 130 | Mayo Clinic | Nov 2011 |
| NCT02594163 | Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma | P2 | terminated | 25 | Seagen Inc. | Oct 2015 | |
| NCT02834286 | Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia | P2 | unknown | 15 | Hospital Universitario Dr. Jose E. Gonzalez | Mar 2015 | |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia | P2 | withdrawn | 0 | Mayo Clinic | Dec 2012 | |
| NCT00376961 | S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | P2 | completed | 68 | SWOG Cancer Research Network | Aug 2006 | |
| NCT02654379 | Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe | — | completed | 1,408 | Hoffmann-La Roche | Dec 2015 | |
| NCT00254410 | CLL | FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | P2 | completed | 30 | M.D. Anderson Cancer Center | Mar 2005 |
| NCT00602836 | Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 45 | Mayo Clinic | Feb 2008 | |
| NCT01662050 | FIL-RBAC500 | Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL | P2 | completed | 57 | Fondazione Italiana Linfomi - ETS | Mar 2012 |
| NCT01078142 | BERT | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | P1/P2 | completed | 39 | Georg Hess, MD | Feb 2010 |
| NCT02253264 | A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients | P1 | completed | 8 | Johns Hopkins University | Nov 2014 | |
| NCT01334502 | Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma | P1 | completed | 26 | Alliance for Clinical Trials in Oncology | Mar 2012 | |
| NCT00963534 | LENA-BERIT | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | P1/P2 | completed | 51 | Lund University Hospital | Sep 2009 |
| NCT01318915 | RESTARRT | Research Study of ATG and Rituximab in Renal Transplantation | Early P1 | terminated | 10 | National Institute of Allergy and Infectious Diseases (NIAID) | Jul 2011 |
| NCT00577993 | FND | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | P3 | completed | 210 | M.D. Anderson Cancer Center | Mar 1998 |
| NCT02053610 | CLL11 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | P3 | completed | 787 | Hoffmann-La Roche | Dec 2009 |
| NCT01998880 | CLL11 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | P3 | completed | 787 | Hoffmann-La Roche | Dec 2009 |
| NCT01010061 | CLL11 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | P3 | completed | 787 | Hoffmann-La Roche | Dec 2009 |
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | P2 | terminated | 442 | National Cancer Institute (NCI) | Jan 2004 | |
| NCT01973387 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | P3 | completed | 160 | Janssen Research & Development, LLC | Oct 2013 | |
| NCT00290498 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | P2 | completed | 67 | M.D. Anderson Cancer Center | Aug 2005 | |
| NCT02200848 | CLL | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | P1 | terminated | 5 | Georgetown University | Apr 2014 |
| NCT00909077 | ITP | The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) | P3 | completed | 155 | Copenhagen University Hospital at Herlev | Aug 2004 |
| NCT03151044 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | P3 | unknown | 408 | FENG Ji-feng | Jul 2016 | |
| NCT02626845 | RENTGPA | Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis | P4 | terminated | 3 | Hospital for Special Surgery, New York | Dec 2015 |
| NCT01900496 | Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | P1 | terminated | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2014 | |
| NCT05063513 | ASTIL | Autologous Stem Cell Transplantation: International Lupus Trial | P2/P3 | withdrawn | 0 | European Society for Blood and Marrow Transplantation | Jul 2009 |
| NCT00645606 | LLC2007SA | Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia | P3 | completed | 542 | University Hospital, Tours | Dec 2007 |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | P3 | completed | 475 | European Organisation for Research and Treatment of Cancer - EORTC | May 1999 | |
| NCT02194374 | CLL | Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Jan 2015 |
| NCT01676558 | DLBCL | A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) | P2 | unknown | 24 | Korea Cancer Center Hospital | Jun 2012 |
| NCT01678417 | 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma | P2 | unknown | 29 | Korea Cancer Center Hospital | Jun 2012 | |
| NCT00801281 | PLRG4 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | P3 | completed | 250 | Polish Lymphoma Research Group | Feb 2007 |
| NCT02419469 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | terminated | 1 | M.D. Anderson Cancer Center | Nov 2015 | |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | P3 | completed | 487 | Millennium Pharmaceuticals, Inc. | May 2008 | |
| NCT00787969 | Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | P1 | completed | 74 | Alliance for Clinical Trials in Oncology | Apr 2009 | |
| NCT00720876 | Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma | P2 | completed | 30 | City of Hope Medical Center | Jul 2008 | |
| NCT02391545 | CONTEMPO | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | P1/P2 | terminated | 55 | SecuraBio | Dec 2014 |
| NCT02623920 | S-BR | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P2 | withdrawn | 0 | University of Arizona | Dec 2015 |
| NCT02219737 | Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | P1 | completed | 26 | National Cancer Institute (NCI) | Sep 2014 | |
| NCT01925612 | DLBCL | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | P2 | terminated | 87 | Seagen Inc. | Aug 2013 |
| NCT02197767 | Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis | P2 | completed | 11 | Mayo Clinic | Nov 2014 | |
| NCT00476164 | RituxiCAN-C4 | Study of Rituximab to Treat Chronic Renal Transplant Rejection | P4 | completed | 62 | King's College London | Jan 2007 |
| NCT01613599 | An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | — | completed | 100 | Genentech, Inc. | Jun 2012 | |
| NCT01471067 | Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | P1 | completed | 33 | M.D. Anderson Cancer Center | Jul 2012 | |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | P2 | terminated | 14 | Ohio State University Comprehensive Cancer Center | May 2013 | |
| NCT01987505 | MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma | P3 | completed | 140 | Hoffmann-La Roche | Nov 2013 | |
| NCT01263704 | A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia | P2 | completed | 42 | Hoffmann-La Roche | Jul 2011 | |
| NCT02204982 | DYNAMO + R | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma | P3 | terminated | 13 | SecuraBio | Sep 2014 |
| NCT01096992 | FBR | Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) | P1/P2 | completed | 51 | M.D. Anderson Cancer Center | Apr 2010 |
| NCT00764517 | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | P2 | completed | 57 | OHSU Knight Cancer Institute | Aug 2008 | |
| NCT00553943 | Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis | P2 | completed | 60 | Lymphoma Study Association | Jul 2007 | |
| NCT00481832 | Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma | P2 | terminated | 50 | Stanford University | Jan 2007 | |
| NCT00695409 | Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | P2 | completed | 122 | City of Hope Medical Center | Mar 2008 | |
| NCT01596127 | Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System | P1/P2 | terminated | 4 | M.D. Anderson Cancer Center | Jan 2013 | |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | P1 | terminated | 35 | National Cancer Institute (NCI) | Aug 2001 | |
| NCT00921414 | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance | P3 | completed | 299 | French Innovative Leukemia Organisation | Sep 2008 | |
| NCT00667615 | DLBCL | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 30 | Memorial Sloan Kettering Cancer Center | Apr 2008 |
| NCT00841945 | Treatment of Aggressive Localized Lymphoma | P3 | terminated | 334 | French Innovative Leukemia Organisation | Apr 2005 | |
| NCT01491841 | BRP | IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma | P1 | completed | 33 | Anne Beaven, MD | Nov 2011 |
| NCT01737177 | R2-B | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL | P2 | completed | 42 | Fondazione Italiana Linfomi - ETS | Jul 2012 |
| NCT02491398 | LLC1315 | Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia | — | completed | 494 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Feb 2016 |
| NCT02484053 | Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders | Early P1 | completed | 20 | Baylor College of Medicine | Jun 2015 | |
| NCT04361409 | Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | P1 | completed | 10 | China Medical University Hospital | May 2013 | |
| NCT01701232 | Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma | P3 | completed | 174 | Biocad | Sep 2011 | |
| NCT01279902 | Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL | P2 | unknown | 32 | Asan Medical Center | Aug 2010 | |
| NCT02390362 | RAMP | Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome | P3 | terminated | 3 | Nationwide Children's Hospital | Jan 2015 |
| NCT00940342 | GM-CSF | Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia | P2 | completed | 130 | M.D. Anderson Cancer Center | Oct 2004 |
| NCT03002038 | Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients | P2/P3 | completed | 86 | Isfahan University of Medical Sciences | Sep 2015 | |
| NCT04494438 | Rituximab for Idiopathic Nephrotic Syndrome | P3 | completed | 30 | Istituto Giannina Gaslini | Jul 2013 | |
| NCT02689986 | CAD5 | Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease | P2 | completed | 43 | Helse Fonna | Jan 2013 |
| NCT01760226 | DA-EPOCH-R | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies | Early P1 | completed | 4 | Baylor College of Medicine | Jan 2013 |
| NCT02571842 | Rituximab in Recurrent IgA Nephropathy | P4 | unknown | 30 | Chulalongkorn University | Jan 2012 | |
| NCT01238692 | LBH589 | A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | P2 | completed | 42 | Sarit Assouline | Nov 2010 |
| NCT03258866 | The Study of Different Dose Rituximab in the Treatment of ITP | P4 | completed | 62 | Shandong University | Jan 2010 | |
| NCT00784589 | Rituximab 3 | Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus | P3 | completed | 90 | University Hospital, Rouen | Jul 2009 |
| NCT00869323 | Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders | P2 | terminated | 3 | Masonic Cancer Center, University of Minnesota | Mar 2009 | |
| NCT00824135 | Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | P1 | completed | 34 | St. Jude Children's Research Hospital | Jan 2009 | |
| NCT00140582 | Primary Rituximab and Maintenance | P3 | completed | 1,217 | Lymphoma Study Association | Dec 2004 | |
| NCT00068250 | Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | P1/P2 | completed | 60 | Radiation Therapy Oncology Group | Jul 2003 | |
| NCT01682044 | Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma | P2 | completed | 20 | Roswell Park Cancer Institute | Apr 2007 | |
| NCT01200589 | HOMER | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy | P3 | terminated | 438 | Novartis Pharmaceuticals | Oct 2010 |
| NCT02649504 | Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia | P3 | withdrawn | 0 | Weill Medical College of Cornell University | Dec 2016 | |
| NCT02605694 | FRESCO | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | P2 | withdrawn | 0 | SecuraBio | Dec 2015 |
| NCT02576275 | BRAVURA | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | P3 | withdrawn | 0 | SecuraBio | Dec 2015 |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | P1/P2 | completed | 39 | SCRI Development Innovations, LLC | Jun 2008 | |
| NCT00536341 | CLL | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | P1/P2 | completed | 64 | SCRI Development Innovations, LLC | Jan 2008 |
| NCT00411086 | Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | P2 | completed | 60 | M.D. Anderson Cancer Center | Nov 2006 | |
| NCT00816595 | Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 68 | Mayo Clinic | Feb 2009 | |
| NCT01832922 | BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | P1 | completed | 8 | Dartmouth-Hitchcock Medical Center | Apr 2013 | |
| NCT00577629 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | P2 | completed | 39 | Duke University | Jun 2005 | |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | P1/P2 | withdrawn | 0 | Mayo Clinic | Oct 2016 | |
| NCT02514772 | ASSIST-RT | GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® | P3 | completed | 107 | Sandoz | Jul 2015 |
| NCT02366663 | SPINOZA | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL | P3 | terminated | 3 | City of Hope Medical Center | Jan 2015 |
| NCT01164098 | Rituximab to Prevent Recurrence of Proteinuria | P3 | terminated | 30 | George W. Burke | Feb 2012 | |
| NCT01810926 | T&B Depletion Non Malignant | P2 | unknown | 130 | Franco Locatelli | Sep 2011 | |
| NCT00918723 | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P1/P2 | completed | 40 | Fred Hutchinson Cancer Center | Jun 2009 | |
| NCT00498316 | Cord Blood Expansion on Mesenchymal Stem Cells | P1 | completed | 98 | M.D. Anderson Cancer Center | Jul 2007 | |
| NCT00425802 | Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | P2 | completed | 61 | Memorial Sloan Kettering Cancer Center | Nov 2006 | |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | P1/P2 | completed | 45 | Millennium Pharmaceuticals, Inc. | Aug 2011 | |
| NCT02438982 | Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome | P3 | completed | 120 | Nilratan Sircar Medical College | May 2015 | |
| NCT02376335 | RITPBC | B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis | P2 | completed | 71 | Newcastle-upon-Tyne Hospitals NHS Trust | Oct 2012 |
| NCT01470196 | CaRD | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia | P2 | completed | 31 | Dana-Farber Cancer Institute | Oct 2011 |
| NCT01678404 | 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma | P2 | unknown | 28 | Korea Cancer Center Hospital | Oct 2011 | |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | P3 | completed | 572 | Hoffmann-La Roche | Aug 2012 | |
| NCT01889797 | PrE0401 | Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | P2 | terminated | 32 | PrECOG, LLC. | Dec 2013 |
| NCT01775631 | Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma | P1 | completed | 47 | Bristol-Myers Squibb | Mar 2013 | |
| NCT01508468 | GEMRITUX | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy | P3 | completed | 80 | Assistance Publique - Hôpitaux de Paris | Jan 2012 |
| NCT01234467 | Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | P2 | completed | 23 | UNC Lineberger Comprehensive Cancer Center | Mar 2011 | |
| NCT01542918 | Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma | P1 | completed | 14 | James Rubenstein | Dec 2012 | |
| NCT01117662 | RIACT | Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients | P3 | terminated | 13 | Hannover Medical School | May 2012 |
| NCT02531308 | DLBCL | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | P2 | terminated | 5 | Rush University Medical Center | Jul 2015 |
| NCT01181258 | NK | Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | P2 | completed | 16 | Masonic Cancer Center, University of Minnesota | Aug 2010 |
| NCT01029730 | Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | P2 | completed | 55 | SCRI Development Innovations, LLC | Mar 2010 | |
| NCT01133158 | R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial | P2 | completed | 61 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Jul 2009 | |
| NCT02222155 | Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis | P2 | completed | 42 | Amgen | Feb 2015 | |
| NCT01453205 | DLBCL | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P2 | completed | 187 | MedImmune LLC | Feb 2012 |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | P1 | completed | 48 | SCRI Development Innovations, LLC | May 2013 | |
| NCT01524068 | A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations | P2 | withdrawn | 0 | University of Pittsburgh | Sep 2012 | |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | P2 | terminated | 105 | Gilead Sciences | Oct 2010 | |
| NCT01719159 | ITT-PMS | Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis | P2 | completed | 23 | Anders Svenningsson | Nov 2009 |
| NCT00513747 | Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | P3 | terminated | 84 | Alliance for Clinical Trials in Oncology | Jan 2008 | |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | P3 | terminated | 311 | Gilead Sciences | Feb 2014 | |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | P3 | withdrawn | 0 | Acerta Pharma BV | May 2016 | |
| NCT01556347 | Multi-Drug Desensitization Protocol for Heart Transplant Candidates | P2 | terminated | 2 | Providence Health & Services | Jul 2012 | |
| NCT00450385 | R-CHOP | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | P2 | terminated | 57 | University of Miami | Apr 2007 |
| NCT00545714 | CLL | A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 86 | Hoffmann-La Roche | Nov 2007 |
| NCT01732913 | Yosemite | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | P3 | terminated | 295 | Gilead Sciences | Jan 2013 |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | P2 | terminated | 102 | Gilead Sciences | Aug 2014 | |
| NCT01732926 | Bridalveil | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | P3 | terminated | 475 | Gilead Sciences | Jan 2013 |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | P4 | terminated | 89 | Hoffmann-La Roche | Jun 2011 | |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | P2 | terminated | 10 | Gilead Sciences | Sep 2015 | |
| NCT01156922 | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome | P2 | terminated | 8 | Haukeland University Hospital | Jun 2010 | |
| NCT00987493 | Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma | P1/P2 | completed | 49 | Swiss Cancer Institute | Sep 2009 | |
| NCT00119392 | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P2 | completed | 42 | Fred Hutchinson Cancer Center | Jun 2004 | |
| NCT01748084 | RECOVER | Rituximab in Systemic Sclerosis | P2/P3 | completed | 22 | Assistance Publique - Hôpitaux de Paris | Apr 2013 |
| NCT02205333 | MEDI6469 | A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | P1/P2 | terminated | 48 | MedImmune LLC | Aug 2014 |
| NCT01731561 | MAINRITSAN 2 | Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis | P3 | completed | 166 | Assistance Publique - Hôpitaux de Paris | Nov 2012 |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | P2 | terminated | 12 | St. Jude Children's Research Hospital | Oct 2014 | |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | P1/P2 | completed | 11 | The Lymphoma Academic Research Organisation | Dec 2012 | |
| NCT01370772 | Intensified Rituimab Prephase Before FCR in Untreated B-CLL | P2 | completed | 140 | French Innovative Leukemia Organisation | May 2011 | |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | P1 | terminated | 7 | Steven P. Treon, MD, PhD | May 2010 | |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | P4 | terminated | 26 | Hoffmann-La Roche | Apr 2011 | |
| NCT01643928 | REFLECTIONS B328-04 | Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) | N/A | completed | 185 | Pfizer | Aug 2012 |
| NCT02113007 | CNS | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | P2 | terminated | 2 | SCRI Development Innovations, LLC | Jul 2014 |
| NCT01719692 | ITP | Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia | N/A | completed | 100 | Institute of Hematology & Blood Diseases Hospital, China | Oct 2012 |
| NCT01990144 | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL | P2 | unknown | 49 | Fondazione Italiana Linfomi - ETS | Nov 2011 | |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | P1/P2 | completed | 14 | Weill Medical College of Cornell University | Jan 2010 | |
| NCT00784927 | Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma | P2 | completed | 36 | Mayo Clinic | Nov 2008 | |
| NCT00294632 | MCL | Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma | P1/P2 | completed | 54 | M.D. Anderson Cancer Center | Feb 2006 |
| NCT00594815 | RT | Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | N/A | completed | 52 | Memorial Sloan Kettering Cancer Center | Aug 2002 |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | P3 | completed | 454 | International Extranodal Lymphoma Study Group (IELSG) | Jan 2003 | |
| NCT02137681 | A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP) | P3 | withdrawn | 0 | Shandong University | May 2014 | |
| NCT00901927 | BMR | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | P2 | terminated | 14 | M.D. Anderson Cancer Center | May 2009 |
| NCT00544219 | PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | N/A | completed | 156 | Swiss Cancer Institute | Sep 2007 | |
| NCT00541034 | Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | P2 | completed | 49 | Memorial Sloan Kettering Cancer Center | May 2005 | |
| NCT01466153 | CLL | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 183 | MedImmune LLC | Feb 2012 |
| NCT01181154 | RAHIA | Rituximab in Auto-Immune Hemolytic Anemia | P3 | completed | 32 | Assistance Publique - Hôpitaux de Paris | Mar 2011 |
| NCT02532192 | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Dec 2015 | |
| NCT02456207 | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | P2 | unknown | 80 | Sinocelltech Ltd. | May 2015 | |
| NCT02417129 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma | P3 | terminated | 2 | Boehringer Ingelheim | Apr 2015 | |
| NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P1 | completed | 40 | Celgene Corporation | Dec 2012 | |
| NCT01765842 | RITULUP | Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy | P3 | terminated | 9 | Fundación Pública Andaluza Progreso y Salud | Nov 2012 |
| NCT01598558 | Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT | N/A | withdrawn | 0 | Sanjiv Sam Gambhir | Jan 2012 | |
| NCT01567475 | (RAD001-R) | The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas | P1 | completed | 21 | The Lymphoma Academic Research Organisation | Dec 2011 |
| NCT01309997 | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease | P2 | completed | 72 | Lee, Stephanie | Mar 2011 | |
| NCT01212094 | Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) | P1/P2 | terminated | 44 | National Institute of Neurological Disorders and Stroke (NINDS) | Sep 2010 | |
| NCT01127841 | RB | Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line | P2 | unknown | 60 | Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | Jul 2009 |
| NCT00107380 | S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | P2 | completed | 86 | SWOG Cancer Research Network | Nov 2005 | |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | P1/P2 | withdrawn | 0 | Western Regional Medical Center | Apr 2015 | |
| NCT01609023 | CaLLypso | A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia | — | completed | 67 | Hoffmann-La Roche | Apr 2012 |
| NCT01295151 | SWITCH | SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | P4 | completed | 122 | Julia Brown | Aug 2011 |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | P1/P2 | completed | 37 | Emory University | Feb 2008 | |
| NCT01046006 | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | P2 | completed | 59 | Meletios A. Dimopoulos | Mar 2007 | |
| NCT00290667 | Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma | P2 | completed | 586 | German High-Grade Non-Hodgkin's Lymphoma Study Group | Feb 2004 | |
| NCT01493479 | FIZZ | Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma | P2 | completed | 76 | The Christie NHS Foundation Trust | Jun 2007 |
| NCT01278745 | Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation | P2 | terminated | 362 | National Institute of Allergy and Infectious Diseases (NIAID) | Sep 2011 | |
| NCT00617929 | Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant | P2 | terminated | 12 | Masonic Cancer Center, University of Minnesota | Jan 2008 | |
| NCT00669877 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | P2 | completed | 56 | M.D. Anderson Cancer Center | Aug 2002 | |
| NCT00422799 | WM | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) | P2 | completed | 63 | Dana-Farber Cancer Institute | Aug 2006 |
| NCT01613027 | An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis | — | completed | 135 | Hoffmann-La Roche | Feb 2012 | |
| NCT01421173 | SCT | Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | P1 | completed | 78 | M.D. Anderson Cancer Center | Aug 2011 |
| NCT01213095 | MZL | Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL) | P2 | completed | 48 | Dong-A University Hospital | Sep 2010 |
| NCT00498368 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | P4 | completed | 34 | Mayo Clinic | Feb 2009 | |
| NCT00718549 | CLL | A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | P3 | completed | 128 | Hoffmann-La Roche | Jul 2009 |
| NCT02584920 | A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma | P1/P2 | completed | 87 | Shanghai Henlius Biotech | Oct 2014 | |
| NCT01022021 | PBSC | Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine | Early P1 | completed | 17 | University of Kansas Medical Center | Jan 2010 |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | P2 | completed | 206 | Millennium Pharmaceuticals, Inc. | Oct 2009 | |
| NCT00895661 | High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas | P2 | completed | 40 | Massachusetts General Hospital | Jul 2009 | |
| NCT00609869 | Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab | P2 | completed | 29 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2007 | |
| NCT00740415 | ManteauRiBVD | Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma | P2 | completed | 39 | French Innovative Leukemia Organisation | Jun 2007 |
| NCT00238238 | Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab | P2 | completed | 97 | Alliance for Clinical Trials in Oncology | Mar 2006 | |
| NCT02420938 | CLL | Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Jul 2015 |
| NCT01759030 | BIORA | Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis | P3 | completed | 181 | Biocad | Dec 2012 |
| NCT01161628 | GVHD | Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) | P2 | completed | 25 | Northside Hospital, Inc. | Apr 2011 |
| NCT01266317 | Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations | P1/P2 | completed | 9 | Michael Donahoe | Mar 2011 | |
| NCT00856245 | Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma | P2 | completed | 21 | University of Kansas Medical Center | Feb 2009 | |
| NCT00335140 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | P2 | terminated | 26 | Eastern Cooperative Oncology Group | Aug 2007 | |
| NCT00590447 | PTLD-1/3 | Risk Stratified Sequential Treatment for CD20-positive PTLD | P2 | completed | 152 | Charite University, Berlin, Germany | Dec 2006 |
| NCT00450801 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | P2 | completed | 22 | University of Miami | Apr 2004 | |
| NCT02332941 | Rituximab | Treatment -Resistant Neovascular Age-Related Macular Degeneration | P1 | completed | 5 | Washington University School of Medicine | Aug 2014 |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | P2 | terminated | 1 | Case Comprehensive Cancer Center | Mar 2014 | |
| NCT01974518 | Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus | P3 | unknown | 20 | Uprety Shraddha | Nov 2013 | |
| NCT01521689 | LLCRlowdoz | Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment | P2 | unknown | 35 | Institut Paoli-Calmettes | Dec 2011 |
| NCT01421667 | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | P2 | completed | 176 | Seagen Inc. | Aug 2011 | |
| NCT01558167 | CLL2P | A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | P1/P2 | completed | 22 | German CLL Study Group | Feb 2011 |
| NCT01269385 | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | P1/P2 | completed | 22 | Mayo Clinic | Jan 2011 | |
| NCT01165112 | TREC | Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma | P1/P2 | completed | 48 | University of Washington | Sep 2010 |
| NCT01178086 | CLL | A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | — | completed | 681 | Hoffmann-La Roche | Feb 2010 |
| NCT01007292 | A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment | P2 | completed | 43 | Astellas Pharma Inc | Nov 2009 | |
| NCT00565331 | Rituximab for Prevention of Rejection After Renal Transplantation | P2/P3 | completed | 280 | Radboud University Medical Center | Dec 2007 | |
| NCT00772655 | Zevalin® First Line in Follicular Lymphoma | P2 | unknown | 60 | Charite University, Berlin, Germany | Oct 2007 | |
| NCT00275054 | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | P3 | completed | 825 | German CLL Study Group | Oct 2005 | |
| NCT00096044 | Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | P2 | completed | 45 | Roswell Park Cancer Institute | Mar 2004 | |
| NCT00994643 | Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma | P2 | completed | 11 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Feb 2009 | |
| NCT00936546 | A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy | P2 | completed | 3 | University Hospital, Ghent | Jun 2009 | |
| NCT01625741 | HYDRIC | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy | P2 | terminated | 6 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Jul 2012 |
| NCT01569451 | GATEWAYII | Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate | P2 | completed | 53 | University of Colorado, Denver | Feb 2012 |
| NCT01549886 | Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma | P2 | terminated | 5 | Spectrum Pharmaceuticals, Inc | Nov 2011 | |
| NCT00581776 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | P2 | completed | 30 | University of Wisconsin, Madison | May 2005 | |
| NCT00641095 | MCLPIII | Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma | P2/P3 | completed | 370 | University College, London | Dec 2006 |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Aug 2014 | |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | P1/P2 | completed | 43 | National Cancer Institute (NCI) | Jul 2011 | |
| NCT01562977 | RGemOx | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL | P2 | completed | 82 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Apr 2011 |
| NCT01021735 | ORBIT | Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy | P4 | completed | 302 | University of Glasgow | Apr 2010 |
| NCT00904722 | Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma | P2 | completed | 32 | M.D. Anderson Cancer Center | Jan 2010 | |
| NCT00974233 | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | P2 | completed | 34 | University of Wisconsin, Madison | Oct 2009 | |
| NCT00301821 | Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | P2 | completed | 107 | Alliance for Clinical Trials in Oncology | Jan 2006 | |
| NCT02983097 | R²-DHAP | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | P1/P2 | terminated | 34 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Nov 2010 |
| NCT01088048 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | P1 | completed | 241 | Gilead Sciences | Mar 2010 | |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | P2 | terminated | 31 | ECOG-ACRIN Cancer Research Group | Apr 2011 | |
| NCT01373229 | CLL | Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) | P1 | completed | 21 | David Rizzieri, MD | Jan 2012 |
| NCT01209130 | A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma | P1 | completed | 91 | Genentech, Inc. | Oct 2010 | |
| NCT00110149 | Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | P2 | terminated | 12 | Beth Israel Deaconess Medical Center | May 2004 | |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | P2 | completed | 63 | Fred Hutchinson Cancer Center | Feb 2009 | |
| NCT00080886 | Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma | P2 | completed | 68 | University of Nebraska | May 2002 | |
| NCT02168907 | CPI-613 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | P1 | terminated | 1 | Wake Forest University Health Sciences | Dec 2014 |
| NCT01611259 | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue | P2 | completed | 50 | Arbeitsgemeinschaft medikamentoese Tumortherapie | May 2012 | |
| NCT01244958 | Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis | P3 | completed | 156 | Frank Behrens | Aug 2010 | |
| NCT00905034 | MOAD | Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage | P2 | completed | 37 | M.D. Anderson Cancer Center | Mar 2009 |
| NCT00453102 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma | P2 | completed | 18 | University of Miami | Feb 2006 | |
| NCT02371096 | Comparative Pharmacokinetic Trial of RGB-03 and MabThera | P1 | unknown | 0 | Gedeon Richter Plc. | — | |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | P3 | completed | 743 | Hoffmann-La Roche | Dec 2012 | |
| NCT01584388 | Rituximab in IgG4-RD: A Phase 1-2 Trial | P1/P2 | completed | 30 | Massachusetts General Hospital | Apr 2012 | |
| NCT01641952 | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent | — | completed | 505 | Hoffmann-La Roche | Oct 2011 | |
| NCT01279616 | SCT | A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease | P2 | terminated | 8 | Nationwide Children's Hospital | Sep 2010 |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | P2 | terminated | 10 | Massachusetts General Hospital | Jul 2010 | |
| NCT01523860 | FLE09 | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma | P2 | completed | 76 | Fondazione Italiana Linfomi - ETS | Jun 2009 |
| NCT00070018 | S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma | P2 | completed | 46 | SWOG Cancer Research Network | Feb 2004 | |
| NCT00637832 | Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma | P2 | terminated | 1 | University of Southampton | Apr 2008 | |
| NCT00911183 | FRAIL-06 | Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial | P2 | completed | 67 | Institut Bergonié | Dec 2008 |
| NCT01592292 | An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy | — | completed | 90 | Hoffmann-La Roche | Nov 2011 | |
| NCT00798785 | Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients | P1/P2 | unknown | 50 | Universitair Ziekenhuis Brussel | Oct 2006 | |
| NCT00381004 | GM-CSF | FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia | P2 | completed | 60 | M.D. Anderson Cancer Center | Sep 2006 |
| NCT02533401 | CLL | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 34 | Hoffmann-La Roche | Feb 2006 |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | P3 | unknown | 360 | European Mantle Cell Lymphoma Network | Jul 2004 | |
| NCT00794820 | Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline | P2 | completed | 66 | M.D. Anderson Cancer Center | Dec 2003 | |
| NCT00562328 | Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia | P2 | completed | 33 | Mayo Clinic | Jan 2008 | |
| NCT01226849 | SGH652 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma | P1 | completed | 6 | Singapore General Hospital | Nov 2010 |
| NCT01014208 | ORCHARRD | Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma | P3 | completed | 447 | GlaxoSmithKline | Mar 2010 |
| NCT00801632 | Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection | P2 | completed | 5 | National Institute of Allergy and Infectious Diseases (NIAID) | Dec 2008 | |
| NCT00765245 | Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma | P2 | completed | 44 | Vanderbilt-Ingram Cancer Center | Oct 2008 | |
| NCT00598169 | Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma | P1 | completed | 23 | AIDS Malignancy Consortium | Nov 2007 | |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | P1/P2 | completed | 38 | Mayo Clinic | Oct 2004 | |
| NCT01290549 | A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | P1 | completed | 95 | Genentech, Inc. | Mar 2011 | |
| NCT01873443 | Long-Term Efficacy and Safety of CT-P10 in Patients With RA | P1 | completed | 87 | Celltrion | May 2013 | |
| NCT01765374 | SEWORRA | Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis | P4 | completed | 30 | University Hospital, Rouen | Feb 2011 |
| NCT01071798 | An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis | — | completed | 1,653 | Hoffmann-La Roche | Jan 2010 | |
| NCT01926639 | Lymvac-1 | Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma | P2 | completed | 14 | Oslo University Hospital | Oct 2009 |
| NCT01830478 | R | Lenalidomide Plus Rituximab (R) in Non Follicular NHL | P2 | unknown | 44 | Gruppo Italiano Studio Linfomi | Apr 2009 |
| NCT00448019 | CLL | FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 64 | M.D. Anderson Cancer Center | Feb 2007 |
| NCT00350545 | A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease | N/A | completed | 37 | Stanford University | Aug 2006 | |
| NCT00369681 | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | P2 | completed | 51 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2006 | |
| NCT00039130 | Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | P2 | completed | 105 | Alliance for Clinical Trials in Oncology | May 2002 | |
| NCT01510184 | PET | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy | P3 | terminated | 79 | Spectrum Pharmaceuticals, Inc | Apr 2012 |
| NCT00369707 | Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL | P2 | completed | 42 | Northwestern University | Aug 2006 | |
| NCT01470456 | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | completed | 50 | Sanofi | Nov 2011 | |
| NCT01181999 | Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma | P2 | unknown | 50 | Chonnam National University Hospital | Aug 2010 | |
| NCT00101010 | Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | P2 | completed | 80 | M.D. Anderson Cancer Center | Sep 2005 | |
| NCT00098774 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma | P2 | completed | 47 | Alliance for Clinical Trials in Oncology | Oct 2004 | |
| NCT01754870 | CLL | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) | P2 | withdrawn | 0 | University of Wisconsin, Madison | Nov 2013 |
| NCT02040116 | Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases | P4 | completed | 19 | Wake Forest University Health Sciences | Feb 2013 | |
| NCT01282476 | Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | P2 | terminated | 18 | Massachusetts General Hospital | Jun 2011 | |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | P2 | terminated | 8 | Hoffmann-La Roche | Jun 2010 | |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | P1/P2 | terminated | 46 | Dana-Farber Cancer Institute | Apr 2010 | |
| NCT00759603 | Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | P2 | completed | 60 | M.D. Anderson Cancer Center | Sep 2008 | |
| NCT00553501 | Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma | P2 | completed | 60 | Alliance for Clinical Trials in Oncology | Mar 2008 | |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | P1 | completed | 9 | City of Hope Medical Center | Jan 2008 | |
| NCT00057811 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | P2 | completed | 97 | Children's Oncology Group | Jun 2004 | |
| NCT01086631 | Rituximab for Autoimmune Retinopathy | P1 | completed | 5 | National Eye Institute (NEI) | Jan 2010 | |
| NCT01670812 | Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia | P3 | unknown | 100 | The First Affiliated Hospital with Nanjing Medical University | Jan 2012 | |
| NCT01525836 | rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP | P3 | completed | 123 | Shandong University | May 2011 | |
| NCT02536664 | Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants | — | completed | 505 | Hoffmann-La Roche | Sep 2009 | |
| NCT00198978 | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | P4 | completed | 377 | Goethe University | Jan 2003 | |
| NCT01290120 | B-ALL | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | P2 | completed | 182 | Northern Italy Leukemia Group | Nov 2002 |
| NCT00299494 | NHL | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | P1/P2 | completed | 119 | Pfizer | May 2006 |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | P2 | terminated | 5 | Duke University | Feb 2012 | |
| NCT01268033 | NEPHRUTIX | Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood | P2/P3 | completed | 26 | University Hospital, Limoges | Dec 2010 |
| NCT00891839 | Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma | P2 | completed | 45 | Cephalon | Jun 2009 | |
| NCT00669318 | Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 41 | Mayo Clinic | Jul 2008 | |
| NCT00546377 | Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | P1/P2 | completed | 50 | Memorial Sloan Kettering Cancer Center | Jul 2005 | |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | P2 | terminated | 17 | New Mexico Cancer Research Alliance | Oct 2004 | |
| NCT02472756 | REFLECT 2 | A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma | — | completed | 41 | Hoffmann-La Roche | Sep 2008 |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | — | approved for marketing | 0 | Gilead Sciences | — | |
| NCT01779167 | THRiL for WM | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia | P2 | terminated | 4 | Weill Medical College of Cornell University | Jun 2012 |
| NCT01539512 | CLL | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | P3 | completed | 220 | Gilead Sciences | Apr 2012 |
| NCT01390441 | MK-8808-002 | A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) | P1 | terminated | 100 | Merck Sharp & Dohme LLC | Jul 2011 |
| NCT00809341 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P2 | terminated | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2009 | |
| NCT00691015 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant | P2 | completed | 48 | Barbara Ann Karmanos Cancer Institute | May 2008 | |
| NCT00387959 | Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 17 | Memorial Sloan Kettering Cancer Center | Jul 2006 | |
| NCT00327678 | ALL | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | P3 | completed | 1,080 | Assistance Publique - Hôpitaux de Paris | May 2006 |
| NCT00005089 | S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma | P2 | completed | 71 | SWOG Cancer Research Network | Apr 2000 | |
| NCT01509300 | HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors | P1/P2 | unknown | 10 | Asan Medical Center | Jan 2012 | |
| NCT01135641 | R-GVHD | Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD) | P2 | completed | 25 | Nantes University Hospital | Jun 2010 |
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | P1 | completed | 103 | Pfizer | Mar 2010 | |
| NCT01056510 | A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) | P4 | completed | 357 | Hoffmann-La Roche | Mar 2010 | |
| NCT00958256 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | P2 | completed | 22 | M.D. Anderson Cancer Center | Aug 2009 | |
| NCT00344149 | Rituximab as Second Line Treatment for ITP | P3 | completed | 112 | Ostfold Hospital Trust | Jun 2006 | |
| NCT02099292 | Mz-135 | Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma | P2 | completed | 103 | Georg Hess, MD | May 2001 |
| NCT01232556 | A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy | P3 | terminated | 338 | Pfizer | Apr 2011 | |
| NCT01534884 | Triad RA | Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis | P1 | completed | 154 | Celltrion | Feb 2012 |
| NCT01423539 | NAVIGATE | A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | P2 | withdrawn | 0 | Genentech, Inc. | Oct 2011 |
| NCT01369849 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P1/P2 | completed | 15 | National Cancer Institute (NCI) | Sep 2011 | |
| NCT01332994 | A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis | P3 | completed | 519 | Hoffmann-La Roche | Mar 2011 | |
| NCT01224093 | MABERYC | An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) | — | completed | 219 | Hoffmann-La Roche | Oct 2010 |
| NCT01156909 | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome | P2 | completed | 29 | Haukeland University Hospital | Oct 2010 | |
| NCT02699892 | RITAM | Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis | — | completed | 130 | Hoffmann-La Roche | Oct 2007 |
| NCT01408342 | Alemtuzumab and Rituximab in Aplastic Anemia | N/A | withdrawn | 0 | Hospital Universitario Dr. Jose E. Gonzalez | Jul 2011 | |
| NCT00689169 | ZBEAM2 | Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | P2 | completed | 75 | Lymphoma Study Association | Aug 2007 |
| NCT00330252 | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | P1 | completed | 29 | Dana-Farber Cancer Institute | May 2006 | |
| NCT00064116 | IDEC-C2B8 | Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma | P3 | completed | 824 | NCIC Clinical Trials Group | May 2001 |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Jul 2011 | |
| NCT01506414 | ITP | Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) | P3 | completed | 91 | Ming Hou | Jun 2009 |
| NCT01015248 | MALT | Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma | P2 | completed | 60 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | May 2009 |
| NCT00388193 | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma | P2 | completed | 20 | PETHEMA Foundation | Aug 2006 | |
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | P2 | completed | 30 | Dana-Farber Cancer Institute | Feb 2005 | |
| NCT00066469 | Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation | P2 | completed | 55 | Children's Oncology Group | Apr 2004 | |
| NCT01716442 | RTX2012 | Rituximab Trial for Pediatric Nephrotic Syndrome | P2/P3 | unknown | 88 | Seoul National University Childrens Hospital | Aug 2012 |
| NCT01718691 | Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma | P2 | completed | 70 | SymBio Pharmaceuticals | Nov 2011 | |
| NCT02461290 | Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1 | — | completed | 99 | Hoffmann-La Roche | Apr 2008 | |
| NCT00401817 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | P2 | completed | 11 | Weill Medical College of Cornell University | Nov 2007 | |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | P2 | completed | 55 | Fred Hutchinson Cancer Center | Aug 2003 | |
| NCT01650727 | P07974 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | P1 | completed | 5 | Merck Sharp & Dohme LLC | Oct 2012 |
| NCT01734057 | ITP | Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) | P3 | withdrawn | 0 | Shandong University | Jul 2012 |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | P2 | terminated | 4 | Hoosier Cancer Research Network | Oct 2010 | |
| NCT00004031 | SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | P3 | completed | 397 | SWOG Cancer Research Network | Jul 1997 | |
| NCT00076752 | Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus | P2 | completed | 9 | National Cancer Institute (NCI) | Jan 2004 | |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | P1 | completed | 186 | Teva Branded Pharmaceutical Products R&D, Inc. | Sep 2010 | |
| NCT01185262 | LLC-LENAR-08 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia | P1 | completed | 25 | MD Anderson International Spain SA | Apr 2009 |
| NCT00831597 | 904 | Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P2 | completed | 61 | Pharmatech | Nov 2008 |
| NCT00595335 | Trial of Rituximab for Graves' Ophthalmopathy | P2/P3 | completed | 25 | Rebecca Bahn | Apr 2008 | |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | P2 | terminated | 14 | Duke University | Jan 2007 | |
| NCT00499018 | DLCL04 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | P3 | unknown | 399 | Fondazione Italiana Linfomi - ETS | Jan 2006 |
| NCT01939730 | Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma | P2 | completed | 42 | M.D. Anderson Cancer Center | Aug 1999 | |
| NCT01403740 | EHEM | Turkish Acquired Haemophilia Registry | — | unknown | 250 | Turkish Society of Hematology | Sep 2011 |
| NCT00907751 | PTTritux | Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura | P2 | completed | 12 | Assistance Publique - Hôpitaux de Paris | May 2010 |
| NCT00496340 | Pento & tBU | Phase II Trial of Pentostatin and Targeted Busulfan | P2 | completed | 42 | H. Lee Moffitt Cancer Center and Research Institute | Jul 2007 |
| NCT00647049 | Freiburg ZNS-NHL Study | P2 | unknown | 78 | University Hospital Freiburg | Jan 2007 | |
| NCT00133991 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia | P2 | completed | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2005 | |
| NCT02569996 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | P3 | completed | 124 | Hoffmann-La Roche | Jul 2005 | |
| NCT00117975 | Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | P2 | completed | 62 | Alliance for Clinical Trials in Oncology | Jun 2005 | |
| NCT01000441 | ROC | Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis | P4 | completed | 300 | University Hospital, Strasbourg, France | Dec 2009 |
| NCT01831505 | Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents | P1 | completed | 4 | Presage Biosciences | Nov 2012 | |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | P1 | completed | 281 | Hoffmann-La Roche | Sep 2009 | |
| NCT00564512 | Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP | P3 | completed | 178 | French Innovative Leukemia Organisation | Nov 2007 | |
| NCT00521014 | GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | P2 | completed | 14 | Memorial Sloan Kettering Cancer Center | Oct 2007 | |
| NCT00392834 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma | P2 | completed | 34 | AIDS Malignancy Consortium | Sep 2006 | |
| NCT00299104 | IMAGE | A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis | P3 | completed | 755 | Genentech, Inc. | Jan 2006 |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | P1/P2 | terminated | 32 | National Cancer Institute (NCI) | Oct 2005 | |
| NCT00299130 | SERENE | A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis | P3 | completed | 511 | Genentech, Inc. | Oct 2005 |
| NCT00671658 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | P2 | completed | 220 | M.D. Anderson Cancer Center | Nov 2002 | |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | P2 | terminated | 135 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2009 | |
| NCT00372905 | Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma | P1/P2 | terminated | 18 | Northwestern University | Jul 2007 | |
| NCT01317901 | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | P1 | completed | 12 | Aptevo Therapeutics | May 2011 | |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation | P2 | terminated | 4 | Barbara Ann Karmanos Cancer Institute | Aug 2010 | |
| NCT00748644 | MAINRITSAN | Efficacy Study of Two Treatments in the Remission of Vasculitis | P3 | completed | 117 | Assistance Publique - Hôpitaux de Paris | Oct 2008 |
| NCT00433537 | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma | P2 | completed | 77 | National Cancer Institute (NCI) | May 2007 | |
| NCT00832234 | BDR-WM | Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia | P2 | completed | 59 | European Myeloma Network B.V. | Sep 2006 |
| NCT00268983 | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma | P3 | completed | 14 | GlaxoSmithKline | Oct 2004 | |
| NCT02097745 | A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies | P3 | completed | 341 | Hoffmann-La Roche | Jun 2004 | |
| NCT00578305 | SCORE | A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate | P3 | completed | 185 | Hoffmann-La Roche | Nov 2007 |
| NCT00392691 | Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | P1 | completed | 20 | Swiss Cancer Institute | Oct 2006 | |
| NCT00397800 | Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma | P1/P2 | unknown | 12 | Technical University of Munich | Jun 2005 | |
| NCT00561379 | Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab | N/A | completed | 350 | Nantes University Hospital | Apr 2005 | |
| NCT00505895 | FM 140 vs FM100 Study in Patients With Multiple Myeloma | P2 | completed | 52 | M.D. Anderson Cancer Center | Jan 2002 | |
| NCT00503425 | DMARD | A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy. | P3 | completed | 215 | Hoffmann-La Roche | Jun 2005 |
| NCT01482754 | Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma | N/A | completed | 30 | National University Hospital, Singapore | May 2012 | |
| NCT01206777 | Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies | P2 | completed | 52 | Ohio State University Comprehensive Cancer Center | Oct 2010 | |
| NCT00509184 | MIR | Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma | P2 | completed | 85 | Klaus Herfarth, MD | Mar 2008 |
| NCT02316613 | OLYMPE | Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) | — | completed | 260 | Hoffmann-La Roche | Feb 2007 |
| NCT00005589 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | P3 | completed | 460 | EBMT Solid Tumors Working Party | Oct 1999 | |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL | P1/P2 | completed | 76 | Weill Medical College of Cornell University | Jan 2004 | |
| NCT00701129 | An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease | P4 | completed | 4 | Genzyme, a Sanofi Company | Oct 2009 | |
| NCT00845832 | A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate | P2 | terminated | 24 | Hoffmann-La Roche | Mar 2009 | |
| NCT00771875 | Randomized Trial for Mixed Acute Rejection | P2 | completed | 30 | University of Cincinnati | Sep 2008 | |
| NCT00576758 | RO5072759 | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma | P2 | completed | 175 | Hoffmann-La Roche | Jan 2008 |
| NCT00221325 | A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | P1 | completed | 14 | University of California, San Francisco | Apr 2007 | |
| NCT00422383 | RA | A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA) | P3 | completed | 378 | Hoffmann-La Roche | Feb 2006 |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | P3 | completed | 683 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Jan 2006 | |
| NCT00193492 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | P2 | completed | 60 | SCRI Development Innovations, LLC | Sep 2005 | |
| NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | P3 | completed | 246 | Gruppo Italiano Terapie Innovative nei Linfomi | May 2005 | |
| NCT00582166 | Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance | P2 | terminated | 18 | University of Wisconsin, Madison | Jan 2005 | |
| NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | P3 | terminated | 1 | Spectrum Pharmaceuticals, Inc | Dec 2012 | |
| NCT01534949 | Triad-DLBCL | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial | P1 | terminated | 1 | Celltrion | Feb 2012 |
| NCT00443651 | SUNDIAL | A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis | P3 | completed | 578 | Genentech, Inc. | Jan 2007 |
| NCT01107951 | Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP | P2 | completed | 21 | Hospital Universitario Dr. Jose E. Gonzalez | Apr 2010 | |
| NCT00740948 | TEARS | Tolerance and Efficacy of Rituximab in Sjogren's Disease | P2/P3 | completed | 122 | University Hospital, Brest | Mar 2008 |
| NCT00537290 | RITAPS | A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome | P2 | completed | 19 | Hospital for Special Surgery, New York | Sep 2007 |
| NCT00451178 | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | P2 | completed | 101 | Eli Lilly and Company | May 2007 | |
| NCT00282347 | LUNAR | A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis | P3 | completed | 144 | Genentech, Inc. | Jan 2006 |
| NCT00134082 | Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma | P1/P2 | completed | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2005 | |
| NCT02157181 | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab | P2 | completed | 89 | Jurgen Barth | Jun 2004 | |
| NCT00280241 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | P2 | completed | 65 | University of Pittsburgh | Jun 2004 | |
| NCT00858117 | A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL | P2 | completed | 30 | Northwestern University | Sep 2005 | |
| NCT00738374 | A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. | P2 | completed | 97 | Hoffmann-La Roche | Nov 2008 | |
| NCT01382940 | RATE-RA | A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis | P4 | completed | 351 | Hoffmann-La Roche | Jul 2011 |
| NCT01358253 | Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia | P4 | completed | 100 | Ruijin Hospital | Dec 2010 | |
| NCT02731560 | PARIS | Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS) | P4 | completed | 74 | Prof. Abid Z. Farooqi | Jan 2010 |
| NCT00855205 | RIPS | Rituximab for Pulmonary Sarcoidosis | P2 | completed | 10 | University of Cincinnati | Jul 2009 |
| NCT00807196 | Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma | P1/P2 | unknown | 20 | Maisonneuve-Rosemont Hospital | Sep 2008 | |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | P1 | terminated | 9 | Dana-Farber Cancer Institute | Oct 2007 | |
| NCT00307125 | Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies | P2 | completed | 757 | National Institute of Allergy and Infectious Diseases (NIAID) | Mar 2006 | |
| NCT00244985 | Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P1/P2 | completed | 42 | Roswell Park Cancer Institute | Sep 2005 | |
| NCT02093026 | RA | Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA) | P2 | completed | 465 | Hoffmann-La Roche | Aug 2002 |
| NCT00901069 | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | P1 | completed | 12 | Shams Shakil | May 2009 | |
| NCT00908583 | Desensitization in Kidney Transplantation | P4 | completed | 44 | University of Cincinnati | May 2009 | |
| NCT00425932 | Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis | P2 | completed | 60 | Gaylis, Norman B., M.D. | Feb 2007 | |
| NCT00436280 | Chemotherapy for Participants With Lymphoma | P2 | completed | 68 | Eli Lilly and Company | Feb 2007 | |
| NCT00169156 | A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma | P2 | completed | 27 | Lymphoma Study Association | Dec 2005 | |
| NCT00169195 | R-GEMOX | Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma | P2 | completed | 49 | Lymphoma Study Association | Apr 2003 |
| NCT01230788 | Rituximab | Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia | N/A | terminated | 1 | Emory University | Sep 2010 |
| NCT00867087 | CMC-544 | Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 64 | Pfizer | Jun 2009 |
| NCT00881387 | Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment | P2 | withdrawn | 0 | University of Miami | Feb 2009 | |
| NCT00736450 | Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | Early P1 | terminated | 37 | University of Nebraska | Jul 2008 | |
| NCT00410982 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | P1 | completed | 145 | M.D. Anderson Cancer Center | Dec 2006 | |
| NCT00248534 | Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma | P2 | terminated | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2005 | |
| NCT02013817 | CLL | CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy | P2 | completed | 43 | Hoffmann-La Roche | Oct 2005 |
| NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | P2 | completed | 164 | Millennium Pharmaceuticals, Inc. | Jan 2010 | |
| NCT00379587 | Rituximab for Prevention of Chronic GVHD | P1/P2 | completed | 65 | Dana-Farber Cancer Institute | Sep 2006 | |
| NCT00060346 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | P2 | terminated | 16 | Eastern Cooperative Oncology Group | Oct 2004 | |
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | P3 | withdrawn | 0 | CTI BioPharma | Sep 2007 | |
| NCT00387023 | Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma | N/A | completed | 12 | M.D. Anderson Cancer Center | Feb 2004 | |
| NCT01381705 | Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma | — | completed | 259 | ECOG-ACRIN Cancer Research Group | Feb 2012 | |
| NCT01299857 | Suiviritux | Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab | P3 | completed | 22 | University Hospital, Rouen | Jun 2011 |
| NCT01087151 | CLL | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 118 | Genentech, Inc. | Aug 2010 |
| NCT01073163 | NHL | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) | P3 | completed | 54 | Cephalon | Feb 2010 |
| NCT01338103 | Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex | N/A | unknown | 10 | Rabin Medical Center | Jan 2010 | |
| NCT00992134 | R-BAC | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma | P2 | completed | 41 | St. Bortolo Hospital | Jun 2009 |
| NCT00646750 | Z-BEAM LDGGB | Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom | P2 | completed | 31 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Jan 2008 |
| NCT00504491 | R-CHOP | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia | P2 | withdrawn | 0 | CABYC | Jul 2007 |
| NCT00472056 | Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | P2 | completed | 93 | M.D. Anderson Cancer Center | Mar 2005 | |
| NCT00954005 | R-GO | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma | P1/P2 | terminated | 56 | German Low Grade Lymphoma Study Group | Jan 2003 |
| NCT00574730 | CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma | N/A | completed | 27 | University of Nebraska | May 2001 | |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | P2 | terminated | 3 | Fred Hutchinson Cancer Center | May 2012 | |
| NCT01009970 | R-COMP | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | P2 | unknown | 50 | Fondazione Italiana Linfomi - ETS | May 2010 |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | terminated | 20 | David Rizzieri | Feb 2008 | |
| NCT00090051 | CLL | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | P3 | completed | 552 | Hoffmann-La Roche | Jul 2003 |
| NCT00282308 | SIERRA | A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate | P2 | completed | 103 | Genentech, Inc. | Jan 2006 |
| NCT01000610 | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate | P4 | completed | 18 | Hoffmann-La Roche | Mar 2008 | |
| NCT01312064 | De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction | P4 | terminated | 2 | National Taiwan University Hospital | Apr 2011 | |
| NCT00949988 | BMS-CA180105 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia | P1/P2 | terminated | 3 | University of California, San Diego | May 2009 |
| NCT01144754 | Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT | — | terminated | 1 | Stanford University | Feb 2009 | |
| NCT00532129 | A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. | P2 | completed | 100 | Hoffmann-La Roche | Nov 2007 | |
| NCT01300793 | V-RICE | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide | P1 | terminated | 6 | University of California, San Francisco | May 2007 |
| NCT00405340 | Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Early P1 | completed | 20 | Mayo Clinic | Oct 2006 | |
| NCT00299182 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | P1/P2 | completed | 50 | M.D. Anderson Cancer Center | Mar 2006 | |
| NCT00144807 | ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | P2 | completed | 128 | Lymphoma Study Association | Dec 2003 | |
| NCT00140660 | ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma | P3 | terminated | 223 | Lymphoma Study Association | Dec 2003 | |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | P1 | terminated | 5 | Case Comprehensive Cancer Center | Jan 2010 | |
| NCT00877006 | BR | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | P3 | completed | 447 | Teva Branded Pharmaceutical Products R&D, Inc. | Apr 2009 |
| NCT00963703 | Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis | N/A | completed | 15 | University of Manitoba | Dec 2007 | |
| NCT00818961 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | P2 | terminated | 36 | Northside Hospital, Inc. | May 2005 | |
| NCT00109967 | CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P2 | completed | 71 | National Cancer Institute (NCI) | May 2005 | |
| NCT00201877 | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma | P2 | completed | 25 | Ohio State University Comprehensive Cancer Center | Dec 2004 | |
| NCT00504504 | Rituximab and ABVD for Hodgkin's Patients | P2 | completed | 85 | M.D. Anderson Cancer Center | Mar 2001 | |
| NCT00860457 | FR | Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 22 | Georgetown University | Feb 2008 |
| NCT00472849 | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | P1/P2 | completed | 92 | M.D. Anderson Cancer Center | May 2007 | |
| NCT00381810 | VOYAGER | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus | P3 | terminated | 31 | Genentech, Inc. | Jun 2006 |
| NCT00726700 | Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | P2 | completed | 109 | Universität des Saarlandes | May 2004 | |
| NCT00416819 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma | N/A | completed | 10 | University of California, San Francisco | Sep 2003 | |
| NCT01539174 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma | P2 | withdrawn | 0 | Fox Chase Cancer Center | — | |
| NCT00504751 | Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL | P2 | completed | 15 | Weill Medical College of Cornell University | May 2007 | |
| NCT01042509 | LowAR | Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease | N/A | completed | 15 | Hospital Universitario Dr. Jose E. Gonzalez | Oct 2009 |
| NCT00960713 | RITAI | The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders | — | completed | 35 | University Hospital, Toulouse | Jun 2009 |
| NCT00738829 | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | P1/P2 | completed | 45 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Oct 2008 | |
| NCT00575406 | NHL-14 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | P2 | completed | 94 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Dec 2007 |
| NCT00331006 | RICH | Rituximab to Treat Severe Hemophilia A | P2 | completed | 23 | Carelon Research | Jun 2006 |
| NCT00927797 | PERLL | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) | P2 | unknown | 185 | Heidelberg University | Feb 2005 |
| NCT00117156 | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | P2 | completed | 26 | Dana-Farber Cancer Institute | Dec 2003 | |
| NCT01406782 | DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402 | — | completed | 200 | Eastern Cooperative Oncology Group | Dec 2011 | |
| NCT00428142 | Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | P2 | completed | 95 | NCIC Clinical Trials Group | May 2007 | |
| NCT00073957 | Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 25 | Beth Israel Deaconess Medical Center | Dec 2003 | |
| NCT01075477 | An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab) | — | completed | 151 | Hoffmann-La Roche | Sep 2009 | |
| NCT00968331 | DLBCL | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | P2 | terminated | 25 | University of Bologna | Mar 2009 |
| NCT00774462 | FORCE | Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis | P2 | completed | 30 | Assistance Publique - Hôpitaux de Paris | Jan 2008 |
| NCT00552461 | PAP | Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis | P2 | completed | 10 | East Carolina University | Jan 2007 |
| NCT00048737 | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | P1/P2 | completed | 70 | M.D. Anderson Cancer Center | Oct 2002 | |
| NCT00869999 | Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | P2 | completed | 26 | Massachusetts General Hospital | May 2009 | |
| NCT00486759 | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | P3 | terminated | 787 | Hoffmann-La Roche | Jul 2007 | |
| NCT00515138 | RICE | A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant | Early P1 | terminated | 7 | University of California, San Francisco | May 2007 |
| NCT01126541 | SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy | P3 | completed | 224 | Hoffmann-La Roche | Sep 2006 | |
| NCT00436904 | Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | P2 | completed | 30 | Mayo Clinic | Dec 2004 | |
| NCT00001586 | Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis | P2 | completed | 105 | National Cancer Institute (NCI) | Sep 1997 | |
| NCT01277172 | TREND | TREatment of degeNerative and Neoplastic Diseases With Rituximab | P2/P3 | unknown | 54 | Probiomed S.A. de C.V. | Oct 2010 |
| NCT01593332 | Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis | P4 | completed | 44 | Mashhad University of Medical Sciences | Jul 2010 | |
| NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | completed | 63 | SymBio Pharmaceuticals | Apr 2010 | |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | P2 | terminated | 12 | Millennium Pharmaceuticals, Inc. | Sep 2009 | |
| NCT00334438 | Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | P1 | completed | 12 | UNC Lineberger Comprehensive Cancer Center | Jul 2006 | |
| NCT00281918 | CLL-8 | Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia | P3 | completed | 817 | Hoffmann-La Roche | Jul 2003 |
| NCT01458548 | PTLD | Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) | P2 | terminated | 70 | Charite University, Berlin, Germany | Dec 2002 |
| NCT00972101 | Infusion of Expanded Cord Blood T Cells | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Sep 2009 | |
| NCT00989352 | PRIMAIN | Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma | P2 | unknown | 56 | University Hospital Freiburg | Sep 2009 |
| NCT00851552 | Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | P2 | terminated | 9 | Roswell Park Cancer Institute | Jan 2009 | |
| NCT00656812 | MALT | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | P2 | completed | 40 | Arbeitsgemeinschaft medikamentoese Tumortherapie | May 2008 |
| NCT00651755 | Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients | N/A | completed | 23 | M.D. Anderson Cancer Center | Mar 2008 | |
| NCT00389818 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 43 | AIDS Malignancy Consortium | Jan 2007 | |
| NCT00468442 | B-Lymphocyte Immunotherapy in Islet Transplantation | P2 | terminated | 2 | National Institute of Allergy and Infectious Diseases (NIAID) | Nov 2006 | |
| NCT00254163 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | P3 | completed | 184 | US Oncology Research | Dec 2003 | |
| NCT00208975 | Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab | P2 | terminated | 15 | Emory University | Jul 2002 | |
| NCT00502840 | A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. | P3 | completed | 193 | Hoffmann-La Roche | Jul 2007 | |
| NCT01066598 | A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD) | P2 | terminated | 1 | University Health Network, Toronto | May 2010 | |
| NCT01350232 | Treatment of Sickle Cell Anemia With Stem Cell Transplant | N/A | terminated | 2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sep 2009 | |
| NCT00475423 | A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. | P2 | completed | 122 | Hoffmann-La Roche | May 2007 | |
| NCT00244855 | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma | P2 | completed | 32 | Fred Hutchinson Cancer Center | May 2004 | |
| NCT00986947 | Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates | P2 | terminated | 20 | Johns Hopkins University | Sep 2009 | |
| NCT00628238 | CLL | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | P2 | unknown | 80 | Chronic Lymphocytic Leukemia Research Consortium | Feb 2008 |
| NCT00656656 | Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus | P2 | completed | 23 | University of Luebeck | Jan 2008 | |
| NCT00455897 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | P2 | terminated | 3 | Massachusetts General Hospital | Dec 2006 | |
| NCT00298272 | Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis | P2 | terminated | 54 | Biogen | May 2006 | |
| NCT00971763 | Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | P2 | completed | 62 | University College, London | Mar 2006 | |
| NCT00525603 | CFAR Study in Patients With Chronic Lymphocytic Leukemia | P2 | completed | 60 | M.D. Anderson Cancer Center | Jun 2005 | |
| NCT00278161 | Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | P2 | completed | 94 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2005 | |
| NCT00074438 | Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis | P2 | completed | 465 | Genentech, Inc. | Jun 2003 | |
| NCT01609010 | A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma | P3 | completed | 313 | Hoffmann-La Roche | Oct 2002 | |
| NCT01144364 | NHL | A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) | P3 | completed | 234 | Hoffmann-La Roche | Jan 2004 |
| NCT01072240 | An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia | — | completed | 92 | Hoffmann-La Roche | Sep 2009 | |
| NCT00578565 | Rituximab in Rheumatoid Arthritis Lung Disease | P3 | completed | 10 | Eric Matteson | May 2007 | |
| NCT00372892 | ITP | Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) | P2 | completed | 60 | Hamilton Health Sciences Corporation | Sep 2006 |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | P2 | terminated | 10 | Dana-Farber Cancer Institute | Jul 2005 | |
| NCT00041132 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | P2 | completed | 56 | SWOG Cancer Research Network | Sep 2002 | |
| NCT00719472 | RATE | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) | P3 | completed | 451 | Genentech, Inc. | Jul 2008 |
| NCT01032122 | Rituximab in Metastatic Melanoma | P1 | terminated | 9 | Medical University of Vienna | Oct 2007 | |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | P2 | terminated | 151 | Seagen Inc. | Sep 2007 | |
| NCT01830465 | VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma | P2 | completed | 45 | Gruppo Italiano Studio Linfomi | Aug 2006 | |
| NCT00029107 | Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis | P2 | completed | 47 | National Institute of Allergy and Infectious Diseases (NIAID) | Dec 2001 | |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | P4 | completed | 545 | Hoffmann-La Roche | Sep 2006 | |
| NCT00472420 | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | P2 | completed | 48 | Hoffmann-La Roche | Jun 2007 | |
| NCT00981838 | NEMO | Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) | P3 | completed | 24 | Mario Negri Institute for Pharmacological Research | Apr 2009 |
| NCT00562965 | NHL | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | P3 | terminated | 29 | Pfizer | Nov 2007 |
| NCT00785330 | Allo-hNHL (FluBuCy) | P2 | completed | 84 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Apr 2004 | |
| NCT00983944 | Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma | P2 | withdrawn | 0 | Ohio State University Comprehensive Cancer Center | Sep 2009 | |
| NCT00151281 | Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma | P2 | completed | 25 | Weill Medical College of Cornell University | Nov 2004 | |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | P2 | completed | 55 | Millennium Pharmaceuticals, Inc. | Sep 2008 | |
| NCT00460109 | Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 24 | Alliance for Clinical Trials in Oncology | Apr 2008 | |
| NCT00415506 | Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation | P1/P2 | completed | 20 | Oregon Health and Science University | Jan 2007 | |
| NCT00493454 | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | P2 | terminated | 6 | M.D. Anderson Cancer Center | Apr 2006 | |
| NCT00274989 | Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia | P2 | completed | 195 | German CLL Study Group | Nov 2005 | |
| NCT00337246 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | P2 | completed | 56 | Cancer Research UK | Jul 2005 | |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | P2 | terminated | 62 | National Cancer Institute (NCI) | Dec 2004 | |
| NCT00309881 | CLL | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) | P2 | completed | 75 | German CLL Study Group | Apr 2003 |
| NCT01307592 | Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma | P2 | unknown | 70 | Auxilio Mutuo Cancer Center | Feb 2011 | |
| NCT00772668 | Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL | N/A | terminated | 3 | University of Miami | Sep 2009 | |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance | P2 | terminated | 21 | Mayo Clinic | Jan 2005 | |
| NCT00098670 | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | P2 | completed | 102 | National Cancer Institute (NCI) | Oct 2004 | |
| NCT01001780 | PCR | Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease | P2 | withdrawn | 0 | University of Rochester | Aug 2009 |
| NCT01345708 | A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia | P2 | completed | 23 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Jan 2009 | |
| NCT00531089 | Rituximab in Patients With Relapsed or Refractory TTP-HUS | P2 | unknown | 60 | Hamilton Health Sciences Corporation | Dec 2007 | |
| NCT00509379 | LYM-2023 | Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma | P2 | completed | 48 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | Sep 2006 |
| NCT00413959 | VRCD | VELCADE,Rituximab,Cyclophosphamide and Decadron | P2 | terminated | 12 | Oncology Specialists, S.C. | Aug 2006 |
| NCT02486952 | MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma | — | completed | 154 | Hoffmann-La Roche | Aug 2005 | |
| NCT00452374 | Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | P1/P2 | completed | 48 | M.D. Anderson Cancer Center | Nov 2004 | |
| NCT01082939 | CFAR | Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 80 | M.D. Anderson Cancer Center | Dec 2002 |
| NCT00007852 | Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | P2 | completed | 44 | University of Nebraska | Sep 2000 | |
| NCT00892827 | Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia | P2 | unknown | 10 | Wolfson Medical Center | Apr 2009 | |
| NCT00771602 | Alemtuzumab + Rituximab Consolidation in CLL | P2 | terminated | 1 | M.D. Anderson Cancer Center | Aug 2008 | |
| NCT00568815 | DLBCL | Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | P2 | completed | 31 | Fudan University | Apr 2007 |
| NCT00186628 | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | P2 | completed | 36 | Stanford University | Jun 2005 | |
| NCT00121199 | Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma | P2 | completed | 73 | National Cancer Institute (NCI) | Jun 2005 | |
| NCT00695097 | The Effect of Rituximab on the Development of Anti-Donor Antibodies | N/A | completed | 18 | University of California, San Francisco | Aug 2004 | |
| NCT00080925 | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | P1 | completed | 20 | National Institutes of Health Clinical Center (CC) | Feb 2004 | |
| NCT00501748 | Safety and Tolerability of Rituximab in Neuromyelitis Optica | P1 | completed | 20 | University of California, San Francisco | Jan 2004 | |
| NCT01456351 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | P3 | completed | 230 | University of Giessen | Sep 2003 | |
| NCT00849355 | CV | Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk | P2 | unknown | 44 | Asociacion Doctor Peset Para el Estudio de la Hematología | Aug 2008 |
| NCT00576433 | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. | P4 | completed | 60 | Hoffmann-La Roche | Dec 2007 | |
| NCT00556699 | A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma | P1 | completed | 22 | Genentech, Inc. | Dec 2007 | |
| NCT00934648 | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate | P4 | completed | 15 | Hoffmann-La Roche | Oct 2007 | |
| NCT00536978 | NK | Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies | P2 | completed | 22 | M.D. Anderson Cancer Center | Sep 2007 |
| NCT02079532 | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor | P3 | completed | 302 | Hoffmann-La Roche | Nov 2006 | |
| NCT00427557 | Cellular Therapy With Cord Blood Cells | P2 | completed | 31 | M.D. Anderson Cancer Center | Oct 2006 | |
| NCT00136396 | Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease | P1/P2 | completed | 30 | Dana-Farber Cancer Institute | Jan 2004 | |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Oct 2010 | |
| NCT00664521 | August III | Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III) | P2 | completed | 27 | Merck KGaA, Darmstadt, Germany | Mar 2008 |
| NCT00690560 | Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma | P2 | completed | 30 | Centre Antoine Lacassagne | May 2007 | |
| NCT00072007 | Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL | P2 | completed | 43 | Swiss Cancer Institute | Jun 2002 | |
| NCT00939328 | S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment | P2 | withdrawn | 0 | SWOG Cancer Research Network | Sep 2009 | |
| NCT00525876 | Non-Myeloablative Allogeneic Stem Cell Transplantation | N/A | completed | 49 | M.D. Anderson Cancer Center | Jan 2005 | |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | P1/P2 | completed | 25 | Genta Incorporated | Nov 2003 | |
| NCT00038844 | Safety and Efficacy of Campath in Nonmyeloablative Transplantation | N/A | completed | 65 | M.D. Anderson Cancer Center | Jun 2001 | |
| NCT01153971 | A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas | P2 | completed | 47 | Hoffmann-La Roche | Jul 2005 | |
| NCT00749112 | Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias | P2/P3 | completed | 19 | Hospital Universitario Dr. Jose E. Gonzalez | Aug 2008 | |
| NCT00426543 | Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome | P2 | completed | 21 | University of Copenhagen | Jan 2007 | |
| NCT00106184 | DM | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | P2 | completed | 200 | University of Pittsburgh | Mar 2006 |
| NCT00385125 | Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL | P2 | unknown | 30 | University of Magdeburg | Aug 2004 | |
| NCT00052936 | Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | P3 | completed | 1,506 | German High-Grade Non-Hodgkin's Lymphoma Study Group | Jan 2001 | |
| NCT01005979 | CR2 | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) | P1 | terminated | 6 | Emory University | Jul 2010 |
| NCT00758693 | CLL | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | P2 | withdrawn | 0 | University of Kentucky | Oct 2008 |
| NCT00312845 | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | P3 | completed | 676 | Millennium Pharmaceuticals, Inc. | Mar 2006 | |
| NCT00088530 | NHL | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | P3 | completed | 140 | CTI BioPharma | Jul 2004 |
| NCT01560117 | Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma | P2 | completed | 29 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Jan 2004 | |
| NCT00281983 | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | P1/P2 | completed | 100 | German CLL Study Group | Jun 2000 | |
| NCT00502853 | A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis. | P4 | completed | 10 | Hoffmann-La Roche | Oct 2007 | |
| NCT01117129 | RESONAR | A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR) | P4 | terminated | 2 | Hoffmann-La Roche | Apr 2010 |
| NCT00848692 | KTS-1-2008 | Drug Intervention in Chronic Fatigue Syndrome | P2/P3 | completed | 30 | Haukeland University Hospital | Jun 2008 |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | P2 | terminated | 7 | Royal Marsden NHS Foundation Trust | May 2008 | |
| NCT00937131 | TTP | The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) | P2 | completed | 40 | University College, London | Mar 2006 |
| NCT00422942 | RA | A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA) | P2 | terminated | 3 | Hoffmann-La Roche | Jan 2006 |
| NCT00229619 | Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia | P2 | completed | 11 | National Heart, Lung, and Blood Institute (NHLBI) | Sep 2005 | |
| NCT00384553 | Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma | P1/P2 | unknown | 30 | University of Magdeburg | Jun 2004 | |
| NCT00072449 | Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma | P2 | terminated | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2004 | |
| NCT00199082 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | P4 | completed | 650 | Nicola Goekbuget | Jul 2002 | |
| NCT00003248 | Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia | P2 | completed | 104 | Alliance for Clinical Trials in Oncology | Mar 1998 | |
| NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | P1 | completed | 9 | SymBio Pharmaceuticals | Nov 2008 | |
| NCT00636792 | VERTICAL | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma | P2 | completed | 73 | Millennium Pharmaceuticals, Inc. | Feb 2008 |
| NCT00482053 | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT | P2 | terminated | 3 | Stanford University | Oct 2006 | |
| NCT00373594 | Therapy for Chronic Cold Agglutinin Disease | P2 | completed | 30 | University of Bergen | Jun 2005 | |
| NCT00842595 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | P2 | completed | 50 | French Innovative Leukemia Organisation | Dec 2003 | |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P1 | terminated | 9 | National Cancer Institute (NCI) | Apr 2010 | |
| NCT00625729 | Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia | P1/P2 | terminated | 6 | Masonic Cancer Center, University of Minnesota | Jan 2008 | |
| NCT00363636 | NHL | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) | P3 | terminated | 340 | Biogen | Sep 2006 |
| NCT01103388 | Rituximab Maintenance After Autologous Transplantation | P3 | terminated | 4 | M.D. Anderson Cancer Center | Aug 2003 | |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P1/P2 | terminated | 81 | National Cancer Institute (NCI) | Apr 2001 | |
| NCT00135499 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | P3 | terminated | 138 | Lymphoma Study Association | Oct 2001 | |
| NCT00504777 | A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents. | P4 | completed | 36 | Hoffmann-La Roche | Jul 2007 | |
| NCT00509678 | Rituxan With or Without Methotrexate in Psoriatic Arthritis | P1 | completed | 6 | Swedish Medical Center | Dec 2006 | |
| NCT00286325 | Rituximab in the Treatment of Patients With Bullous Pemphigoid | P1/P2 | completed | 8 | Duke University | Mar 2005 | |
| NCT00588094 | Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | P2 | completed | 20 | Memorial Sloan Kettering Cancer Center | Oct 2003 | |
| NCT01088724 | FCD-R | Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) | P4 | completed | 4 | A.O. Ospedale Papa Giovanni XXIII | Feb 2002 |
| NCT00724971 | CMC-544 | Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | P1 | completed | 10 | Pfizer | Jul 2008 |
| NCT00500058 | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 | P1 | completed | 24 | GlaxoSmithKline | Jul 2007 | |
| NCT00799773 | STAR | Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) | P3 | terminated | 3 | Carelon Research | Apr 2009 |
| NCT00655837 | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | P1 | completed | 33 | Seagen Inc. | Apr 2008 | |
| NCT00193479 | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 51 | SCRI Development Innovations, LLC | Apr 2003 | |
| NCT00147121 | JCOG0203 | Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) | P2/P3 | completed | 300 | Haruhiko Fukuda | Sep 2002 |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | P2 | completed | 35 | M.D. Anderson Cancer Center | Apr 2002 | |
| NCT00820469 | PK-rituximab | Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab | P4 | completed | 20 | University Hospital, Toulouse | Sep 2008 |
| NCT00384150 | NHL | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | P3 | terminated | 16 | Biogen | Nov 2007 |
| NCT00039195 | Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma | P2 | completed | 98 | Memorial Sloan Kettering Cancer Center | Nov 2006 | |
| NCT00259974 | RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy | P3 | completed | 60 | Assistance Publique - Hôpitaux de Paris | Apr 2006 | |
| NCT00290407 | CLL | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) | P2 | terminated | 2 | University of Louisville | Mar 2006 |
| NCT00104299 | RAVE | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | P2/P3 | completed | 197 | National Institute of Allergy and Infectious Diseases (NIAID) | Jan 2005 |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | P2 | completed | 48 | National Cancer Institute (NCI) | Jan 2003 | |
| NCT01047072 | Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis | P2 | withdrawn | 0 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | — | |
| NCT00147966 | Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study) | P2 | completed | 24 | University of California, San Diego | Jun 2008 | |
| NCT00517049 | A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) | P2 | completed | 49 | Genentech, Inc. | Mar 2008 | |
| NCT00550342 | Rituximab Treatment of Focal Segmental Glomerulosclerosis | P2 | withdrawn | 0 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Jan 2008 | |
| NCT00558181 | LT-CLL-001 | High-dose Methylprednisolone and Rituximab in High Risk B-CLL | P2 | completed | 29 | Vilnius University | Sep 2007 |
| NCT00364819 | Initial Study of Rituximab to Treat Primary Biliary Cirrhosis | P1/P2 | completed | 6 | University of California, Davis | Jan 2007 | |
| NCT00556192 | Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus | P2 | completed | 20 | Chinese University of Hong Kong | Jun 2006 | |
| NCT01224769 | Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders | — | completed | 109 | Gruppo Italiano Studio Linfomi | Sep 2005 | |
| NCT00908986 | Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis | N/A | withdrawn | 0 | Northwell Health | Dec 2008 | |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | P1 | terminated | 4 | M.D. Anderson Cancer Center | May 2007 | |
| NCT00432653 | Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis | P2/P3 | unknown | 20 | Charite University, Berlin, Germany | Mar 2007 | |
| NCT00279305 | TN05 | Rituximab in New Onset Type 1 Diabetes | P2 | completed | 87 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Aug 2005 |
| NCT00053027 | Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | P2 | completed | 30 | Alliance for Clinical Trials in Oncology | Feb 2003 | |
| NCT00547534 | BVR | Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma | P2 | completed | 31 | University of Rochester | Oct 2007 |
| NCT00424502 | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker. | P4 | completed | 20 | Hoffmann-La Roche | Jan 2007 | |
| NCT00427791 | Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia | P2 | completed | 23 | M.D. Anderson Cancer Center | Jul 2005 | |
| NCT00261118 | Rituximab in Active Ulcerative Colitis | P2/P3 | completed | 24 | Royal Liverpool University Hospital | Apr 2004 | |
| NCT00086775 | Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia | P2 | completed | 0 | Bayer | Jul 2003 | |
| NCT01702038 | Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE | P2 | withdrawn | 0 | National Institute of Allergy and Infectious Diseases (NIAID) | Sep 2009 | |
| NCT00020943 | Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | P2 | completed | 79 | Alliance for Clinical Trials in Oncology | Jun 2001 | |
| NCT00398372 | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment | N/A | completed | 500 | Stanford University | Nov 2000 | |
| NCT00980304 | R Retreatment in 1st Relapsed DLBCL | P2 | unknown | 0 | Shanghai Jiao Tong University School of Medicine | — | |
| NCT03069248 | Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon | P2 | completed | 36 | Sunnybrook Health Sciences Centre | Jun 2000 | |
| NCT00101829 | Anti-CD20 Antibody Therapy for Sjogren's Syndrome | P1 | completed | 12 | National Institute of Allergy and Infectious Diseases (NIAID) | Apr 2004 | |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | P1/P2 | completed | 36 | John Byrd | Oct 2002 | |
| NCT00462345 | A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies. | P4 | completed | 40 | Hoffmann-La Roche | Jun 2007 | |
| NCT00424749 | Rituxan in Churg Strauss Syndrome With Renal Involvement | P2 | terminated | 4 | Fernando Fervenza | Jun 2007 | |
| NCT00427856 | GX15-070MS | Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) | P2 | completed | 7 | Gemin X | Mar 2007 |
| NCT00396812 | RA | Rituximab for the Treatment of Early Rheumatoid Arthritis (RA) | P1/P2 | terminated | 4 | National Institute of Allergy and Infectious Diseases (NIAID) | Nov 2006 |
| NCT00143065 | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 8 | Ohio State University Comprehensive Cancer Center | Aug 2005 | |
| NCT00308087 | PREMIER | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma | P2 | terminated | 75 | Genzyme, a Sanofi Company | May 2006 |
| NCT00444912 | NHL | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | P2 | completed | 30 | Genzyme, a Sanofi Company | Feb 2006 |
| NCT00965289 | High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma | P2 | completed | 42 | Nantes University Hospital | Apr 2002 | |
| NCT00366418 | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia | P1 | completed | 4 | National Heart, Lung, and Blood Institute (NHLBI) | Aug 2006 | |
| NCT00472225 | Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease | P2 | unknown | 42 | The Korean Society of Hematopoietic Stem Cell Transplantation | May 2007 | |
| NCT00476229 | Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies | N/A | completed | 20 | M.D. Anderson Cancer Center | Jun 2006 | |
| NCT00091897 | Rituximab to Treat Stiff Person Syndrome | P2 | completed | 24 | National Institute of Neurological Disorders and Stroke (NINDS) | Sep 2004 | |
| NCT00049036 | Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | P2 | completed | 106 | National Cancer Institute (NCI) | Mar 2003 | |
| NCT00033423 | Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P1 | terminated | 18 | University of Alabama at Birmingham | Aug 2001 | |
| NCT00003659 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia | P2 | completed | 39 | Memorial Sloan Kettering Cancer Center | Sep 1998 | |
| NCT00691652 | Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma | P1/P2 | terminated | 2 | OHSU Knight Cancer Institute | May 2008 | |
| NCT00251277 | Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura | P1/P2 | withdrawn | 0 | Weill Medical College of Cornell University | Nov 2005 | |
| NCT00032019 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | P2 | completed | 78 | Alliance for Clinical Trials in Oncology | Feb 2002 | |
| NCT00269113 | A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma | P3 | completed | 360 | Hoffmann-La Roche | Sep 1998 | |
| NCT00896519 | GM-CSF | GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma | P2 | unknown | 30 | French Innovative Leukemia Organisation | Mar 2009 |
| NCT00893477 | GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma | P2 | unknown | 60 | French Innovative Leukemia Organisation | Mar 2009 | |
| NCT00517699 | A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. | P2 | terminated | 5 | Hoffmann-La Roche | Sep 2007 | |
| NCT00424151 | Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy | P1/P2 | completed | 12 | Silkiss, Rona Z., M.D., FACS | Dec 2006 | |
| NCT00275613 | Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis | P1 | completed | 10 | Mayo Clinic | Nov 2005 | |
| NCT00096460 | BMT CTN 0202 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) | P2/P3 | terminated | 30 | Medical College of Wisconsin | Aug 2004 |
| NCT00199004 | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab | P4 | completed | 60 | Johann Wolfgang Goethe University Hospital | Apr 2004 | |
| NCT00619671 | A Pilot Trial of Rituxan in Refractory Myasthenia Gravis | P1/P2 | completed | 10 | University of Vermont | Apr 2004 | |
| NCT00058292 | Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P1 | completed | 44 | Northwestern University | Apr 2000 | |
| NCT01272908 | RESET | A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET) | P3 | completed | 120 | Hoffmann-La Roche | Jul 2006 |
| NCT00833534 | Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant | P2 | withdrawn | 0 | Fred Hutchinson Cancer Center | Feb 2009 | |
| NCT00863187 | Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab | N/A | unknown | 100 | Rambam Health Care Campus | Feb 2009 | |
| NCT00567229 | Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma | P2 | terminated | 3 | Memorial Sloan Kettering Cancer Center | Nov 2007 | |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia | P2 | completed | 23 | Dana-Farber Cancer Institute | Oct 2005 | |
| NCT00243412 | RUMBA | A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate | P2 | completed | 42 | Genentech, Inc. | Aug 2005 |
| NCT00053092 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma | P2 | completed | 82 | Institute of Cancer Research, United Kingdom | Oct 2002 | |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | P2 | terminated | 4 | Jean M. Tersak, M.D. | Jul 2005 | |
| NCT00379431 | A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab | P2 | completed | 9 | University Hospital, Ghent | Nov 2006 | |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | P1/P2 | withdrawn | 0 | Cancer Research UK | Jan 2009 | |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | P2 | withdrawn | 0 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Jan 2009 | |
| NCT01054781 | DLBCL | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | P2 | completed | 91 | Samsung Medical Center | Jan 2009 |
| NCT00371904 | RAPTURE | Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients | P2 | unknown | 192 | Hunter and New England Health | Apr 2006 |
| NCT00140595 | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 | P3 | completed | 380 | Lymphoma Study Association | Dec 2003 | |
| NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | P2 | completed | 40 | SCRI Development Innovations, LLC | Apr 2002 | |
| NCT00648037 | EBV | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT | N/A | completed | 26 | Memorial Sloan Kettering Cancer Center | Mar 2008 |
| NCT00446251 | MMF | Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant | P2 | completed | 14 | University of Washington | Dec 2006 |
| NCT00502996 | A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis. | P3 | completed | 246 | Hoffmann-La Roche | Feb 2006 | |
| NCT00259805 | A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis | P1 | completed | 10 | California Pacific Medical Center Research Institute | Jan 2005 | |
| NCT01538641 | GROC | Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas | P2 | completed | 43 | Auxilio Mutuo Cancer Center | Oct 2003 |
| NCT00285389 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | P2 | completed | 39 | French Innovative Leukemia Organisation | Feb 2002 | |
| NCT00734773 | Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL | Early P1 | withdrawn | 0 | Northwestern University | Nov 2008 | |
| NCT00486421 | Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura | Early P1 | completed | 22 | Mayo Clinic | Jan 2007 | |
| NCT00440388 | Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma | P2 | completed | 23 | Ascenta Therapeutics | Oct 2006 | |
| NCT00363350 | Rituximab Treatment in Sjogren's Syndrome | P1/P2 | completed | 30 | University Medical Center Groningen | Aug 2006 | |
| NCT00499343 | G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients | P2 | completed | 84 | M.D. Anderson Cancer Center | Jan 2004 | |
| NCT00137995 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | P3 | completed | 481 | Lymphoma Study Association | Jun 2003 | |
| NCT00723658 | S0629 | S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | P2 | withdrawn | 0 | SWOG Cancer Research Network | Sep 2008 |
| NCT00204659 | CHOP | Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 30 | University Hospital Tuebingen | Mar 2003 |
| NCT02622503 | A Study on Rheumatoid Arthritis Patients Treated With Rituximab | — | completed | 81 | Hoffmann-La Roche | Apr 2008 | |
| NCT00087009 | Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation | P1 | terminated | 3 | Memorial Sloan Kettering Cancer Center | May 2004 | |
| NCT00003820 | Rituximab in Treating Patients With Hodgkin's Lymphoma | P2 | completed | 39 | Ranjana Advani | Jan 1999 | |
| NCT00137969 | EXPLORER | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus | P2/P3 | completed | 262 | Genentech, Inc. | May 2005 |
| NCT00770562 | ITP | A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) | P3 | completed | 103 | Hoffmann-La Roche | Jul 2005 |
| NCT00854321 | KuoRituxi1 | Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital | — | completed | 49 | Kuopio University Hospital | Nov 2004 |
| NCT01124526 | RFC | Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma | P4 | completed | 75 | Asociacion Espanola de Hematologia y Hemoterapia | Sep 2004 |
| NCT00555542 | An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis | P2 | completed | 10 | Chinese University of Hong Kong | Jul 2006 | |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | P2 | terminated | 3 | Dana-Farber Cancer Institute | Jul 2006 | |
| NCT00347971 | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma | P1 | completed | 23 | ZymoGenetics | Jun 2006 | |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | P2 | terminated | 16 | Dana-Farber Cancer Institute | Sep 2004 | |
| NCT00193466 | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | completed | 40 | SCRI Development Innovations, LLC | Jan 2002 | |
| NCT00007865 | Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | P2 | completed | 0 | University of Nebraska | Sep 2000 | |
| NCT00167791 | Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant | N/A | withdrawn | 0 | University of Wisconsin, Madison | Jul 2005 | |
| NCT00182650 | Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma | P1 | completed | 5 | City of Hope Medical Center | Jun 2004 | |
| NCT00076349 | NHL | SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) | P2 | completed | 66 | Cephalon | Apr 2004 |
| NCT00031642 | Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation | P1/P2 | completed | 26 | University of Nebraska | Jan 2002 | |
| NCT00176475 | Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | P1 | terminated | 2 | University of Medicine and Dentistry of New Jersey | Jan 2005 | |
| NCT00774202 | Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP | P2/P3 | completed | 17 | Weill Medical College of Cornell University | Nov 2003 | |
| NCT00142116 | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia | P2 | completed | 25 | Steven P. Treon, MD, PhD | May 2003 | |
| NCT00005601 | Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | P2 | completed | 58 | Alliance for Clinical Trials in Oncology | Oct 2000 | |
| NCT00003849 | Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | P2 | completed | 39 | Alliance for Clinical Trials in Oncology | Jul 1999 | |
| NCT01998893 | A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma | P2 | completed | 38 | Hoffmann-La Roche | Jan 1997 | |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | P1 | terminated | 28 | National Cancer Institute (NCI) | Jan 2008 | |
| NCT00664599 | Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease | P2 | completed | 20 | Tehran University of Medical Sciences | Apr 2006 | |
| NCT00656084 | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | P2 | completed | 16 | US Oncology Research | Dec 2004 | |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | P1/P2 | completed | 29 | University of Washington | Dec 2007 | |
| NCT00244361 | Effectiveness of Rituximab in Pediatric OMS Patients. | P1/P2 | completed | 25 | National Pediatric Neuroinflammation Organization, Inc. | Jun 2005 | |
| NCT00261547 | Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients | P1/P2 | withdrawn | 0 | Massachusetts General Hospital | Dec 2005 | |
| NCT00367497 | R-ESHAP | Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | P2 | terminated | 5 | Keio University | Aug 2005 |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | P4 | completed | 168 | Biogen | Oct 2003 | |
| NCT02006706 | A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy | P3 | completed | 15 | Hoffmann-La Roche | Aug 2006 | |
| NCT00255593 | Safety and Efficacy Study of Rituximab in Renal Transplantation | P1 | completed | 140 | Karolinska University Hospital | Nov 2005 | |
| NCT00040950 | Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P1 | completed | 0 | Jonsson Comprehensive Cancer Center | Mar 2002 | |
| NCT00012051 | Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | P3 | completed | 340 | Commissie Voor Klinisch Toegepast Onderzoek | Sep 2000 | |
| NCT00050245 | Rituximab to Treat Neuropathy With Anti-MAG Antibodies | P2 | completed | 30 | National Institute of Neurological Disorders and Stroke (NINDS) | Nov 2002 | |
| NCT00476515 | Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor | P1 | withdrawn | 0 | Massachusetts General Hospital | Mar 2007 | |
| NCT00280878 | Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma | P2 | completed | 12 | Bayside Health | Jan 2006 | |
| NCT00214266 | A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation | P2 | completed | 31 | University of Wisconsin, Madison | Jan 2005 | |
| NCT00081861 | Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 13 | M.D. Anderson Cancer Center | Mar 2004 | |
| NCT00086203 | CLL | Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) | P2 | completed | 0 | Point Therapeutics | — |
| NCT00238368 | Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant | P2 | completed | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Feb 2004 | |
| NCT00258206 | Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma | P2 | completed | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Dec 2004 | |
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | P3 | withdrawn | 0 | CTI BioPharma | Aug 2007 | |
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | P2 | terminated | 7 | Janssen-Cilag G.m.b.H | Feb 2006 | |
| NCT00250861 | IL-2 | Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma | P2 | terminated | 110 | US Oncology Research | Oct 2005 |
| NCT00697996 | Rituximab for Pediatric Renal Transplant Rejection | P2/P3 | completed | 20 | Stanford University | Jun 2005 | |
| NCT00071396 | Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders | P2 | completed | 48 | M.D. Anderson Cancer Center | Oct 2002 | |
| NCT00311129 | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL | P2 | completed | 41 | Genzyme, a Sanofi Company | Dec 2005 | |
| NCT00003757 | Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy | P2 | completed | 25 | Swiss Cancer Institute | Feb 1998 | |
| NCT00689845 | Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma | N/A | unknown | 120 | University Hospital Southampton NHS Foundation Trust | Jun 2007 | |
| NCT00578591 | Rituximab GVHD | Rituximab for GVHD | P2 | withdrawn | 0 | Baylor College of Medicine | Jun 2007 |
| NCT00307593 | RATTRAP | RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides | N/A | completed | 20 | Assistance Publique - Hôpitaux de Paris | May 2004 |
| NCT00343447 | Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia | P2 | withdrawn | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Aug 2006 | |
| NCT00216762 | Safety Study of Rituximab (Rituxan®) in Chronic Urticaria | P1/P2 | terminated | 15 | Johns Hopkins University | Jan 2006 | |
| NCT00642655 | IVIG | Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation | P1/P2 | completed | 20 | Cedars-Sinai Medical Center | Sep 2005 |
| NCT00060684 | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | P1 | completed | 30 | CTI BioPharma | Dec 2001 | |
| NCT00579592 | Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation | N/A | terminated | 11 | University of Wisconsin, Madison | Apr 2006 | |
| NCT00425217 | Rituximab in Membranous Nephropathy | P2/P3 | completed | 15 | Mayo Clinic | Aug 2004 | |
| NCT00062114 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | P2 | completed | 84 | Alliance for Clinical Trials in Oncology | Apr 2004 | |
| NCT00242996 | Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma | P2 | completed | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2004 | |
| NCT00416923 | Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma | P1 | completed | 10 | University of California, San Francisco | Aug 2002 | |
| NCT00216164 | Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P2 | terminated | 8 | Hoosier Cancer Research Network | Apr 2005 | |
| NCT00142155 | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia | N/A | completed | 300 | Dana-Farber Cancer Institute | Jan 2002 | |
| NCT00210379 | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma | P2 | completed | 64 | International Extranodal Lymphoma Study Group (IELSG) | Nov 2000 | |
| NCT00429065 | Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. | — | unknown | 30 | Instituto Nacional de Cancerologia de Mexico | Jan 2007 | |
| NCT00261612 | BORID | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma | P2 | unknown | 16 | Medical University of Vienna | Jan 2005 |
| NCT00169143 | Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma | P2 | completed | 60 | Lymphoma Study Association | May 2004 | |
| NCT00143871 | Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma | P2 | completed | 35 | University of Michigan Rogel Cancer Center | Apr 2001 | |
| NCT00003716 | Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy | P2 | completed | 25 | Stanford University | Mar 1998 | |
| NCT00797810 | Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults | P4 | unknown | 25 | University of Bologna | Dec 2006 | |
| NCT00267826 | Immunopharmacological Effects of Rituximab in Atopic Dermatitis | N/A | completed | 6 | University of Bern | Dec 2005 | |
| NCT00097188 | A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis | P2 | completed | 104 | Genentech, Inc. | Dec 2004 | |
| NCT00169208 | Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma | P2 | completed | 50 | Lymphoma Study Association | Apr 2001 | |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | P2 | terminated | 30 | University of Southern California | Aug 2000 | |
| NCT00006708 | S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P3 | terminated | 7 | SWOG Cancer Research Network | Oct 2000 | |
| NCT00404157 | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g | P3 | withdrawn | 0 | Genentech, Inc. | — | |
| NCT00150111 | Rituximab in the Treatment of Graves' Disease | P1/P2 | completed | 20 | Odense University Hospital | Jun 2003 | |
| NCT00281931 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia | P2 | terminated | 21 | German CLL Study Group | Sep 1999 | |
| NCT00120198 | Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients | P2 | terminated | 50 | Geriatric Oncology Consortium | Mar 2005 | |
| NCT00201721 | Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia | P2 | completed | 28 | Ohio State University Comprehensive Cancer Center | Jul 2002 | |
| NCT00556127 | DLBCL | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | P2 | completed | 94 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | Jun 2002 |
| NCT00003150 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma | P3 | completed | 630 | Eastern Cooperative Oncology Group | Dec 1997 | |
| NCT00393107 | Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab | P2 | completed | 54 | Gruppo Italiano Studio Linfomi | Mar 2000 | |
| NCT00346684 | RIPL | Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) | P2 | completed | 0 | University of Cologne | Jul 2006 |
| NCT00400764 | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas | P1/P2 | terminated | 72 | Genentech, Inc. | Jun 2006 | |
| NCT00070447 | Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | P2 | completed | 0 | National Cancer Institute (NCI) | Nov 2003 | |
| NCT00333008 | NHL | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | P2 | unknown | 27 | The Alvin and Lois Lapidus Cancer Institute | May 2006 |
| NCT00274794 | VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL | N/A | completed | 55 | The Cleveland Clinic | Feb 2000 | |
| NCT00324831 | GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | P3 | suspended | 480 | Favrille | — | |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | P2 | terminated | 52 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT00265915 | Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia | P2 | terminated | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2005 | |
| NCT00055640 | Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | P2 | completed | 9 | Case Comprehensive Cancer Center | Oct 2002 | |
| NCT00301301 | GEM-P | A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) | — | completed | 39 | Royal Marsden NHS Foundation Trust | — |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | P2 | withdrawn | 0 | AIDS Malignancy Consortium | Feb 2006 | |
| NCT01392716 | A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma | P2 | completed | 48 | Hoffmann-La Roche | Oct 1997 | |
| NCT00266227 | SUNRISE | A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate | P3 | completed | 559 | Genentech, Inc. | Jan 2006 |
| NCT00974792 | Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma | P2 | unknown | 150 | Cancer Research UK | Jan 2006 | |
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas | P2 | terminated | 15 | University of Southern California | Apr 2005 | |
| NCT00169468 | Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma | P2 | completed | 48 | Lymphoma Study Association | Jan 2005 | |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | P3 | terminated | 800 | CTI BioPharma | Jan 2005 | |
| NCT00127569 | Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy | P2 | terminated | 25 | French National Agency for Research on AIDS and Viral Hepatitis | May 2003 | |
| NCT00036491 | Anti-CD20 in Systemic Lupus Erythematosus | P1/P2 | completed | 24 | National Institute of Allergy and Infectious Diseases (NIAID) | Jan 2001 | |
| NCT01713738 | ITP | Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) | P1/P2 | completed | 36 | Neufeld, Ellis J, MD, PhD | May 2003 |
| NCT00141700 | Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma | P2 | terminated | 30 | University of Michigan Rogel Cancer Center | Mar 2003 | |
| NCT00049413 | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | P2 | completed | 0 | Hoag Memorial Hospital Presbyterian | Jun 2002 | |
| NCT00265928 | Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | P2 | terminated | 46 | University of Virginia | — | |
| NCT00005592 | Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | P2 | completed | 23 | University of Alabama at Birmingham | Nov 1999 | |
| NCT00003658 | Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers | P2 | completed | 60 | Memorial Sloan Kettering Cancer Center | Sep 1998 | |
| NCT00230035 | LIST | Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) | P2 | withdrawn | 0 | National Institute of Allergy and Infectious Diseases (NIAID) | Sep 2005 |
| NCT00210340 | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | P1 | withdrawn | 0 | International Extranodal Lymphoma Study Group (IELSG) | — | |
| NCT00072592 | An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies | P1 | completed | 10 | National Institute of Allergy and Infectious Diseases (NIAID) | Oct 2003 | |
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma | P2 | completed | 40 | SCRI Development Innovations, LLC | Oct 2003 | |
| NCT00062296 | Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | P2 | completed | 5 | Fox Chase Cancer Center | Mar 2003 | |
| NCT00169169 | Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma | P3 | terminated | 430 | Lymphoma Study Association | Oct 1999 | |
| NCT00004889 | Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia | P2 | completed | 8 | Jonsson Comprehensive Cancer Center | Dec 1999 | |
| NCT00293072 | SLE | Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis | P2 | completed | 20 | Cambridge University Hospitals NHS Foundation Trust | Mar 2002 |
| NCT00001563 | EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma | P2 | completed | 39 | National Cancer Institute (NCI) | Jan 1997 | |
| NCT00098488 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | P1 | terminated | 30 | National Cancer Institute (NCI) | Apr 2005 | |
| NCT01851551 | Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | P1/P2 | completed | 22 | Acrotech Biopharma Inc. | Sep 2001 | |
| NCT00003963 | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation | P2 | completed | 14 | Jonsson Comprehensive Cancer Center | May 1999 | |
| NCT00100737 | IL-2 | Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) | P2 | terminated | 300 | Chiron Corporation | — |
| NCT00082836 | Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma | N/A | completed | 10 | Memorial Sloan Kettering Cancer Center | Dec 2004 | |
| NCT00110006 | Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma | N/A | withdrawn | 0 | Case Comprehensive Cancer Center | Dec 2004 | |
| NCT00136552 | Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden | P3 | completed | 360 | Lymphoma Study Association | May 2000 | |
| NCT00180882 | LMBA02 Protocol for Patients With a Burkitt Lymphoma | P3 | unknown | 260 | Gustave Roussy, Cancer Campus, Grand Paris | Oct 2004 | |
| NCT00093769 | Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | P2 | completed | 15 | Jonsson Comprehensive Cancer Center | Aug 2004 | |
| NCT00258336 | Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma | P2 | unknown | 56 | Favrille | Aug 2004 | |
| NCT02693210 | A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis | P2 | completed | 161 | Hoffmann-La Roche | Feb 2001 | |
| NCT00089115 | Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | P3 | terminated | 0 | Favrille | Jul 2004 | |
| NCT00087425 | Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | P2 | completed | 48 | National Institute on Aging (NIA) | Jul 2004 | |
| NCT00180895 | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL | P2 | terminated | 40 | Gustave Roussy, Cancer Campus, Grand Paris | Jun 2004 | |
| NCT00147953 | Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma | P2 | completed | 30 | University of Cologne | Jun 2004 | |
| NCT00087529 | OLYMPUS | A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis | P2/P3 | completed | 439 | Genentech, Inc. | Jun 2004 |
| NCT00057447 | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | P1/P2 | terminated | 24 | InterMune | Mar 2003 | |
| NCT00059904 | Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jan 2003 | |
| NCT00086944 | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | P1/P2 | completed | 25 | National Cancer Institute (NCI) | May 2004 | |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | P2 | completed | 66 | Millennium Pharmaceuticals, Inc. | May 2004 | |
| NCT00078598 | A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma | P3 | unknown | 506 | Corixa Corporation | Apr 2004 | |
| NCT00003554 | Rituximab in Treating Patients With Multiple Myeloma | P2 | completed | 0 | The Cleveland Clinic | Nov 1998 | |
| NCT01388959 | A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma | P2 | completed | 40 | Hoffmann-La Roche | Nov 1998 | |
| NCT00080847 | S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma | P2 | terminated | 160 | National Cancer Institute (NCI) | Mar 2004 | |
| NCT00324779 | Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia | P2 | completed | 79 | University Hospital Erlangen | Mar 2004 | |
| NCT00161564 | A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone | P2 | withdrawn | 0 | Weill Medical College of Cornell University | Feb 2004 | |
| NCT00005609 | Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia | P2 | completed | 0 | Eastern Cooperative Oncology Group | Apr 2000 | |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | P2 | terminated | 60 | National Cancer Institute (NCI) | Jan 2004 | |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | P2 | terminated | 82 | National Cancer Institute (NCI) | Nov 2003 | |
| NCT00126243 | CHOP | Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | P2 | terminated | 60 | French National Agency for Research on AIDS and Viral Hepatitis | Jan 1999 |
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | P1/P2 | completed | 28 | National Cancer Institute (NCI) | Jul 2003 | |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | P1 | completed | 18 | National Cancer Institute (NCI) | Jul 2003 | |
| NCT00070083 | Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | P1 | completed | 0 | British Columbia Cancer Agency | Jul 2003 | |
| NCT00026351 | Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | P2 | completed | 0 | Pharmatech Oncology | Dec 2000 | |
| NCT00004260 | Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | P1 | completed | 0 | Mayo Clinic | Oct 1999 | |
| NCT00069966 | Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse | P2 | unknown | 0 | Theradex | Apr 2003 | |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | P1 | completed | 37 | National Cancer Institute (NCI) | Apr 2003 | |
| NCT00060294 | Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia | P1 | terminated | 0 | Jonsson Comprehensive Cancer Center | Apr 2003 | |
| NCT00052923 | Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma | P3 | completed | 427 | Eastern Cooperative Oncology Group | Mar 2003 | |
| NCT00057343 | Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | P3 | terminated | 400 | Biogen | Mar 2003 | |
| NCT00225212 | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | P2 | completed | 35 | Stanford University | Nov 1997 | |
| NCT00004112 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | P3 | completed | 0 | University of Nebraska | Sep 1999 | |
| NCT01148446 | ANZINTER3 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | P3 | completed | 226 | Fondazione Italiana Linfomi - ETS | Jan 2003 |
| NCT00003397 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | P2 | completed | 25 | University of Maryland, Baltimore | Sep 1998 | |
| NCT00005631 | Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Nov 1999 | |
| NCT00244127 | Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL. | P2 | unknown | 75 | Zeneus Pharma | Oct 2002 | |
| NCT00045864 | Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. | P2 | completed | 0 | Chiron Corporation | — | |
| NCT00045877 | Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments | P2/P3 | completed | 0 | Chiron Corporation | — | |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma | P1 | terminated | 36 | National Cancer Institute (NCI) | Jun 2002 | |
| NCT00003356 | Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | P1/P2 | completed | 58 | University of Rochester | Nov 1997 | |
| NCT00003280 | Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma | P3 | completed | 240 | Swiss Cancer Institute | Jan 1998 | |
| NCT00031902 | Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | P1 | unknown | 0 | Lymphoma Trials Office | Oct 2001 | |
| NCT00026182 | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | P2 | completed | 99 | National Cancer Institute (NCI) | Oct 2001 | |
| NCT00020800 | Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia | P2 | completed | 7 | Jonsson Comprehensive Cancer Center | Sep 2001 | |
| NCT00017381 | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | Early P1 | completed | 30 | National Cancer Institute (NCI) | Apr 2001 | |
| NCT00028717 | Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | P3 | unknown | 400 | Commissie Voor Klinisch Toegepast Onderzoek | Feb 2001 | |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | P1 | completed | 30 | National Cancer Institute (NCI) | Dec 2000 | |
| NCT00005652 | Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura | P2 | completed | 20 | University of Alabama at Birmingham | Dec 2000 | |
| NCT00028665 | Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma | P2 | completed | 37 | Case Comprehensive Cancer Center | Jun 2000 | |
| NCT00001805 | A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab | P2 | completed | 20 | National Cancer Institute (NCI) | Mar 1999 | |
| NCT00435955 | Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma | P3 | unknown | 240 | Azienda Ospedaliera San Giovanni Battista | Mar 2000 | |
| NCT00006669 | Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma | P2 | withdrawn | 0 | Medstar Health Research Institute | Sep 1999 | |
| NCT00004039 | Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma | P2 | withdrawn | 0 | Hoag Memorial Hospital Presbyterian | Jun 1998 | |
| NCT00003663 | Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma | P2 | withdrawn | 0 | Hoag Memorial Hospital Presbyterian | Jun 1998 | |
| NCT00003605 | Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma | P2 | withdrawn | 0 | Hoag Memorial Hospital Presbyterian | May 1998 | |
| NCT00005959 | Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | P2 | unknown | 0 | Amgen | Dec 1999 | |
| NCT00004040 | Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy | P2 | withdrawn | 0 | Hoag Memorial Hospital Presbyterian | Jun 1998 | |
| NCT00003595 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma | P3 | completed | 120 | National Cancer Institute (NCI) | Jan 1999 | |
| NCT00003204 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma | P3 | completed | 515 | National Cancer Institute (NCI) | Mar 1998 | |
| NCT00168740 | Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | P3 | completed | 150 | Biogen | Apr 1995 |
Rituximab clinical trials: frequently asked questions
- How many Rituximab clinical trials are there?
- 2053 Rituximab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 262 are actively recruiting participants. 987 are marked completed.
- Are Rituximab clinical trials recruiting in 2026?
- Yes — 262 Rituximab trials are actively recruiting in 2026, with 1419 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Rituximab being studied for?
- Rituximab is being studied for Lymphoma, Chronic Lymphocytic Leukemia, Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma and 1520 more. The trials are grouped by indication on this page.
- What phase is Rituximab in?
- Rituximab clinical trials span 77 Phase 4, 367 Phase 3, 950 Phase 2, 246 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Rituximab clinical trials?
- The lead sponsor across the most Rituximab trials is M.D. Anderson Cancer Center, with 625 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Rituximabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: